<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="/resources/spdi-openaccess-jats.xsl"?>
<!DOCTYPE response [
	
<!ENTITY % article SYSTEM "http://jats.nlm.nih.gov/archiving/1.2/JATS-archivearticle1.dtd">
<!ENTITY % book-part-wrapper SYSTEM "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
	]><response><apiMessage>This XML was provided by Springer Nature</apiMessage><query>doi:10.1007/978-3-319-89315-0_2</query><apiKey>87ba7cb21f89ce78154df796840621f4</apiKey><result><total>1</total><start>1</start><pageLength>2</pageLength><recordsDisplayed>1</recordsDisplayed></result><records><book-part-wrapper dtd-version="2.0" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><collection-meta collection-type="series"><collection-id collection-id-type="publisher-id">10155</collection-id><title-group><title>Biomathematical and Biomechanical Modeling of the Circulatory and Ventilatory Systems</title><alt-title>Biomathematical,Biomechanical Modeling of Circulatory</alt-title></title-group><issn publication-format="print">2193-1682</issn><issn publication-format="electronic">2193-1690</issn></collection-meta><book-meta><book-id book-id-type="doi">10.1007/978-3-319-89315-0</book-id><book-id book-id-type="publisher-id">978-3-319-89315-0</book-id><book-id book-id-type="book-title-id">460479</book-id><book-title-group><book-title>Vasculopathies</book-title><subtitle>Behavioral, Chemical, Environmental, and Genetic Factors</subtitle></book-title-group><contrib-group><contrib contrib-type="author"><name><surname>Thiriet</surname><given-names>Marc</given-names></name><address><email>Marc.Thiriet@inria.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.464004.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0174 8385</institution-id><institution content-type="org-division">INRIA project team REO</institution><institution content-type="org-name">Université Pierre et Marie Curie, Laboratoire Jacques-Louis Lions</institution></institution-wrap><addr-line content-type="city">Paris</addr-line><country country="FR">France</country></aff></contrib-group><pub-date date-type="pub"><string-date>2018-01-01</string-date></pub-date><book-volume-number>8</book-volume-number><isbn content-type="ppub">978-3-319-89314-3</isbn><isbn content-type="epub">978-3-319-89315-0</isbn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher><permissions><copyright-statement content-type="compact">© Springer International Publishing AG, part of Springer Nature 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Springer International Publishing AG, part of Springer Nature</copyright-holder></permissions><custom-meta-group><custom-meta><meta-name>publisher-imprint-name</meta-name><meta-value>Springer</meta-value></custom-meta><custom-meta><meta-name>book-chapter-count</meta-name><meta-value>7</meta-value></custom-meta><custom-meta><meta-name>media-type</meta-name><meta-value>eBook</meta-value></custom-meta><custom-meta><meta-name>contains-esm</meta-name><meta-value>No</meta-value></custom-meta><custom-meta><meta-name>book-product-type</meta-name><meta-value>Monograph</meta-value></custom-meta><custom-meta><meta-name>book-subject-primary</meta-name><meta-value>Physics</meta-value></custom-meta><custom-meta><meta-name>book-subject-secondary</meta-name><meta-value>Biological and Medical Physics, Biophysics</meta-value></custom-meta><custom-meta><meta-name>book-subject-secondary</meta-name><meta-value>Biomedical Engineering and Bioengineering</meta-value></custom-meta><custom-meta><meta-name>book-subject-secondary</meta-name><meta-value>Mathematical and Computational Biology</meta-value></custom-meta><custom-meta><meta-name>book-subject-secondary</meta-name><meta-value>Systems Biology</meta-value></custom-meta><custom-meta><meta-name>book-subject-secondary</meta-name><meta-value>Engineering Fluid Dynamics</meta-value></custom-meta><custom-meta><meta-name>book-subject-secondary</meta-name><meta-value>Cardiology</meta-value></custom-meta><custom-meta><meta-name>book-subject-collection</meta-name><meta-value>Physics and Astronomy</meta-value></custom-meta></custom-meta-group></book-meta><book-part book-part-type="chapter" id="b978-3-319-89315-0_2" seq="2"><book-part-meta><book-part-id book-part-id-type="doi">10.1007/978-3-319-89315-0_2</book-part-id><book-part-id book-part-id-type="chapter">2</book-part-id><title-group><label>Chapter 2</label><title>Cardiovascular Risk Factors and Markers</title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Thiriet</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.464004.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0174 8385</institution-id><institution content-type="org-division">INRIA project team REO</institution><institution content-type="org-name">Université Pierre et Marie Curie, Laboratoire Jacques-Louis Lions</institution></institution-wrap><addr-line content-type="city">Paris</addr-line><country country="FR">France</country></aff></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>02</month><year>2019</year></pub-date><fpage>91</fpage><lpage>198</lpage><pub-history><date date-type="registration"><day>11</day><month>06</month><year>2018</year></date><date date-type="online"><day>19</day><month>02</month><year>2019</year></date></pub-history><permissions><copyright-statement content-type="compact">© Springer International Publishing AG, part of Springer Nature 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Springer International Publishing AG, part of Springer Nature</copyright-holder></permissions><abstract xml:lang="en" id="Abs1" specific-use="web-only"><title>Abstract</title><p id="Par1">Cardiovascular risk is assessed for the prediction and appropriate management of patients using collections of identified risk markers obtained from clinical questionnaire information, concentrations of certain blood molecules (e.g., N-terminal proB-type natriuretic peptide fragment and soluble receptors of tumor-necrosis factor-α and interleukin-2), imaging data using various modalities, and electrocardiographic variables, in addition to traditional risk factors.</p></abstract><custom-meta-group><custom-meta><meta-name>chapter-type</meta-name><meta-value>OriginalPaper</meta-value></custom-meta><custom-meta><meta-name>chapter-grants-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>metadata-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>abstract-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodypdf-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodyhtml-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bibliography-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>esm-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>open-access</meta-name><meta-value>false</meta-value></custom-meta><custom-meta><meta-name>online-first</meta-name><meta-value>false</meta-value></custom-meta><custom-meta><meta-name>pdf-file-reference</meta-name><meta-value>BodyRef/PDF/978-3-319-89315-0_Chapter_2.pdf</meta-value></custom-meta><custom-meta><meta-name>output-medium</meta-name><meta-value>Online</meta-value></custom-meta><custom-meta><meta-name>pdf-type</meta-name><meta-value>Typeset</meta-value></custom-meta><custom-meta><meta-name>target-type</meta-name><meta-value>OnlinePDF</meta-value></custom-meta></custom-meta-group><notes notes-type="Motto"><p><italic>Quamdiu vivimus, necesse habemus semper quærere[As long as we live, we must always investigate](H. de Lubac, [1896–1991])</italic> [<xref ref-type="bibr" rid="CR11">223</xref>]</p></notes></book-part-meta><body><p id="Par2">Cardiovascular risk is assessed for the prediction and appropriate management of patients using collections of identified risk markers obtained from clinical questionnaire information, concentrations of certain blood molecules (e.g., N-terminal proB-type natriuretic peptide fragment and soluble receptors of tumor-necrosis factor-α and interleukin-2 [IL-2]), imaging data using various modalities, and electrocardiographic variables, in addition to traditional risk factors. These risk markers and factors can be combined to form standard cardiovascular risk scores (e.g., the Framingham risk score). These risk markers and factors can also be ranked according to their efficiency in predicting each cardiovascular outcome.</p><p id="Par3">The term <italic>biomarker</italic> has been defined as an indicator of physiological or pathophysiological processes and hence used for diagnostic, prognostic,<xref ref-type="fn" rid="Fn1">1</xref> and/or therapeutic purposes. Biomarker is defined by the National Institutes of Health as an entity “that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention.” In a pathophysiological context, the useless prefix <italic>bio</italic> is omitted.</p><p id="Par5">Markers of redox stress encompass molecules modified by interactions with reactive oxygen species (ROS) (i.e., proteins, lipids, carbohydrates, and DNA) and molecules of the antioxidant defense [<xref ref-type="bibr" rid="CR5">90</xref>]. Examples of circulating markers that have a value in addition to traditional cardiovascular risk factors include glycated hemoglobin (HbA1c) for glycemic control in diabetes, high-sensitivity troponin-I (hsTnnI) and C-reactive protein (hsCRP) for cardiovascular risk prediction, and N-terminal proB-type natriuretic peptide for heart failure (HF).</p><p id="Par6">A <index-term id="ITerm1"><term>Risk marker</term></index-term><italic>risk marker</italic> is not necessarily involved in the cause or set of causes of a cardiovascular disease (CVD), like a <index-term id="ITerm2"><term>Risk factor</term></index-term><italic>risk factor</italic>.</p><p id="Par7"><index-term id="ITerm3"><term>Marker</term></index-term>Markers of pathological conditions serve to: <list list-type="order"><list-item><p id="Par8">Detect and sort individuals at risk for CVDs</p></list-item><list-item><p id="Par9">Monitor disease progression</p></list-item><list-item><p id="Par10">Select therapy and assess treatment efficacy</p></list-item></list> Hence, features that determine the clinical utility of a marker include (1) the ease and cost of measurement, (2) its sensitivity and specificity, and (3) evidence for guiding management and improving patient outcome.</p><p id="Par11">A <italic>competing risk or cause</italic> precludes the occurrence of another risk or cause. For example, an adverse event is a competing cause with respect to death attributable to any cardiovascular event.</p><p id="Par12">The health of individuals can be defined, at least partly, by low levels of adverse markers of CVD. Cardiovascular health also relies on sets of risk factors that determine long-term survival and quality of life (Vol. 7, Chap. 2. Context of Cardiac Diseases). Clinical markers and factors, in particular, those related to inflammation, adverse remodeling, and thrombosis, assess the risk for CVD, which is refined using biological constants and imaging data.</p><p id="Par13">The risk factors comprise behavioral habits, such as smoking, physical inactivity, eating pattern (food quantity, meal composition and frequency, and use of processed, canned, and frozen food), which have an impact on the body weight, along with blood concentrations of cholesterol and glucose, and secondarily on arterial pressure [<xref ref-type="bibr" rid="CR12">224</xref>].</p><p id="Par14">In addition to clinical markers that are used for early detection, prevention of acute cardiovascular events targets modifiable risk factors, especially changes in habits (e.g., smoking cessation and supervised exercise) and therapy.</p><p id="Par15">Most CVD is indeed related to risk factors that can be controlled or treated, such as hypertension (systolic and diastolic arterial pressure greater than 18.6 kPa [SBP&gt; 140 mmHg] and 12.0 kPa [DBP&gt; 90 mmHg], respectively), dyslipoproteinemia, obesity, tobacco smoking, physical inactivity, and diabetes. The leading CVD risk factors comprise <index-term id="ITerm4"><term>Hypertension</term></index-term>hypertension (∼13% deaths), followed by tobacco use (∼9%), <index-term id="ITerm5"><term>Hyperglycemia</term></index-term>hyperglycemia (∼6%), lack of physical activity (∼6%), and <index-term id="ITerm6"><term>obesity</term></index-term>obesity (∼5%) [<xref ref-type="bibr" rid="CR1">30</xref>].</p><p id="Par16">Cardiovascular risk factors are similar for men and women. <list list-type="bullet"><list-item><p id="Par17">The <italic>total risk</italic> of a person can be estimated by summing the risk imparted by each of the major risk factors.</p></list-item><list-item><p id="Par18">The <italic>absolute risk</italic> is defined as the probability of developing CVD over a given time period.</p></list-item><list-item><p id="Par19">The <italic>relative risk</italic> is the ratio of the absolute risk of a given patient to that of a low-risk group, that is:</p><p id="Par20"><list list-type="bullet"><list-item><p id="Par21">Systolic and diastolic blood pressure lower than 130 and 80 mmHg</p></list-item><list-item><p id="Par22">Total cholesterol concentration ranging from 160 to 199 mg/dl</p></list-item><list-item><p id="Par23">Low-density lipoprotein (LDL)<sup>CS</sup> ranging from 100 to 129 mg/dl<xref ref-type="fn" rid="Fn2">2</xref> and a 1-mmol reduction in LDL<sup>CS</sup> in middle-aged individuals for 5 years being estimated to yield a 20% decrease in CVD risk [<xref ref-type="bibr" rid="CR8">121</xref>]</p></list-item><list-item><p id="Par25">High-density lipoproteins (HDLs)<sup>CS</sup> greater than or equal to 45 mg/dl for men or 55 mg/dl for women</p></list-item><list-item><p id="Par26">Nonsmoker</p></list-item><list-item><p id="Par27"><index-term id="ITerm7"><term>Diabetes</term></index-term>Absence of diabetes mellitus [<xref ref-type="bibr" rid="CR14">226</xref>]</p></list-item></list></p></list-item></list></p><p id="Par28">The major <italic>independent cardiovascular risk factors</italic> include cigarette smoking, physical inactivity, aging, hypertension, obesity, diabetes, and dyslipoproteinemia with hypercholesterolemia and elevated LDL<sup>CS</sup> concentration but decreased HDL<sup>CS</sup> concentration [<xref ref-type="bibr" rid="CR14">226</xref>].</p><p id="Par29">Behavioral risk factors are shared by <index-term id="ITerm8"><term>atherosclerosis</term></index-term>atherosclerosis complications (myocardial infarction [MI] and stroke) and diabetes, <index-term id="ITerm9"><term>Cancer</term></index-term>cancer, and respiratory disease [<xref ref-type="bibr" rid="CR1">30</xref>].</p><p id="Par30">Hypertension is a primary risk factor for stroke, especially long-term large variations of both systolic and diastolic arterial pressure observed in a series of medical examinations (either measured or recorded by ambulatory blood pressure monitoring), such as early morning (arousal) arterial pressure surges [<xref ref-type="bibr" rid="CR15">227</xref>]. Large variations in arterial pressure can result from abnormal baroreceptor functioning, excessive sympathetic activity, elevated sensitivity to the renin–angiotensin axis, transient high-salt diet, acute fluctuations in body weight, sleep disorders, and ingestion of nonsteroidal anti-inflammatory drugs [<xref ref-type="bibr" rid="CR16">228</xref>]. In addition, excessive arterial pressure reductions during treatment (SBP&lt; 16.0 kPa [&lt; 120 mmHg]; DBP&lt; 9.3 kPa [&lt; 70 mmHg) can increase the cardiovascular event rate.</p><p id="Par31">Coronary arterial calcium score is the most important predictor of adverse coronary events, whereas fasting glycemia and carotid ultrasonographic measures are salient predictors of stroke [<xref ref-type="bibr" rid="CR17">229</xref>].</p><p id="Par32"><italic>Predisposing risk factors</italic>, such as a family history of premature coronary artery disease, ethnic characteristics, and psychosocial factors (hostility, depression, and social isolation), worsen the independent risk factors.</p><p id="Par33"><italic>Conditional risk factors</italic> encompass hypertriglyceridemia; a high proportion of small, dense LDLs; elevated plasmatic concentrations of <index-term id="ITerm10"><term>Homocysteine</term></index-term>homocysteine and <index-term id="ITerm11"><term>Lipoprotein-A</term></index-term>lipoprotein-A; and the presence of prothrombotic factors (e.g., fibrinogen) and inflammatory markers (e.g., C-reactive protein [CRP]).</p><p id="Par34">Risk factors can be also categorized as modifiable and nonmodifiable. <italic>Modifiable risk factors</italic> include behavioral, metabolic, and other controllable risk factors. <list list-type="bullet"><list-item><p id="Par35">Behavioral risk factors include: <list list-type="order"><list-item><p id="Par36">Tobacco smoking</p></list-item><list-item><p id="Par37">Physical inactivity</p></list-item><list-item><p id="Par38">Unhealthy hypercaloric diet rich in lipids and salt</p></list-item><list-item><p id="Par39">Abuse of illicit substances (e.g., amphetamines, cocaine, ecstasy, and heroin), which is associated with an increased risk of ischemic and hemorrhagic <index-term id="ITerm12"><term>Stroke</term></index-term>strokes</p></list-item><list-item><p id="Par40">Harmful use of alcohol</p></list-item></list></p></list-item><list-item><p id="Par41">Metabolic risk factors comprise: <list list-type="order"><list-item><p id="Par42">Hypertension</p></list-item><list-item><p id="Par43">Hyperglycemia and diabetes</p></list-item><list-item><p id="Par44">Hyperlipidemia and hypercholesterolemia</p></list-item><list-item><p id="Par45">Obesity</p></list-item></list></p></list-item><list-item><p id="Par46">Other modifiable risk factors consist of: <list list-type="order"><list-item><p id="Par47">Poverty and low educational status</p></list-item><list-item><p id="Par48">Psychological factors (e.g., stressful life and depression)</p></list-item><list-item><p id="Par49"><index-term id="ITerm13"><term>Hyperhomocysteinemia</term></index-term>Hyperhomocysteinemia</p></list-item><list-item><p id="Par50">Air pollution, particularly in populated agglomerations, which, in general, do not meet the ambient air quality standards</p></list-item></list></p></list-item></list></p><p id="Par51">Some major CVD risk factors cannot be controlled: <list list-type="bullet"><list-item><p id="Par52"><index-term id="ITerm14"><term>Aging</term></index-term>Aging, with augmented frequency of CVD</p></list-item><list-item><p id="Par53">Gender, a man being at a greater risk for CVD than a premenopausal woman</p></list-item><list-item><p id="Par54">Family history, that is, inherited genetic predisposition</p></list-item><list-item><p id="Par55">Ethnicity<xref ref-type="fn" rid="Fn3">3</xref></p></list-item></list></p><p id="Par57">Additional risk factors encompass inflammatory disorders, infection, pollution, and cardiac atrial disorders, independently of atrial fibrillation [<xref ref-type="bibr" rid="CR18">230</xref>]. Almost all patients with atherosclerosis have lesions in many arterial territories and risk factors. Major risk factors for limb and visceral <index-term id="ITerm16"><term>Ischemia</term></index-term>ischemia (i.e., kidney, bowel, liver, or spleen), which are usually late-stage manifestations of atherosclerosis, include hypertension, smoking, and diabetes [<xref ref-type="bibr" rid="CR19">231</xref>].</p><p id="Par58">Because atherosclerosis is involved in both abdominal aortic aneurysms (AAAs) and coronary stenoses, these two types of vascular lesions share primary risk factors (i.e., age, smoking, high LDL<sup>CS</sup> or total cholesterol concentration, and male sex). On the other hand, the role of hypertension in AAA genesis is less well established than in chronic obstructive airways disease (CoAD), and White race is more relevant to AAA than to CoAD [<xref ref-type="bibr" rid="CR20">232</xref>].</p><p id="Par59">In a sample of 4232 men and women aged 60 years, the plasmatic concentration of <index-term id="ITerm17"><term>PCSK</term></index-term>PCSK9<xref ref-type="fn" rid="Fn4">4</xref> is associated with the future risk for CVD (e.g., myocardial infarction and ischemic stroke), even after adjustments for established CVD risk factors (LDL<sup>CS</sup>, HDL<sup>CS</sup>, LP<sub>A</sub>, TGs, hypertension, diabetes, smoking, <index-term id="ITerm18"><term>Overweight</term></index-term>overweight, obesity, and physical inactivity), and statin use [<xref ref-type="bibr" rid="CR22">234</xref>].</p><p id="Par61">The American Heart Association cardiovascular health score is inversely related to CVD. According to the Framingham Study (mean age 58 years, 55% women), circulation markers of subclinical CVD comprise [<xref ref-type="bibr" rid="CR23">235</xref>]: <list list-type="order"><list-item><p id="Par62">Structural and functional criteria: <list list-type="bullet"><list-item><p id="Par63">Reduced ankle–brachial index (ABI)</p></list-item><list-item><p id="Par64">Carotid intima–media thickness and possible <index-term id="ITerm19"><term>Stenosis</term></index-term>stenosis</p></list-item><list-item><p id="Par65"><index-term id="ITerm20"><term>Cardiac hypertrophy</term></index-term>Left ventricular hypertrophy</p></list-item><list-item><p id="Par66">Left ventricular systolic dysfunction</p></list-item><list-item><p id="Par67">Microalbuminuria</p></list-item></list></p></list-item><list-item><p id="Par68">In addition to lifestyle: <list list-type="bullet"><list-item><p id="Par69">Smoking status<xref ref-type="fn" rid="Fn5">5</xref></p></list-item><list-item><p id="Par71">Body mass index</p></list-item><list-item><p id="Par72">Physical activity</p></list-item><list-item><p id="Par73">Diet<xref ref-type="fn" rid="Fn6">6</xref></p></list-item></list></p></list-item><list-item><p id="Par75">In addition to mechanical parameter values:</p><p id="Par76"><list list-type="bullet"><list-item><p id="Par77">Blood pressure</p></list-item></list></p></list-item><list-item><p id="Par78">Blood concentrations of agents related to lipid and glucose metabolism, inflammation, and thrombosis (Tables <xref rid="Tab1" ref-type="table">2.1</xref>, <xref rid="Tab2" ref-type="table">2.2</xref>, <xref rid="Tab3" ref-type="table">2.3</xref>, and <xref rid="Tab4" ref-type="table">2.4</xref>):
<table-wrap id="Tab1"><label>Table 2.1</label><caption xml:lang="en"><p>Examples of risk factors related to lipid metabolism (Source: [<xref ref-type="bibr" rid="CR26">238</xref>]; <italic>lpPLA2</italic> lipoprotein-associated phospholipase-A2, <italic>PCSK</italic> proprotein convertase subtilisin/kexin, <sub>S</sub><italic>PLA2</italic> secretory PLA2)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Marker</p></th><th align="left"><p>Features</p></th></tr></thead><tbody><tr><td align="left"><p>Oxidized Phospholipids</p></td><td align="left"><p>Released by redox stress</p></td></tr><tr><td align="left"/><td align="left"><p>Binds to ApoB100+ lipoproteins</p></td></tr><tr><td align="left"/><td align="left"><p>Transport by lipoprotein-A</p></td></tr><tr><td align="left"><p>PCSK9</p></td><td align="left"><p>Released by statins</p></td></tr><tr><td align="left"/><td align="left"><p>Degrades hepatocytic LDLR</p></td></tr><tr><td align="left"><p>LpPLA2</p></td><td align="left"><p>Released by inflammation</p></td></tr><tr><td align="left"/><td align="left"><p>Depletion of oxPLs from lipoproteins</p></td></tr><tr><td align="left"><p><sub>S</sub>PLA2</p></td><td align="left"><p>Released by inflammation</p></td></tr><tr><td align="left"/><td align="left"><p>Processes LDLs into smaller and denser LDLs</p></td></tr></tbody></table><table-wrap-foot><p>In diabetic patients, cholesterol esters and sphingo-, phospho-, and glycerolipids are linked to an elevated risk for adverse cardiovascular events</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2.2</label><caption xml:lang="en"><p>Examples of risk markers related to inflammation and thrombosis (Source: [<xref ref-type="bibr" rid="CR26">238</xref>])</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Marker</p></th><th align="left"><p>Features</p></th></tr></thead><tbody><tr><td align="left"><p>Endothelial</p></td><td align="left"><p>Released in endothelial dysfunction</p></td></tr><tr><td align="left"><p>microvesicles</p></td><td align="left"><p>and vascular injury</p></td></tr><tr><td align="left"><p>Platelet-derived microvesicles</p></td><td align="left"><p>Deposition of inflammatory and clotting mediators</p></td></tr><tr><td align="left"/><td align="left"><p>Interaction with endotheliocyte</p></td></tr><tr><td align="left"><p>Red blood capsule (RBC)-derived</p></td><td align="left"><p>Released from entrapped RBCs in the thrombus</p></td></tr><tr><td align="left"><p>microvesicles</p></td><td align="left"><p>Increases thrombin generation</p></td></tr><tr><td align="left"><p>C-reactive protein</p></td><td align="left"><p>Produced by hepatocytes exposed to interleukin-6</p></td></tr><tr><td align="left"><p><sup>D</sup>Dimer</p></td><td align="left"><p>Marker of thrombosis</p></td></tr><tr><td align="left"/><td align="left"><p>Released by fibrin degradation</p></td></tr><tr><td align="left"><p>Interleukin-6</p></td><td align="left"><p>Primed production of fibrinogen, pentraxin-1,</p></td></tr><tr><td align="left"/><td align="left"><p>and other acute phase reactants</p></td></tr><tr><td align="left"><p>Myeloperoxidase</p></td><td align="left"><p>Stored in leukocyte granules</p></td></tr><tr><td align="left"/><td align="left"><p>Converts H<sub>2</sub>O<sub>2</sub> to other ROS</p></td></tr><tr><td align="left"/><td align="left"><p>that suppress nitric oxide and oxidize proteins</p></td></tr><tr><td align="left"><p>Monocyte</p></td><td align="left"><p>Mo1 (classical CD14+ + FCγ R3−)</p></td></tr><tr><td align="left"/><td align="left"><p>Mo2 (intermediate CD14+ + FCγ R3+ )</p></td></tr><tr><td align="left"/><td align="left"><p>Mo3 (alternative CD14+ FCγ R3+ )</p></td></tr><tr><td align="left"><p>Circulating</p></td><td align="left"><p>Involved in endothelial repair and</p></td></tr><tr><td align="left"><p>progenitor cells</p></td><td align="left"><p>angiogenesis</p></td></tr></tbody></table><table-wrap-foot><p>In inflammatory sites, neutrophils phagocytose necrotic regions and release their granule content, such as myeloperoxidase, which contributes to redox stress. The subsequent proliferative phase involves many different cellular populations, such as monocytes, fibroblasts, and endothelial progenitor cells. Three types of monocytes, classical (Mo1), intermediate (Mo2), and alternative monocytes (Mo3), are defined according to expression of the lipopolysaccharide coreceptors CD14 and FCγ R3</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 2.3</label><caption xml:lang="en"><p>Examples of risk markers related to injury, healing, and fibrosis (<bold>Part 1</bold>; Source: [<xref ref-type="bibr" rid="CR26">238</xref>]; <italic>DAMP</italic> damage-associated molecular pattern, <italic>GDF</italic> growth differentiation factor, <italic>IL</italic> interleukin, <italic>MMP</italic> matrix metallopeptidase)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Marker</p></th><th align="left"><p>Features</p></th></tr></thead><tbody><tr><td align="left"><p>Copeptin</p></td><td align="left"><p>Marker of vasopressin secretion</p></td></tr><tr><td align="left"/><td align="left"><p>Released by hemodynamic stress and inflammation</p></td></tr><tr><td align="left"><p>Cystatin-C</p></td><td align="left"><p>Marker of glomerular filtration rate</p></td></tr><tr><td align="left"><p>Galectin-3</p></td><td align="left"><p>Mediates aldosterone-induced fibrosis</p></td></tr><tr><td align="left"/><td align="left"><p>and transforming growth factorβ -primed myofibroblast activation</p></td></tr><tr><td align="left"/><td align="left"><p>Released by inflammation and fibrosis</p></td></tr><tr><td align="left"><p>GDF15</p></td><td align="left"><p>Acts via Tβ R1/2</p></td></tr><tr><td align="left"/><td align="left"><p>Reduces neutrophil recruitment</p></td></tr><tr><td align="left"/><td align="left"><p>Favors macrophage chemotaxis</p></td></tr><tr><td align="left"/><td align="left"><p>Released by inflammation and redox stress</p></td></tr><tr><td align="left"><p>IL1RL1<sup>S</sup></p></td><td align="left"><p>Upon IL33 binding, primes T<sub>H2</sub> cytokine response</p></td></tr><tr><td align="left"/><td align="left"><p>Blocks activation of IL1RL1</p></td></tr><tr><td align="left"/><td align="left"><p>Favors myocardial hypertrophy and fibrosis</p></td></tr><tr><td align="left"/><td align="left"><p>Released by cellular stresses</p></td></tr><tr><td align="left"><p>MMP9</p></td><td align="left"><p>Initiates transforming growth factorβ signaling</p></td></tr><tr><td align="left"/><td align="left"><p>Degrades matrix components, cytokines, and DAMPs</p></td></tr><tr><td align="left"/><td align="left"><p>Released by inflammation and redox stress</p></td></tr></tbody></table><table-wrap-foot><p>Copeptin is the C-terminal fragment of vasopressin (or antidiuretic hormone)</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table 2.4</label><caption xml:lang="en"><p>Examples of risk markers related to injury, healing, and fibrosis (<bold>Part 2</bold>; Source: [<xref ref-type="bibr" rid="CR26">238</xref>]; <sub>MR</sub><italic>proAdm</italic> midregional fragment of adrenomedullin precursor, <sub>MR</sub><italic>proANP</italic> midregional fragment of type-A natriuretic peptide [ANP] precursor, <sub>NT</sub><italic>proBNP</italic> inactive N-terminal fragment of BNP precursor, <italic>TGF</italic> transforming growth factor)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Marker</p></th><th align="left"><p>Features</p></th></tr></thead><tbody><tr><td align="left"><p><sub>MR</sub>proAdm</p></td><td align="left"><p>Triggers vasodilation</p></td></tr><tr><td align="left"/><td align="left"><p>Released by myocardial stretch</p></td></tr><tr><td align="left"><p><sub>MR</sub>proANP</p></td><td align="left"><p>Inhibits the renin–angiotensin–aldosterone axis</p></td></tr><tr><td align="left"/><td align="left"><p>Provokes diuresis and natriuresis</p></td></tr><tr><td align="left"/><td align="left"><p>Released by myocardial stretch</p></td></tr><tr><td align="left"><p><sub>NT</sub>proBNP</p></td><td align="left"><p>Inhibits the renin–angiotensin–aldosterone axis</p></td></tr><tr><td align="left"/><td align="left"><p>and the sympathetic nervous system</p></td></tr><tr><td align="left"/><td align="left"><p>Induces vasodilation</p></td></tr><tr><td align="left"/><td align="left"><p>Provokes diuresis and natriuresis</p></td></tr><tr><td align="left"/><td align="left"><p>Released by myocardial stretch</p></td></tr><tr><td align="left"><p>TGFβ</p></td><td align="left"><p>Suppresses inflammation</p></td></tr><tr><td align="left"/><td align="left"><p>Promotes repair, but also fibrosis</p></td></tr><tr><td align="left"/><td align="left"><p>Released by inflammation</p></td></tr><tr><td align="left"><p>Troponin-I/T</p></td><td align="left"><p>Released by proteolysis upon CMC death</p></td></tr><tr><td align="left"/><td align="left"><p>Released by myocardial infarction</p></td></tr></tbody></table></table-wrap><list list-type="bullet"><list-item><p id="Par79">Cholesterol, in particular, LDP–cholesterol (LDL<sup>CS</sup>) and its regulator <index-term id="ITerm21"><term>PCSK</term></index-term>proprotein convertase subtilisin/kexin PCSK9
</p></list-item><list-item><p id="Par80">Glucose</p></list-item><list-item><p id="Par81"><index-term id="ITerm22"><term>Natriuretic peptide</term></index-term>Natriuretic peptides (Table <xref rid="Tab5" ref-type="table">2.5</xref>) in addition to N-terminal fragments of A- (atrial; ANP) and B-type (brain; BNP) natriuretic peptide precursors (<sub>NT</sub>proANP and <sub>NT</sub>proBNP)<xref ref-type="fn" rid="Fn7">7</xref><table-wrap id="Tab5"><label>Table 2.5</label><caption xml:lang="en"><p>Several cardiokines can serve as CVD markers (Source: [<xref ref-type="bibr" rid="CR4">71</xref>])</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Cardiokine</p></th><th align="left"><p>Expression</p></th></tr></thead><tbody><tr><td align="left"><p>ANP</p></td><td align="left"><p>Highly expressed in hypertensive rats</p></td></tr><tr><td align="left"><p>BNP</p></td><td align="left"><p>Weakly expressed in fasting mice</p></td></tr><tr><td align="left"><p>GDF8</p></td><td align="left"><p>Highly expressed when skeletal muscle mass rises</p></td></tr><tr><td align="left"><p>GDF15</p></td><td align="left"><p>Highly expressed in patients with cardiac hypertrophy</p></td></tr><tr><td align="left"/><td align="left"><p>and chronic heart failure</p></td></tr><tr><td align="left"><p>CTRP9</p></td><td align="left"><p>Weakly expressed in diabetic patients and after</p></td></tr><tr><td align="left"/><td align="left"><p>acute myocardial infarction</p></td></tr></tbody></table><table-wrap-foot><p>Cardiokines are proteins secreted from the heart</p></table-wrap-foot></table-wrap></p></list-item><list-item><p id="Par83">Plasminogen activator inhibitor-1</p></list-item><list-item><p id="Par84">Aldosterone</p></list-item><list-item><p id="Par85">C-reactive protein (or pentraxin-1)</p></list-item><list-item><p id="Par86"><sup>D</sup>Dimer<xref ref-type="fn" rid="Fn8">8</xref></p></list-item><list-item><p id="Par88">Fibrinogen</p></list-item><list-item><p id="Par89"><index-term id="ITerm26"><term>Homocysteine</term></index-term>Homocysteine</p></list-item><list-item><p id="Par90">Troponins<xref ref-type="fn" rid="Fn9">9</xref></p></list-item><list-item><p id="Par92">Growth differentiation factor (GDF15)</p></list-item></list></p></list-item></list> Hence, an overlap exists between risk factors and markers.</p><p id="Par93">Lipoproteins (i.e., water-soluble protein–lipid complexes) mediate the transport of cholesterol and lipids in blood. Linkage of cholesterol to lipoproteins (HDLs and LDLs) enables its back and forth motion in blood between the liver and other organs. Relatively high concentration of cholesterol tethered to ApoB-containing (ApoB+ ) LDLs is an <index-term id="ITerm28"><term>atherosclerosis</term></index-term>atherosclerosis risk marker. Cholesterol ester links to <index-term id="ITerm29"><term>ApoA1</term></index-term> ApoA1+ HDLs. Therefore, concentrations of low- (LDL<sup>CS</sup>) and HDL –cholesterol (HDL<sup>CS</sup>) and TG (or triacylglycerol [TAG]) are measured to identify patients with a high risk for CVD.</p><p id="Par94">The measure non-HDL<sup>CS</sup> combines the cholesterol content of LDLs, lipoprotein-A (LP<sub>A</sub>), an LDL-like particle linked to ApoA, and TG-rich lipoproteins (remnants, i.e., intermediate-density lipoproteins (IDLs), VLDLs, and chylomicron remnants), TGs being mainly carried by remnants. In treated patients, non-HDL<sup>CS</sup> level is more closely associated with coronary atherosclerosis progression than LDL<sup>CS</sup> concentration [<xref ref-type="bibr" rid="CR27">239</xref>].</p><p id="Par95">Values of certain markers differ significantly according to gender, such as markers of lipid metabolism, adiposity, inflammation, endothelial and renal dysfunction, and cardiac stress [<xref ref-type="bibr" rid="CR28">240</xref>]. <list list-type="bullet"><list-item><p id="Par96">Women have higher concentrations of HDL and HDL<sup>CS</sup>, leptin,<sup>D</sup>dimer, homoarginine, and <sup>NT</sup>proBNP.</p></list-item><list-item><p id="Par97">Women have lower concentrations of LDL<sup>CS</sup>, adiponectin, the chemokine CCL2, troponin-T (TNNT), cystatin-C, symmetrical and asymmetrical dimethylarginine, lipoprotein-associated phospholipase-A2, and soluble endothelial cell adhesion molecules.</p></list-item></list></p><p id="Par98">The benefit of drugs administered in addition to a recommended healthy lifestyle generally exceeds the therapeutic risk. However, cholesterol-lowering therapy in patients with LDL<sup>CS</sup> concentrations below a certain threshold is unfounded. A treatment threshold is aimed at avoiding treating patients at a low risk for atherosclerosis-associated complications. The LDL<sup>CS</sup> concentration is monitored to adjust therapy according to its effects.</p><p id="Par99"><index-term id="ITerm30"><term>Marker</term></index-term>Measurements of alternative cardiovascular markers (e.g., coronary artery calcium) in addition to concentrations of LDL<sup>CS</sup> and <index-term id="ITerm31"><term>CRP (Ptx1)</term></index-term>high-sensitivity C-reactive protein (hsCRP), PWV index (e.g., ABI), etc., used in therapy decisions (e.g., statins), provide additional information when a treatment decision is uncertain.<xref ref-type="fn" rid="Fn10">10</xref> These markers are aimed at identifying individuals a priori defined in the lower risk population who nevertheless can experience an adverse event (MI and stroke) if left untreated, as, in fact, they can belong to a higher risk population when these alternative markers are incorporated in scoring.</p><p id="Par101">Dying parenchymal cells and leukocytes release small DNA fragments into the bloodstream. Blood concentrations of fragmented DNA increase in CVD, among other maladies. Because each cell type has a unique DNA methylation pattern, a source of plasmatic DNA can be identified using cell-specific DNA methylation markers [<xref ref-type="bibr" rid="CR29">241</xref>].</p><p id="Par102">Single-stranded DNA aptamers are oligonucleotides that contain approximately 50 bases. They can bind proteins with high specificity and affinity and can be used to identify early CVD markers.</p><p id="Par103"><index-term id="ITerm32"><term>Dickkopf</term></index-term>Dickkopf-related protein Dkk4, a Wnt inhibitor, and <index-term id="ITerm33"><term>Cryptic</term></index-term>cryptic, a transforming growth factor (TGF) inhibitor, are relevant targets in the context of myocardial injury [<xref ref-type="bibr" rid="CR30">242</xref>].</p><p id="Par104">Dietary habits are modifiable risk factors. <index-term id="ITerm34"><term>Gut flora</term></index-term>Intestinal microbiota and bacterial metabolites are connected to dietary composition. <index-term id="ITerm35"><term>TMAO</term></index-term>Gut flora-derived metabolite trimethylamine <sup>N</sup>oxide (TMAO) is a small organic compound generated from betaine, carnitine, and choline [<xref ref-type="bibr" rid="CR31">243</xref>].<xref ref-type="fn" rid="Fn11">11</xref> It accumulates in fishes, especially elasmobranchs,<xref ref-type="fn" rid="Fn12">12</xref> and protects against the protein-destabilizing effect<xref ref-type="fn" rid="Fn13">13</xref> and ligand-binding inhibition of urea at high concentrations in addition to adverse effects of temperature, salinity, and hydrostatic pressure. Its blood concentration, which depends on diet composition in addition to the activity of gut flora and liver FMO, increases after ingesting trimethylammonium-containing nutrients (<sup>L</sup>carnitine and phosphatidylcholine-rich food), such as red meat, eggs, and fish [<xref ref-type="bibr" rid="CR32">244</xref>]. Trimethylamine oxide is a risk factor for major adverse cardio- and cerebrovascular events (ACaVCeVE), especially in patients with chronic kidney disease. Plasmatic TMAO concentration correlates positively with ACaVCeVE and mortality [<xref ref-type="bibr" rid="CR32">244</xref>]. Trimethylamine oxide, which impairs cholesterol and bile acid metabolism and the activity of sterol transporters in the liver and intestine, activates inflammation, and markedly reduces reverse cholesterol transport, may favor the formation of macrophage scavenger receptors and foam cells in the arterial wall [<xref ref-type="bibr" rid="CR31">243</xref>, <xref ref-type="bibr" rid="CR32">244</xref>]. In mice, the inhibition of hepatic FMO3, which is controlled by the bile acid-activated <index-term id="ITerm36"><term>FXR (NR1h4/5)</term></index-term>farnesoid X receptor (FXR), and microbial TMAO production counters atherogenesis.</p><p id="Par108">Current clinical risk stratification methods (e.g., Framingham score) do not suffice to predict CVD. Many events happen in patients identified to be at a low or moderate risk; a large fraction of patients at risk are identified by a major event. Therefore, better risk stratification tools are needed.</p><sec id="Sec1"><title>Environmental Stressors</title><p id="Par109">Environmental stressors, such as air pollution and noise, are cardiovascular risk factors. In particular, Asian windblown sand dust (Asian dust [kosa]) originating in the deserts of China and East Asia that mixes with air pollutants during atmospheric transport and contains microbes correlates not only with respiratory diseases but also with acute <index-term id="ITerm37"><term>Myocardial infarction</term></index-term>MI at least in men older than 75 years, living in southwestern Japan and having hypertension, diabetes mellitus, and, above all, chronic kidney disease [<xref ref-type="bibr" rid="CR33">245</xref>].</p><sec id="Sec2"><title>Air Pollution</title><p id="Par110"><index-term id="ITerm38"><term>Air pollution</term></index-term>Air pollution is a major environmental risk factor. Air pollutants include <italic>particulate matter</italic>, <italic>gaseous pollutants</italic>, and <italic>volatile organic compounds</italic> (VOCs).</p><p id="Par111">Particulate matter is classified into three categories according to the size of airborne microparticles: <list list-type="order"><list-item><p id="Par112">Coarse (2.5≤aerodynamic caliber &lt; 10 μm [10<sup>−5</sup> m]; PM<sub>10</sub>)</p></list-item><list-item><p id="Par113">Fine (0.1≤aerodynamic caliber &lt; 2.5 μm; PM<sub>2.5</sub>)</p></list-item><list-item><p id="Par114">Ultrafine particles (aerodynamic caliber &lt; 0.1 μm [10<sup>−7</sup> m]; PM<sub>0.1</sub>), also called nanoparticles</p></list-item></list></p><p id="Par115">Particles are represented by concentrations of PM<sub>2.5</sub> and PM<sub>10</sub> particles, the latter comprising ultrafine, fine, and coarse particles.<xref ref-type="fn" rid="Fn14">14</xref> Nanoparticles suspended in air (nanoaerosol; size <inline-formula id="IEq1"><alternatives><mml:math id="IEq1_Math"><mml:mi fontfamily="cmsy10" mathvariant="script">O</mml:mi></mml:math><tex-math id="IEq1_TeX">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}
$${\mathcal O}$$
\end{document}</tex-math><inline-graphic specific-use="web" mime-subtype="GIF" xlink:href="460479_1_En_2_Chapter_IEq1.gif"/></alternatives></inline-formula>[10<sup>−9</sup> m]) contribute to indoor air pollution exposure.</p><p id="Par117">Among PM, inhalable particles of aerodynamic caliber less than 10 μm can travel deep into the bronchial tree inside lungs. Air pollution facilitates and exacerbates respiratory infections.</p><p id="Par118">In fact, environmental toxins cause numerous acute and chronic illnesses, particularly cardiovascular maladies, especially in individuals with diabetes during episodes of high air pollution exposure [<xref ref-type="bibr" rid="CR35">247</xref>]. Exposure to air polluted with fine PM (PM<sub>2.5</sub>) augments the risk for cardiovascular morbidity and mortality via <index-term id="ITerm39"><term>Endothelial dysfunction</term></index-term> endothelial dysfunction and systemic <index-term id="ITerm40"><term>Inflammation</term></index-term>inflammation. Air pollution exacerbates existing maladies and can be involved in the development of CVDs (atherosclerosis, cardiac arrhythmias, HF, <index-term id="ITerm41"><term>Stroke</term></index-term>stroke, and <index-term id="ITerm42"><term>Venous thromboembolism</term></index-term>venous thromboembolism) [<xref ref-type="bibr" rid="CR36">248</xref>]. In mice, concentrated ambient PM<sub>2.5</sub> potentiates atherosclerotic plaque vulnerability.</p><p id="Par119">In Canada, Europe, and the USA, a 10 μg/m<sup>3</sup> increase in PM<sub>10</sub> is associated with a 0.2–0.6% increase in all-cause mortality [<xref ref-type="bibr" rid="CR36">248</xref>]. In Europe, a 10 μg/m<sup>3</sup> elevation of NO<sub>2</sub> causes a 0.4% augmentation in the cardiovascular mortality rate. In China, outdoor air pollution ranks fourth among preventable causes of diseases, current PM<sub>2.5</sub> concentrations (61 μg/m<sup>3</sup>) having increased from those during the Beijing Olympic games (55 μg/m<sup>3</sup>), which were already much higher than World Health Organization standard (10 μg/m<sup>3</sup>) [<xref ref-type="bibr" rid="CR37">249</xref>].</p><p id="Par120">According to the World Health Organization, outdoor air pollution in both cities and rural areas in 2012 is estimated to cause 3.7 million premature deaths worldwide per year, 88% of those premature deaths occurring in low- and middle-income countries [<xref ref-type="bibr" rid="CR38">250</xref>]. Reducing outdoor emissions from household coal and biomass energy systems, agricultural waste incineration, forest fires, and certain agroforestry activities (e.g., charcoal production) may reduce rural air pollution sources in developing regions.</p><p id="Par121">According to the Global Burden of Disease study in 2010, air pollution may be responsible for about 6% of all-cause and all-age deaths, in addition to development and exacerbation of respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease, and pulmonary cancers) [<xref ref-type="bibr" rid="CR36">248</xref>].</p><p id="Par122">Air pollution ranks as the ninth contributor among modifiable disease risk factors, that is, above low physical activity, high-sodium diet, high cholesterol, and drug use [<xref ref-type="bibr" rid="CR36">248</xref>].</p><p id="Par123">Acute exposure to environmental toxicants can lead to angina, arrhythmia, MI, and HF. Repeated exposure to air pollution can cause <index-term id="ITerm43"><term>Inflammation</term></index-term>vascular inflammation and <index-term id="ITerm44"><term>Redox stress</term></index-term>redox stress, thereby promoting <index-term id="ITerm45"><term>atherosclerosis</term></index-term>atherosclerotic plaque expansion and rupture [<xref ref-type="bibr" rid="CR34">246</xref>]. Long-term exposure increases the risk for CoAD-caused death.</p><p id="Par124">Inhalation of combustion-derived nanoparticles that incorporate soluble reactive organic compounds, polycyclic aromatic hydrocarbons, and oxidized transition metals causes pulmonary inflammation with secondary or direct cardiovascular effects after passage from airways and pulmonary alveoli into the blood circulation.</p><p id="Par125">Combustion-derived nanoparticulate matter induces cardiovascular effects via classical and alternative pathways (Table <xref rid="Tab6" ref-type="table">2.6</xref>).
<table-wrap id="Tab6"><label>Table 2.6</label><caption xml:lang="en"><p>Direct and indirect vascular effects of combustion-derived nanoparticulate matter (Source: [<xref ref-type="bibr" rid="CR34">246</xref>])</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Process</p></th><th align="left"><p>Mechanism</p></th></tr></thead><tbody><tr><td align="left"><p>Inflammation and redox stress</p></td><td align="left"><p>Cytokine release</p></td></tr><tr><td align="left"/><td align="left"><p>Release of bone marrow-derived neutrophils</p></td></tr><tr><td align="left"/><td align="left"><p>and monocytes</p></td></tr><tr><td align="left"/><td align="left"><p>Increased formation of ROS</p></td></tr><tr><td align="left"><p>Thrombosis</p></td><td align="left"><p>Elevation of fibrinogen concentration</p></td></tr><tr><td align="left"/><td align="left"><p>Promotion of platelet activation and aggregation</p></td></tr><tr><td align="left"/><td align="left"><p>Reduction in tissue plasminogen activator level</p></td></tr><tr><td align="left"><p>Hypertension</p></td><td align="left"><p>Vasoconstriction</p></td></tr><tr><td align="left"><p>Atheroma destabilization</p></td><td align="left"><p>Inflammation induced-plaque progression and rupture</p></td></tr><tr><td align="left"><p>Heart rhythm</p></td><td align="left"><p>Stimulation of irritant receptors in the airways</p></td></tr><tr><td align="left"/><td align="left"><p>and reflex activation of the autonomous nervous system</p></td></tr></tbody></table></table-wrap><list list-type="bullet"><list-item><p id="Par126">The <italic>classical pathway</italic> is defined by indirect effects that result from pulmonary <index-term id="ITerm46"><term>Inflammation</term></index-term>inflammation caused by inhaled particulate matter. Lung inflammation provokes heightened plasma concentrations of cytokines, such as <index-term id="ITerm47"><term>Interleukin</term></index-term> IL1β and IL6 and <index-term id="ITerm48"><term>CSF2</term></index-term>colony-stimulating factor CSF2, in addition to the release of bone marrow-derived <index-term id="ITerm49"><term>Neutrophil</term></index-term>neutrophils and <index-term id="ITerm50"><term>Monocyte</term></index-term>monocytes into blood circulation [<xref ref-type="bibr" rid="CR34">246</xref>].</p></list-item><list-item><p id="Par127">The <italic>alternative pathway</italic> is related to the passage from the lung into the blood circulation of inhaled fine PM and nanoparticles, directly across the alveolocapillary membrane or after ingestion by alveolar macrophages. Particles can cross the lung–blood barrier according to particle size, charge, and chemical composition. Once in the blood, particles can interact with the vascular endothelium and provoke endothelium dysfunction, <index-term id="ITerm51"><term>Redox stress</term></index-term>redox stress, and <index-term id="ITerm52"><term>Inflammation</term></index-term>inflammation.</p></list-item></list></p><p id="Par128">Short-duration exposure (hours to weeks) to particulate matter PM<sub>2.5</sub> can provoke the occurrence of an event (fatal or not) related to a cardiovascular malady [<xref ref-type="bibr" rid="CR35">247</xref>].</p><p id="Par129">In young, healthy, nonsmoking adults, episodic exposures to elevated PM<sub>2.5</sub> levels raise the <index-term id="ITerm53"><term>EC</term></index-term>endotheliocyte (EC) apoptosis rate as well as densities of circulating <index-term id="ITerm54"><term>Monocyte</term></index-term>monocytes and <index-term id="ITerm55"><term>T lymphocyte</term></index-term>T lymphocytes (but not B lymphocytes) and concentrations of Anx5+ Itgα2b− pecam1+ endothelial <index-term id="ITerm56"><term>Microvesicle</term></index-term>microvesicles containing arterial-, venous-, and lung-specific <index-term id="ITerm57"><term>Marker</term></index-term>markers (but not selectin+ microvesicles)<xref ref-type="fn" rid="Fn15">15</xref> and cause an antiangiogenic profile [<xref ref-type="bibr" rid="CR39">251</xref>]. These microparticles carry metallopeptidases, which can damage endothelium, erode eventual <index-term id="ITerm58"><term>atherosclerosis</term></index-term>atherosclerotic plaques, and cleave soluble adhesion molecules. Elevated blood concentrations of endothelium-derived microvesicles shed from activated and apoptotic cells demonstrate endothelial damage, even in young, healthy nonsmokers.</p><p id="Par131">On the one hand, blood concentrations of proangiogenic factors (EGF, PDGF, VEGF, soluble TNFSF5, CCL5, and CXCL1) decrease. Exposure to PM<sub>2.5</sub> provokes loss of trophic and angiogenic factors, thereby increasing the apoptosis rate of ECs and endothelial injury [<xref ref-type="bibr" rid="CR39">251</xref>]. On the other hand, blood concentrations of antiangiogenic factors (TNFSF1 and CXCL10) and other proinflammatory cytokines (IL1β and IL6) and chemokines (CCL2 to CCL4 and CXCL8), in addition to soluble endothelial adhesion molecules (icam1<sup>S</sup> and vcam1<sup>S</sup>) rise. Proinflammatory cytokines and chemokines (e.g., TNFSF1, IL6, and CXCL8) can be released by alveolar <index-term id="ITerm59"><term>Macrophage</term></index-term>macrophages or bronchial epitheliocytes exposed to airborne particles. Both TNFSF1 and CXCL10 are secreted by activated <index-term id="ITerm60"><term>T lymphocyte</term></index-term>T lymphocytes, <index-term id="ITerm61"><term>Monocyte</term></index-term>monocytes, and <index-term id="ITerm62"><term>EC</term></index-term>ECs. The mild inflammatory state is characterized by augmented densities of circulating CD4+ CD8+ T lymphocytes, <index-term id="ITerm63"><term>Monocyte</term></index-term>CD14+ monocytes, and <index-term id="ITerm64"><term>NK cell</term></index-term>Fcγ R3+ natural killer cells, but not CD19+ cells. Moreover, upon PM<sub>2.5</sub> exposure, <index-term id="ITerm65"><term>Platelet</term></index-term>platelet–monocyte aggregates increase, establishing a procoagulation state [<xref ref-type="bibr" rid="CR39">251</xref>]. Systemic inflammation due to PM<sub>2.5</sub> inhalation can thus favor athero- and <index-term id="ITerm66"><term>Thrombosis</term></index-term>thrombogenesis.</p><p id="Par132">The PM<sub>2.5</sub>-induced pattern of released cytokines, chemokines, and endothelial microparticles differs from that resulting from inhalation of other toxins, such as tobacco smoke. Although smoking is also associated with EC apoptosis and a decrease in plasmatic concentrations of <index-term id="ITerm67"><term>EGF</term></index-term>EGF, <index-term id="ITerm68"><term>TNFSF</term></index-term>TNFSF5, and CXCL1, it is generally characterized by elevated blood concentrations of <index-term id="ITerm69"><term>VEGF</term></index-term>VEGF, owing to the stimulatory effect of nicotine and <index-term id="ITerm70"><term>Hypoxia</term></index-term>hypoxia induced by CO in cigarette smoke and not by augmented plasmatic concentrations of TNFSF1 and CCL2 [<xref ref-type="bibr" rid="CR39">251</xref>].</p><p id="Par133">In long-term PM<sub>2.5</sub> exposure, an approximately 10% increase in all-cause mortality is observed per 10-μg/m<sup>3</sup> average elevation. Longer-term exposure (years) reduces life expectancy (months or a few years). Long-term exposure to air pollution correlates with cardiovascular mortality. Air pollution is linked to cardiovascular morbidity via <index-term id="ITerm71"><term>Redox stress</term></index-term>redox stress, <index-term id="ITerm72"><term>Inflammation</term></index-term>inflammation, <index-term id="ITerm73"><term>Endothelial dysfunction</term></index-term>endothelial dysfunction, <index-term id="ITerm74"><term>Thrombosis</term></index-term>platelet hyperreactivity, altered fibrinolysis, and hence thrombogenicity and arrhythmogenesis.</p><p id="Par134">Exposure to ultrafine carbon particles alters cardiac frequency and its variability (i.e., perturbation of the autonomic function in addition to that caused by diabetes) in <index-term id="ITerm75"><term>T2DM</term></index-term>type 2 diabetes mellitus (T2DM) patients [<xref ref-type="bibr" rid="CR40">252</xref>]. These disturbances persist many hours after the end of exposure.</p><p id="Par135">Recently emitted ultrafine particles and aged fine PM are both associated with changes in cardiac function in T2DM patients and individuals with impaired glucose tolerance in urban zones [<xref ref-type="bibr" rid="CR41">253</xref>].</p><p id="Par136">Environmental risk factors include indoor and outdoor air pollution. Most of the pollutant exposure commonly occurs indoors (i.e., at home, school, working place, and other community sites), as, along with indoor pollutants, outdoor air pollutants infiltrate buildings.</p><p id="Par137">In addition to outdoor air pollution, indoor smoke resulting from cooking and home heating with biomass fuels and coal is a health risk for about 3 billion people [<xref ref-type="bibr" rid="CR38">250</xref>].</p><p id="Par138">Air pollution in accommodation, particularly due to the use of solid fuels, was a leading risk factor of altered health in sub-Saharan Africa and southern Asia in 2010 [<xref ref-type="bibr" rid="CR42">254</xref>]. Mitigation of air pollution can reduce the burden of CVDs [<xref ref-type="bibr" rid="CR38">250</xref>].</p><p id="Par139">Approximately 80% of outdoor air pollution-related premature deaths are caused by cardiac ischemia and stroke, 14% by chronic obstructive pulmonary disease or acute lower respiratory infections, and 6% by pulmonary cancer.<xref ref-type="fn" rid="Fn16">16</xref></p><p id="Par141">Temporal variation of daily average air pollution concentrations is more related to weather (i.e., wind direction and speed and atmospheric stability) that affects pollutant dispersion than the intensity of pollutant sources [<xref ref-type="bibr" rid="CR36">248</xref>]. In addition, temperature and sunlight affect chemical reaction rates (e.g., ozone formation rate).</p><sec id="Sec3"><title>Airborne Pollutants</title><p id="Par142">Air components encompass airborne <italic>particulate matter</italic> (or toxic aerosol; i.e., particles from multiple sources and various sizes and compositions; Vol. 6, Chap. 4. Physiology of Ventilation) and <italic>gaseous pollutants</italic> (ozone [O<sub>3</sub>], nitrogen dioxide [NO<sub>2</sub>], carbon monoxide [CO], sulfur dioxide [SO<sub>2</sub>], and volatile organic compounds [e.g., benzene]).</p><p id="Par143">Environmental toxins exist in air, water, and in the food supply. They include volatile organic compounds, polychlorinated biphenyls, phthalates, pesticides, dioxins, asbestos, heavy metals (aluminum, arsenic, cadmium, lead, and mercury), chlorine, and mycotoxins, among others. Although many phytochemicals are normally toxins at high doses, their consumption at relatively low doses activates an adaptive cellular stress response that protects cells.</p><p id="Par144">Among pollutants, transition metals (e.g., copper, iron, nickel, vanadium, and zinc), organic compounds, semiquinones, and endotoxin (e.g., lipopolysaccharide) are relevant to cardiovascular pathological conditions, as these PM-related components are able to prime <index-term id="ITerm76"><term>Redox stress</term></index-term>redox stress and <index-term id="ITerm77"><term>Inflammation</term></index-term>inflammation. Certain features of ultrafine particles (e.g., high surface area, particle number, metal and organic carbon content) may augment cardiovascular risk after short-term exposure [<xref ref-type="bibr" rid="CR35">247</xref>].</p><p id="Par145">Semivolatile organic compounds found in both the gas and particle phases constitute with volatile organic compounds (VOCs) a large category of pollutants (e.g., benzene, (1,3)-butadiene, toluene, xylene, and polycyclic aromatic hydrocarbons) [<xref ref-type="bibr" rid="CR35">247</xref>]. They emanate from both combustion and fugitive emissions and with secondary formation. Volatile organic compounds can be converted into less or more toxic substances. They can be oxidized in the atmosphere, becoming semivolatile organic compounds, and then contribute to the composition of PM<sub>2.5</sub>.</p><p id="Par146">Concentrations of PM<sub>10</sub> and PM<sub>2.5</sub> are typically measured in mass per volume of air (μg/m<sup>3</sup>), whereas ultrafine particles are often measured by their number per cubic centimeter (Table <xref rid="Tab7" ref-type="table">2.7</xref>) [<xref ref-type="bibr" rid="CR35">247</xref>].
<table-wrap id="Tab7"><label>Table 2.7</label><caption xml:lang="en"><p>Typical concentration peaks of various types of ambient air pollutants (Source: [<xref ref-type="bibr" rid="CR35">247</xref>] <italic>ppb</italic> parts per billion, <italic>ppm</italic> parts per million)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><p>Typical peak</p></th></tr><tr><th align="left"><p>Pollutant</p></th><th align="left"><p>(average hourly concentration)</p></th></tr></thead><tbody><tr><td align="left"><p>O<sub>3</sub></p></td><td align="left"><p>200 ppb</p></td></tr><tr><td align="left"><p>NO<sub>2</sub></p></td><td align="left"><p>200 ppb</p></td></tr><tr><td align="left"><p>NO</p></td><td align="left"><p>200 ppb</p></td></tr><tr><td align="left"><p>SO<sub>2</sub></p></td><td align="left"><p>150 ppb</p></td></tr><tr><td align="left"><p>CO</p></td><td align="left"><p>20 ppm</p></td></tr><tr><td align="left"><p>NH<sub>3</sub></p></td><td align="left"><p>100 ppb</p></td></tr><tr><td align="left"><p>HNO<sub>3</sub></p></td><td align="left"><p>10 ppb</p></td></tr><tr><td align="left"><p>Methane</p></td><td align="left"><p>5 ppm</p></td></tr><tr><td align="left"><p>Formaldehyde</p></td><td align="left"><p>40 ppb</p></td></tr><tr><td align="left"><p>Acetaldehyde</p></td><td align="left"><p>20 ppb</p></td></tr><tr><td align="left"/><td align="left"><p>(24-h average concentration)</p></td></tr><tr><td align="left"><p>PM<sub>10</sub></p></td><td align="left"><p>300 μg/m<sup>3</sup></p></td></tr><tr><td align="left"><p>PM<sub>2.5</sub></p></td><td align="left"><p>100 μg/m<sup>3</sup></p></td></tr><tr><td align="left"><p>PM<sub>0.1</sub></p></td><td align="left"><p>100,000/cm<sup>3</sup></p></td></tr><tr><td align="left"><p>Nonmethane hydrocarbons (volatile organic carbons)</p></td><td align="left"><p>250 μg/m<sup>3</sup></p></td></tr><tr><td align="left"><p>Propane</p></td><td align="left"><p>500 μg/m<sup>3</sup></p></td></tr><tr><td align="left"><p>Benzene</p></td><td align="left"><p>100 μg/m<sup>3</sup></p></td></tr><tr><td align="left"><p>(1,3)-Butadiene</p></td><td align="left"><p>10 μg/m<sup>3</sup></p></td></tr><tr><td align="left"><p>Sulfate</p></td><td align="left"><p>30 μg/m<sup>3</sup></p></td></tr><tr><td align="left"><p>Nitrate</p></td><td align="left"><p>20 μg/m<sup>3</sup></p></td></tr><tr><td align="left"><p>Organic carbon</p></td><td align="left"><p>30 μg/m<sup>3</sup></p></td></tr><tr><td align="left"><p>Elemental carbon</p></td><td align="left"><p>10 μg/m<sup>3</sup></p></td></tr><tr><td align="left"><p>Polycyclic</p></td><td align="left"><p>200 ng/m<sup>3</sup></p></td></tr><tr><td align="left"><p>aromatic hydrocarbon</p></td><td align="left"/></tr></tbody></table><table-wrap-foot><p>More than 98% of the air pollutant mass in urban zones is composed of gases or vapor-phase compounds that have independent, synergistic, or antagonistic effects with each other and with PM. Nitrogen oxides, carbon monoxide, sulfur dioxide, PM<sub>2.5</sub>, and carbon dioxide originate mainly from the combustion of fuel or other high-temperature industrial processes. Ammonia, methane, pesticides, reduced sulfur compounds, resuspended dust, and natural coarse particles derive chiefly from noncombustion surface or fugitive releases that arise from human (e.g., agriculture) and natural (e.g., erosion) activities. Secondary pollutants emanate primarily from chemical reactions in the atmosphere among directly emitted pollutants (e.g., ozone; hydroxyl radical; peroxyacetyl nitrate; nitric, formic, and acetic acid; formaldehyde; acrolein; PM-associated sulfate, nitrate, and ammonium; many of the organic compounds in PM<sub>2.5</sub>; inorganic and organic acids; and volatile organic carbons)</p></table-wrap-foot></table-wrap></p><p id="Par147">Aerosol, a suspension of liquid or solid particles of organic and inorganic substances in air, is thus constituted of particles that have various sizes, shapes, chemical and physical properties, and chemical components. Major components include sulfate, nitrate, ammonia, sodium chloride, black carbon, mineral dust, and water.</p><p id="Par148">Environmental tobacco smoke, organic compounds (polycyclic aromatic hydrocarbons, volatile organic substances, formaldehyde, naphthalene), carbon monoxide, and benzo[a]pyrene have a detrimental effect on health [<xref ref-type="bibr" rid="CR36">248</xref>].</p><p id="Par149">However, PM affects health more than any other pollutant [<xref ref-type="bibr" rid="CR38">250</xref>]. In addition, it plays a major role in global climate change, which alters ecosystems, along with food production and the water supply.</p><p id="Par150">Analysis of mixtures of pollutants emitted by given sources (e.g., traffic-related pollution, power plants, steel mills, and wood smoke) can be more pertinent to investigations of health outcomes and to the development of effective air quality strategies [<xref ref-type="bibr" rid="CR35">247</xref>].</p><p id="Par151"><italic>Primary pollutants</italic>, such as soot particles and oxides of nitrogen and sulfur, are emitted from the combustion of fossil fuels. Major sources of nitrogen dioxide are motorized vehicles, industrial sources, and residential heating.</p><p id="Par152"><italic>Secondary pollutants</italic> are formed in the atmosphere from other components. In particular, ozone is formed from photochemical reactions of nitrogen oxides and volatile organic components.</p><p id="Par153">Both <italic>acute</italic> and <italic>chronic exposure</italic> to high levels of air pollution disturb the endothelial function [<xref ref-type="bibr" rid="CR44">256</xref>]. Expression of <index-term id="ITerm78"><term>Redox stress</term></index-term>redox stress markers (e.g., NOS2 and nitrotyrosine) increases after exposure to diesel gas exhaust.</p><p id="Par154">Oxidized lipids can mediate adverse vascular effects of air pollutants, especially particulate matter PM<sub>2.5</sub>. In mice, PM<sub>2.5</sub> increases 7-<italic>ketocholesterol</italic>, an oxidated form of cholesterol and a major component of oxysterols, in plasma <index-term id="ITerm79"><term>IDL</term></index-term>IDLs and <index-term id="ITerm80"><term>LDL</term></index-term>LDLs and in aortic <index-term id="ITerm81"><term>atherosclerosis</term></index-term>atherosclerotic plaques concomitantly with increased ScaRb3 expression in plaque macrophages [<xref ref-type="bibr" rid="CR44">256</xref>]. 7-Ketocholesterol can be continuously formed on the surface of cholesterol-loaded lipoproteins.</p><p id="Par155">In addition, air pollution favors uptake of 7-ketocholesterol through ScaRb3 by <index-term id="ITerm82"><term>Macrophage</term></index-term>macrophages. Exposure to engine emissions increases not only the <index-term id="ITerm83"><term>ScaR</term></index-term>scavenger receptor ScaRb3 but also ScaRe1, thereby dysregulating the metabolism of oxidized lipids [<xref ref-type="bibr" rid="CR44">256</xref>]. On the other hand, 7-ketocholesterol can be exported from cells to lipoproteins. For example, <index-term id="ITerm84"><term>ABC</term></index-term>ABCg1 carries 7-ketocholesterol and 7β-hydroxycholesterol to HDLs, hence protecting cells. Once they are subjected to 7-ketocholesterol, cholesterol ingress increases in ECs and cholesterol egress decreases in macrophages [<xref ref-type="bibr" rid="CR44">256</xref>].</p><p id="Par156">Chronic exposure to PM<sub>2.5</sub> increases the generation of derivatives of oxidized phospholipids. In airways, derivatives (oxPAPC) of 1-palmitoyl 2-arachidonyl sn-glycero 3-phosphorylcholine (PAPC), a dominant phospholipid of surfactant, comprise 1-palmitoyl 2-(5-oxovaleroyl) sn-glycero 3-phosphocholine and 1-palmitoyl 2-glutaroyl sn-glycero 3-phosphocholine). These derivatives have elevated concentrations in circulating lipoproteins (LDLs and HDLs). The generation of derivatives of oxidized phospholipids, such as oxPAPCs, stimulates <index-term id="ITerm85"><term>NFκB</term></index-term>NFκB and then expression of proinflammatory genes (e.g., the chemokine CCL2) via toll-like receptor TLR4 and <index-term id="ITerm86"><term>NOx</term></index-term>NADPH oxidase (TLR4–NOx2 pathway), hence mobilizing bone marrow-derived mononuclear cells [<xref ref-type="bibr" rid="CR44">256</xref>].</p></sec><sec id="Sec4"><title>Determinants of Air Pollution Exposure</title><p id="Par157">Pollutant emission or formation rate, atmospheric lifetime, weather pattern, and diurnal and seasonal cycles in solar radiation and temperature impact on pollutant concentrations.</p><p id="Par158">The gaseous pollutants nitrogen oxides and carbon monoxide, in addition to the particle constituents elemental carbon and volatile organic compounds, are emitted during combustion, and their concentrations peak during rush hour [<xref ref-type="bibr" rid="CR35">247</xref>]. Photochemical oxidants (e.g., ozone and secondary PM<sub>2.5</sub> and VOCs) peak in the afternoon.</p><p id="Par159">Meteorological conditions affect pollutant concentrations. A stationary atmosphere, that is, a period of low horizontal and vertical mixing in the lower atmosphere, gradually accumulates regionally multiple pollutant types.</p><p id="Par160">The microenvironment and individual activities (e.g., trafficking duration, indoor sources, tobacco smoke and occupational exposure, and degree of indoor penetration of background pollution) cause between-subject variability of pollutant exposure.</p></sec><sec id="Sec5"><title>Aerosol Classification</title><p id="Par161">Aerosol classifiers select a monodisperse aerosol. Aerosol particles can be classified according to electrostatic forces and drag using a <italic>differential mobility analyzer</italic>. Charged particles move in an electric field with a velocity that depends on the particle size and number of elementary charges on the particle. However, particles can have the same electrical mobility, but different numbers of charges and sizes.</p><p id="Par162"><italic>Aerosol particle mass analyzer</italic> that comprises two coaxial electrodes rotating at an equal angular velocity categorizes aerosol particles according to their mass-to-charge ratio using centrifugal and electrostatic forces applied on charged particles in opposite directions. Particles with mass-to-charge ratios greater and smaller than that set by the force balance adhere to the outer and inner cylinder, respectively. In fact, the <italic>Couette centrifugal particle mass analyzer</italic>, in which the inner cylinder rotates slightly faster than the outer cylinder, has better performance [<xref ref-type="bibr" rid="CR45">257</xref>].</p><p id="Par163">In addition, equivalent aerodynamic diameter can be derived from particle relaxation time.<xref ref-type="fn" rid="Fn17">17</xref> The <italic>aerodynamic aerosol classifier</italic> uses a centrifugal force and sheath flow between two concentric cylinders rotating at the same angular velocity to produce a monodisperse aerosol [<xref ref-type="bibr" rid="CR46">258</xref>]. Different particle sizes are distinguished by changing the rotational speed. Particles with short relaxation times exit the classifier through a gap in the outer cylinder with the exhaust flow, those with long relaxation times impact and adhere to the outer cylinder.</p><p id="Par165">Coarse particles result mainly from the resuspension of soil and road dust by wind or moving vehicles along with construction work and industrial emissions. Fine particles are engendered by combustion. They are composed of carbon, transition metals, and complex organic molecules, in addition to sulfate and nitrate formed in the atmosphere from volatile organic compounds, SO<sub>2</sub>, and NO<sub>2</sub>. They can travel large distances (&gt; 100 km). Ultrafine particles are generated by motorized vehicles.</p><p id="Par166">Air pollution-linked mortality is due to exposure to suspended PM of 10 μm or less in diameter (PM<sub>10</sub>), which contributes to cardiovascular (Vol 7, Chap. 2. Context of Cardiac Diseases) and respiratory diseases and cancers [<xref ref-type="bibr" rid="CR38">250</xref>]. Small particulate pollution has an impact on health, even at very low concentrations. No health-damage threshold has been identified. However, guideline values are proposed (PM<sub>2.5</sub>: annual mean 10 μg/m<sup>3</sup> and 24-h mean 25 μg/m<sup>3</sup>; PM<sub>10</sub>: annual mean 20 μg/m<sup>3</sup> and 24-h mean 50 μg/m<sup>3</sup>).</p></sec><sec id="Sec6"><title>Air Filtration</title><p id="Par167">The effects of PM can be attenuated by technological advancements and regulations. For example, enhanced urban public transport associated with proper traveling of cyclists and pedestrians can lower urban air pollution, encourage physical activity, lessen traffic injuries, and reduce the mobility cost [<xref ref-type="bibr" rid="CR42">254</xref>]. Improved home insulation in addition to ameliorated heating and cooking systems and indoor ventilation can reduce vulnerability to diseases.</p><p id="Par168">Air filtration is the most effective method for air sampling and cleaning. Nanofiber filtration has a good filtration efficiency and low resistance to air flow. However, nanoparticles with their given physical properties (surface area, shape, density, diffusivity, rigidity, electric charge, and aerodynamics) behave differently than microparticles. Yet, conventional filters are replaced by nanofibrous filters. The interfacial behavior between nanoparticles and nanofibers (caliber 10–100 nm) remains to be investigated.</p><p id="Par169">Factors that influence the efficiency of a fiber filter in capturing particles include: <list list-type="bullet"><list-item><p id="Par170">Particle characteristics (size, physical state, chemical composition, density, charge distribution, and concentration)</p></list-item><list-item><p id="Par171">Filter characteristics (material type, fiber caliber, filter thickness, porosity, packing fiber density, filter fiber orientation, and electrical property)</p></list-item><list-item><p id="Par172">Collection (mechanical and electrostatic) mechanisms</p></list-item><list-item><p id="Par173">Operating conditions (temperature, filtrated air flow rate [face velocity], pressure, and viscosity)</p></list-item><list-item><p id="Par174">Thermal rebound associated with the Brownian motion</p></list-item></list></p><p id="Par175">Nanoparticles (size≤1 nm) may have a sufficiently high impact velocity to rebound from the surface upon collision (<italic>thermal rebound</italic>) [<xref ref-type="bibr" rid="CR47">259</xref>]. Rebound of nanoparticles depends on the relative humidity of the air. However, the influence of thermal rebound on the collection efficiency may be low, as the filter is a fibrous medium consisting of entangled fibers; hence, the probability of rebound throughout the finite filter thickness is low.</p><p id="Par176">Particle removal relies on four particle collection mechanisms. <list list-type="bullet"><list-item><p id="Par177"><italic>Inertial impaction</italic> occurs when the particle near a filter fiber changes its direction of travel and collides with the filter fiber.</p></list-item><list-item><p id="Par178"><italic>Interception</italic> appears when a particle is carried by air that flows very close to a filter fiber.</p></list-item><list-item><p id="Par179"><italic>Diffusion</italic> due to Brownian motion causes the particle to impact the filter fiber.</p></list-item><list-item><p id="Par180"><italic>Electrostatic attraction</italic> between particles and filter fibers is caused by Coulombic and dielectrophoretic attraction forces. In a heterogeneous electric field, a dielectric particle becomes electrically polarized due to charge separation that creates a dipole and bears a net dielectrophoretic force. The magnitude of this force, which can be exerted on neutral particles, depends on the medium and particle properties (shape, size, and electrical features) and on the frequency of the electric field. If a suspended particle has a polarizability higher than the medium, the dielectrophoretic force attracts the particle toward regions of higher electric field (positive dielectrophoretic force) and conversely (negative dielectrophoretic force).</p></list-item></list></p><p id="Par181">The combined effect of these mechanisms governs the penetration of particles through the filter. Interception and inertial impaction are dominant collection processes for microparticles and diffusion for nanoparticles. At low air flow rates (face velocities) and hence high residence times, diffusion and electrostatic forces can contribute to the capture efficiency. For an order of magnitude of the particle size ranging from 10 to 100 nm and face velocity from 10 to 100 mm/s, the filtration efficiency augments at a low face velocity, whatever the particles’ shape [<xref ref-type="bibr" rid="CR48">260</xref>].</p><p id="Par182">Humidity influences the filtration performance, at least for a particle size greater than 100 nm. Using mechanical filters, elevated relative humidity raises capillary force and filtration [<xref ref-type="bibr" rid="CR48">260</xref>]. On the other hand, using charged filters, the filtration decreases as the humidity increases, as water molecules can remove charges from filter fibers.</p><p id="Par183">Two major classes of filters comprise fibrous and membrane filters. The important filter characteristics are efficiency (capacity to arrest the passage of and hold airborne particles), dust holding capacity, face velocity, and pressure drop. The quality factor (QF) evaluates the filter performance: <disp-formula id="Equ1"><label>2.1</label><alternatives><mml:math id="Equ1_Math"><mml:mtable columnalign="right left"><mml:mtr><mml:mtd class="align-1"><mml:mi mathvariant="normal">QF</mml:mi><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:mfrac><mml:mrow><mml:mo>ln</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>∕</mml:mo><mml:mi>P</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>Δ</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>,</mml:mo></mml:mtd><mml:mtd class="align-2"/><mml:mtd/></mml:mtr></mml:mtable></mml:math><tex-math id="Equ1_TeX">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}
$$\displaystyle \begin{aligned} \mathrm{QF} = \dfrac{\ln(1/P)}{\varDelta p}, \end{aligned} $$
\end{document}</tex-math><graphic specific-use="web" mime-subtype="GIF" xlink:href="460479_1_En_2_Chapter_Equ1.gif"/></alternatives></disp-formula> where <italic>P</italic> is the penetration and <italic>Δp</italic> the pressure drop across the filter. The latter increases for a given face velocity when the filter becomes dirty.</p><p id="Par184">In conventional aerosol filtration theory, diffusion is supposed to be the dominant transport means of submicron particles, and impaction of these aerosol particles is followed by adhesion. The classical filtration theory also assumes that nanoparticles<xref ref-type="fn" rid="Fn18">18</xref> adhere when they strike a filter with a Brownian motion. However, nanoparticles (size&lt; 10 nm) may have a sufficiently high impact velocity to rebound from the surface upon collision (thermal rebound) [<xref ref-type="bibr" rid="CR47">259</xref>]. Rebound of nanoparticles depends on the relative humidity of the air. Membrane-coated filters, that is, filters coated with a polytetrafluoroethylene membrane, can be considered as two combined layers, a fibrous and membrane layer. They may control nanoparticle spreading.</p><p id="Par186">Investigations quantify atmospheric pollution, measure immersed particle properties, particle size distributions, and particle filtration efficiency; and determine nanoparticle toxicology and aerosol pulmonary dose.</p><p id="Par187">The relative particle velocity with respect to the air flow velocity is the migration velocity. An external force, such as gravity and electrostatic force, is required to separate particles and select a given particle size. <italic>Impactors</italic> endowed with a nozzle and an impaction plate or a receiving tube enable particle classification according to inertia. Large particles with high inertia tend to cross gas flow streamlines, whereas small particles with low inertia remain in the gas flow.</p></sec><sec id="Sec7"><title>Biological Mechanisms</title><p id="Par188">Inhalation of PM can operate via [<xref ref-type="bibr" rid="CR35">247</xref>] (1) the release of proinflammatory mediators and cells (e.g., cytokines along with activated immunocytes and platelets), vasculoactive molecules (e.g., angiotensin, endothelin, and histamine), or microparticles from pulmonary cells, (2) perturbation of the autonomic nervous system via stimulation of lung receptors and irritant and afferent nerves, and (3) passage of ultrafine particles or particle constituents (e.g., organic compounds and metals) into the blood.</p><p id="Par189">In addition to the role of copollutants, pollutant features (size, charge, solubility, surface chemistry [e.g., the ROS-producing potential of metals, organic compounds, and semiquinones], and aggregation) are involved in their clearance (or retention rate) and interaction with pulmonary epitheliocytes and immunocytes, and within cells with organelles (e.g., mitochondrion) or molecules (e.g., cytochrome P450 and NADPH oxidase), and hence in pulmonary <index-term id="ITerm87"><term>Inflammation</term></index-term>inflammation and <index-term id="ITerm88"><term>Redox stress</term></index-term>redox stress [<xref ref-type="bibr" rid="CR35">247</xref>].</p><p id="Par190">Blood concentrations of stress hormones (corticotropin-releasing and adrenocorticotropic hormone, cortisol, cortisone, and catecholamines, adrenaline and noradrenaline), metabolites (amino acids, glucose, fatty acids, and other lipid types), and markers of redox stress and inflammation were investigated in response to PM exposure in 55 healthy Shanghai college students. Exposure to PM<sub>2.5</sub> increases significantly concentrations of stress hormones and markers of insulin resistance, along with blood pressure, and provokes redox stress and inflammation [<xref ref-type="bibr" rid="CR49">261</xref>]. Exposure to PM<sub>2.5</sub> can thus activate the hypothalamus–pituitary–adrenal and sympathetic–adrenal axes, contributing to adverse metabolic and cardiovascular effects. The hypothalamus releases corticotropin-releasing hormone, which stimulates the anterior pituitary gland, which secretes adrenocorticotropic hormone (ACTH) into the blood, reaching the adrenal cortex, where it stimulates the synthesis and release of glucocorticoids, mainly cortisol and cortisone. The synthesis and secretion of catecholamines in the adrenal medulla is regulated by preganglionic sympathetic neurons. Glucocorticoids can also modulate catecholamine synthesis via phenylethanolamine methyltransferase. Conversely, adrenaline can stimulate ACTH secretion from the pituitary gland. Glucocorticoids provoke vasoconstriction. In addition, they increase metabolic rate and energy expenditure, glycemia, as well as lipolysis, lipid oxidation, and proteolysis, and they favor insulin resistance. Catecholamines augment glycolysis and lipolysis, cause vasoconstriction, and raise cardiac output and formation of proinflammatory cytokines. Exposure to PM<sub>2.5</sub> may also stimulate the secretion in the pineal gland via β-adrenoceptors of melatonin, a circadian cycle regulator, which has an anti-inflammatory effect and is a ROS scavenger. In addition, greater levels of lysolipids (e.g., lysophosphatidylcholine and lysophosphatidylethanolamine) accompany higher PM exposure. Indoor air purification for 48 h not only reduces personal exposure to fine PM but also yields cardiopulmonary benefits following consecutive exposures [<xref ref-type="bibr" rid="CR49">261</xref>].</p></sec><sec id="Sec8"><title>Cardiovascular Events</title><p id="Par191">Some individuals can be more susceptible to air pollution than the general population at a given pollutant concentration, especially the elderly, those who are obese, and patients with diabetes, chronic lung disease, coronary atherosclerosis, or HF, in addition to humans with low socioeconomic status. On the other hand, vulnerability refers to subjects at greater risk, as they are exposed more frequently to high pollutant concentrations.</p><p id="Par192">Infraclinical changes can occur in individuals in response to PM<sub>2.5</sub> exposure. Short-term exposure to PM<sub>2.5</sub> (hours to weeks) can contribute to arrhythmias, myocardial ischemia, and strokes. Long-term PM<sub>2.5</sub> exposure increases the risk for cardiovascular mortality.</p><p id="Par193"><index-term id="ITerm89"><term>Inflammation</term></index-term>Inflammation with elevated circulating markers (CRP, fibrinogen, TNFSF1, IL1β, IL6, and soluble adhesion molecules [e.g., icam1]) can be detected after PM inhalation [<xref ref-type="bibr" rid="CR35">247</xref>]. Pollutant exposure raises plasma concentrations of <index-term id="ITerm90"><term>C-reactive protein</term></index-term>CRP and <index-term id="ITerm91"><term>Fibrinogen</term></index-term>fibrinogen that alter expression by leukocytes of <index-term id="ITerm92"><term>adhesion molecule</term></index-term>adhesion molecules. Artery wall inflammation destabilizes atheromatous plaques.</p><p id="Par194">Moreover, pollutant nanoparticles that alter the features of arterial and venous <index-term id="ITerm93"><term>EC</term></index-term>ECs and enhance <index-term id="ITerm94"><term>Platelet</term></index-term>platelet activation and aggregation may act as foci for <index-term id="ITerm95"><term>Thrombus</term></index-term>thrombus formation [<xref ref-type="bibr" rid="CR34">246</xref>]. Exposure to PM<sub>10</sub> can be associated with elevated platelet aggregation and concentrations of fibrinogen, von Willebrand factor, and plasminogen activator inhibitor PAI1 [<xref ref-type="bibr" rid="CR35">247</xref>]. In addition, release of tissue plasminogen activator that participates in fibrinolysis is reduced after diesel exhaust inhalation.</p><p id="Par195">Furthermore, prolonged exposure to PM generates <index-term id="ITerm96"><term>Vasoconstriction</term></index-term>vasoconstriction, hence favoring <index-term id="ITerm97"><term>Hypertension</term></index-term>hypertension. In particular, exposure to black carbon, a component of fine PM derived from vehicular pollution, is associated with hypertension. In older adults, short- to moderate-term ambient black carbon concentrations are correlated with blood mitochondrial abundance, a compensatory response that attenuates the cardiac effects of pollution [<xref ref-type="bibr" rid="CR50">262</xref>]. A 2-h exposure to diesel exhaust alters the pulmonary vasomotor tone, thereby increasing pulmonary vascular resistance, under stress (but not rest) conditions (i.e., at high cardiac output) [<xref ref-type="bibr" rid="CR51">263</xref>]. On the other hand, diesel exhaust exposure does not affect concentration of plasmatic endothelin-1 or exhaled nitric oxide (NO). Air pollution can thus potentiate acquired pulmonary hypertension.</p><p id="Par196"><index-term id="ITerm98"><term>Redox stress</term></index-term>Redox stress is linked to inflammation, as it is often induced by and elicits inflammation. It can remain confined to the cell level and hence not be directly observable by circulating markers. However, some studies show that ambient PM can increase the plasmatic concentration of <index-term id="ITerm99"><term>Homocysteine</term></index-term>homocysteine, a mediator of redox stress [<xref ref-type="bibr" rid="CR35">247</xref>].</p><p id="Par197">Lead can be absorbed via the respiratory and gastrointestinal tracts (inhalation of lead-containing dust and gas exhaust) and through the skin. Ninety-nine per cent of blood lead content is bound to RBCs. Bones serve as the main lead repository in the body. The kidney is a principal organ of lead excretion.</p><p id="Par198">Chronic lead exposure causes <index-term id="ITerm100"><term>hypertension</term></index-term>hypertension and cardiovascular disease. It favors <index-term id="ITerm101"><term>Redox stress</term></index-term>redox stress. It activates <index-term id="ITerm102"><term>NFκB</term></index-term>NFκB, promoting inflammation [<xref ref-type="bibr" rid="CR52">264</xref>]. In addition, it downregulates expression of soluble guanylate cyclase β subunit and limits <index-term id="ITerm103"><term>NO</term></index-term>NO availability, hence reducing endothelium-dependent vasorelaxation; augments activity of adrenoceptors, protein kinase-C, and plasma angiotensin convertase, as well as endothelin production; upregulates <index-term id="ITerm104"><term>PGhS</term></index-term>PGhS2 expression, raising concentration of vasoconstrictory <index-term id="ITerm105"><term>Thromboxane</term></index-term>thromboxane and lowering that of vasodilatory prostacyclin; attenuates atrial natriuretic peptide production; and disturbs calcium signaling in vSMCs, thereby inducing <index-term id="ITerm106"><term>Vasoconstriction</term></index-term>vasoconstriction [<xref ref-type="bibr" rid="CR52">264</xref>]. Moreover, lead induces endothelial injury, impedes endothelial repair and angiogenesis, diminishes endotheliocyte growth, but stimulates vSMC proliferation. It also reduces production of proteoglycans and tissue plasminogen activator, and raises that of plasminogen activator inhibitor (PAI1).</p><p id="Par199">In two large European cohorts (144,082 adult participants), greater road traffic noise exposure is associated with a higher level of high-sensitivity CRP, TGs, and HDL. Greater air pollution exposure (PM<sub>10</sub> and NO<sub>2</sub>) is linked to higher TG and CRP concentrations [<xref ref-type="bibr" rid="CR53">265</xref>]. Moreover, exposure to road traffic noise and air pollution raises fasting glycemia.</p><sec id="Sec9"><title>Heart Ischemia and Stroke</title><p id="Par200">Ischemic cardiac events are related to long-term exposure to elevated PM<sub>2.5</sub> levels [<xref ref-type="bibr" rid="CR35">247</xref>]. <index-term id="ITerm107"><term>Myocardial infarction</term></index-term>The risk for an adverse post-MI outcome (death, subsequent infarction, or congestive HF) rises with greater exposure to PM<sub>10</sub>. Fatal coronary events can be statistically correlated with PM<sub>2.5</sub> exposure.</p><p id="Par201"><index-term id="ITerm108"><term>Stroke</term></index-term>Nonfatal and fatal cerebrovascular diseases increase with prolonged exposure to PM<sub>2.5</sub>, with a small statistically significant correlation [<xref ref-type="bibr" rid="CR35">247</xref>].</p></sec><sec id="Sec10"><title>Cardiac Arrhythmias and Heart Failure</title><p id="Par202">Cardiac arrhythmias can appear in the context of exposure to fine PM and related pollutants. Death due to arrhythmias and HF is associated with prolonged exposure to PM<sub>2.5</sub> [<xref ref-type="bibr" rid="CR35">247</xref>]. Hospitalization for heart failure can be linked to short-term changes in PM exposure.</p></sec><sec id="Sec11"><title>Arterial and Venous Diseases</title><p id="Par203">A nearly statistically significant positive association can be found between daily changes in PM pollution and hospitalizations for peripheral vascular diseases [<xref ref-type="bibr" rid="CR35">247</xref>]. The risk for deep vein <index-term id="ITerm109"><term>Thrombosis</term></index-term>thrombosis augments with long-term PM<sub>10</sub> exposure.</p></sec></sec></sec><sec id="Sec12"><title>Noise</title><p id="Par204">Whereas certain types of sounds and music have beneficial effects on cardiovascular physiology, tempo, melodic structure, and periods of silence being crucial factors that have an impact on blood flow parameters and baroreflex, chronic low-intensity noise disturbs sleep and activity. Disturbed sleep and repetitive exposure to noise are risk factors [<xref ref-type="bibr" rid="CR54">266</xref>]. Noise engendered by road, railway, and air traffic augments the incidence of hypertension and atherosclerosis complications (MI and stroke). Night-time noise alters endothelial function and sleep quality and tends to increase arterial pressure [<xref ref-type="bibr" rid="CR55">267</xref>]. Vitamin C significantly improves flow-mediated dilation, suggesting the occurrence of redox stress upon noise exposure.</p><p id="Par205">Noise does indeed cause redox stress and endothelial dysfunction. Although noise increases NOS3 production, it decreases NO concentrations due to NOS3 uncoupling. It raises not only vascular <index-term id="ITerm110"><term>ROS</term></index-term>ROS production but also inflammation marker levels along with circulating concentrations of stress hormones (adrenaline and cortisol). Monocytes, macrophages, natural killer cells, and neutrophils infiltrate vascular walls. Reactive oxygen species are linked to various pathways (PI3K–PKB, FoxO, TGFβ1, NFκB, and ET1). Noise increases vascular expression not only of endothelin-1 but also of <index-term id="ITerm111"><term>NOx</term></index-term>NOx2 mainly via the Agt2–AT<sub>1</sub> axis [<xref ref-type="bibr" rid="CR55">267</xref>].</p><p id="Par206">Moreover, noise activates the sympathetic nervous system. In mice exposed to intermittent noise mimicking aircraft noise delivered in short episodes (peak sound A-weighting intensity 85 dBA; mean sound intensity 72 dBA) for 4 days at the most increases systolic blood pressure, cardiac frequency, and plasmatic concentrations of IL-6, noradrenaline, and angiotensin-2 (Agt2) [<xref ref-type="bibr" rid="CR55">267</xref>].<xref ref-type="fn" rid="Fn19">19</xref></p></sec></sec><sec id="Sec13"><title>Transcripts</title><p id="Par208">Precision medicine relies on identification of additional risk markers linked to pathogenic genetic variations (Chap. <ext-link xlink:href="10.1007/978-3-319-89315-0_7" ext-link-type="doi">7</ext-link>). Many gene variants affect blood pressure and lipid concentrations.</p><p id="Par209">Transcription, the first stage of gene expression, consists of translating information from a DNA segment, that is, a protein-coding gene (among&gt; 22,000 protein-coding genes), to a pre-messenger RNA molecule, which is spliced and exported into the cytosol. Translation converts information contained in a mature mRNA into a polypeptide that engenders a protein properly folded and located within the cell.</p><p id="Par210">Ribonucleic acids are classified into protein-coding messenger RNAs (mRNAs) and nonprotein-coding RNAs (ncRNAs). In addition, the superclass of RNAs include many nucleotide-derived coenzymes, self-processing ribozymes, metabolite-binding riboswitches, and even ribosomes [<xref ref-type="bibr" rid="CR56">268</xref>]. Many of the most common signaling molecules are also formed from RNA nucleotides or their precursors. The most widespread second messengers include the cyclic ribonucleotides cAMP and cGMP, in addition to pyrimidine nucleotides such as cytidine and uridine triphosphate. Other signaling effectors comprise cyclic adenosine diphosphate–ribose and nicotinic acid adenine dinucleotide phosphate, in addition to the dimeric signaling mediator diadenosine tetraphosphate (AP<sub>4</sub>A).</p><p id="Par211">Messenger RNA elements, riboswitches, bind to small molecules to regulate gene expression. Among numerous riboswitch classes, many regulate gene transcription in response to the selective binding of coenzymes and signaling mediators derived from RNA monomers or their precursors.</p><p id="Par212">Nonprotein-coding RNAs (ncRNAs) comprise functional RNAs that are not translated into proteins. They include spliceosomal (small nuclear) RNAs, transfer (tRNAs), ribosomal (rRNAs), and other types of small (sncRNAs; &lt; 200 nucleotides [nts]) and <index-term id="ITerm112"><term>lncRNA</term></index-term>long ncRNAs (lncRNAs; &gt; 200 nts).</p><p id="Par213"><index-term id="ITerm113"><term>aaRS</term></index-term>Aminoacyl–tRNA synthetases (aaRSs) act during the first stage of ribosome-dependent protein synthesis. These enzymes attach the appropriate amino acid (aminoacylation) onto cognate tRNA isoacceptors (AA–tRNA<sup>AA</sup>; AA: a given type of amino acid). They are categorized into two groups according to their chemical properties, catalytic domain architecture, and consensus sequences<xref ref-type="fn" rid="Fn20">20</xref> in addition to subgroups based on their mechanistic properties, anticodon-binding domain characteristics, and structural motif organization [<xref ref-type="bibr" rid="CR57">269</xref>].</p><p id="Par215">Mammalian aaRSs differ from those of prokaryotes and lower eukaryotes, as they associate as multienzyme complexes. Nine aaRSs (ArgRS, GlnRS, IleRS, LeuRS, LysRS, and MetRS, along with <index-term id="ITerm114"><term>AspRS (DaRS)</term></index-term>aspartyl– [AspRS or DaRS] and <index-term id="ITerm115"><term>EPRS</term></index-term>glutamyl–prolyl–tRNA synthetases [Glu–ProRS or EPRS]) and three auxiliary aminoacyl–tRNA synthetase-interacting multifunctional proteins (AIMP1–AIMP3) assemble into a multi-aaRS complex that operates in alternating activities of its members [<xref ref-type="bibr" rid="CR57">269</xref>]. Under some circumstances, one of the aaRSs or AIMPs is released to trigger cell signaling (Table <xref rid="Tab8" ref-type="table">2.8</xref>).<xref ref-type="fn" rid="Fn21">21</xref><table-wrap id="Tab8"><label>Table 2.8</label><caption xml:lang="en"><p>Activities of free aminoacyl–tRNA synthetases (aaRSs) and aaRS-interacting multifunctional proteins (AIMPs) released from the human aaRS–AIMP complex (Source: [<xref ref-type="bibr" rid="CR57">269</xref>])</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Proteins</p></th><th align="left"><p>Activities</p></th></tr></thead><tbody><tr><td align="left"><p>Group-<italic>II</italic></p></td><td align="left"><p>Extracellular inflammatory cytokine</p></td></tr><tr><td align="left"><p>LysRS</p></td><td align="left"><p>Plasmalemmal viral assembly agent</p></td></tr><tr><td align="left"/><td align="left"><p>Nuclear transcriptional controller</p></td></tr><tr><td align="left"><p>Glu–ProRS</p></td><td align="left"><p>Translational silencing</p></td></tr><tr><td align="left"><p>GlnRS</p></td><td align="left"><p>Antiapoptosis</p></td></tr><tr><td align="left"><p>MetRS</p></td><td align="left"><p>rRNA transcription</p></td></tr><tr><td align="left"><p>IleRS</p></td><td align="left"><p>Autoimmunity</p></td></tr><tr><td align="left"><p>AIMP1</p></td><td align="left"><p>Cytokine activation of macrophages</p></td></tr><tr><td align="left"><p>AIMP2</p></td><td align="left"><p>Degradation of FBP, a transcriptional activator of MyC</p></td></tr><tr><td align="left"><p>AIMP3</p></td><td align="left"><p>P53 induction and DNA repair via nuclear ATMK and</p></td></tr><tr><td align="left"/><td align="left"><p>ATRK activation</p></td></tr></tbody></table><table-wrap-foot><p>Lysyl–tRNA synthetases are unique among the aminoacyl–tRNA synthetases, as they belong to category <italic>I</italic> or <italic>II</italic> aaRSs</p></table-wrap-foot></table-wrap></p><p id="Par217">In addition to their canonical role in translation, aaRSs have auxiliary functions in nutritional stress response, apoptosis, and cell survival along with the regulation of gene transcription and transcript translation via linkage to transcription factors or tRNA-like molecule, RNA splicing,<xref ref-type="fn" rid="Fn22">22</xref> inflammation via recruitment of immunocytes, and <index-term id="ITerm116"><term>angiogenesis</term></index-term>angiogenesis, as some aaRSs and/or their secreted cleavage products contribute to controlling EC survival, proliferation, and migration via activation of <index-term id="ITerm117"><term>ERK</term></index-term>ERK1, ERK2, <index-term id="ITerm118"><term>P38MAPK</term></index-term>P38MAPK, and <index-term id="ITerm119"><term>PKB</term></index-term>PKB (Table <xref rid="Tab9" ref-type="table">2.9</xref>) [<xref ref-type="bibr" rid="CR59">271</xref>]. <table-wrap id="Tab9"><label>Table 2.9</label><caption xml:lang="en"><p>Aminoacyl–tRNA synthetases (aaRSs) and aaRS-associated anti- and pro-angiogenic and angiostatic proteins (Source: [<xref ref-type="bibr" rid="CR59">271</xref>])</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Molecule</p></th><th align="left"><p>Effect on angiogenesis</p></th></tr></thead><tbody><tr><td align="left" colspan="2"><p><italic>AaRS acting outside the cell</italic></p></td></tr><tr><td align="left"><p>ThrRS</p></td><td align="left"><p>Proangiogenic agent</p></td></tr><tr><td align="left"><p>(TaRS)</p></td><td align="left"><p>Stimulates endotheliocyte migration</p></td></tr><tr><td align="left"><p>TrpRS</p></td><td align="left"><p>Angiostatic agent; interacts with cadherin upon loss of its</p></td></tr><tr><td align="left"><p>(WaRS)</p></td><td align="left"><p>WHEP domain by alternative splicing or after secretion by ElaNE</p></td></tr><tr><td align="left"/><td align="left"><p>Truncated TrpRS (miniWRS) disrupts between-endotheliocyte</p></td></tr><tr><td align="left"/><td align="left"><p>contacts and inhibits ERK1/2, NOS3, PKB</p></td></tr><tr><td align="left"><p>TyrRS</p></td><td align="left"><p>Proangiogenic agent secreted and cleaved into</p></td></tr><tr><td align="left"><p>(YaRS)</p></td><td align="left"><p>N- and C-terminal fragments by ElaNE</p></td></tr><tr><td align="left"/><td align="left"><p>N-terminal fragment (miniYRS) activates ERK1/2, NOS3, PKB, Src</p></td></tr><tr><td align="left"/><td align="left"><p>C-terminal fragment elicits immunocyte migration</p></td></tr><tr><td align="left"/><td align="left"><p>MiniYRS interacts with CXCR1</p></td></tr><tr><td align="left" colspan="2"><p><italic>AaRS acting inside the cell</italic></p></td></tr><tr><td align="left"><p>Glu–ProRS</p></td><td align="left"><p>Cytoplasmic angiostatic agent; phosphorylated Glu–ProRS binds to mitochondrial ribosomal protein MRPL13, glyceraldehyde 3-phosphate dehydrogenase, and synaptotagmin-binding, cytoplasmic RNA-interacting protein (SynCRIP or hnRNPq) to form the interferon-γ-activated inhibitor of translation (GAIT) complex</p></td></tr><tr><td align="left"/><td align="left"><p>Interferon-γ liberates Glu–ProRS from</p></td></tr><tr><td align="left"/><td align="left"><p>the multisynthetase complex and GAIT complex</p></td></tr><tr><td align="left"><p>SerRS</p></td><td align="left"><p>Nuclear angiostatic agent; it binds to VEGFA promoter and</p></td></tr><tr><td align="left"><p>(SaRS)</p></td><td align="left"><p>prevents MyC-primed VEGFA transcription</p></td></tr><tr><td align="left" colspan="2"><p><italic>AaRS-interacting multifunctional proteins</italic></p></td></tr><tr><td align="left"><p>AIMP1,</p></td><td align="left"><p>Caspase-7 cleaves the C-terminus from AIMP1 that forms EMAP2 endotheliocyte–monocyte-activating polypeptide EMAP2, a chemoattractant released in response to apoptotic signals Extracellular pro- and antiangiogenic agents at low and high concentrations via TNFSF1-mediated angiogenesis, and Apoptosis that is linked to upregulated TNFRSF1 formation, respectively</p></td></tr><tr><td align="left"/><td align="left"><p>EMAP2 regulates angiogenesis via CXCR3</p></td></tr></tbody></table><table-wrap-foot><p>They are classified according to the location of angiogenic action, outside or inside the cell (ElaNE: neutrophil expressed elastase)</p></table-wrap-foot></table-wrap></p><p id="Par219">Loss-of-function mutations in TARS and IARS genes that encode threonyl– and isoleucyl–tRNA synthetases (premature stop codon and point mutation, respectively) upregulate synthesis of proteins implicated in the <index-term id="ITerm120"><term>UPR</term></index-term>unfolded protein response (UPR; e.g., ATF4, ATF6, and XBP1)<xref ref-type="fn" rid="Fn23">23</xref> in addition to vascular endothelial growth factor (VEGFa) via UPR-stimulated activating transcription factor ATF4 and increase branching angiogenesis [<xref ref-type="bibr" rid="CR61">273</xref>]. The ATF4–VEGF pathway does indeed prime <index-term id="ITerm121"><term>eIF2α K3 (PERK)</term></index-term>angiogenesis,<xref ref-type="fn" rid="Fn24">24</xref> whereas secreted TaRS signaling supports angiogenesis independently of its synthetase activity. In fact, many aaRSs can promote angiogenesis upon nutrient depletion, which launches UPR and VEGF production, or via extracellular mechanisms [<xref ref-type="bibr" rid="CR60">272</xref>].</p><p id="Par222">In murine embryonic ECs, formation of JmjD8, which belongs to the JmjC category<xref ref-type="fn" rid="Fn25">25</xref> and promotes TNFSF1-primed <index-term id="ITerm122"><term>NFκB</term></index-term>NFκB signaling, is upregulated during their differentiation. It regulates both endothelial sprouting and metabolism, as it interacts with <index-term id="ITerm123"><term>PK</term></index-term>pyruvate kinase-M2 [<xref ref-type="bibr" rid="CR62">274</xref>].<xref ref-type="fn" rid="Fn26">26</xref></p><p id="Par225">Small nonprotein-coding RNAs include <index-term id="ITerm124"><term>MicroRNA</term></index-term>microRNAs (miRs), P-element-induced wimpy testis-interacting-associated RNAs (piRNAs), and endogenous small interfering RNAs (endo-siRNAs).</p><p id="Par226">Long nonprotein-coding RNAs operate as signals,<xref ref-type="fn" rid="Fn27">27</xref> decoys,<xref ref-type="fn" rid="Fn28">28</xref> guides,<xref ref-type="fn" rid="Fn29">29</xref> and scaffolds.<xref ref-type="fn" rid="Fn30">30</xref> They control the chromatin structure and hence can repress gene transcription. They also participate in post-transcriptional regulation, in particular in cell metabolism and differentiation [<xref ref-type="bibr" rid="CR63">275</xref>].</p><p id="Par231">The nucleoplasm and cytoplasm contain numerous small ribonucleoprotein complexes, the small nuclear (snRNPs) and cytoplasmic RNPs (scRNPs), respectively. They are composed of at least one protein and a small stable RNA (&lt; ∼300 nt). SnRNPs and scRNPs regulate nuclear and cytosolic RNA processing (i.e., pre-mRNA splicing and mRNA translation). Hence, other subsets of ncRNAs include (1) Components of the Ro (Ro60) ribonucleoprotein, <index-term id="ITerm125"><term>YRNA</term></index-term><sup>Y</sup>RNAs,<xref ref-type="fn" rid="Fn31">31</xref> (2) small cytoplasmic RNAs (scRNAs or<sup>7SL</sup>RNAs), and (3) constituents of large cytoplasmic ribonucleoproteins, the <index-term id="ITerm126"><term>Vault</term></index-term><italic>vaults</italic>.</p><p id="Par233"><index-term id="ITerm127"><term>YRNA</term></index-term><sup>Y</sup>RNAs are small ncRNAs (∼100 nt) transcribed by RNA polymerase-3 that form stem–loop structures. Ro small cytoplasmic ribonucleoproteins are a subgroup of La ribonucleoproteins.<xref ref-type="fn" rid="Fn32">32</xref> The Ro RNPs are stable and cytoplasmic, whereas the majority of the La RNPs turn over rapidly and reside in the nucleus [<xref ref-type="bibr" rid="CR65">277</xref>]. These components of Ro RNPs are bound to 60-kDa Ro protein, which can be detected in the blood of patients with autoimmune diseases, such as systemic lupus erythematosus (or simply lupus)<xref ref-type="fn" rid="Fn33">33</xref> and Sjögren’s syndrome.<xref ref-type="fn" rid="Fn34">34</xref> Binding to Ro60 is a prerequisite for the export of <sup>Y</sup>RNAs from the nucleus to the cytoplasm [<xref ref-type="bibr" rid="CR64">276</xref>].</p><p id="Par237">Ubiquitous small cytoplasmic RNA component 7SL of the signal recognition particle (SRP) serves as a scaffold for the six SRP proteins (SRP9, SRP14, SRP19, SRP54, SRP68, and SRP72) [<xref ref-type="bibr" rid="CR66">278</xref>]. It links to the ribosome and assists translocation of nascent presecretory proteins to the endoplasmic reticulum<xref ref-type="fn" rid="Fn35">35</xref> and then to secretory pathway, sorting them for membrane insertion or secretion from the cell.</p><p id="Par239">Vaults participate in nucleocytoplasmic transfer. They include the major <xref ref-type="fn" rid="Fn36">36</xref> and two minor vault proteins, PARP4<xref ref-type="fn" rid="Fn37">37</xref> and TEP1,<xref ref-type="fn" rid="Fn38">38</xref> in addition to various small untranslated RNAs (i.e., vault RNA components vaultrc1–vaultrc3 [vtRNA1-1–vtRNA1-3] and vtRNA2-1 [or pre-miR886]).<xref ref-type="fn" rid="Fn39">39</xref></p><p id="Par244">However, within the transcriptome, bifunctional RNAs have both coding and noncoding functions and can serve as both messenger and nonprotein-coding RNAs [<xref ref-type="bibr" rid="CR67">279</xref>], although bifunctional RNAs comprise RNAs that have two different ncRNA functions.<xref ref-type="fn" rid="Fn40">40</xref> They include [<xref ref-type="bibr" rid="CR69">282</xref>]: <list list-type="order"><list-item><p id="Par246">mRNAs (e.g., TNFRSF17as, Dmpk, H2B, Mdfic,<xref ref-type="fn" rid="Fn41">41</xref> fortilin,<xref ref-type="fn" rid="Fn42">42</xref> Sra) either with an intrinsic noncoding function (base pairing, scaffolding, and quenching) or with a nonprotein-coding isoform due to alternative splicing or allele-specific transcripts with variants that destroy coding potential</p></list-item><list-item><p id="Par249">lncRNAs (e.g., ac074183.4, cgat1, ctd2651B20.6, dancr, gas5, malat1, snhg8, rp5-875o13.1, rp11-21n3.1, rp11-220i1.1, rp11-354p17.9, and rpph1) containing a small open reading frame that are strongly associated with ribosomes and thus encoding small peptides (&lt; 100 amino acids)</p></list-item></list></p><p id="Par250">Nonprotein-coding RNAs can be identified within <index-term id="ITerm129"><term>Exosome</term></index-term>exosomes, which are intercellular communication shuttles formed from multivesicular bodies and then secreted. They contain miRs, rRNAs, tRNAs, lncRNAs, piRNAs, and small nuclear (snRNAs) and nucleolar RNAs (snoRNAs). Among them, miRs and lncRNAs, which regulate cell signaling, have an altered expression in pathogenesis and hence are additional markers.</p><sec id="Sec14"><title>MicroRNAs</title><p id="Par251"><index-term id="ITerm130"><term>MicroRNA</term></index-term>Aberrantly regulated nonprotein-coding RNAs, such as short microRNAs and long nonprotein-coding RNAs that are released into the bloodstream, where their concentrations differ thus from those in healthy subjects, contribute to cardiovascular pathophysiology.</p><p id="Par252">MicroRNAs are linked to CVD risk factors, such as hyperlipidemia, hypertension, obesity, diabetes, lack of physical activity, and smoking. They participate in CVD, especially atherosclerosis and aneurysms.</p><p id="Par253">MicroRNAs (content 18–22 nucleotides; Vol. 11, Chap. 3. Small Nonprotein-Coding RNAs—MicroRNAs) are transcribed from genomic mir loci by RNA polymerase-2 assisted by epigenetic regulators, enhancers, and transcription factors into transcripts, the primary microRNAs, which are capped, polyadenylated, and spliced. These mir transcripts contain either a single miR or a miR cluster. The primary mir transcript is processed by the nuclear microprocessor complex that contains the ribonuclease-3 <index-term id="ITerm131"><term>Drosha</term></index-term>drosha and the double-stranded RNA-binding protein DGCR8 (or pasha).<xref ref-type="fn" rid="Fn43">43</xref> The precursor microRNA is then exported into the cytoplasm using exportin-5 in conjunction with Ran. The cytosolic ribonuclease-3 <index-term id="ITerm132"><term>Dicer</term></index-term>dicer generates the mature miR–miR<sup>⋆</sup> duplex. Then, dicer, in cooperation with the RNA-induced silencing complex (RISC)-loading complex subunit transactivation-responsive RNA-binding protein TARBP2, recruits argonaute-2 to the bound miR. Argonaute proteins, which unwind the double strand and incorporate one of the two miR strands into the RISC, lead to mRNA translation repression or degradation.<xref ref-type="fn" rid="Fn44">44</xref> Therefore, argonaute proteins are key elements of gene silencing and microRNAs regulate amounts of proteins produced from target mRNAs.</p><p id="Par257">For example, miR504, which resides in an intron of the <index-term id="ITerm133"><term>FGF</term></index-term>Fgf13 gene, targets <index-term id="ITerm134"><term>P53</term></index-term>p53 mRNA [<xref ref-type="bibr" rid="CR72">285</xref>]. The FGF subtype, FGF13, does not function like a regular growth factor. In the nucleolus, it represses transcription of ribosomal RNA and hence protein synthesis. On the other hand, P53 prevents transcription of the Fgf13 locus and thus synthesis of both FGF13 and miR504 (negative feedback loop).</p><p id="Par258">MiR33 targets autophagy regulators and effectors in macrophages, diminishing lipid droplet catabolism and free cholesterol generation and subsequent efflux [<xref ref-type="bibr" rid="CR73">286</xref>]. Concentration of oxysterol-binding protein-like protein OSBPL6 and hence cholesterol transfer is also regulated by microRNAs. MiR548p reduces ApoB secretion and lipid synthesis via HMGCoAR and long-chain fatty acylCoA synthase ACSL4 [<xref ref-type="bibr" rid="CR73">286</xref>].</p><p id="Par259">Some microRNAs, such as miR1, miR126, miR138, miR143, and miR145, participate in cardiogenesis via angiogenesis, establishment of cardiac cell polarity, development of the cardiac conduction system, cardiac patterning, or smooth myocyte differentiation. Often, these miRs regulate the core cardiac transcriptional network [<xref ref-type="bibr" rid="CR74">287</xref>].</p><p id="Par260">Two miRs are highly expressed in vascular smooth myocytes and ECs, miR221 and miR222, which preclude EC migration and proliferation and hence angiogenesis, but favor vSMC proliferation and migration and counter apoptosis [<xref ref-type="bibr" rid="CR75">288</xref>]. MiR221 and miR222 reduce NOS3 expression and can cause <index-term id="ITerm135"><term>Endothelial dysfunction</term></index-term>endothelial dysfunction.</p><p id="Par261">In patients, circulating miR15b-5p allows the differentiation of individuals with well and poorly developed collateral vessels, as miR15b-5p produced in vascular ECs regulates <index-term id="ITerm136"><term>angiogenesis</term></index-term>angiogenesis [<xref ref-type="bibr" rid="CR73">286</xref>]. Proangiogenic miR126a is implicated in <index-term id="ITerm137"><term>Lymphangiogenesis</term></index-term>lymphangiogenesis via VEGFR3 signaling. Suppression of angiopoietin-2 formation by miR150 enables repair of vascular injury.</p><p id="Par262"><list list-type="bullet"><list-item><p id="Par263">MiR182-3p modulates a vascular smooth myocyte phenotype.</p></list-item><list-item><p id="Par264">MiR22 plays a role in smooth myocyte differentiation.</p></list-item><list-item><p id="Par265">MiR155 supports the migration of smooth myocyte progenitors via CCL2.</p></list-item><list-item><p id="Par266">MiR590-3p increases vSMC contractility and represents a risk factor for hypertension in the presence of genetic defects [<xref ref-type="bibr" rid="CR73">286</xref>].</p></list-item></list></p><p id="Par267">MiR125b is associated with vascular calcification [<xref ref-type="bibr" rid="CR73">286</xref>]. MiR146a targets the transcript encoding polo-like kinase PLK2 to induce bone marrow cell apoptosis and senescence [<xref ref-type="bibr" rid="CR73">286</xref>].</p><p id="Par268"><index-term id="ITerm138"><term>Redox stress</term></index-term>Redox stress due to excessive ROS production and insufficient scavenging is linked to aging, hypertension, hypercholesterolemia, diabetic vasculopathy, atherosclerosis, and ischemia. <index-term id="ITerm139"><term>ROS</term></index-term>Reactive oxygen species increase expression of MIR200 family members (miR141, miR200a–miR200c, and miR429) [<xref ref-type="bibr" rid="CR76">289</xref>].<xref ref-type="fn" rid="Fn45">45</xref></p><sec id="Sec15"><title>Endothelial Mechanical Stress-Responsive MicroRNAs</title><p id="Par277">The vascular endothelium forms a barrier that regulates its permeability. Moreover, this mechanosensor controls leukocyte adhesion, blood coagulation, the vasomotor tone, and vascular cell proliferation, especially that of smooth myocytes, in addition to angiogenesis.</p><p id="Par278">MicroRNAs and histone deacetylases (HDACs) control gene expression and hence endothelial function. MiR10a pertains to the endothelial mechanical stress-responsive microRNAs.<xref ref-type="fn" rid="Fn46">46</xref> It targets <index-term id="ITerm144"><term>GATA</term></index-term>Gata6, which elicits <index-term id="ITerm145"><term>Vcam</term></index-term>vcam1 synthesis (an anti-inflammatory effect). Mechano-miR10a expression is regulated by<index-term id="ITerm146"><term>KLF</term></index-term>KLF2 via <index-term id="ITerm147"><term>RAR (NR1b1/2/3)</term></index-term>RARα–RARE binding, which heterodimerizes with <index-term id="ITerm148"><term>RXR (NR2b1/2/3)</term></index-term>RXRα to bind RARE in the enhancer region of target genes [<xref ref-type="bibr" rid="CR81">294</xref>].<xref ref-type="fn" rid="Fn47">47</xref> According to the local flow pattern, <index-term id="ITerm149"><term>HDAC</term></index-term> HDAC3, HDAC5, and HDAC7, which link to <index-term id="ITerm150"><term>MEF</term></index-term>myocyte enhancer factor MEF2, thereby hampering production of anti-inflammatory KLF2, or NR2b1, operate as mechanosensitive repressors and enhancers, respectively.</p><p id="Par281">Vascular ECs in strongly curved segments with low wall shear stress (WSS) induce a quiescent-to-activated phenotypic transition of adjacent smooth myocytes and hyperplasia. Endothelial microRNAs, such as miR126-3p and miR200a-3p, are released in low WSS regions via activation of the SNAREs, vesicle-associated membrane protein VAMP3<xref ref-type="fn" rid="Fn48">48</xref> and synaptosomal-associated protein SnAP23 [<xref ref-type="bibr" rid="CR82">295</xref>]. These miRs then favor hyperplasia of recipient vSMCs.</p></sec><sec id="Sec16"><title>Regulators of Vascular Smooth Myocyte Phenotype</title><p id="Par283">Vascular smooth myocytes (vSMCs) are not irreversibly differentiated, because they can modify their phenotype according to environmental conditions, whereas fully differentiated smooth myocytes (SMCs) are refractive to PDGFbb stimulation.</p><p id="Par284">In large and medium-sized blood vessels, they constitute the main cellular population of the media. They are organized in a variable number of monolayers of circumferentially oriented vSMCs.</p><p id="Par285">The <italic>arterial media</italic> contains quiescent and contractile vSMCS surrounded by their own basement membrane, immersed in an extracellular matrix, and a small quantity of macrophages and fibroblasts.</p><p id="Par286"><index-term id="ITerm151"><term>HSPG</term></index-term>Heparan sulfate proteoglycans (HSPGs) are major components of the vSMC <index-term id="ITerm152"><term>Glycocalyx</term></index-term><italic>glycocalyx</italic>. The glycocalyx contains heparan and chondroitin sulfate proteoglycans and hyaluronic acid in addition to glycoproteins with terminal sialic acids.</p><p id="Par287">The <italic>basement membrane</italic> surrounding vSMCs contains predominantly collagen-4, laminin, and HSPGs, such as perlecan and syndecan. HSPGs are low-affinity receptors that sequester growth factors such as FGF2, which can modify vSMC phenotype, hence priming proliferation.</p><p id="Par288">Proteoglycans are proteins bearing glycosaminoglycans (GAGs). Glycosaminoglycans are long linear (unbranched) polysaccharide chains, which are also termed mucopolysaccharides. They encompass chondroitin (ChS), dermatan (DeS), heparan (HeS), and keratan sulfate (KeS), as well as heparin and hyaluronan, DeS being stereoisomeric variants of ChS. ChS and DeS interact with various types of extracellular molecules, such as growth factors, cytokines, chemokines, and morphogens, and are therefore involved in cell adhesion, proliferation, and migration.</p><p id="Par289">The <italic>medial interstitial matrix</italic> contains collagen-1 and -3, various types of glycoproteins (e.g., fibronectin, tenascin, thrombospondin, and vitronectin), and chondroitin sulfate proteoglycans such as versican [<xref ref-type="bibr" rid="CR83">296</xref>].</p><p id="Par290">Under normal conditions, vascular SMC differentiation is controlled by messengers such as TGFβ; plasma membrane components, such as adhesion molecules; matrix constituents, such as collagen and elastin; mechanical forces; neuronal signals; and intercellular interactions.</p><p id="Par291">On the other hand, dedifferentiated vSMCs synthesize matrix metallopeptidases (MMPs), tissue inhibitors of metallopeptidases (TIMPs), and matrix components.</p><p id="Par292"><index-term id="ITerm153"><term>Heparinase</term></index-term>Lysosomal heparin lyases (or heparinase)<xref ref-type="fn" rid="Fn49">49</xref> released by macrophages remove HS chains and favor vSMC proliferation.</p><p id="Par295"><index-term id="ITerm154"><term>Heparanase</term></index-term>Heparanase is an endoglycosidase that cleaves HS from the cell surfaces and matrix constituents, hence facilitating the release of exosomes and subsequent intercellular communication in addition to remodeling the extracellular matrix.</p><p id="Par296">The dedifferentiated vSMC can activate programmed cell death pathways and elaborate proinflammatory cytokines [<xref ref-type="bibr" rid="CR85">298</xref>]. Migration, proliferation, and death of vSMCs are events regulated by HSPGs and hence cell surface (extracellular) HS sulfataseheparan sulfate sulfatase-1 [<xref ref-type="bibr" rid="CR86">299</xref>]<xref ref-type="fn" rid="Fn50">50</xref></p><p id="Par299">Furthermore, activated vSMCs can be involved in efferocytosis and phagocytosis, ossification, reverse cholesterol transport, and foam cell formation.</p><p id="Par300"><index-term id="ITerm155"><term>Intimal hyperplasia</term></index-term>Phenotype switch and abnormal vSMC proliferation and migration constitute a major process in the genesis of arterial wall diseases, especially neointima formation, a hallmark of atherosclerosis and post-stenting restenosis.</p><p id="Par301">Once they are exposed to stressors, vSMCs change their phenotype, that is, they dedifferentiate from their quiescent contractile phenotype to a state characterized by abnormal proliferation, migration, matrix synthesis, and inflammation. This dedifferentiation contributes to maladaptive remodeling of the vascular wall (e.g., atherogenesis, post-angioplasty intimal hyperplasia, aneurysmal degeneration, and medial calcinosis).</p><p id="Par302">Cell motility relies on cycles of cell protrusion and retraction and of formation and disruption of cell–matrix adhesion sites, on polarized vesicular transfer and exocytosis, and, at the nanoscale, <index-term id="ITerm156"><term>ERK</term></index-term>extracellular signal-regulated kinase (ERK). The MAPK module component ERK and its effector kinase, <index-term id="ITerm157"><term>RSK</term></index-term>p90 ribosomal S6 kinase (RSK), regulate cell migration mainly via phosphorylation of various substrates [<xref ref-type="bibr" rid="CR87">300</xref>].</p><p id="Par303">The Ras–Raf–MAP2K–ERK–RSK pathway is activated by liganded receptor protein Tyr kinases (i.e., growth factors) and stimulated integrins. Activated ERK translocates into the nucleus, where it phosphorylates some transcription factors, thereby regulating gene expression. It also phosphorylates (activates) various types of kinases (RSKs, MSKs, and MNKs). <index-term id="ITerm158"><term>MKnK</term></index-term>Cytosolic MKnKs regulate mRNA translation, as they phosphorylate eukaryotic translation initiation factor eIF4e. <index-term id="ITerm159"><term>MSK</term></index-term>Nuclear MSKs also regulate gene transcription, as they phosphorylate transcription factors, high-mobility group nucleosome-binding domain-containing protein HMGN1, and histone H3 [<xref ref-type="bibr" rid="CR87">300</xref>]. Nuclear and cytosolic RSKs phosphorylate various transcription factors in the nucleus and the 40S ribosomal subunit protein S6 and eIF4b in the cytoplasm.</p><p id="Par304">Therefore, ERK regulates cell motility via genomic and nongenomic effects. It engenders motile mesenchymal cells from polarized epitheliocytes. Epithelial–mesenchymal transition is triggered by various transcription factors (e.g., <index-term id="ITerm160"><term>Snai</term></index-term>Snai1 and Snai2, <index-term id="ITerm161"><term>Twist</term></index-term>Twist1, and <index-term id="ITerm162"><term>ZEB</term></index-term>ZEB1 and ZEB2) [<xref ref-type="bibr" rid="CR87">300</xref>]. Both ERK and RSK phosphorylate regulators of cell protrusion and retraction, cell–matrix adhesion, and exocytosis (Table <xref rid="Tab10" ref-type="table">2.10</xref>). <table-wrap id="Tab10"><label>Table 2.10</label><caption xml:lang="en"><p>Components of the cell motility machinery phosphorylated by ERK or RSK (Source: [<xref ref-type="bibr" rid="CR87">300</xref>]; <italic>AbI</italic> Abelson kinase interactor, <italic>CKI</italic> cyclin-dependent kinase inhibitor, <italic>EPH</italic> erythropoietin-producing hepatocyte receptor protein Tyr kinase, <italic>Exo</italic> exocyst subunit, <italic>FAK</italic> focal adhesion kinase, <italic>MLCK</italic> myosin light chain kinase, <italic>SH3P</italic> SH3 domain-containing protein, <italic>SorbS3</italic> sorbin and SH3 domain-containing protein-3 [vinexin], <italic>vasp</italic> vasodilator-stimulated phosphoprotein, <italic>WAVe</italic> WASP family verprolin homolog)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Substrate</p></th><th align="left"><p>Effect</p></th></tr></thead><tbody><tr><td align="left" colspan="2"><p><italic>ERK</italic></p></td></tr><tr><td align="left"><p>AbI1</p></td><td align="left"><p>Actin polymerization, cell protrusion</p></td></tr><tr><td align="left"><p>Calpain-2</p></td><td align="left"><p>Focal adhesion dynamics</p></td></tr><tr><td align="left"><p>Cortactin</p></td><td align="left"><p>Actin polymerization, cell protrusion</p></td></tr><tr><td align="left"><p>Exo70</p></td><td align="left"><p>Exocyst assembly, exocytosis</p></td></tr><tr><td align="left"><p>FAK</p></td><td align="left"><p>Focal adhesion dynamics</p></td></tr><tr><td align="left"><p>MLCK</p></td><td align="left"><p>Myosin-2 activation</p></td></tr><tr><td align="left"><p>Paxillin</p></td><td align="left"><p>Focal adhesion dynamics</p></td></tr><tr><td align="left"><p>Rac1</p></td><td align="left"><p>Actin polymerization, cell protrusion</p></td></tr><tr><td align="left"><p>RhoGAP31</p></td><td align="left"><p>Inactivation of Rac and CDC42</p></td></tr><tr><td align="left"><p>RhoGEF2</p></td><td align="left"><p>Rho activation, cell retraction</p></td></tr><tr><td align="left"><p>Sorbs3</p></td><td align="left"><p>Cell spreading (SorbS3α)</p></td></tr><tr><td align="left"/><td align="left"><p>Actin stress fiber formation (SorbS3β)</p></td></tr><tr><td align="left"><p>Wave2</p></td><td align="left"><p>Actin polymerization, cell protrusion</p></td></tr><tr><td align="left" colspan="2"><p><italic>RSK</italic></p></td></tr><tr><td align="left"><p>CKI1b</p></td><td align="left"><p>Rho inhibition (cell retraction)</p></td></tr><tr><td align="left"><p>EPHa2</p></td><td align="left"><p>Phosphorylation of EPHa2 (cell motility)</p></td></tr><tr><td align="left"><p>Filamin-A</p></td><td align="left"><p>Filamentous actin crosslinking</p></td></tr><tr><td align="left"><p>Plastin-2</p></td><td align="left"><p>Filamentous actin bundling</p></td></tr><tr><td align="left"><p>SH3P2</p></td><td align="left"><p>Cytoplasmic anchor for myosin-1E</p></td></tr><tr><td align="left"><p>Vasp</p></td><td align="left"><p>Actin polymerization, cell protrusion</p></td></tr></tbody></table><table-wrap-foot><p>Cell protrusions are formed by the extension of lamellipodia and filopodia (i.e., sheet- and needle-like structures) at the leading edge of cells in response to motility stimuli</p></table-wrap-foot></table-wrap></p><p id="Par305">Cell movement is induced by activation of the small GTPase Ras, which in turn stimulates both PI3K and ERK axes. The PI3K pathway stimulates actin polymerization and the formation of a protrusion (a lamellipodium) at the leading edge of the moving cell via activation of the small GTPase Rac1 and protein kinase PKB.</p><p id="Par306">The ERK kinase phosphorylates MLC kinase, cortactin, WASP family protein member WASF2 (wave2), and FAK, among other substrates, thereby promoting cell migration.<xref ref-type="fn" rid="Fn51">51</xref></p><p id="Par310">In addition, ERK phosphorylates (activates) MLCK, which phosphorylates myosin light chain and activates myosin-2 [<xref ref-type="bibr" rid="CR87">300</xref>]. Its effector RSK phosphorylates (inactivates) SH3P2,<xref ref-type="fn" rid="Fn52">52</xref> an inhibitor of the nanomotor myosin-1E,<xref ref-type="fn" rid="Fn53">53</xref> disrupting SH3P2–Myo1e tethering and enabling Myo1e to move to the lamellipodium tip, where it facilitates cell motion [<xref ref-type="bibr" rid="CR88">301</xref>].</p><p id="Par313">Among the four isozymes (RSK1–RSK4), RSK1 impedes actin elongation, as it phosphorylates (inactivates) VASP [<xref ref-type="bibr" rid="CR87">300</xref>]. On the other hand, VASP is also phosphorylated by PKA and then re-localizes to lamellipodia.</p><p id="Par314">Ribosomal s6 kinase (RSK) phosphorylates filamin-A, a dimeric actin crosslinker, at the same site phosphorylated by PAK, and, among plastins (Pls1–Pls3), Pls2 that then form actin bundles.</p><p id="Par315">Focal cell–matrix adhesions are mediated by heterodimeric transmembrane integrins, which interact with matrix components (e.g., collagen, fibronectin, and vitronectin) and cytosolic constituents, transducing bidirectional signals between the extra- and intracellular media (outside–in and inside–out signaling).</p><p id="Par316">Focal adhesion kinase (FAK) and SRC family kinases (SFKs) participate in proteic complex formation at the cytoplasmic tail of integrins. Autophosphorylated FAK recruits various SFKs, which further phosphorylate FAK and process FAK-associated proteins such as the docker paxillin, thereby accelerating formation of signaling complexes at focal adhesion sites. Extracellular-signal-regulated kinase (ERK) phosphorylates both FAK and paxillin in focal adhesion sites, increasing FAK–Pax binding and eliciting cell adhesions and protrusions [<xref ref-type="bibr" rid="CR87">300</xref>].</p><p id="Par317">Sorbin and SH3 domain-containing protein Sorbs3 (or vinexin) are other regulators of cell spreading and growth factor signaling at focal adhesion sites [<xref ref-type="bibr" rid="CR87">300</xref>]. Among several alternative forms (Sorbs3α–Sorbs3γ), Sorbs3β is phosphorylated by ERK at the leading edge of moving cells, decreasing cell spreading and motility.</p><p id="Par318">Calpain-2 cleaves proteins involved in cell–matrix adhesion and cell protrusion, such as FAK, SFKs, cortactin, integrins, and paxillin [<xref ref-type="bibr" rid="CR87">300</xref>]. ERK phosphorylates (activates) calpain-2. Calpain-2 can complex with ERK and FAK at focal adhesion sites. Calpain-2 also cleaves linkers of focal adhesions to the cytoskeleton, such as spectrin and talin, thereby eliciting the turnover of adhesion complexes.</p><p id="Par319">In the retracting tail of migrating cells, RhoA, RhoB, and RhoC are implicated in the detachment of cell–matrix adhesions and myosin-2-mediated cell retraction. These small Rho GTPases activate rock that phosphorylates (activates) LIMK, which phosphorylates (inhibits) cofilin, precluding further actin polymerization. Rock also phosphorylates (inhibits) myosin phosphatase, supporting myosin-based contractile force.</p><p id="Par320">Extracellular-signal-regulated kinase (ERK) phosphorylates (activates) RhoGEF2 in focal adhesions in response to stretch. On the other hand, ERK phosphorylates (activates) RhoGAP7 in focal adhesions, thereby enabling cycles of Rho deactivation–reactivation. Therefore, ERK functions as a spatiotemporal regulator of cell retraction. In addition, ERK phosphorylates RhoA, priming its ubiquitination and subsequent proteasomal degradation [<xref ref-type="bibr" rid="CR87">300</xref>]. Furthermore, RSK phosphorylates cyclin-dependent kinase inhibitor CKI1b, which is then sequestered in the cytoplasm, where it binds to Rho, hampering its activity.</p><p id="Par321">Polarized endo- and exocytosis during cell migration is defined by internalization of membrane proteins, such as integrins and RTKs, at the cell trailing edge to be recycled to the leading edge and displacement of secretory vesicles carrying newly synthesized proteins from the Golgi body to the leading edge. These processes are controlled by the small GTPases of the ARF, Rab, Ral, and Rho superfamilies. The octameric proteic complex exocyst tethers secretory vesicles to the plasma membrane. ERK phosphorylates the exocyst component Exo70, promoting its binding to other exocyst components and secretion of matrix metallopeptidases [<xref ref-type="bibr" rid="CR87">300</xref>].</p><sec id="Sec17"><title>Transcription Factors</title><p id="Par322">Phenotypic switching of vSMCs involves both activators of SMC dedifferentiation and repressors of SMC differentiation, such as <index-term id="ITerm163"><term>ELk/TcF</term></index-term>ETS-like factor ELk1, once it is phosphorylated by ERK, <index-term id="ITerm164"><term>ETS</term></index-term>E26 transformation-specific sequence ETS1, <index-term id="ITerm165"><term>FoxO</term></index-term>forkhead box-containing FoxO4, <index-term id="ITerm166"><term>FHL</term></index-term>four-and-a-half LIM-only FHL2 <index-term id="ITerm167"><term>HRT</term></index-term>hairy and enhancer of split-related HRT2, and <index-term id="ITerm168"><term>KLF</term></index-term>Krüppel-like transcription factor KLF4, <index-term id="ITerm169"><term>SP</term></index-term>specificity protein SP1, and <index-term id="ITerm170"><term>YY</term></index-term>yin yang transcription factor YY1, which act in a coordinated manner [<xref ref-type="bibr" rid="CR89">302</xref>].</p><p id="Par323">Serum response factor and its cofactor promote differentiation of vSMCs. Myocardin (Myocd) is the most powerful serum response factor (SRF) cofactor from embryogenesis to adulthood, as myocardin stimulates SRF-initiated gene transcription. The SRF–Myocd couple activates smooth and cardiac muscle gene promoters. Both SRF and Myocd undergo post-translational modification (e.g., phosphorylation), which affects SRF–Myocd activity in SMC differentiation.</p><p id="Par324">The SRF homodimer connects to the CC(A/T)<sub>6</sub>GG (CArG) DNA consensus sequence, which is found in promoters and introns of SMC-specific genes. Transforming growth factor-β provokes SRF expression and stimulates SMC differentiation.</p><p id="Par325">Myocardin selectively induces transcription of most of the CArG-containing genes, especially SMC marker genes, such as those encoding smooth muscle α-actin (actα2) and myosin heavy chain (MyH11), transgelin, calponin,<xref ref-type="fn" rid="Fn54">54</xref> and telokin, but not the CArG-containing early response gene FOS [<xref ref-type="bibr" rid="CR89">302</xref>]. Myocardin mediates inducible expression of CArG-containing SMC marker genes in response to Agt2, TGFβ, PDGFbb, and the Ca<sub>V</sub>1–RhoA axis.</p><p id="Par327"><index-term id="ITerm171"><term>Runx</term></index-term>On the other hand, the osteogenic Runt-related transcription factor Runx2 is a SRF corepressor, as it tethers to SRF and hinders SRF–Myocd complex formation.</p><p id="Par328"><index-term id="ITerm172"><term>Olfactomedin</term></index-term>Olfactomedin-2 (Olfm2)<xref ref-type="fn" rid="Fn55">55</xref> regulates TGFβ-induced SMC differentiation from mesenchymal stem cells, Runx2 being undetectable [<xref ref-type="bibr" rid="CR94">307</xref>]. Olfm2 promotes the dissociation of SRF from HRT2, a transcriptional repressor for SMC genes.</p><p id="Par334">On the other hand, in a different cellular context, Olfm2 also participates in mature vSMC phenotype switching, Runx2 being substantially present in mature SMCs. It promotes their proliferation and migration, hence favoring vascular wall remodeling [<xref ref-type="bibr" rid="CR94">307</xref>]. Although TGFβ triggers formation of Olfm2 and SMC markers in mesenchymal progenitor cells, it does not significantly induce Olfm2 expression in mature rat aortic SMCs, whereas PDGFbb primes synthesis of Runx2 and Olfm2 in SMCs [<xref ref-type="bibr" rid="CR94">307</xref>]. Olfm2 facilitates interaction of SRF with Runx2, thereby hampering SRF–Myocd interaction.</p><p id="Par335">The gene promoters contain not only a distal CArG element but also a G/C-rich repressor element located proximal to the CArG element. The G/C element binds to <index-term id="ITerm173"><term>SP</term></index-term>specificity proteins SP1 and SP3, <index-term id="ITerm174"><term>KLF</term></index-term>members of the KLF family, and early growth response transcription factor <index-term id="ITerm175"><term>EGR</term></index-term>EGR1, which are normally absent in differentiated SMCs, but rapidly induced upon vascular injury [<xref ref-type="bibr" rid="CR89">302</xref>]. For example, PDGFbb counters SRF attachment to the CArG–G/C–CArG motif within the MYH11 and TAGLN promoters of genes encoding smooth muscle myosin heavy chain and transgelin, respectively.</p><p id="Par336">FHL2 interacts with SRF and binds to the promoter of SMC-specific CArG-containing genes in response to RhoA [<xref ref-type="bibr" rid="CR89">302</xref>]. It precludes SRF-mediated transcription of SMC-specific genes, as it competes with MRTFa for SRF binding.</p><p id="Par337">HRT2 prevents myocardin-dependent transactivation of the MYH11 and TAGLN gene promoters [<xref ref-type="bibr" rid="CR89">302</xref>]. In addition, it tethers to SRF and hampers SRF binding to CArG box motifs.</p><p id="Par338">Yin yang-YY1 represses SRF binding and Fos activity, hence skeletal and cardiac muscle α-actin formation. However, its overexpression can transactivate the TAGLN promoter in cultured rat aortic SMCs [<xref ref-type="bibr" rid="CR89">302</xref>].</p></sec><sec id="Sec18"><title>Krüppel-Like Factors</title><p id="Par339">Krüppel-like factor KLF4 was identified as a binding factor to the G/C-rich TGFB promoter and also connects to the MYH11 and TAGLN promoters. It suppresses expression of myocardin and activation by myocardin of SMC marker genes; competes for binding of SRF to CArG regions, hence reducing SRF binding to CArG-containing SMC marker genes; and provokes hypoacetylation of histone H4 at CArG regions (transcriptional silencing) [<xref ref-type="bibr" rid="CR89">302</xref>].</p><p id="Par340">KLF4 along with platelet-derived growth factor (PDGFbb), notch, and TGF-β affects the vSMC differentiation status [<xref ref-type="bibr" rid="CR85">298</xref>]. Moreover, contractile and synthetic vSMC phenotypes are controlled by numerous microRNAs. MicroRNAs are indeed major regulators in vSMC proliferation and migration.</p><p id="Par341"><index-term id="ITerm176"><term>KLF</term></index-term>Among 20 members of the KLF family, anti-inflammatory KLF2, KLF4, proproliferative KLF5, and KLF6 play important roles in the vasculature. KLF1 is essential for erythrocyte maturation.</p><p id="Par342">In the vascular wall, KLF2 is exclusively synthesized in ECs, its synthesis being inhibited by inflammatory IL-1β. It induces NOS3 expression; but impedes cytokine-primed formation of adhesion molecules (e.g., E-selectin and vcam1) [<xref ref-type="bibr" rid="CR95">308</xref>].</p><p id="Par343">KLF4 operates in endothelial inflammation, macrophage gene expression, and vSMC phenotype [<xref ref-type="bibr" rid="CR96">309</xref>]. In ECs, KLF4, the production of which is induced by proinflammatory agents, induces expression of multiple anti-inflammatory and anti-thrombotic factors (e.g., NOS3 and thrombomodulin) [<xref ref-type="bibr" rid="CR97">310</xref>].<xref ref-type="fn" rid="Fn56">56</xref></p><p id="Par345">KLF4 prevents Jun expression and hence <index-term id="ITerm177"><term>Intimal hyperplasia</term></index-term>intimal hyperplasia. It can also block the PDGFbb–PDGFR–ERK axis and vSMC proliferation primed by PDGFbb. Furthermore, it induces the expression of <index-term id="ITerm178"><term>P53</term></index-term>P53 and subsequently that of CKI1a and represses that of <index-term id="ITerm179"><term>ID</term></index-term>ID3 and <index-term id="ITerm180"><term>RAR (NR1b1/2/3)</term></index-term>retinoic acid receptor RARα (NR1b1), which suppresses CKI1a synthesis. It also promotes the production of several cell cycle inhibitors (CKI1b, DM2, and RB) and represses that of cell cycle stimulators (cyclin-D1 and ornithine decarboxylase) [<xref ref-type="bibr" rid="CR96">309</xref>].</p><p id="Par346">On the other hand, KLF4 can be a potent transcriptional repressor of SMC differentiation markers (ACTA2, CNN1, TAGLN, and MYH11 gene encoding smooth muscle α-actin, calponin-1, smooth muscle myosin heavy chain, and transgelin, respectively), functioning as an effector of PDGFbb, which induces phosphorylation of <index-term id="ITerm181"><term>ELk/TcF</term></index-term>ELk1 via the MAP2K1/2–ERK1/2 axis, re-localizing ELk1 to the nucleus, where it competes with myocardin, thereby blocking SRF–myocardin interaction [<xref ref-type="bibr" rid="CR96">309</xref>]. In the context of gene repression, KLF4 recruits <index-term id="ITerm182"><term>HDAC</term></index-term>HDAC2, which deacetylates histone H4, hence causing chromatin compaction. It also downregulates the formation of paired-related homeobox-derived protein <index-term id="ITerm183"><term>PrRx</term></index-term>PrRx1 and <index-term id="ITerm184"><term>MRTF</term></index-term>MRTFs.</p><p id="Par347">However, acetylated KLF4 can also promote synthesis of smooth muscle actin-α2, myosin heavy chain-11, and transgelin [<xref ref-type="bibr" rid="CR96">309</xref>]. In the context of gene activation, KLF4 recruits <index-term id="ITerm185"><term>KAT</term></index-term>KAT3b to gene promoters. KAT3b acetylates KLF4 in addition to histones. Moreover, KLF4 phosphorylation enhances its transactivation capacity, hence facilitating vSMC differentiation.</p><p id="Par348">Therefore, KLF4 activity depends on post-translational modifications (acetylation, phosphorylation, and sumoylation) induced by various messengers and effectors (PDGFR, Tβ R, and RAR).</p><p id="Par349">In addition, KLF4 supports the synergistic action of ECs and mural macrophages, which originate from circulating and then resident monocytes. It transactivates <index-term id="ITerm186"><term>LXR (NR1h2/3)</term></index-term>liver X receptor (NR1h2/3) and <index-term id="ITerm187"><term>CS25H</term></index-term>cholesterol 25-hydroxylase, which forms 25-hydroxycholesterol, thereby reducing inflammasome activity in ECs, promoting M1-to-M2 phenotypic transition in macrophages, and protecting against atherosclerosis susceptibility [<xref ref-type="bibr" rid="CR98">311</xref>].</p><p id="Par350"><index-term id="ITerm188"><term>Cyclosporin</term></index-term>Cyclosporine-A (CSa), a PP3 inhibitor, suppresses vSMC proliferation. In vSMC, it upregulates the expression of <index-term id="ITerm189"><term>P53</term></index-term>P53 and KLF4 [<xref ref-type="bibr" rid="CR99">312</xref>]. KLF4 hinders vSMC proliferation, as it elicits CDKN1A gene transcription. It facilitates migration, as it also promotes Mmp3 gene transcription. In addition, it supports the formation of MMP9 and collagen-8. It represses transcription of MYOCD and vSMC differentiation marker genes (ACTA2, SMTN, and TAGLN). In addition, CSa acutely and transiently represses MyH11 production.</p><p id="Par351">KLF5 activates the PDGFA genes, thereby favoring in-stent neointima formation in rabbits [<xref ref-type="bibr" rid="CR89">302</xref>]. In response to vascular injury, KLF5 is induced in proliferating vSMCs; it initiates the production of EGR1, PDGFa, PDGFb, PAI1 (serpin-E1), NOS2, and VEGFRs [<xref ref-type="bibr" rid="CR96">309</xref>]. KLF5 can reverse KLF4-induced suppression of SMC marker gene expression. It can also induce the expression of NMHCB and PDGFA genes, which encode nonmuscle myosin heavy chain NMHCb (myosin-10) and PDGFa genes in vSMCs.</p><p id="Par352">Upon vascular injury, in ECs, KLF6 triggers synthesis of TGFβ and its receptors and urokinase plasminogen activator [<xref ref-type="bibr" rid="CR96">309</xref>].</p></sec><sec id="Sec19"><title>Growth Factors and Autacoids</title><p id="Par353">Under normal conditions, vSMCs, endowed with their contractile apparatus, are maintained in a quiescent and contractile state. On the other hand, vSMCs can switch their phenotype from a quiescent to a synthetic state associated with formation of a new extracellular matrix and the capacity of proliferation and migration from the media to the intima.</p><p id="Par354">The pathogenic phenotype can be countered by HSPGs, <index-term id="ITerm190"><term>NO</term></index-term>NO, prostaglandins, and TGFβ.</p><p id="Par355">The vSMC phenotype change is triggered by various growth factors, cytokines, and other stimulators released upon vascular injury, such as epidermal (EGF), fibroblast (particularly FGF1 and FGF2), and IGF1, PDGFbb, vascular endothelial growth factor (VEGF), angiotensin-2, endothelin-1, thrombin, tumor-necrosis factor-α (TNFSF1), and IL-1 [<xref ref-type="bibr" rid="CR100">313</xref>]. Among these factors, PDGFs and FGFs are the most potent for initiating the phenotypic switch and for controlling vSMC proliferation and migration [<xref ref-type="bibr" rid="CR103">316</xref>].</p><sec id="Sec20"><title>Platelet-Derived Growth Factors</title><p id="Par356"><index-term id="ITerm191"><term>PDGF</term></index-term>Three dimeric PDGF isoforms (PDGFaa, PDGFab, and PDGFbb) tether to two reeceptor protomers (PDGFRα–PDGFRβ). PDGFs stimulate proliferation and migration of SMCs in addition to fibroblasts and gliocytes via PDGFRβ. Among PDGFs, PDGFab and PDGFbb support vSMC migration, whereas PDGFaa inhibits migration induced by PDGFab and PDGFbb via heparin-binding fibronectin [<xref ref-type="bibr" rid="CR101">314</xref>]. Cell adhesion to <index-term id="ITerm192"><term>Fibronectin</term></index-term>fibronectin (but not to collagen-4) suppresses vSMC migration. Vascular SMCs and platelets produce PDGFbb in response to acute vascular injury.</p><p id="Par357">However, administration of an antibody that neutralizes activity of PDGFaa, PDGFbb, and PDGFab reduces proliferation and migration of medial SMCs in a rat carotid artery balloon injury model [<xref ref-type="bibr" rid="CR89">302</xref>]. Whereas inhibition of PDGFRβ prevents SMC accumulation after vascular injury, that of PDGFRα does not impede SMC accumulation. Vascular SMC fate is thus mainly affected by PDGFbb, which signals via PDGFRβ, rather than PDGFRα.</p><p id="Par358">Platelet-derived growth factor (PDGFbb) functions not only as a growth stimulator but also as a repressor of SMC protein production at both the transcriptional and post-transcriptional levels linked to degradation of SMC marker transcripts and proteins. In addition, PDGFbb cooperates with IL1β to repress vSMC differentiation via the PI3K–PKB–S6K pathway.</p><p id="Par359">The principal plasma membrane-associated HSPGs include transmembrane <index-term id="ITerm193"><term>Syndecan</term></index-term>syndecans and membrane-anchored <index-term id="ITerm194"><term>Glypican</term></index-term>glypican using a glycosylphosphatidylinositol chain. PDGFaa increases syndecan-1 production and causes HSPG accumulation on vSMCs more efficiently than does PDGFbb, whereas both PDGF isoforms decrease formation of <index-term id="ITerm195"><term>Perlecan</term></index-term>perlecan, another HSPG. PDGFaa thus influences the interaction of SMCs with heparin-binding matrix proteins, thereby suppressing vSMC migration.</p></sec><sec id="Sec21"><title>Fibroblast Growth Factors</title><p id="Par360">The FGF family comprises 22 members that act via their receptors (FGFR1–FGFR4), triggering assembly of a ternary complex with the adaptors FRS2 and GRB2 and the GEF, SOS, which activates the Ras–MAPK signaling cascade.</p><p id="Par361"><index-term id="ITerm196"><term>FGF</term></index-term>Among FGFs, FGF12 expression is elevated in contractile vSMCs but downregulated in synthetic vSMCs. It induces and maintains the quiescent vSMC phenotype [<xref ref-type="bibr" rid="CR102">315</xref>]. Moreover, it prevents cell proliferation via <index-term id="ITerm197"><term>P53</term></index-term>P53. It upregulates synthesis of myocardin and serum response factor via P38MAPK. Synthesis of FGF12 is inhibited by PDGFbb [<xref ref-type="bibr" rid="CR102">315</xref>].</p></sec><sec id="Sec22"><title>Transforming Growth Factor</title><p id="Par362"><index-term id="ITerm198"><term>TGF</term></index-term>TGFβ mediates vSMC phenotype switch from the synthetic to the contractile state. It connects to and activates Tβ R2, which then associates with and activates Tβ R1, which phosphorylates SMAD2 and SMAD3, eventually priming production of contractile proteins in pericytes and smooth myocytes [<xref ref-type="bibr" rid="CR103">316</xref>].</p><p id="Par363">On the other hand, TGFβ which signals via SMAD3 stimulates rather than inhibits vSMC proliferation via phosphorylation and nuclear export of CKI1b [<xref ref-type="bibr" rid="CR104">317</xref>]. The TGFβ–SMAD3 axis also launches the synthesis of fibronectin and collagen-1 in vSMCs.</p><p id="Par364">The inhibitor of both vSMC proliferation and migration and the stimulator of vSMC proliferation according to the circumstances, TGFβ, signal via various pathways. It does indeed operate via ERK, JNK, and P38MAPK along with PI3K and most commonly SMADs (receptor-activated SMAD2 and SMAD3, common SMAD4, and inhibitory SMAD6 and SMAD7) [<xref ref-type="bibr" rid="CR104">317</xref>]. Activated TGFβ receptor phosphorylates (activates) SMAD3, which then complexes with SMAD4. The SMAD3–SMAD4 complex translocates to the nucleus, where it connects to SMAD-binding elements and regulates transcription of target genes. Inhibitory SMADs antagonize TGFβ signaling, as they either prevent activation of receptor-activated SMADs or prime Tβ R degradation.</p><p id="Par365"><index-term id="ITerm199"><term>SKi</term></index-term>The repressor of TGFβ signaling, SKi, precludes vSMC proliferation stimulated by TGFβ in addition to vSMC autophagy induced by oxLDLs and PDGF via hampering of PKB phosphorylation, thereby downregulating production of proliferating cell nuclear antigen (PCNA) [<xref ref-type="bibr" rid="CR105">318</xref>]. Autophagy inducers PDGF and oxLDLs are also involved in vSMC phenotype transition and aberrant proliferation. Decayed production of SKi is thus implicated in <index-term id="ITerm200"><term>Intimal hyperplasia</term></index-term>intimal hyperplasia. MiR21 impedes SKi synthesis, thereby suppressing P38MAPK–CKI1a/CKI1b signaling and favoring vSMC proliferation [<xref ref-type="bibr" rid="CR106">319</xref>].</p><p id="Par366">Upon endothelium and internal elastic lamina injury (after angioplasty, near anastomoses of vascular grafts, and in ruptured atherosclerotic lesions), vSMCs can be exposed to blood flow and hence subjected to shear and stretch engendered by the hemodynamic stress field. They align in the streamwise direction. These mechanical stresses enhance NO production but impede vSMC migration and proliferation predominantly via TGFβ1 in an autocrine manner [<xref ref-type="bibr" rid="CR107">320</xref>]. After exposure of vSMCs to flow, synthesis of TGFβ1 and tissue-type <index-term id="ITerm201"><term>tPA</term></index-term>plasminogen activator, which converts plasminogen to plasmin, an activator of latent inactive TGFβ1 form, rises [<xref ref-type="bibr" rid="CR108">321</xref>]. In addition, hemodynamic stress can prevent vSMC migration, as it lowers PDGFRβ and MMP2 formation [<xref ref-type="bibr" rid="CR109">322</xref>]. Hemodynamic stress suppresses SMC migration, as it increases NO production and impedes <index-term id="ITerm202"><term>MMP</term></index-term>MMP2 activity [<xref ref-type="bibr" rid="CR110">323</xref>]. <index-term id="ITerm203"><term>Mechanotransduction</term></index-term>Vascular ECs and SMCs directly exposed to hemodynamic stress (shear) detected by mechanosensors (glycocalyx, GPCRs, adhesion molecules, and ion channels) modify their NO production rate.</p></sec><sec id="Sec23"><title>Semaphorins</title><p id="Par367"><index-term id="ITerm204"><term>Semaphorin</term></index-term>Semaphorin-3E is a regulator of cell migration and proliferation; its expression progressively decays during intimal hyperplasia. Sema3e prevents vSMC migration and proliferation via its receptor <index-term id="ITerm205"><term>Plexin</term></index-term>plexin-D1 and inactivation of the <index-term id="ITerm206"><term>Rap</term></index-term>Rap1–PKB axis [<xref ref-type="bibr" rid="CR111">324</xref>]. On the other hand, after vascular injury, the mutual PDGFbb–sema3e inhibition favors neointimal formation. On the one hand, PDGFbb downregulates sema3e formation in vSMCs. On the other, sema3e precludes synthesis of the PDGFb protomer in ECs via <index-term id="ITerm207"><term>EGR</term></index-term>EGR1, PDGFb being the most potent mitogen for vSMCs. In addition, P53 induces sema3e expression, hence suppressing vSMC proliferation and intimal hyperplasia after vascular injury [<xref ref-type="bibr" rid="CR111">324</xref>].</p></sec><sec id="Sec24"><title>Heparin</title><p id="Par368"><index-term id="ITerm208"><term>Heparin</term></index-term>Heparin is a GAG that prevents cell migration and proliferation, particularly vSMC proliferation via inhibition of <index-term id="ITerm209"><term>PKC</term></index-term>PKCα, suppressing phosphorylation of myristoylated alanine-rich PKC substrate, and promotes the contractile phenotype [<xref ref-type="bibr" rid="CR112">325</xref>]. Heparin impedes the transcription of several genes associated with cell cycle progression (e.g., MyB, MyC, and Fos), the mitochondrial adenine nucleotide translocator (or ATP–ADP carrier) SLC25a5, and histone H3.</p></sec><sec id="Sec25"><title>Prostaglandins</title><p id="Par369">The balance between thromboxane and prostacyclin is altered in cardiovascular disease. <index-term id="ITerm210"><term>PGi<sub>2</sub></term></index-term>Prostacyclin counters vSMC dedifferentiation using the PtgIR–Gs–AC–cAMP–PKA axis [<xref ref-type="bibr" rid="CR113">326</xref>]. Prostacyclin is a vasodilator and a potent inhibitor of platelet activation and vSMC proliferation. This main product of prostaglandin-H synthase PGhS2 (or cyclooxygenase COx2) is derived from arachidonic acid in vascular endotheliocytes. It acts via its cognate <index-term id="ITerm211"><term>PtgIR</term></index-term>PtgIR (IP) receptor. On the other hand, <index-term id="ITerm212"><term>Thromboxane</term></index-term>thromboxane TxA<sub>2</sub> is a potent activator of platelets and a vasoconstrictor. It is produced by PGhS1 (COx1) from arachidonic acid and released by activated platelets. Loss of prostacyclin and NO causes EC dysfunction and SMC dedifferentiation.</p></sec><sec id="Sec26"><title>Lactate</title><p id="Par370">Lactate concentration that increases upon ischemia can shift vSMC behavior to the synthetic phenotype [<xref ref-type="bibr" rid="CR114">327</xref>]. Vascular smooth myocytes cultured in lactate-enriched medium have a synthetic phenotype and a larger proliferation and migration rate with respect to those grown in glucose-free and standard media. These changes are accompanied by an increased expression of monocarboxylic acid transporters. In pigs, concentrations of lactate, lactate dehydrogenase, and monocarboxylic acid transporter in addition to vSMC proliferation rate are greater in ischemic regions than in other sites.</p></sec></sec><sec id="Sec27"><title>Intracellular Regulators</title><p id="Par371"><index-term id="ITerm213"><term>PKB</term></index-term>Protein kinase-B is activated by hormones such as insulin, growth factors, and cytokines. It regulates cell metabolism, survival, differentiation, proliferation, and migration. Members of the PKB family (PKB1–PKB3) play distinct roles. Multiple factors can explain the distinct role of PKB isoforms, such as cell type, subcellular localization, expression level of the PKB subtypes in addition to their substrates and regulators, and interference with other signaling cascades. For example, PKB1 promotes and PKB2 inhibits migration of mouse embryonic fibroblasts using distinct facets of the Rac–PAK pathway [<xref ref-type="bibr" rid="CR115">328</xref>].</p><p id="Par372">In vECs, PKB1, the major isoform, is involved in angiogenesis and in inflammation. In vSMCs, the structurally similar (but not identical) PKB1 and PKB2, which are formed at similar concentrations, exert opposing effects on the cell phenotype, although they share many substrates. PKB1 promotes vSMC proliferation and migration and hence the dedifferentiated phenotype, PKB2, supports the differentiated phenotype [<xref ref-type="bibr" rid="CR115">328</xref>]. In addition, PKB1 can play an antiapoptotic role. Moreover, PKB1 can inhibit PKB2.</p><p id="Par373">Rapamycin, a TORC1 inhibitor stored in a drug-eluting stent, is aimed at avoiding intimal hyperplasia, as it prevents vSMC proliferation and migration. TORC1 represses insulin and IGF1 action and hence PI3K signaling, as it phosphorylates (inhibits) insulin receptor substrate IRS1. Its inhibition thus activates PKB. The latter phosphorylates (inactivates) transcription factors of the <index-term id="ITerm214"><term>FoxO</term></index-term>FOXO family (FoxO1, FoxO3a, and FoxO4), leading to their nuclear exclusion and cytosolic sequestration by 14-3-3 proteins. Rapamycin activates the PKB2 isoform.</p><p id="Par374">Rapamycin launches vSMC differentiation via myocardin and PKB2 and subsequent nuclear exclusion of forkhead box-derived transcription factor FoxO4 (but neither FoxO1 nor FoxO3), thereby preventing its binding to the MYOCD promoter and subsequent MYOCD gene transcription [<xref ref-type="bibr" rid="CR115">328</xref>]. FoxO4 interacts with both myocardin and SRF and thus hinders myocardin action. In addition, FoxO4 supports MMP9 formation, thereby assisting vSMC migration. On the other hand, myocardin promotes synthesis of smooth muscle contractile proteins. In addition, the transcription factor GATA6 is another PKB2 substrate that promotes SMC differentiation [<xref ref-type="bibr" rid="CR115">328</xref>].</p></sec><sec id="Sec28"><title>MicroRNAs</title><p id="Par375">Let7g, miR21, miR29, miR126, miR132, miR145, miR146a, miR155, miR221, and miR222 are implicated in <index-term id="ITerm215"><term>SMC dysfunction</term></index-term>vSMC dysfunction associated with aberrant vSMC proliferation and migration and <index-term id="ITerm216"><term>Intimal hyperplasia</term></index-term>adverse intimal remodeling in atherosclerosis and restenosis. Vascular injury downregulates formation of miR143 and miR145, which cause vSMC differentiation and repress vSMC proliferation, but upregulates miR21, miR146a, and miR222, eliciting synthetic vSMC phenotype. Other important miRs include antiproliferative miR1, miR133, and miR195 and proproliferative miR21, miR221, miR222, and miR146a.</p><p id="Par376">Let7g controls autophagy and apoptosis of vSMCs exposed to oxidized LDLs [<xref ref-type="bibr" rid="CR116">329</xref>]. <index-term id="ITerm217"><term>oxLDL</term></index-term>Oxidized LDLs (10–40 μg/ml) elicit <index-term id="ITerm218"><term>Autophagy</term></index-term>autophagy via beclin-1 (Atg6), MAP1LC3 (Atg8), and Atg5 in addition to <index-term id="ITerm219"><term>apoptosis</term></index-term>apoptosis via <index-term id="ITerm220"><term>BCL2</term></index-term>BCL2 and BCL2L1 on the one hand and BAX and caspase-3 on the other. Let7g impedes autophagy, as <index-term id="ITerm221"><term>Lipoxygenase</term></index-term>lipoxygenase LOx1 expression and intracellular <index-term id="ITerm222"><term>ROS</term></index-term>ROS generation decline. In airway SMCs, Let7g also hampers synthesis of LOx1 and Oct1.</p><p id="Par377"><index-term id="ITerm223"><term>Myocardin</term></index-term>Myocardin is a cardiac and smooth myocyte-specific transcription cofactor that promotes their differentiation, but impedes proliferation, partly via <index-term id="ITerm224"><term>HDAC</term></index-term>HDAC4 and <index-term id="ITerm225"><term>HAND</term></index-term>HAND2. Myocardin induces expression of miR1 in CMCs and in SMCs [<xref ref-type="bibr" rid="CR117">330</xref>]. Transcription of the MIR1 gene depends on SRF in the myocardium and transcription factors of the <index-term id="ITerm226"><term>MyoD</term></index-term>MyoD family in skeletal muscles. Spindle-shaped SMCs possess higher amounts of both myocardin and miR1 than epithelioid SMCs. MicroRNA-1 targets <index-term id="ITerm227"><term>PIM</term></index-term>PIM1 and prevents vSMC proliferation.</p><p id="Par378">MiR21 favors vSMC proliferation and <index-term id="ITerm228"><term>Intimal hyperplasia</term></index-term>intimal hyperplasia after vascular injury via downregulation of the expression of proapoptotic proteins BCL2 and PTen [<xref ref-type="bibr" rid="CR85">298</xref>]. It also prevents SKi action, hence priming vSMC proliferation and migration induced by oxLDLs [<xref ref-type="bibr" rid="CR106">319</xref>]. It also contributes to TGFβ-regulated endothelial-to-mesenchymal transition. Differentiation of pulmonary SMCs induced by BMPs is mediated by miR21, partly via suppression of programmed cell death protein PdCD4 [<xref ref-type="bibr" rid="CR118">331</xref>]. On the other hand, differentiation of aortic SMCs can reduce miR21 expression.</p><p id="Par379">Like miR21, miR31 regulates aberrant vSMC proliferation [<xref ref-type="bibr" rid="CR119">332</xref>]. In proliferative vSMCs, proproliferative miR31 expression is upregulated by <index-term id="ITerm229"><term>ERK</term></index-term>ERK. It then targets large tumor suppressor homolog LATS2.</p><p id="Par380">Formation of miR24 and miR29a is primed by myocardin, the former being implicated in atherosclerosis retardation and the latter in matrix remodeling and fibrosis [<xref ref-type="bibr" rid="CR85">298</xref>].</p><p id="Par381">MiR26a hampers vSMC differentiation, thereby favoring their proliferation and migration via the TGFβ pathway, as it hinders production of SMAD1 and SMAD4 [<xref ref-type="bibr" rid="CR85">298</xref>].</p><p id="Par382">MiR29 expression is lost in calcified vSMCs in vitro and in calcified rat arteries in vivo. MiR29 targets ADAMTS7, which represses vSMC calcification [<xref ref-type="bibr" rid="CR85">298</xref>].</p><p id="Par383">MicroRNAs contribute to sexual differentiation. Female-specific miR29b targets DNA methyltransferases DNMT3a and DNMT3b [<xref ref-type="bibr" rid="CR120">333</xref>]. <index-term id="ITerm230"><term>oxLDL</term></index-term>Oxidized LDL raises aortic SMC migration, as it upregulates synthesis of MMP2 and MMP9 via diminished DNA methylation by DNMT3b [<xref ref-type="bibr" rid="CR121">334</xref>]. Upon oxLDL exposure, miR29b targets DNMT3b and promotes migration of arterial SMCs.</p><p id="Par384"><index-term id="ITerm231"><term>apoptosis</term></index-term>Apoptosis of vSMCs favored by <index-term id="ITerm232"><term>Redox stress</term></index-term>redox stress, partly via JNK, intervenes in vascular remodeling and atherosclerotic plaque instability. <index-term id="ITerm233"><term>JNK</term></index-term>JNK is a substrate of miR92a in macrophages. In quiescent vSMCs, miR92a is produced at a low level. Its synthesis is hampered by H<sub>2</sub>O<sub>2</sub> [<xref ref-type="bibr" rid="CR122">335</xref>]. Conversely, miR92a represses H<sub>2</sub>O<sub>2</sub>-primed vSMC apoptosis, as it inhibits MAP2K4–JNK1 signaling.</p><p id="Par385">MicroRNA-124 expression is downregulated in proliferative vascular diseases. MiR124 targets specificity protein SP1 and attenuates PDGFbb-induced vSMC proliferation and differentiation [<xref ref-type="bibr" rid="CR123">336</xref>].</p><p id="Par386">Histone H3 Lys9 methyltransferase KMT1a and associated repressive epigenetic mark H<sub>3</sub>K<sub>9</sub>me<sup>3</sup> prevents sustained inflammatory gene expression (heterochromatic silencing and euchromatic transcriptional repression). MiR125b targets KMT1a, thereby favoring production of inflammatory cytokines and chemokines, such as IL6 and CCL2 [<xref ref-type="bibr" rid="CR124">337</xref>]. MiR125b promotes the proinflammatory response in <index-term id="ITerm234"><term>Diabetes</term></index-term>diabetic vSMCs that possess a preactivated phenotype with augmented inflammatory gene expression. Hence, miR125b favors diabetic vSMC phenotype. Expression of miR125b and MIR200 family members is upregulated in vSMCs of <index-term id="ITerm235"><term>T2DM</term></index-term>T2DM db/db mice with respect to control db/+ mice.</p><p id="Par387">MicroRNA-126, one of the most abundant endothelial miRs, the transcription of which is regulated by ETS1 (a substrate of miR155, miR221, and miR222), ETS2, and flow-dependent KLF2, attenuates the rate of EC proliferation and supports VEGF-primed apoptosis decay and migration [<xref ref-type="bibr" rid="CR118">331</xref>]. Thus, endothelial miR126 modulates angiogenesis. Activated and apoptotic ECs release miR126 in microvesicles and transfer it to adjoining cells, regulating SMC turnover. Argonaute-2, a component of the miR-induced silencing complex, is transmitted with miR126 via extracellular vesicles (EVs) and facilitates miR126 transfer from ECs to SMCs. Endothelial miR126 represses transcripts encoding <index-term id="ITerm236"><term>FoxO</term></index-term>FoxO3, <index-term id="ITerm237"><term>BCL2</term></index-term>BCL2, and <index-term id="ITerm238"><term>IRS</term></index-term>IRS1 [<xref ref-type="bibr" rid="CR125">338</xref>].</p><p id="Par388"><index-term id="ITerm239"><term>angiotensin</term></index-term>Angiotensin-2 induces miR132–miR212 cluster synthesis in vSMCs and increases inflammatory gene transcription [<xref ref-type="bibr" rid="CR126">339</xref>]. MiR132 targets the PTEN transcript. The miR132–miR212 cluster mediates Agt2-induced CCL2 production in vSMCs.</p><p id="Par389">MiR133 is synthesized in vSMCs, whereas miR1 concentration is negligible. It represses vSMC phenotype switch. The miR133a1–miR1-2, miR133a2–miR1-1, and miR206–miR133b clusters are bicistronic, the latter being produced in skeletal muscles, but not in the heart. MiR133 production is regulated by <index-term id="ITerm240"><term>ERK</term></index-term>ERK1 and ERK2 [<xref ref-type="bibr" rid="CR127">340</xref>]. MiR133 suppresses formation of the transcription factor <index-term id="ITerm241"><term>SP1</term></index-term>SP1, which induces synthesis of cyclin-dependent kinase inhibitor CKI1b and subsequently cell cycle arrest.</p><p id="Par390"><index-term id="ITerm242"><term>Diabetes</term></index-term>In diabetes, miR138 also regulates vSMC proliferation and migration [<xref ref-type="bibr" rid="CR73">286</xref>].</p><p id="Par391">Cardiovascular-specific miR143 and miR145 encoded by a bicistronic gene cluster abound in vSMCs. Transcription of the miR143–miR145 cluster is primed by <index-term id="ITerm243"><term>SRF</term></index-term>SRF and its coactivators, <index-term id="ITerm244"><term>Myocardin</term></index-term>myocardin and <index-term id="ITerm245"><term>MRTF</term></index-term>myocardin-related transcription factors. They are atheroprotective and prevent <index-term id="ITerm246"><term>Intimal hyperplasia</term></index-term>intimal hyperplasia induced by vascular injury, which launches vSMC dedifferentiation and cytoskeletal remodeling. MiR143 and miR145 are also transferred from ECs to vSMCs by extracellular vesicles; KLF2 increases their amount in ECs and triggers their release via microvesicles [<xref ref-type="bibr" rid="CR118">331</xref>]. They play a crucial role in cooperation with other miRNAs, such as miR1 and miR24, in the differentiation and proliferation of vSMCs. MiR1, the formation of which is triggered by myocardin in vSMCs, precludes cell proliferation but inhibits myocardin-induced vSMC contractility. The Jag1–notch axis can also induce transcription of the miR143–miR145 cluster. MiR143 and miR145 repress <index-term id="ITerm247"><term>KLF</term></index-term>Krüppel-like factors KLF4 and KLF5 that inhibit myocardin, thereby supporting vSMC differentiation and repressing their proliferation. <index-term id="ITerm248"><term>TGF</term></index-term>TGFβ and <index-term id="ITerm249"><term>BMP</term></index-term>BMP4 are potent inducers of contractile vSMC phenotype; they prevent vSMC proliferation and migration. KLF4 hampers activation of the CArG box by SRF and its coactivators. TGFβ and BMP4 downregulate KLF4 synthesis via miR143 and miR145 [<xref ref-type="bibr" rid="CR128">341</xref>]. In addition, miR143 also reduces the production of <index-term id="ITerm250"><term>ELk/TcF</term></index-term>ETS-like factor ELk1, hence promoting synthetic phenotype. Furthermore, miR145 downregulates <index-term id="ITerm251"><term>ACE</term></index-term> ACE. <index-term id="ITerm252"><term>angiotensin</term></index-term>Angiotensin-2 is a vasoconstrictor that also exerts a proinflammatory effect via IL6 and CCL2 and elicits vSMC proliferation and hypertrophy, mostly via AT<sub>1</sub>, the <index-term id="ITerm253"><term>MAPK</term></index-term>MAPK module, <index-term id="ITerm254"><term>NFκB</term></index-term>NFκB, and CREB [<xref ref-type="bibr" rid="CR126">339</xref>]. Conversely, miR143 and miR145 are repressed by ACE, KLF4, and KLF5, which then favor neointima formation [<xref ref-type="bibr" rid="CR85">298</xref>]. In addition, miR145 targets slit-robo GTPase-activating protein SRGAP1 (RhoGAP13) and SRGAP2 (RhoGAP34), adducin-3, slingshot-2 phosphatase, and calmodulin kinase CamK2δ, which are involved in the regulation of SRF activity and actin dynamics [<xref ref-type="bibr" rid="CR118">331</xref>]. Genetic deficiency in miR143 and miR145 in mice shifts the vSMC phenotype from a contractile to a synthetic state.</p><p id="Par392">MiR146a targets <index-term id="ITerm255"><term>KLF</term></index-term>Krüppel-like factor KLF4, thereby promoting vSMC proliferation and <index-term id="ITerm256"><term>Intimal hyperplasia</term></index-term>intimal hyperplasia [<xref ref-type="bibr" rid="CR129">342</xref>]. KLF4 competes with KLF5 for MIR146A promoter binding; KLF4 and KLF5 exert opposing effects on the MIR146A promoter, KLF4 impeding MIR146A gene transcription. MiR146a and KLF4 form a feedback loop to regulate each other’s expression and vSMC proliferation.</p><p id="Par393">MiR155 supports vSMC proliferation [<xref ref-type="bibr" rid="CR130">343</xref>]. <index-term id="ITerm257"><term>STK3</term></index-term>STK3 (MST2), a component of MAPK modules and the hippo pathway,<xref ref-type="fn" rid="Fn57">57</xref> mediates miR155-primed inflammation and redox stress, which lead to vSMC proliferation and vascular remodeling. Inflammation and redox stress, which occur after vascular injury, are coordinated by the <index-term id="ITerm258"><term>ERK</term></index-term>ERK1/2 pathway. STK3 interacts with cRaf, thereby competing with MAP2K and regulating ERK1/2 signaling. Downregulation of STK3 expression by proproliferative miR155 activates ERK1/2 signaling, as it facilitates the interaction between cRaf and MAP2K, and then boosts vSMC proliferation. In addition, miR155 supports migration of smooth myocyte progenitors via CCL2 [<xref ref-type="bibr" rid="CR73">286</xref>].</p><p id="Par395">MiR155, which is synthesized and secreted upon KLF5 stimulation in vSMCs, is a potent regulator of the endothelial barrier, as it regulates production of endothelial tight junction proteins [<xref ref-type="bibr" rid="CR131">344</xref>]. Exosomes originating from vSMCs transfer miR155 from SMCs to ECs, which then alter tight junction renewal and hence the integrity of the endothelial barrier, increasing endothelial permeability. Moreover, miR155 in ECs impedes their proliferation and migration and hence re-endothelialization.</p><p id="Par396">MiR182 expression is markedly downregulated during vSMC dedifferentiation [<xref ref-type="bibr" rid="CR132">345</xref>]. MiR182 increases synthesis of SMC-specific contractile proteins and prevents SMC proliferation and migration in basal conditions and upon PDGFbb exposure. It targets the Fgf9 transcript. FGF9 is a potent mitogen secreted from bone marrow-derived cells that drives neovascular maturation via PDGFRβ, which resides particularly on vSMCs and pericytes, the production of which is upregulated by sonic hedgehog [<xref ref-type="bibr" rid="CR133">346</xref>].</p><p id="Par397">MiR182-3p counters vSMC proliferation and migration via <index-term id="ITerm259"><term>ERK</term></index-term>ERK [<xref ref-type="bibr" rid="CR134">347</xref>]. This microRNA targets <index-term id="ITerm260"><term>MyADM</term></index-term>myeloid-associated differentiation marker (MyADM), hence repressing <index-term id="ITerm261"><term>Intimal hyperplasia</term></index-term>intimal hyperplasia. <index-term id="ITerm262"><term>ADMA</term></index-term>The NOS inhibitor, asymmetrical dimethylarginine (ADMA), downregulates miR182-3p production, thereby supporting intimal hyperplasia.</p><p id="Par398">The subunit of the AP1 transcription factor complex, JunB, promotes blood vessel development and maintenance but precludes cell proliferation and inflammation. Under hypoxia, JunB regulates angiogenesis, as it upregulates synthesis of VEGFa, core-binding factor CBFβ, which with Runx forms the heterodimeric core-binding transcription complex CBF, and MMP13, a CBF target. Components of the AP1 complex regulate expression of various microRNAs (miR21, miR101, miR144, miR155, and miR203) [<xref ref-type="bibr" rid="CR135">348</xref>]. MiR182 is a JunB target implicated in <index-term id="ITerm263"><term>Lymphangiogenesis</term></index-term>lymphangiogenesis, at least in zebrafish [<xref ref-type="bibr" rid="CR135">348</xref>]. MiR182 attenuates <index-term id="ITerm264"><term>FoxO</term></index-term>FoxO1 formation to avoid its overproduction, hence driving proper lymphangiogenesis.</p><p id="Par399">MicroRNA-195 abounds in vSMCs [<xref ref-type="bibr" rid="CR136">349</xref>]. It impedes vSMC proliferation, migration, and synthesis of IL1β and IL6 and the CXCL8 chemokine. It represses translation from Cdc42, CCND1, and Fgf1 transcripts.</p><p id="Par400">MiR200 downregulates expression of the zinc finger E-box-binding homeobox-containing transcription factor <index-term id="ITerm265"><term>ZEB</term></index-term>ZEB1, hence raising production of proinflammatory <index-term id="ITerm266"><term>PGhS</term></index-term>PGhS2 (COx2) and CCL2 [<xref ref-type="bibr" rid="CR85">298</xref>].</p><p id="Par401"><index-term id="ITerm267"><term>Estradiol</term></index-term>Estrogens such as estradiol (E<sub>2</sub>) protect vascular walls via miR203 production, which is upregulated in vSMCs via NR3a1 (ERα) [<xref ref-type="bibr" rid="CR137">350</xref>]. The transcription factors ZEB1 and <index-term id="ITerm268"><term>AP</term></index-term>AP1 mediate E<sub>2</sub>-induced upregulation of miR203 transcription. MiR203 represses <index-term id="ITerm269"><term>Abl</term></index-term>Abl1 and <index-term id="ITerm270"><term>P63</term></index-term>P63 production and vSMC (but not vEC) proliferation.</p><p id="Par402">MiR221 and miR222 are expressed by a gene cluster of the X chromosome in vSMCs and ECs [<xref ref-type="bibr" rid="CR118">331</xref>]. They favor <index-term id="ITerm271"><term>Intimal hyperplasia</term></index-term>neointima growth. Therefore, downregulation of miR143 and miR145 expression and upregulation of miR221 and miR222 after vascular injury support intimal hyperplasia. Proliferation of vSMCs results from the elimination of cyclin-dependent kinase inhibitors CKI1b and CKI1c by miR221 and miR222. On the other hand, they impede EC proliferation. Whereas miR221 and miR222 lower the vSMC apoptosis rate and support the latter’s migration, they hinder EC migration and favor apoptosis. Moreover, miR221 and miR222 prevent <index-term id="ITerm272"><term>angiotensin</term></index-term>angiotensin-2-induced inflammation, as they suppress the formation of VEGFR1, vcam1, and CCL2, thereby reducing leukocyte recruitment and adhesion [<xref ref-type="bibr" rid="CR118">331</xref>]. In addition, miR221 suppresses the synthesis of <index-term id="ITerm273"><term>SCFR</term></index-term>SCFR in SMCs, which initiates myocardin production.</p><p id="Par403"><index-term id="ITerm274"><term>angiotensin</term></index-term>Angiotensin-2 regulates the long nonprotein-coding RNA <index-term id="ITerm275"><term>lncAng362</term></index-term>lncAng362, which is responsible for the production of two microRNAs implicated in vSMC proliferation, miR221 and miR222 [<xref ref-type="bibr" rid="CR138">351</xref>]. In fact, angiotensin-2 controls the production of many lncRNAs, downregulating that of lncAng219 and lncAng249 and upregulating that of lncAng112, lncAng162, and lncAng362. Production of lncAng362, miR221, and miR222 is upregulated once vSMCs are exposed to Agt2.</p><p id="Par404"><index-term id="ITerm276"><term>Hyperglycemia</term></index-term>Hyperglycemia contributes to abnormal vSMC activation. Hyperglycemia stimulates vSMC proliferation and migration via <index-term id="ITerm277"><term>ERK</term></index-term>ERK and <index-term id="ITerm278"><term>ROS</term></index-term>ROS. In addition, hyperglycemia hinders vSMC apoptosis, as it upregulates the expression of antiapoptotic proteins <index-term id="ITerm279"><term>BCL2</term></index-term>BCL2 and BCL2L1. Furthermore, hyperglycemia inactivates <index-term id="ITerm280"><term>AMPK</term></index-term>AMPK, which can improve endothelial function and suppress vSMC proliferation and migration. On the other hand, family with sequence similarity protein Fam3b (its secretory form named pancreatic-derived factor and abbreviated pander),<xref ref-type="fn" rid="Fn58">58</xref> which is secreted from the endocrine pancreas, can provoke apoptosis of α and β cells. It is cosecreted with insulin from β cells by hyperglycemia [<xref ref-type="bibr" rid="CR139">352</xref>]. It boosts vSMC proliferation and migration and precludes miR322-5p expression. Conversely, miR322-5p impedes Fam3b-primed vSMC proliferation and migration.</p><p id="Par406">MiR424 (ortholog of rat miR322) concentration decays shortly after induction of vSMC proliferation and then rises. It precludes vSMC proliferation and migration without affecting apoptosis [<xref ref-type="bibr" rid="CR140">353</xref>]. It targets cyclin-D1 and Ca<sup>2+</sup>-regulating proteins calumenin (directly) and stromal-interacting molecule STIM1 (indirectly), lowering store-operated Ca<sup>2+</sup> entry. It is upregulated after vascular injury, thereby protecting against restenosis.</p><p id="Par407">Cyclin-D1 transcript is a substrate of antiproliferative miR365 [<xref ref-type="bibr" rid="CR141">354</xref>]. It lowers PDGFbb-primed vSMC proliferation, as it blocks G1–S transition. On the other hand, vSMC proliferation triggered by PDGFbb and angiotensin-2 downregulates miR365 expression.</p><p id="Par408">Oxidized LDLs induce vSMC proliferation, downregulate the synthesis of miR490-3p and <index-term id="ITerm281"><term>IGF</term></index-term>IGF1, but upregulate that of pappalysin-1 (or PAPPa)<xref ref-type="fn" rid="Fn59">59</xref> and IGF2 in vSMCs [<xref ref-type="bibr" rid="CR142">355</xref>]. Overproduction of PAPPa and the resulting activation of proinflammatory IGF in vSMCs may promote their proliferation, but IGF1 may have anti-inflammatory and antioxidant effects. MiR490-3p targets PAPPA, countering the effect of oxLDLs and suppressing the PAPPa metallopeptidase effect and hence IGFBP4 cleavage.</p><p id="Par410"><index-term id="ITerm282"><term>Diabetes</term></index-term>In diabetes mellitus, vascular smooth myocytes acquire a proatherogenic and proinflammatory phenotype. Diabetes mellitus is linked to elevated concentrations of glucose, advanced glycation end products, growth factors, and oxidized lipids that favor <index-term id="ITerm283"><term>vSMC dysfunction</term></index-term>vSMC dysfunction. In vSMCs of <index-term id="ITerm284"><term>T2DM</term></index-term>T2DM mice, 135miRs are differentially expressed, among which several regulate vSMC function. MiR504, the production of which is upregulated, targets the adaptor <index-term id="ITerm285"><term>GRB</term></index-term>GRB10 and transcription factor <index-term id="ITerm286"><term>EGR</term></index-term>EGR2 [<xref ref-type="bibr" rid="CR143">356</xref>]. It provokes a vSMC phenotype switch, as it downregulates expression of contractile genes and upregulates that of <index-term id="ITerm287"><term>ERK</term></index-term>ERK1 and ERK2, thereby promoting vSMC proliferation and migration. High concentrations of glucose and palmitic acid increase miR504 formation and the expression of inflammatory genes.</p><p id="Par411">The PDGFbb stimulant elicits vSMC proliferation and suppresses miR599 synthesis [<xref ref-type="bibr" rid="CR144">357</xref>]. Conversely, miR599 represses vSMC proliferation and migration in addition to the synthesis of PCNA, an auxiliary protein of DNA polymerase-δ involved in the control of DNA replication, and of cellular proliferation marker protein MKi67, an antigen identified by monoclonal antibody Ki67, which is encoded by the MKI67 gene and linked to the perichromosomal layer during mitosis, acting as a surfactant [<xref ref-type="bibr" rid="CR145">358</xref>]. In addition, miR599 suppresses production of collagen-1 and -5 and proteoglycan. In vSMCs, the TGFB2 transcript is a substrate of miR599 [<xref ref-type="bibr" rid="CR144">357</xref>]. TGFβ2 can reverse miR599-primed prevention of vSMC proliferation along with collagen and proteoglycan synthesis. MiR590-3p increases vSMC contractility and represents a risk factor for hypertension in the presence of genetic defects [<xref ref-type="bibr" rid="CR73">286</xref>].</p><p id="Par412">miR638 is one of the most significantly downregulated in human aortic vSMCs during their proliferation and migration launched by PDGFbb [<xref ref-type="bibr" rid="CR146">359</xref>]. Conversely, miR638 hinders vSMC proliferation, as it targets <index-term id="ITerm288"><term>NR4a3</term></index-term>the nuclear receptor NR4a3 (NOR1), subsequently impeding cyclin-D1 production.</p></sec></sec><sec id="Sec29"><title>Platelet MicroRNAs</title><p id="Par413"><index-term id="ITerm289"><term>Platelet</term></index-term>Platelets, which contain mRNA and can thus synthesize new proteins (e.g., integrin-α<sub>3</sub>, or glycoprotein-3A, and fibrinogen receptor), are a major source of miRs, <index-term id="ITerm290"><term>YRNA</term></index-term><sup>Y</sup>RNAs, <index-term id="ITerm291"><term>circRNA</term></index-term>circular RNAs, and lncRNAs.</p><p id="Par414">Newly formed platelets are larger, more reticulated, and more reactive than older platelets; they also contain a higher amount of RNA and can thus produce greater amounts of proteins, especially α granule-stored proteins. On the other hand, platelets may inherit their miR content during shedding from megakaryocytes.</p><p id="Par415">Platelets release <index-term id="ITerm292"><term>Microvesicle</term></index-term>microvesicles and <index-term id="ITerm293"><term>Exosome</term></index-term>exosomes, especially during activation. Inappropriate activation of platelets initiates <index-term id="ITerm294"><term>Thrombosis</term></index-term>thrombosis. <index-term id="ITerm295"><term>MicroRNA</term></index-term>MicroRNAs can thus be used as markers of platelet activation [<xref ref-type="bibr" rid="CR147">360</xref>].</p><p id="Par416">Whereas the platelet miR expression pattern remains stable over the lifespan of the platelet in healthy individuals, it is markedly altered in <index-term id="ITerm296"><term>Diabetes</term></index-term>diabetes, after <index-term id="ITerm297"><term>Myocardial infarction</term></index-term>myocardial infarction, and in <index-term id="ITerm298"><term>Cancer</term></index-term>cancer (Table <xref rid="Tab11" ref-type="table">2.11</xref>) [<xref ref-type="bibr" rid="CR147">360</xref>]. MiR release from platelets may result from shedding of microvesicles and synthesis of mature miRs from precursor miRs. On the other hand, activation of calpain that targets dicer lowers the concentrations of several platelet miRs. <table-wrap id="Tab11"><label>Table 2.11</label><caption xml:lang="en"><p>Platelet microRNA] (Source: [<xref ref-type="bibr" rid="CR147">360</xref>])</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>MicroRNA</p></th><th align="left"><p>Target (effect)</p></th></tr></thead><tbody><tr><td align="left"><p>MiR96</p></td><td align="left"><p>Vamp8 mRNA (vesicle-associated membrane protein),</p></td></tr><tr><td align="left"/><td align="left"><p>VAMP8 being involved in platelet degranulation</p></td></tr><tr><td align="left"/><td align="left"><p>(reduced platelet reactivity)</p></td></tr><tr><td align="left"><p>MiR126</p></td><td align="left"><p>Adam9 mRNA</p></td></tr><tr><td align="left"/><td align="left"><p>Adamlysin-9 attenuates platelet–collagen adhesion</p></td></tr><tr><td align="left"/><td align="left"><p>(augmented platelet reactivity)</p></td></tr><tr><td align="left"><p>MiR223</p></td><td align="left"><p>P2RY12 mRNA</p></td></tr><tr><td align="left"/><td align="left"><p>Gi2-coupled P2Y<sub>12</sub> receptor activated by ADP primes</p></td></tr><tr><td align="left"/><td align="left"><p>platelet aggregation and granule secretion</p></td></tr><tr><td align="left"/><td align="left"><p>(reduced platelet reactivity)</p></td></tr><tr><td align="left"><p>MiR376c,</p></td><td align="left"><p>Pctp mRNA (phosphatidylcholine transfer protein),</p></td></tr><tr><td align="left"><p>miR599</p></td><td align="left"><p>(lowered PAR<sub>4</sub> [thrombin receptor] reactivity)</p></td></tr></tbody></table></table-wrap></p></sec><sec id="Sec30"><title>Hepatic MicroRNAs Operating in Metabolism</title><p id="Par417">Because the liver is a major organ in the regulation of lipid, cholesterol, and glucose metabolism,<xref ref-type="fn" rid="Fn60">60</xref><index-term id="ITerm300"><term>MicroRNA</term></index-term>hepatic microRNAs, such as miR24,<xref ref-type="fn" rid="Fn61">61</xref> miR29,<xref ref-type="fn" rid="Fn62">62</xref> miR30c,<xref ref-type="fn" rid="Fn63">63</xref> miR33,<xref ref-type="fn" rid="Fn64">64</xref> miR33<sup>⋆</sup>,<xref ref-type="fn" rid="Fn65">65</xref> miR122,<xref ref-type="fn" rid="Fn66">66</xref> miR144,<xref ref-type="fn" rid="Fn67">67</xref> miR148a,<xref ref-type="fn" rid="Fn68">68</xref> and miR223,<xref ref-type="fn" rid="Fn69">69</xref> packaged in microvesicles and proteic complexes,<xref ref-type="fn" rid="Fn70">70</xref> affect hepatic metabolism and hence are linked to <index-term id="ITerm308"><term>Metabolic syndrome</term></index-term>metabolic syndrome, <index-term id="ITerm309"><term>Non-alcoholic fatty liver disease</term></index-term>non-alcoholic fatty liver disease, <index-term id="ITerm310"><term>T2DM</term></index-term>T2DM, and <index-term id="ITerm311"><term>atherosclerosis</term></index-term>atherosclerosis; they can thus serve as <index-term id="ITerm312"><term>Marker</term></index-term>markers [<xref ref-type="bibr" rid="CR148">361</xref>].</p><p id="Par429"><index-term id="ITerm313"><term>ApoB100</term></index-term>Apolipoprotein-B is an essential scaffold in <index-term id="ITerm314"><term>VLDL</term></index-term>VLDL assembly. MiR548p interacts with the 3<italic>′</italic>-untranslated region of the APOB mRNA and promotes its post-transcriptional degradation, thereby reducing ApoB synthesis and secretion from hepatocytes. Furthermore, miR548p significantly decreases lipoprotein production in addition to lipid synthesis in hepatocytes, as it lowers the activity of <index-term id="ITerm315"><term>HMGCR</term></index-term>3-hydroxy 3-methylglutarylCoA reductase and <index-term id="ITerm316"><term>ACSL</term></index-term>long-chain acylCoA synthetase ACSL4<xref ref-type="fn" rid="Fn71">71</xref> involved in cholesterol and fatty acid synthesis, but does not affect fatty acid oxidation [<xref ref-type="bibr" rid="CR153">366</xref>].</p></sec><sec id="Sec31"><title>MicroRNAs and Mitochondrial Function and Dysfunction</title><p id="Par431"><index-term id="ITerm317"><term>Mitochondrion</term></index-term>MicroRNAs participate in the regulation of mitochondrial metabolism and ATP production via proteins implicated in substrate transport, glycolysis, fatty acid β-oxidation, ketone catabolism, and coupled processing by the tricarboxylic acid cycle (TCAC) and electron transport chain (ETC).</p><p id="Par432">The metabolism evolves from fatty acid oxidation to glycolysis during <index-term id="ITerm318"><term>Hypoxia</term></index-term>hypoxia, especially in the context of hypertension-induced <index-term id="ITerm319"><term>Heart failure</term></index-term>HF, as expression of fatty acid oxidation enzymes is downregulated and that of glycolytic enzymes is upregulated [<xref ref-type="bibr" rid="CR154">367</xref>].</p><p id="Par433">Mitochondria import various species of ncRNAs, such as tRNAs; 5S rRNA, which is the most abundant mitochondrial RNA type; miRs; and lncRNAs [<xref ref-type="bibr" rid="CR155">368</xref>]. Polynucleotide phosphorylase of the mitochondrial intermembrane space that processes mitochondrial transcripts promotes the import of ncRNAs through the inner mitochondrial membrane into the mitochondrial matrix.</p><p id="Par434">The term <italic>mitomicroRNAs</italic> refers to microRNAs located inside the mitochondrion, <italic>category 1</italic><sup>Mt</sup>miRs being encoded by the mitochondrial genome and <italic>category 2</italic><sup>Mt</sup>miRs being transcribed in the nucleus and imported to the mitochondrion (Table <xref rid="Tab12" ref-type="table">2.12</xref>). For example, preLet7b, pre-miR302a, and their corresponding mature miRs lodge in the mitochondrion. Most category-2 <sup>Mt</sup>miRs originate from loci pertaining to mitochondrial gene clusters or close to mitochondrial genes. MitomicroRNAs may interact with transcripts encoded in the mitochondrion. <table-wrap id="Tab12"><label>Table 2.12</label><caption xml:lang="en"><p>MicroRNAs and mitochondrial function (Source: [<xref ref-type="bibr" rid="CR155">368</xref>]; <italic>CcOx4</italic> cytochrome-C oxidase subunit-4, <italic>CcOx10</italic> cytochrome-C oxidase protoheme-9 farnesyltransferase, <italic>ISCu</italic> iron–sulfur cluster assembly scaffold)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Type</p></th><th align="left"><p>Location</p></th><th align="left"><p>Targets</p></th><th align="left"><p>Effect</p></th></tr></thead><tbody><tr><td align="left"><p>MiR1</p></td><td align="left"><p>Cardiac and</p></td><td align="left"><p>IGF1</p></td><td align="left"><p>Regulation of mitochondrial protein</p></td></tr><tr><td align="left"/><td align="left"><p>skeletal myocytes</p></td><td align="left"/><td align="left"><p>synthesis, metabolism and apoptosis</p></td></tr><tr><td align="left"><p>MiR23a/b</p></td><td align="left"><p>Ubiquitous</p></td><td align="left"><p>Glutaminase</p></td><td align="left"><p>Tumor suppression</p></td></tr><tr><td align="left"><p>MiR30</p></td><td align="left"><p>Heart</p></td><td align="left"><p>P53</p></td><td align="left"><p>Inhibition of mitochondrial fission</p></td></tr><tr><td align="left"><p>group</p></td><td align="left"/><td align="left"/><td align="left"><p>and apoptosis</p></td></tr><tr><td align="left"><p>MiR210</p></td><td align="left"><p>Ubiquitous</p></td><td align="left"><p>CCOX10,</p></td><td align="left"><p>Cell adaptation and survival</p></td></tr><tr><td align="left"/><td align="left"/><td align="left"><p>ISCU</p></td><td align="left"><p>under hypoxia</p></td></tr><tr><td align="left"><p>MiR338</p></td><td align="left"><p>Brain</p></td><td align="left"><p>CCOX4</p></td><td align="left"><p>Regulation of axonal energy metabolism</p></td></tr><tr><td align="left"><p>MiR378</p></td><td align="left"><p>Heart</p></td><td align="left"><p>Caspase-3</p></td><td align="left"><p>Inhibition of apoptosis</p></td></tr></tbody></table></table-wrap></p><p id="Par435">Certain mitomicroRNAs can act as translational activators, as they promote translation of mitochondrial transcripts using a specific miR–mRNA base pairing [<xref ref-type="bibr" rid="CR155">368</xref>]. Under certain conditions, once it is recruited to the 5<italic>′</italic>-end of target mRNAs and/or internal ribosome entry sites, miR1 can activate translation in the cytosol. MiR1 recruits the ND1 and COX1 mRNAs to mitochondrial ribosomes.</p><p id="Par436">In addition to <sup>Mt</sup>miRs, several cytosolic microRNAs modulate mitochondrial function. Brain-specific miR338 lowers the formation of the cytochrome-C oxidase subunit CcOx4 encoded in the nucleus [<xref ref-type="bibr" rid="CR155">368</xref>]. MiR210, which is induced by <index-term id="ITerm320"><term>HIF</term></index-term>HIF1α under <index-term id="ITerm321"><term>Hypoxia</term></index-term>hypoxia, can repress oxidative phosphorylation, as it targets transcripts encoding cytochrome-C oxidase assembly protein CcOx10 and iron–sulfur cluster scaffold (ISCu).</p><p id="Par437">Several miRs participate in intrinsic <index-term id="ITerm322"><term>apoptosis</term></index-term>apoptosis. In cardiac and skeletal myocytes, miR1, the formation of which is induced by <index-term id="ITerm323"><term>Hyperglycemia</term></index-term>hyperglycemia, diminishes mitochondrial membrane potential and provokes cytochrome-C release via IGF1 [<xref ref-type="bibr" rid="CR155">368</xref>]. In the heart, miR378 downregulates caspase-3 expression and hence impedes apoptosis.</p><p id="Par438">Certain miRs such as those of the MIR30 family, which abound in the heart, modulate mitochondrial dynamics. They regulate mitochondrial fission and fusion via the P53–DRP1 axis, as they decrease amounts of P53 and subsequently of DRP1, hence favoring fusion to support energy demand and raising the threshold of apoptotic activation in CMCs [<xref ref-type="bibr" rid="CR155">368</xref>].</p><p id="Par439"><index-term id="ITerm324"><term>Heart failure</term></index-term>In HF, impaired fatty acid β-oxidation increases circulating free fatty acid (FFA) concentration, which is detected by the liver that uses FFAs as substrates for <index-term id="ITerm325"><term>Ketone</term></index-term>ketogenesis. Ketones enter the bloodstream, from which they are taken up by CMCs, the rate of oxidation matching the rate of delivery. Cardiac ketolysis carried out by 3-hydroxybutyrate dehydrogenase BDH1, succinylCoA:3-oxoacidCoA transferase (SCOT), and acetoacetyl-CoA thiolase produces acetyl-CoA [<xref ref-type="bibr" rid="CR154">367</xref>].</p><p id="Par440">In CMCs, some microRNAs (e.g., miR181c and miR378) translocate to mitochondria and affect expression of the mitochondrial transcripts (Table <xref rid="Tab13" ref-type="table">2.13</xref>) [<xref ref-type="bibr" rid="CR154">367</xref>]. <table-wrap id="Tab13"><label>Table 2.13</label><caption xml:lang="en"><p>MicroRNAs affecting the mitochondrial metabolism, the expression of which is upregulated in heart failure (Source: [<xref ref-type="bibr" rid="CR154">367</xref>]; <italic>Arl</italic> ADP ribosylation factor-like transcript, <italic>ETC</italic> electron transport chain, <italic>FABP</italic> fatty acid-binding protein, <italic>Hk</italic> hexokinase, <italic>Hsp</italic> heat shock protein, <italic>ISCu</italic> iron–sulfur cluster assembly scaffold homolog, <italic>MTATP6</italic> mitochondrially encoded ATP synthase (<sup>ETC</sup>complex-<italic>V</italic> ) F0 subunit-6, <italic>MTCO1</italic> mitochondrially encoded cytochrome-C oxidase subunit-1 [<sup>ETC</sup>complex-<italic>IV</italic> component], <italic>PDHB</italic> mitochondrial pyruvate dehydrogenase subunit-β, <italic>PFKM</italic> phosphofructokinase muscle isozyme, <italic>PGC</italic> PPARγ coactivator, <italic>PKM</italic> pyruvate kinase muscle isozyme, <italic>Ppar</italic> peroxisome proliferator-activated receptor, <italic>Vdac</italic> voltage-dependent anion channel)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Type</p></th><th align="left"><p>Targets</p></th></tr></thead><tbody><tr><td align="left"><p>MiR21</p></td><td align="left"><p>Pparα (NR1C1 [<italic>↓</italic> fatty acid oxidation])</p></td></tr><tr><td align="left"><p>MiR24</p></td><td align="left"><p>Fabp4</p></td></tr><tr><td align="left"><p>MiR27</p></td><td align="left"><p>Pparγ (NR1C3)</p></td></tr><tr><td align="left"><p>MiR26a</p></td><td align="left"><p>PDHB</p></td></tr><tr><td align="left"><p>MiR29a</p></td><td align="left"><p>Vdac1/2,</p></td></tr><tr><td align="left"/><td align="left"><p>transcripts of proteins involved in fibrosis</p></td></tr><tr><td align="left"><p>MiR103</p></td><td align="left"><p>Pparα</p></td></tr><tr><td align="left"><p>MiR181c</p></td><td align="left"><p>MTCO1 (in mitochondria and BCL2 in the cytosol)</p></td></tr><tr><td align="left"><p>MiR199a</p></td><td align="left"><p>Hk2, PFKM, PKM2,</p></td></tr><tr><td align="left"/><td align="left"><p>Pparδ (NR1C2 [<italic>↓</italic> fatty acid oxidation])</p></td></tr><tr><td align="left"><p>MiR210</p></td><td align="left"><p>ISCU1/2</p></td></tr><tr><td align="left"><p>MiR320</p></td><td align="left"><p>PFKM, Hsp20</p></td></tr><tr><td align="left"><p>MiR378</p></td><td align="left"><p>MTATP6, Pparα</p></td></tr><tr><td align="left"><p>MiR424</p></td><td align="left"><p>Arl2</p></td></tr><tr><td align="left"><p>MiR696</p></td><td align="left"><p>PGC1α (<italic>↓</italic>NRF1/2;</p></td></tr><tr><td align="left"/><td align="left"><p><italic>↓</italic>mitochondrial amount and activity)</p></td></tr></tbody></table><table-wrap-foot><p>Production of iron–sulfur clusters are used for reduction–oxidation reactions by TCAC enzymes and <sup>ETC</sup>complex-<italic>I</italic> to -<italic>III</italic>. The assembly proteins ISCu1 and ISCu2 are chaperones for the assembly of iron–sulfur clusters in addition to transport of these clusters to their functional location in the cell</p></table-wrap-foot></table-wrap></p><p id="Par441"><index-term id="ITerm326"><term>Hypoxia</term></index-term>Hypoxia and <index-term id="ITerm327"><term>Redox stress</term></index-term>redox stress affect expression of microRNAs and hence mRNAs. Furthermore, these stressors contribute to oxidation of metabolic enzymes, altering their activity.</p><p id="Par442">Formation of both <index-term id="ITerm328"><term>NOx</term></index-term>NOx2 and NOx4 can be induced by <index-term id="ITerm329"><term>HIF</term></index-term>HIF1α during hypoxia. <index-term id="ITerm330"><term>Heart failure</term></index-term>In HF, upregulated expression of NOx2 can partly result from downregulated miR17. In addition, the baseline constitutive expression of NOx4 is augmented by hypercholesterolemia that downregulates miR25 production. On the other hand, increased miR25 expression in HF inhibits serca2a production. In HF, downregulated synthesis of serca2 and RyR2 is associated with an altered expression of <index-term id="ITerm331"><term>CK</term></index-term>CK [<xref ref-type="bibr" rid="CR156">369</xref>].</p><p id="Par443"><index-term id="ITerm332"><term>Aging</term></index-term>In most aging-related diseases, mitochondrial <index-term id="ITerm333"><term>ROS</term></index-term>ROS are produced by the ETC, which requires NADH and is hence countered by enzymes that need NADPH as cofactor. The nicotinamide nucleotide transhydrogenase (NNT) is an antioxidative enzyme that regenerates NADPH from NADH; it uses the proton gradient to generate NADPH from NADH and NADP<sup>+</sup>, hence linking mitochondrial respiration and detoxification by the thioredoxin–peroxiredoxin processor (∼80%) or glutathione peroxidase (∼20%) of H<sub>2</sub>O<sub>2</sub>, which is produced from mitochondrial superoxide radical by spontaneous dismutation and/or by manganese-containing superoxide dismutase SOD2 and by citric acid cycle enzymes, such as aconitase and α-ketoglutarate dehydrogenase [<xref ref-type="bibr" rid="CR157">370</xref>].<xref ref-type="fn" rid="Fn72">72</xref></p><p id="Par445">The enzyme NNT promotes TRdx and TRdx reductase activity. Mitochondrial NADPH can also be regenerated by isocitrate dehydrogenase IDH2 and mitochondrial NADP-dependent malic enzymes (ME2 and ME3).</p><p id="Par446">An adverse metabolic context reverses the NNT processing direction, consuming NADPH to support NADH and ATP production [<xref ref-type="bibr" rid="CR158">371</xref>]. <index-term id="ITerm334"><term>Heart failure</term></index-term>In HF, changes in the mitochondrial proteome lead to decreased expression of two NADPH-producing proteins, mitochondrial NNT and IDH2 [<xref ref-type="bibr" rid="CR156">369</xref>]. The latter yields the highest contribution to overall NADPH regenerating capacity in cardiac mitochondria (∼70%; NNT: ∼22%; ME: ∼8%) [<xref ref-type="bibr" rid="CR158">371</xref>].</p><p id="Par447"><index-term id="ITerm335"><term>Redox stress</term></index-term>Redox stress in HF is caused by increased expression of prooxidant aconitase, reduced formation of antioxidant superoxide dismutase, in addition to hypersensitivity of the ETC and ATP synthase to glutathionylation [<xref ref-type="bibr" rid="CR154">367</xref>].</p><p id="Par448">Apoptosis of cardiac cells is caused by upregulated synthesis of apoptotic proteins such as <index-term id="ITerm336"><term>VDAC/porin</term></index-term>voltage-dependent anion channel, which acts in the mitochondrial permeability transition pore. The major outer mitochondrial membrane importer of ATP constituents and exporter of ATP, VDAC1, has downregulated expression in end-stage heart failure owing to upregulated miR29a [<xref ref-type="bibr" rid="CR154">367</xref>].</p><p id="Par449">Synthesis of adenine nucleotide transporter ANT1, the inner mitochondrial membrane transporter of ADP and ATP, is inhibited by miR424, which suppresses production of ARL2 [<xref ref-type="bibr" rid="CR159">372</xref>]. ARL2 complexes with its partner ARL2BP, and, both being predominantly cytosolic, enter the mitochondrion and bind to ANT1 (but not to ANT2).</p><p id="Par450">MiR141, a member of the MIR200 family, targets the inner mitochondrial membrane phosphate transporter, SLC25a3, which provides inorganic phosphate to the mitochondrial matrix for ATP production [<xref ref-type="bibr" rid="CR75">288</xref>].</p><p id="Par451">Mitochondria constitute the most redox-active cellular compartment; the mitochondrial matrix of CMCs has a highly reduced redox potential with respect to the cytosol [<xref ref-type="bibr" rid="CR3">69</xref>, <xref ref-type="bibr" rid="CR160">373</xref>]. Glutathione peroxidase inactivates H<sub>2</sub>O<sub>2</sub> using reduced glutathione. Glutathione is produced in the cytosol and accumulates in the mitochondrial matrix, where it is primarily found in the reduced state, mainly because of NADPH produced by the TCAC. Distinct glutathione nanodomains exist in the <index-term id="ITerm337"><term>Redoxome</term></index-term><italic>redoxomes</italic> of CMCs, that is, the cytosol, mitochondrion, and other redox-active organelles. Oxidants are also produced in nanodomains inside redoxomes.</p><p id="Par452">Increased <index-term id="ITerm338"><term>ROS</term></index-term>ROS generation upon cellular stress provokes a reductive stress in the cytosol and mitochondria and oxidative stress upon reoxygenation [<xref ref-type="bibr" rid="CR3">69</xref>]. On the other hand, upon prolonged ROS exposure and chronic ischemia, the cytosol and mitochondria are more oxidized media. In addition, ROS scavenging by antioxidants influences redox status. Increased production of reductants such as accumulation of reduced glutathione and NADPH in addition to elevated activity of antioxidant enzymes can result from reductive countering of radicals upon oxidative stress.</p><p id="Par453">Redox stress can involve NFE2L2, HSPs, ROS, and G6PD [<xref ref-type="bibr" rid="CR3">69</xref>]. Antioxidant flux depends on mitochondrial substrate catabolism along with thioredoxin and glutathione.</p><p id="Par454">Because they modulate mitochondrial metabolism, several miRNAs act as oncogenes or tumor suppressors [<xref ref-type="bibr" rid="CR155">368</xref>]. Production of miR23a and miR23b, which control expression of mitochondrial <index-term id="ITerm339"><term>glutaminase</term></index-term>glutaminase,<xref ref-type="fn" rid="Fn73">73</xref> is downregulated upon oncogenic activation (e.g., MyC overexpression)<xref ref-type="fn" rid="Fn74">74</xref> and accompanied by decreased <index-term id="ITerm340"><term>ROS</term></index-term>ROS synthesis, as glutamine is a substrate for glutathione formation, and by increased ATP synthesis via the TCAC.</p><p id="Par462"><index-term id="ITerm341"><term>Cardiac hypertrophy</term></index-term>Expression of both miR23a and miR23b is induced in cardiac hypertrophy. In addition, miR15b, miR16,<xref ref-type="fn" rid="Fn75">75</xref> miR195, and miR424, which preclude formation of ARL2 and lower ATP concentration, affect mitochondrial integrity in CMCs [<xref ref-type="bibr" rid="CR75">288</xref>]. These members of the MIR15 family undergo upregulated expression in ischemia–reperfusion injury and cardiac hypertrophy.</p><p id="Par464"><index-term id="ITerm342"><term>Ischemia</term></index-term>Ischemia is characterized by hypoxia. <index-term id="ITerm343"><term>HIF</term></index-term>The HIF pathway provokes a metabolic shift (<italic>Pasteur effect</italic>) from aerobic mitochondrial oxidative phosphorylation to anaerobic glycolysis, an event linked to repression of mitochondrial genesis and production of glycolytic enzymes (e.g., <index-term id="ITerm344"><term>LDH</term></index-term>lactate dehydrogenase, LDHa, which converts pyruvate to lactate) and activation of <index-term id="ITerm345"><term>PDHK</term></index-term>pyruvate dehydrogenase kinase (PDHK, which decreases glucose utilization and increases fatty acid metabolism and intervenes in ROS generation).<xref ref-type="fn" rid="Fn76">76</xref> During hypoxia, mitochondrial <index-term id="ITerm346"><term>ROS</term></index-term>ROS formation rises and repression of the oxidative metabolism by HIF maintains redox homeostasis. During chronic hypoxia and hence ischemia, oxidative metabolism can be maintained, at least in fibroblasts under hypoxia, but generates toxic ROS levels [<xref ref-type="bibr" rid="CR75">288</xref>].</p><p id="Par466">miR210, which is regulated by <index-term id="ITerm347"><term>NFκB</term></index-term>NFκB and <index-term id="ITerm348"><term>ELk/TcF</term></index-term>ELk1, is upregulated by hypoxia. <index-term id="ITerm349"><term>HIF</term></index-term>HIF1α represses oxidative phosphorylation and activity of mitochondrial ETC via miR210 in many cell types [<xref ref-type="bibr" rid="CR75">288</xref>].</p><p id="Par467">MiR210 impedes synthesis of <index-term id="ITerm350"><term>ISCu</term></index-term>ISCu1 and ISCu2 (which participates in the assembly of iron–sulfur clusters present in several ETC and TCAC components), transferrin receptor, mitochondrial cytochrome-C oxidase assembly protein (protoheme-9 farnesyltransferase) CcOx10 (a component of <sup>ETC</sup>complex-<italic>I</italic> and -<italic>IV</italic> ), mitochondrial heme synthase (ferrochelatase [FeCh], the subunit of succinate dehydrogenase SDHd, which oxidizes succinate to fumarate), glycerol 3-phosphate dehydrogenase-1-like protein (GPD1L, which modulates the NAD<sup>+</sup>/ NADH ratio), and NADH dehydrogenase (ubiquinone)-1α (NADH–ubiquinone oxidoreductase) subunit NDUFα4 [<xref ref-type="bibr" rid="CR75">288</xref>]. MiR210 may protect ECs and skeletal and cardiac myocytes against redox stress. However, miR210 can raise <index-term id="ITerm351"><term>ROS</term></index-term>ROS production at least in some cell types and provokes cellular senescence.</p></sec><sec id="Sec32"><title>MicroRNAs as Risk Markers</title><p id="Par468">MicroRNAs can be released into the extracellular space and blood circulation in vesicles or linked to proteic binding partners, which avoid miR destruction.</p><p id="Par469">Certain microRNAs originating from the heart or other sources can be used as risk markers (Tables <xref rid="Tab14" ref-type="table">2.14</xref>, <xref rid="Tab15" ref-type="table">2.15</xref>, and <xref rid="Tab16" ref-type="table">2.16</xref>) [<xref ref-type="bibr" rid="CR26">238</xref>, <xref ref-type="bibr" rid="CR217">430</xref>]. Concentrations of the cardiac and muscular miRs (miR1, miR133, miR208, and miR499) are elevated in the bloodstream after <index-term id="ITerm352"><term>Myocardial infarction</term></index-term>MI. <table-wrap id="Tab14"><label>Table 2.14</label><caption xml:lang="en"><p>Examples of microRNAs used as risk markers (Source: [<xref ref-type="bibr" rid="CR26">238</xref>]; <italic>BNP</italic> brain natriuretic peptide, <italic>vSMC</italic> vascular smooth myocyte)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Type</p></th><th align="left"><p>Features</p></th></tr></thead><tbody><tr><td align="left"><p>MiR1</p></td><td align="left"><p>Marker of CMC necrosis</p></td></tr><tr><td align="left"><p>MiR21</p></td><td align="left"><p>Marker of fibrosis</p></td></tr><tr><td align="left"><p>MiR28</p></td><td align="left"><p>Marker of fibrosis</p></td></tr><tr><td align="left"><p>MiR33a</p></td><td align="left"><p>Marker of fibrosis</p></td></tr><tr><td align="left"><p>MiR126</p></td><td align="left"><p>Reduced in diabetes</p></td></tr><tr><td align="left"/><td align="left"><p>Regulates endothelial and vascular integrity</p></td></tr><tr><td align="left"/><td align="left"><p>Modulates formation of adhesion molecules</p></td></tr><tr><td align="left"/><td align="left"><p>High amount in platelet microvesicles</p></td></tr><tr><td align="left"><p>MiR133</p></td><td align="left"><p>Marker of CMC necrosis</p></td></tr><tr><td align="left"/><td align="left"><p>Modulates vSMC phenotype</p></td></tr><tr><td align="left"><p>MiR143/145</p></td><td align="left"><p>Released by mechanical stress</p></td></tr><tr><td align="left"/><td align="left"><p>Modulates vSMC phenotype</p></td></tr><tr><td align="left"><p>MiR150</p></td><td align="left"><p>Inversely linked to post-infarction remodeling</p></td></tr><tr><td align="left"/><td align="left"><p>High amount in platelet microvesicles</p></td></tr><tr><td align="left"/><td align="left"><p>Role in megakaryopoiesis</p></td></tr><tr><td align="left"><p>MiR155</p></td><td align="left"><p>Released by inflammation</p></td></tr><tr><td align="left"/><td align="left"><p>Regulates macrophage activity and lipid uptake</p></td></tr><tr><td align="left"><p>MiR197</p></td><td align="left"><p>Inversely associated with myocardial infarction</p></td></tr><tr><td align="left"><p>MiR208</p></td><td align="left"><p>Marker of CMC necrosis</p></td></tr><tr><td align="left"/><td align="left"><p>(mir208 gene in the intron of the MYH6 gene)</p></td></tr><tr><td align="left"><p>MiR223</p></td><td align="left"><p>Inversely associated with myocardial infarction</p></td></tr><tr><td align="left"/><td align="left"><p>Highly expressed in platelets</p></td></tr><tr><td align="left"><p>MiR499</p></td><td align="left"><p>Marker of CMC necrosis</p></td></tr><tr><td align="left"/><td align="left"><p>(mir499 gene in the intron of the MYH7 gene)</p></td></tr><tr><td align="left"><p>MiR328</p></td><td align="left"><p>Released by atrial fibrillation</p></td></tr><tr><td align="left"><p>MiR622</p></td><td align="left"><p>Released in heart failure</p></td></tr><tr><td align="left"/><td align="left"><p>Its concentration correlates with that of BNP</p></td></tr></tbody></table></table-wrap><table-wrap id="Tab15"><label>Table 2.15</label><caption xml:lang="en"><p>Cardiac microRNAs as markers of cardiovascular maladies (Source: [<xref ref-type="bibr" rid="CR163">376</xref>])</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>MicroRNA</p></th><th align="left"><p>Level of evolution of the disease</p></th></tr><tr><th align="left"/><th align="left"><p>(target)</p></th></tr></thead><tbody><tr><td align="left"><p>MiR1</p></td><td align="left"><p><italic>↑</italic> in coronary atherosclerosis, myocardial infarction</p></td></tr><tr><td align="left"/><td align="left"><p><italic>↓</italic> in tachycardia, atrial fibrillation</p></td></tr><tr><td align="left"/><td align="left"><p>(fatty acid-binding protein FABP3)</p></td></tr><tr><td align="left"><p>MiR133a/b</p></td><td align="left"><p><italic>↑</italic> in coronary atherosclerosis, myocardial infarction,</p></td></tr><tr><td align="left"/><td align="left"><p>tachycardia, and heart failure</p></td></tr><tr><td align="left"><p>MiR208a/b</p></td><td align="left"><p><italic>↑</italic> in coronary atherosclerosis, myocardial infarction,</p></td></tr><tr><td align="left"/><td align="left"><p>viral myocarditis, and heart failure</p></td></tr><tr><td align="left"><p>MiR423-5p</p></td><td align="left"><p><italic>↑</italic> in myocardial infarction and dilated cardiomyopathy</p></td></tr><tr><td align="left"><p>MiR499</p></td><td align="left"><p><italic>↑</italic> in myocardial infarction, viral myocarditis,</p></td></tr><tr><td align="left"/><td align="left"><p>and heart failure</p></td></tr></tbody></table></table-wrap><table-wrap id="Tab16"><label>Table 2.16</label><caption xml:lang="en"><p>Noncardiac microRNAs as markers of cardiovascular maladies (Source: [<xref ref-type="bibr" rid="CR163">376</xref>])</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>MicroRNA</p></th><th align="left"><p>Level of evolution of the disease</p></th></tr></thead><tbody><tr><td align="left"><p>MiR21</p></td><td align="left"><p><italic>↑</italic> in coronary atherosclerosis, myocardial infarction</p></td></tr><tr><td align="left"/><td align="left"><p>hypertrophic cardiomyopathy, and heart failure</p></td></tr><tr><td align="left"/><td align="left"><p><italic>↓</italic> in atrial fibrillation</p></td></tr><tr><td align="left"><p>MiR27a</p></td><td align="left"><p><italic>↑</italic> in myocardial infarction</p></td></tr><tr><td align="left"/><td align="left"><p>and hypertrophic cardiomyopathy</p></td></tr><tr><td align="left"/><td align="left"><p><italic>↓</italic> in heart failure</p></td></tr><tr><td align="left"><p>MiR30c/d</p></td><td align="left"><p><italic>↓</italic> in coronary atherosclerosis</p></td></tr><tr><td align="left"/><td align="left"><p><italic>↑</italic> in hypertrophic cardiomyopathy</p></td></tr><tr><td align="left"><p>MiR106a-5p</p></td><td align="left"><p><italic>↓</italic> in myocardial infarction and heart failure</p></td></tr><tr><td align="left"><p>MiR122</p></td><td align="left"><p><italic>↑</italic> in coronary atherosclerosis</p></td></tr><tr><td align="left"><p>MiR126</p></td><td align="left"><p><italic>↑</italic> in myocardial infarction</p></td></tr><tr><td align="left"/><td align="left"><p><italic>↓</italic> in heart failure</p></td></tr><tr><td align="left"><p>MiR134</p></td><td align="left"><p><italic>↑</italic> in coronary atherosclerosis, myocardial infarction</p></td></tr><tr><td align="left"><p>MiR145</p></td><td align="left"><p><italic>↓</italic> in coronary atherosclerosis</p></td></tr><tr><td align="left"/><td align="left"><p>and atrial fibrillation</p></td></tr><tr><td align="left"/><td align="left"><p><italic>↑</italic> in heart failure</p></td></tr><tr><td align="left"><p>MiR146a</p></td><td align="left"><p><italic>↑</italic> in atrial fibrillation</p></td></tr><tr><td align="left"/><td align="left"><p><italic>↓</italic> in heart failure</p></td></tr><tr><td align="left"><p>MiR150</p></td><td align="left"><p><italic>↓</italic> in atrial fibrillation</p></td></tr><tr><td align="left"><p>MiR197</p></td><td align="left"><p><italic>↑</italic> in coronary atherosclerosis</p></td></tr><tr><td align="left"><p>MiR199a</p></td><td align="left"><p><italic>↑</italic> in coronary atherosclerosis</p></td></tr><tr><td align="left"/><td align="left"><p>and hypertrophic cardiomyopathy</p></td></tr><tr><td align="left"/><td align="left"><p><italic>↓</italic> in heart failure</p></td></tr><tr><td align="left"><p>MiR223</p></td><td align="left"><p><italic>↑</italic> in coronary atherosclerosis</p></td></tr><tr><td align="left"><p>MiR328</p></td><td align="left"><p><italic>↑</italic> in myocardial infarction</p></td></tr><tr><td align="left"/><td align="left"><p><italic>↓</italic> in atrial fibrillation, heart failure</p></td></tr><tr><td align="left"><p>MiR486</p></td><td align="left"><p><italic>↑</italic> in coronary atherosclerosis, myocardial infarction</p></td></tr></tbody></table><table-wrap-foot><p>As myocardial infarction marker, they are as significant as cardiac microRNAs</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec33"><title>MicroRNAs Involved in Adverse Cardiac Remodeling</title><p id="Par470">MicroRNAs participate in regulating transcript translation and degradation during cardiac genesis and remodeling (Table <xref rid="Tab17" ref-type="table">2.17</xref>). MiR21, miR29a, miR129, miR210, miR211, miR320, and miR423, along with Let7c, are highly expressed in the fetal heart and in postnatal cardiac development [<xref ref-type="bibr" rid="CR164">377</xref>]. Members of the MIR1 (miR1-1 and miR1-2) and MIR133 (miR133a1–miR133a2 and miR133b) and miR206 are muscle-specific microRNAs; miR1 and miR133 are also produced in adequate amounts during the early stage of cardiogenesis. MiR1 targets the transcription factor <index-term id="ITerm353"><term>HAND</term></index-term>HAND2, which promotes CMC proliferation, in addition to the transcriptional repressor HDAC4. MiR133 acts on the nuclear factor NELFA.<xref ref-type="fn" rid="Fn77">77</xref><table-wrap id="Tab17"><label>Table 2.17</label><caption xml:lang="en"><p>MicroRNAs in cardiac fate (Source: [<xref ref-type="bibr" rid="CR164">377</xref>])</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Context</p></th><th align="left"><p>Involved microRNAs</p></th></tr></thead><tbody><tr><td align="left"><p>Cardiogenesis</p></td><td align="left"><p>MiR1/21/29a/129/133a/210/211/320/423,</p></td></tr><tr><td align="left"/><td align="left"><p>Let7c</p></td></tr><tr><td align="left"><p>Ventricular septal defect</p></td><td align="left"><p>MiR1/181c</p></td></tr><tr><td align="left"><p>Tetralogy of Fallot</p></td><td align="left"><p>MiR421/940</p></td></tr><tr><td align="left"><p>Bicuspid aortic valve</p></td><td align="left"><p>MiR26a/30b/141/195</p></td></tr><tr><td align="left"><p>Cardiac remodeling</p></td><td align="left"><p>MiR1/21/133/195/208/214</p></td></tr><tr><td align="left"><p>Atrial fibrillation</p></td><td align="left"><p>MiR1/328</p></td></tr><tr><td align="left"><p>Ventricular arrhythmia</p></td><td align="left"><p>MiR1</p></td></tr><tr><td align="left"><p>Hypertension</p></td><td align="left"><p>MiR20a/132/155/181/212/663</p></td></tr><tr><td align="left"><p>Heart failure</p></td><td align="left"><p>MiR1/21–23/29/92b/130/195/199,</p></td></tr><tr><td align="left"/><td align="left"><p>miR210/320a/423-5p/499/622</p></td></tr><tr><td align="left"><p>Atherosclerosis</p></td><td align="left"><p>MiR33/122/126/145/155/370</p></td></tr><tr><td align="left"><p>Myocardial infarction</p></td><td align="left"><p>MiR1/15/24/133a/208b/499</p></td></tr></tbody></table></table-wrap></p><p id="Par472">Loss of miR1 and miR133 leads to ventricular septal defects and cardiac chamber dilation. In ventricular septal defects, expression of miR181c rises. In the human heart, miR196a is associated with the HoxB8 (or Hox2D)–sonic hedgehog pathway implicated in cardiac septation, valve formation, and outflow tract morphogenesis. Tetralogy of Fallot, the most common congenital cyanotic disorder, is linked to an overexpression of miR421 in ventriculomyocytes, whereas miRNA940 is underexpressed [<xref ref-type="bibr" rid="CR164">377</xref>]. In bicuspid aortic valve, a congenital valvulopathy, miR26a, miR30b, miR141, and miR195 concentrations are weak.</p><p id="Par473">In adverse cardiac remodeling, that is, hypertension-induced hypertrophy, miR1 and miR133 expression is downregulated, whereas that of miR21, miR195, miR208, and miR214 is upregulated [<xref ref-type="bibr" rid="CR164">377</xref>].</p><p id="Par474">In ventricular arrhythmias, arrhythmogenic miR1 represses expression of the KCNJ2 and GJA1 genes that encode K<sub>IR</sub>2.1 channel and connexin-43 [<xref ref-type="bibr" rid="CR164">377</xref>]. On the other hand, miR1 concentration is reduced in atrial fibrillation, which is linked to miR328.</p><p id="Par475">Profibrotic miR33a is produced predominantly by cardiofibroblasts, which ensures necessary acute wound healing (<italic>cardiac reactive fibrosis</italic>) [<xref ref-type="bibr" rid="CR165">378</xref>]. On the other hand, <index-term id="ITerm354"><term>Cardiac fibrosis</term></index-term><italic>cardiac replacement fibrosis</italic> linked to adverse remodeling, which upregulates miR33a expression in the heart, is deleterious. In <sup>CFB</sup>mir33<sup>−∕−</sup> (i.e., only in cardiofibroblasts), cardiac fibrosis is attenuated in response to hypertension. Depletion of miR33a impedes <index-term id="ITerm355"><term>PKB</term></index-term>PKB activation but favors ABCa1 expression. MiR33 can control cardiofibroblast proliferation, as it can target CDK6, CcnD1, and P53 in some cell types [<xref ref-type="bibr" rid="CR151">364</xref>], but CDK4 is predominant over CDK6 in fibroblasts [<xref ref-type="bibr" rid="CR165">378</xref>]. In fact, miR33a preserves the cholesterol content of membrane rafts, which enable PKB activation and cardiofibroblast proliferation.<xref ref-type="fn" rid="Fn78">78</xref> On the other hand, upregulated synthesis of ABCa1, which permits efflux of intracellular free cholesterol to extracellular cholesterol acceptor <index-term id="ITerm356"><term>ApoA1</term></index-term>ApoA1, depletes the cholesterol content of membrane rafts and alters the proliferative capacity of cardiofibroblasts.</p><p id="Par477">Some microRNAs are associated with matrix degradation and pathological cardiac remodeling caused by prolonged overactivation of the <index-term id="ITerm357"><term>Renin–angiotensin–aldosterone axis</term></index-term>renin–angiotensin–aldosterone axis and <index-term id="ITerm358"><term>Sympathetic</term></index-term>sympathetic nervous system in addition to hypertension, valve stenosis or regurgitation, myocarditis, familial and acquired cardiomyopathies, and MI (e.g., miR100 and miR101) [<xref ref-type="bibr" rid="CR168">381</xref>]. MiR101 regulates Rab1a formation; miR100 and miR101 (along with miR15b, miR20a, miR92a, and miR132), prime apoptosis, as they target inhibitors of the intrinsic apoptosis pathway.</p><p id="Par478">Many microRNAs favor or counter <index-term id="ITerm359"><term>Cardiac hypertrophy</term></index-term>maladaptive cardiac hypertrophy (Tables <xref rid="Tab18" ref-type="table">2.18</xref> and <xref rid="Tab19" ref-type="table">2.19</xref>) and <index-term id="ITerm360"><term>Cardiac fibrosis</term></index-term>fibrosis (Tables <xref rid="Tab20" ref-type="table">2.20</xref> and <xref rid="Tab21" ref-type="table">2.21</xref>). <table-wrap id="Tab18"><label>Table 2.18</label><caption xml:lang="en"><p>Antihypertrophic microRNAs in the heart (Source: [<xref ref-type="bibr" rid="CR168">381</xref>] <italic>AtG</italic> autophagy-related gene product, <italic>CamK</italic> calcium–calmodulin-dependent kinase, <italic>Ccn</italic> cyclin, <italic>FABP</italic> fatty acid-binding protein, <italic>Fbln</italic> fibulin, <italic>GATA</italic> GATA-binding protein, <italic>HAND</italic> heart and neural crest derivatives expressed protein, <italic>IGF</italic> insulin-like growth factor, <italic>KAT</italic> lysine (K) acetyltransferase, <italic>Ksr</italic> kinase suppressor of Ras, <italic>MAPK</italic> mitogen-activated protein kinase, <italic>NCX</italic> sodium–calcium exchanger, <italic>NFAT</italic> nuclear factor of activated T-cells, <italic>TnnI3K</italic> troponin-I type-3-interacting kinase, <italic>Twf</italic> actin-binding twinfilin homolog [PTK9], <italic>WHSC2</italic> Wolf–Hirschhorn syndrome candidate protein-2, or negative elongation factor NeLFa, <italic>XBP1</italic> X-box-binding protein)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>MiRs</p></th><th align="left"><p>Transcript targets (effect)</p></th></tr></thead><tbody><tr><td align="left"><p>MiR1</p></td><td align="left"><p>Fabp3, FBLN2, Hand2, Igf1, TWF1</p></td></tr><tr><td align="left"/><td align="left"><p>(in addition to Cdk9, FN1, RASGAP, Rheb)</p></td></tr><tr><td align="left"><p>MiR9</p></td><td align="left"><p>Myocardin (<italic>↓</italic> NFAT3)</p></td></tr><tr><td align="left"><p>MiR26b</p></td><td align="left"><p>GATA4</p></td></tr><tr><td align="left"><p>MiR30-3p</p></td><td align="left"><p>Xbp1</p></td></tr><tr><td align="left"><p>MiR34a</p></td><td align="left"><p>ATG9A</p></td></tr><tr><td align="left"><p>MiR98</p></td><td align="left"><p>CCND2</p></td></tr><tr><td align="left"><p>MiR101</p></td><td align="left"><p>RAB1A</p></td></tr><tr><td align="left"><p>MiR133</p></td><td align="left"><p>Cdc42, RHOA, WHSC2 (or NELFA)</p></td></tr><tr><td align="left"><p>MiR145</p></td><td align="left"><p>GATA6</p></td></tr><tr><td align="left"><p>MiR150</p></td><td align="left"><p>KAT3B</p></td></tr><tr><td align="left"><p>MiR185</p></td><td align="left"><p>CAMK2D, Ncx1, Nfat3</p></td></tr><tr><td align="left"><p>MiR223</p></td><td align="left"><p>TNNI3K</p></td></tr><tr><td align="left"><p>MiR378</p></td><td align="left"><p>Mapk1, Igf1r, Grb2, Ksr1</p></td></tr></tbody></table></table-wrap><table-wrap id="Tab19"><label>Table 2.19</label><caption xml:lang="en"><p>Prohypertrophic microRNAs in the heart (Source: [<xref ref-type="bibr" rid="CR168">381</xref>] <italic>BECN1</italic> autophagy-related beclin-1, <italic>CDKN1B</italic> transcript encoding cyclin-dependent kinase inhibitor-1B [CKI1b], <italic>DYRK</italic> dual-specificity Tyr (Y) phosphorylation-regulated kinase, <italic>FBxO32</italic> F-box only protein-32, or atrogin-1, <italic>Fox</italic> forkhead box transcription factor, <italic>GRB</italic> growth factor receptor-bound protein, <italic>GSK</italic> glycogen synthase kinase, <italic>HDAC</italic> histone deacetylase, <italic>LPA</italic><sub>1</sub>, lysophosphatidic acid receptor-1, <italic>MAPK</italic> mitogen-activated protein kinase, <italic>MED</italic> mediator complex subunit, <italic>MSTN</italic> myostatin, <italic>PPAR</italic>γ, peroxisome proliferator-activated receptor-γ, or nuclear receptor NR1c3, <italic>PDLIM5</italic> PDZ and LIM domain-containing protein-5, or enigma homolog [enigma-like PDZ and LIM domain-containing protein EnH1], <italic>PTen</italic> phosphatase and tensin homolog, <italic>serca</italic> sarco(endo)plasmic reticulum Ca<sup>2+</sup> ATPase, <italic>SIRT</italic> silent information regulator-2, <italic>SorbS</italic> sorbin and SH3 domain-containing protein, <italic>TP53INP1</italic> tumor protein P53-inducible nuclear protein-1, <italic>TriM63</italic> tripartite motif-containing protein-63, or muscle-specific RING finger-containing protein MuRF1)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>MiRs</p></th><th align="left"><p>Transcript targets (effect)</p></th></tr></thead><tbody><tr><td align="left"><p>MiR19a/b</p></td><td align="left"><p>FBXO32, TRIM63 (<italic>↑</italic> NFAT)</p></td></tr><tr><td align="left"><p>MiR21</p></td><td align="left"><p>PTEN (TOR activation)</p></td></tr><tr><td align="left"><p>MiR21-3p</p></td><td align="left"><p>Hdac8, SORBS2, PDLIM5</p></td></tr><tr><td align="left"><p>MiR22</p></td><td align="left"><p>Sirt1, Hdac4, PTEN</p></td></tr><tr><td align="left"><p>MiR23a</p></td><td align="left"><p>FOXO3A, LPAR1</p></td></tr><tr><td align="left"><p>MiR27b</p></td><td align="left"><p>PPARG</p></td></tr><tr><td align="left"><p>MiR30a</p></td><td align="left"><p>BECN1</p></td></tr><tr><td align="left"><p>MiR30a-3p</p></td><td align="left"><p>Xbp1</p></td></tr><tr><td align="left"><p>MiR155</p></td><td align="left"><p>Tp53inp1</p></td></tr><tr><td align="left"><p>MiR199a</p></td><td align="left"><p>GSK3B (TOR activation)</p></td></tr><tr><td align="left"><p>MiR199b</p></td><td align="left"><p>Dyrk1a (NFAT activation)</p></td></tr><tr><td align="left"><p>MiR208a/b</p></td><td align="left"><p>MED13, MSTN</p></td></tr><tr><td align="left"><p>MiR212–miR132 group</p></td><td align="left"><p>FOXO3 (<italic>↑</italic> NFAT)</p></td></tr><tr><td align="left"><p>MiR221</p></td><td align="left"><p>CDKN1B</p></td></tr><tr><td align="left"><p>MiR328</p></td><td align="left"><p>SERCA2A (NFAT activation)</p></td></tr><tr><td align="left"><p>MiR350</p></td><td align="left"><p>Mapk8/9/11/14 (NFAT activation)</p></td></tr></tbody></table></table-wrap><table-wrap id="Tab20"><label>Table 2.20</label><caption xml:lang="en"><p>Antifibrotic microRNAs in the heart (Source: [<xref ref-type="bibr" rid="CR168">381</xref>] <italic>Col</italic> collagen, <italic>CTGF</italic> connective tissue growth factor, <italic>Eln</italic> elastin, <italic>Fbn</italic> fibrillin, <italic>Fos</italic> FBJ murine osteosarcoma viral proto-oncogene homolog, <italic>IL</italic> interleukin, <italic>Snai1</italic> zinc finger-containing snail homolog, <italic>TGF</italic> transforming growth factor)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>MiRs</p></th><th align="left"><p>Transcript targets (effect)</p></th></tr></thead><tbody><tr><td align="left"><p>Let7i</p></td><td align="left"><p>COL1A2, Il6</p></td></tr><tr><td align="left"><p>MiR24</p></td><td align="left"><p>FURIN (Pcsk3; <italic>↓</italic> TGFβ)</p></td></tr><tr><td align="left"><p>MiR26a</p></td><td align="left"><p>COL1A1, Ctgf</p></td></tr><tr><td align="left"><p>MiR29a/b/c</p></td><td align="left"><p>ELN, FBN1, COL1A1/A2, COL3A1</p></td></tr><tr><td align="left"><p>MiR29b</p></td><td align="left"><p>TGFB1</p></td></tr><tr><td align="left"><p>MiR30</p></td><td align="left"><p>Ctgf</p></td></tr><tr><td align="left"><p>MiR101a</p></td><td align="left"><p>FOS, TGFBR1</p></td></tr><tr><td align="left"><p>MiR133</p></td><td align="left"><p>Ctgf</p></td></tr><tr><td align="left"><p>MiR133a</p></td><td align="left"><p>COL1A1, Pp3, SERCA2A, SNAI1</p></td></tr></tbody></table><table-wrap-foot><p>In the vasculature, miR29 expression is upregulated during aging; it represses synthesis of matrix proteins in smooth myocytes and participates in the regulation of aneurysm formation; miR29b-3p counters fibrosis</p></table-wrap-foot></table-wrap><table-wrap id="Tab21"><label>Table 2.21</label><caption xml:lang="en"><p>Profibrotic microRNAs in the heart (Source: [<xref ref-type="bibr" rid="CR168">381</xref>] <italic>Apln</italic> apelin, <italic>PTen</italic> phosphatase and tensin homolog, <italic>Spry</italic> sprouty homolog)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>MiRs</p></th><th align="left"><p>Transcript targets</p></th></tr></thead><tbody><tr><td align="left"><p>miR21</p></td><td align="left"><p>SPRY1 (MAPK activation), PTEN (<italic>↑</italic> MMP2)</p></td></tr><tr><td align="left"><p>miR125b</p></td><td align="left"><p>APLN</p></td></tr></tbody></table><table-wrap-foot><p>Concentration of profibrotic miR21-5p, which causes cardiac fibrosis, does not correlate with atherosclerotic plaque fibrosis [<xref ref-type="bibr" rid="CR169">382</xref>]</p></table-wrap-foot></table-wrap></p><p id="Par479">Concentrations of circulating microRNAs depend on disease states and can thus serve as markers of CVD evolution. Microvesicles and HDLs can transport miRs in blood and deliver them to cells.</p><p id="Par480"><index-term id="ITerm361"><term>MicroRNA</term></index-term>MiR208a and miR208b, which are encoded by introns of the MYH6 and MYH7 genes respectively, are also involved in the mutually incompatible regulation of MHC6 and MHC7 expression in adverse cardiac hypertrophy, downregulating MYH6 and upregulating MYH7 expression [<xref ref-type="bibr" rid="CR170">383</xref>]. They regulate MYH7 expression via the mediator complex subunit Med13 and myostatin [<xref ref-type="bibr" rid="CR171">384</xref>].</p><p id="Par481">MicroRNA-146a concentration moderately increases in the left ventricular wall of patients with aortic stenosis. Overexpression of miR146a in CMCs provoked cardiac hypertrophy [<xref ref-type="bibr" rid="CR172">385</xref>]. MiR146a reduces the formation of dihydrolipoyl succinyltransferase (DLST).<xref ref-type="fn" rid="Fn79">79</xref> MiR181c can act in the mitochondrion of CMCs, where it targets MTCOI mRNA, which encodes cytochrome-C oxidase catalytic subunit-1 (CcOx1) and provokes remodeling of <sup>ETC</sup>complex-<italic>IV</italic> [<xref ref-type="bibr" rid="CR173">386</xref>].</p></sec><sec id="Sec34"><title>MicroRNAs in Obesity and Diabetes</title><p id="Par489">Increased adiposity, obesity, and diabetes are linked to redox stress and inflammation. Mitochondrial <index-term id="ITerm364"><term>ROS</term></index-term>ROS overproduction results from hyperglycemia in the diabetic microvasculature, whereas in the diabetic macrovascular and heart, it is the consequence of increased fatty acid oxidation and insulin resistance [<xref ref-type="bibr" rid="CR75">288</xref>].</p><p id="Par490">In obese subjects, redox stress in adipose tissue is associated with chronic low-grade inflammation. Three miRs target antioxidant, anti-inflammatory, and antiapoptotic heme oxygenase HOx1, miR155, miR183, and miR872 [<xref ref-type="bibr" rid="CR75">288</xref>].</p><p id="Par491">In adipose tissue of obese mice, miR221 and miR222 trigger hypoxia and the formation of miR27, which hampers production of PPARγ and C/EBPα [<xref ref-type="bibr" rid="CR75">288</xref>].</p><p id="Par492">In diabetes, concentrations of proinflammatory mediators, such as advanced glycation end products, PGhS2, cytokines IL6 and TNFSF1, and chemokines CCL2 and CX<sub>3</sub>CL1, rise, thereby favoring vSMC proliferation, redox stress, and vascular complications. In vSMCs of diabetic mice, expression of miR125b and MIR200 family members is upregulated, enhancing transcription of proinflammatory genes via an epigenetic process [<xref ref-type="bibr" rid="CR75">288</xref>].</p><p id="Par493">In diabetic subjects, miR34a and miR504 also play a role in vascular smooth myocyte dysfunction, whereas miR126 targets tissue factor and reduces thrombogenicity and miR191 impedes wound repair, as it hinders migration of fibroblasts and favors apoptosis of dermal fibroblasts [<xref ref-type="bibr" rid="CR73">286</xref>].</p><p id="Par494"><index-term id="ITerm365"><term>circHipk3</term></index-term>The circular RNA Hipk3 (circHipk3) acts as a miR30a-3p sponge, thereby increasing VEGFc, Fzd4, and Wnt2 formation. Its production is upregulated in diabetic retinal ECs [<xref ref-type="bibr" rid="CR174">387</xref>]. CircHIPK3 affects survival, proliferation, and migration, and hence the angiogenic capacity of retinal ECs. In vivo, circHIPK3 thus controls diabetic proliferative retinopathy; the silencing of circHIPK3 alleviates retinal vascular dysfunction.</p></sec><sec id="Sec35"><title>MicroRNAs Involved in Atherosclerosis</title><p id="Par495">When <index-term id="ITerm366"><term>atherosclerosis</term></index-term>atherosclerotic lesions become unstable, miR concentrations increase. MiR29 may contribute to inflammation and plaque destabilization [<xref ref-type="bibr" rid="CR175">388</xref>]. Other microRNAs, such as miR92, miR126, miR145, and miR155, are implicated in the initiation of endothelial dysfunction and macrophage activity.</p><p id="Par496">MiR155 has both anti- and proatherogenic effects according to the disease stage [<xref ref-type="bibr" rid="CR73">286</xref>]. MiR150-5p, miR365a-3p, and miR1275 are linked to coronary atherosclerosis. The angiomicroRNAs miR378 and Let7b are upregulated in CD34+ + progenitor cells in response to MI.</p><p id="Par497">In patients with atherosclerosis, especially with coronary stenoses and acute coronary syndrome (ACS),<xref ref-type="fn" rid="Fn80">80</xref> miR133a, miR133b, miR208a, miR208b, and miR499, can serve as diagnostic and/or prognostic markers across different progression stages [<xref ref-type="bibr" rid="CR176">389</xref>]. MiR1<xref ref-type="fn" rid="Fn81">81</xref> and miR145b<xref ref-type="fn" rid="Fn82">82</xref> are also ACS markers, with miR1 having a higher sensitivity for all types of MI and miR145 for ST segment elevation myocardial infarction (STEMI). In addition, miR1, miR21, miR122, miR134, miR14525, miR37026, and miR49931 correlate positively with CoAD severity. The greatest prognostic or diagnostic value is yielded by the miR132–miR150–miR186 combination. Both miR208a and miR208b, which are exclusively produced in CMCs, are the early detectable specific diagnostic MI markers with respect to cTnIn and cTnnT. MiR320a and miR49922 are also sensitive and specific MI diagnostic markers. For some investigators, only miR126,<xref ref-type="fn" rid="Fn83">83</xref> miR223, and miR19736 provide an MI risk.</p><p id="Par502">The identified miRs regulate endothelial function and angiogenesis (miR1 and miR133), vSMC differentiation (miR133 and miR145), communication between vEC and vSMC (miR145), apoptosis (miR1, miR133, and miR499), and CMC differentiation (miR1, miR133, miR145, miR208, and miR499), and repress cardiac hypertrophy (miR133). Their shared targets include mRNAs encoding CKI1a, ETS1,<xref ref-type="fn" rid="Fn84">84</xref> Fscn1,<xref ref-type="fn" rid="Fn85">85</xref> HCN4,<xref ref-type="fn" rid="Fn86">86</xref> IGF1R,<xref ref-type="fn" rid="Fn87">87</xref> LASP1,<xref ref-type="fn" rid="Fn88">88</xref> PNP,<xref ref-type="fn" rid="Fn89">89</xref> and Tagln2 [<xref ref-type="bibr" rid="CR176">389</xref>].<xref ref-type="fn" rid="Fn90">90</xref></p><p id="Par510">Matrix metallopeptidases degrade collagens, elastin, proteoglycans, and glycoproteins, such as fibronectin and laminin. They are counteracted by TIMPs. <index-term id="ITerm367"><term>CSF2</term></index-term>In unstable atherosclerotic lesions, the myelopoietic growth factor CSF2,<xref ref-type="fn" rid="Fn91">91</xref> which is involved in the development of mononuclear phagocytes only during inflammation, favors the <index-term id="ITerm371"><term>TIMP</term></index-term>TIMP3− phenotype of macrophages, which are more invasive and sensitive to apoptosis than TIMP3+ macrophages [<xref ref-type="bibr" rid="CR178">391</xref>]. The density of TIMP3− macrophages is higher in unstable than in stable plaques. In macrophages, CSF2 reduces TIMP3 production via miR181b, thereby favoring plaque instability and aneurysm development [<xref ref-type="bibr" rid="CR179">392</xref>]. Tissue inhibitors of metallopeptidases protect against the progression of atherosclerosis and AAAs.<xref ref-type="fn" rid="Fn92">92</xref> In addition, miR181b, which is overexpressed in developed atherosclerotic plaques and AAAs, precludes elastin production by vSMCs. Moreover, miR181b is a potent regulator of <index-term id="ITerm372"><term>NFκB</term></index-term>NFκB signaling in the vascular endothelium, as it targets the KPNA4 (or IPOA3) gene, which encodes karyopherin-α4 (or importin-α3), required for the nuclear translocation of NFκB, thereby downregulating Kpnα4 and NFκB nuclear translocation in the vascular endothelium [<xref ref-type="bibr" rid="CR178">391</xref>, <xref ref-type="bibr" rid="CR179">392</xref>].<xref ref-type="fn" rid="Fn93">93</xref> MiR181b also favors the M2 phenotype in atherosclerotic lesions, as it also targets notch-1 [<xref ref-type="bibr" rid="CR180">393</xref>], in addition to promoting development of NK cells from hematopoietic progenitor cells [<xref ref-type="bibr" rid="CR181">394</xref>].</p><p id="Par514">Some miRs (miR29b-3p, miR126-3p, miR145-5p, and miR155-5p) exhibit a transcoronary concentration gradient (TCG) within the coronary circulation between its entry (aortic orifices) and exit (venous coronary sinus; Table <xref rid="Tab22" ref-type="table">2.22</xref>) [<xref ref-type="bibr" rid="CR169">382</xref>]. They appear in the coronary circulation in the early stages of coronary atherosclerosis. They are related to vulnerable plaques observed by optical coherence tomography with the presence of thin-cap fibroatheroma [<xref ref-type="bibr" rid="CR169">382</xref>]. On the other hand, miR29b-3p, miR126-3p, miR145-5p, and miR155-5p have negative TCGs in subjects without vulnerable plaques. Uptake of circulating atheroprotective miR126-3p and miR145-5p in the coronary vessels stabilizes atherosclerotic lesions. <index-term id="ITerm373"><term>Platelet</term></index-term>Platelets can contribute to transcoronary miR concentrations; miR223-3p, which is highly expressed in platelets, but weakly expressed in ECs, also has a negative TCG [<xref ref-type="bibr" rid="CR169">382</xref>]. <table-wrap id="Tab22"><label>Table 2.22</label><caption xml:lang="en"><p>MicroRNA (miR) transcoronary concentration gradients (TCGs) during the main evolution phases of coronary atherosclerosis (Source: [<xref ref-type="bibr" rid="CR175">388</xref>])</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Type</p></th><th align="left"><p>Positive TCG</p></th><th align="left"><p>Negative TCG</p></th></tr></thead><tbody><tr><td align="left"><p>Endothelial</p></td><td align="left"><p>MiR92/126/133,</p></td><td align="left"><p>MiR17a/181a/222</p></td></tr><tr><td align="left"><p>dysfunction</p></td><td align="left"><p>miR145/155</p></td><td align="left"/></tr><tr><td align="left"><p>Atherosclerosis</p></td><td align="left"><p>MiR126/145/155,</p></td><td align="left"><p>ND</p></td></tr><tr><td align="left"/><td align="left"><p>miR208a/221</p></td><td align="left"/></tr><tr><td align="left"><p>Acute coronary</p></td><td align="left"><p>MiR133a/208a,</p></td><td align="left"><p>MiR92a/126/155</p></td></tr><tr><td align="left"><p>syndrome</p></td><td align="left"><p>miR499</p></td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Transcoronary concentration gradients of several miRs are associated with atherosclerotic lesion vulnerability. In particular, miR126-3p and miR126-5p are secreted into the coronary circulation by activated ECs covering atherosclerotic plaques via release of apoptotic bodies and/or protein-bound miRs. Negative transcoronary gradients of miR126-3p, miR126-5p, and miR145-5p may result from the uptake and/or degradation during the transcoronary passage in subjects with predominantly stable coronary atherosclerotic plaques [<xref ref-type="bibr" rid="CR169">382</xref>]</p></table-wrap-foot></table-wrap></p><p id="Par515"><index-term id="ITerm374"><term>Exosome</term></index-term>Cardiomyocytes cultured under ischemic conditions release exosomes that promote <index-term id="ITerm375"><term>angiogenesis</term></index-term>angiogenesis via miR143 and miR222, the most abundant microRNAs in ischemic exosomes [<xref ref-type="bibr" rid="CR182">395</xref>]. Intramyocardial delivery of ischemic exosomes improves neovascularization following MI.</p></sec><sec id="Sec36"><title>MicroRNAs Involved in Stroke</title><p id="Par516"><index-term id="ITerm376"><term>Stroke</term></index-term>Two major categories of strokes include <italic>ischemic</italic> (∼87%) and <italic>hemorrhagic strokes</italic>, which are mainly caused by emboli and bleeding respectively. Ischemic stroke can result from carotid artery atherosclerosis, either from hypoperfusion due to high-grade stenosis or emboli upon plaque ulceration, even in relatively small lesions (∼20%) [<xref ref-type="bibr" rid="CR183">396</xref>].</p><p id="Par517">MicroRNAs can serve as markers to assess atherosclerotic plaque rupture and embolic stroke risk. MicroRNA expression is deregulated in human carotid plaques, causing lesion growth, instability, and rupture (Tables <xref rid="Tab23" ref-type="table">2.23</xref>, <xref rid="Tab24" ref-type="table">2.24</xref>, <xref rid="Tab25" ref-type="table">2.25</xref>, and <xref rid="Tab26" ref-type="table">2.26</xref>). <table-wrap id="Tab23"><label>Table 2.23</label><caption xml:lang="en"><p>MicroRNAs and atherogenesis (<bold>Part 1</bold>; Source: [<xref ref-type="bibr" rid="CR183">396</xref>]; <italic>asterisk</italic> [<italic>miR</italic><sup>∗</sup>] microRNAs regulated by hemodynamic stress, + [−] miR protecting [amplifying] effect on atherosclerogenesis)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Process</p></th><th align="left"><p>Involved miR species</p></th></tr></thead><tbody><tr><td align="left"><p>NOS activity</p></td><td align="left"><p>+ : miR153/221/222</p></td></tr><tr><td align="left"><p>Collagen synthesis (fibrous cap)</p></td><td align="left"><p>+ : miR21/29b/126/145/192</p></td></tr><tr><td align="left"><p>Collagen degradation by MMPs</p></td><td align="left"><p>+ : miR24/29</p></td></tr><tr><td align="left"><p>(fibrous cap thinning)</p></td><td align="left"/></tr><tr><td align="left"><p>Endotheliocyte activation</p></td><td align="left"><p>+ : miR/92a<sup>∗</sup>/217/663<sup>∗</sup>/712<sup>∗</sup></p></td></tr><tr><td align="left"><p>and inflammation</p></td><td align="left"><p>−: Let7g, miR10a<sup>∗</sup>, miR17-3p/31/124a/125,</p></td></tr><tr><td align="left"/><td align="left"><p>miR126/126-5pa<sup>∗</sup>/143/145a<sup>∗</sup>/146a/146b,</p></td></tr><tr><td align="left"/><td align="left"><p>miR155/181b/221/222</p></td></tr><tr><td align="left"><p>Monocyte differentiation</p></td><td align="left"><p>+ : miR222/424/503</p></td></tr><tr><td align="left"/><td align="left"><p>−: miR17/20a/106a</p></td></tr><tr><td align="left"><p>Macrophage activation</p></td><td align="left"><p>+ : miR125b/155/342-5p</p></td></tr><tr><td align="left"/><td align="left"><p>−: miR9/21/124/125a-5p/146a/146b/147/223</p></td></tr><tr><td align="left"><p>Apoptosis</p></td><td align="left"><p>MiR24/155</p></td></tr></tbody></table></table-wrap><table-wrap id="Tab24"><label>Table 2.24</label><caption xml:lang="en"><p>MicroRNAs and atherogenesis (<bold>Part 2</bold>; Source: [<xref ref-type="bibr" rid="CR183">396</xref>]; <italic>asterisk</italic> [<italic>miR</italic><sup>∗</sup>] microRNAs regulated by hemodynamic stress, + [−] miR’s protective [amplifying] effect on atherosclerogenesis)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Process</p></th><th align="left"><p>Involved miR species</p></th></tr></thead><tbody><tr><td align="left"><p>Smooth myocyte proliferation</p></td><td align="left"><p>+ : miR26a/31/146a/155/208/221/222</p></td></tr><tr><td align="left"><p>and migration</p></td><td align="left"><p>−: Let7d, miR1/10a/29/100/132/133/143/145,</p></td></tr><tr><td align="left"/><td align="left"><p>miR195/204/424/638/663</p></td></tr><tr><td align="left"><p>Apoptosis</p></td><td align="left"><p>MiR21/126</p></td></tr><tr><td align="left"><p>T-cell differentiation and activation</p></td><td align="left"><p>+ : miR17–92/146a/155/182/326</p></td></tr><tr><td align="left"/><td align="left"><p>−: miR125b/181a</p></td></tr><tr><td align="left"><p>Foam cell formation</p></td><td align="left"><p>−: miR9/125a-5p/146a/155</p></td></tr><tr><td align="left"><p>Cholesterol egress</p></td><td align="left"><p>−: miR10b/26/27/33a/33b/106b/144/145/155,</p></td></tr><tr><td align="left"/><td align="left"><p>miR302a/758</p></td></tr><tr><td align="left"/><td align="left"><p>−: miR223/378</p></td></tr><tr><td align="left"><p>Intraplaque angiogenesis</p></td><td align="left"><p>+ : Let7f, miR23/24/27/92a/126/130a/132/150,</p></td></tr><tr><td align="left"/><td align="left"><p>miR210/218/378</p></td></tr><tr><td align="left"/><td align="left"><p>−: miR15b/16/20a/21/26a/100/200/221/222/223</p></td></tr><tr><td align="left"><p>Wall remodeling</p></td><td align="left"><p>+ : miR21/155/221/222</p></td></tr><tr><td align="left"/><td align="left"><p>−: miR26/143/145</p></td></tr></tbody></table></table-wrap><table-wrap id="Tab25"><label>Table 2.25</label><caption xml:lang="en"><p>Targets and effects of main microRNA species involved in atherosclerosis (<bold>Part 1</bold>; Source: [<xref ref-type="bibr" rid="CR183">396</xref>]; <italic>ABC</italic> ATP-binding cassette transporter, <italic>BCL</italic> B-cell lymphoma protein, <italic>DNMT</italic> DNA methyltransferase, <italic>FABP</italic> fatty acid-binding protein, <italic>LDLR</italic> low-density lipoprotein receptor, <italic>LPL</italic> lipoprotein lipase, <italic>MMP</italic> matrix metallopeptidase, <italic>Sema</italic> semaphorin, <italic>SIRT</italic> sirtuin, <italic>TGF</italic> transforming growth factor, <italic>TIMP</italic> tissue inhibitor of metallopeptidase)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>microRNA</p></th><th align="left"><p>Main targets</p></th><th align="left"><p>Effects</p></th></tr></thead><tbody><tr><td align="left"><p>Let7f</p></td><td align="left"><p>Timp1</p></td><td align="left"><p>Matrix degradation by MMPs, macrophage infiltration</p></td></tr><tr><td align="left"><p>Let7g</p></td><td align="left"><p>TGFB, Sirt1</p></td><td align="left"><p>Repression of endothelial inflammation</p></td></tr><tr><td align="left"><p>MiR17–92</p></td><td align="left"><p>ABCA1, Ldlr,</p></td><td align="left"><p>Cholesterol efflux</p></td></tr><tr><td align="left"/><td align="left"><p>SEMA6A</p></td><td align="left"><p>Angiogenesis</p></td></tr><tr><td align="left"><p>MiR21</p></td><td align="left"><p>Mmp9, Bcl2,</p></td><td align="left"><p>Macrophage infiltration</p></td></tr><tr><td align="left"/><td align="left"><p>FABP7</p></td><td align="left"><p>SMC proliferation</p></td></tr><tr><td align="left"><p>MiR29a</p></td><td align="left"><p>Lpl</p></td><td align="left"><p>Lipid uptake and inflammatory cytokine secretion</p></td></tr><tr><td align="left"><p>MiR29b</p></td><td align="left"><p>DNMT3B</p></td><td align="left"><p>MMP2/9 synthesis (cell migration)</p></td></tr><tr><td align="left"><p>MiR92a</p></td><td align="left"><p>Integrin</p></td><td align="left"><p>NFκB activation, monocyte adhesion</p></td></tr><tr><td align="left"><p>MiR99a</p></td><td align="left"><p>TGFB</p></td><td align="left"><p>Chemotaxis, proliferation, apoptosis, fibrosis</p></td></tr></tbody></table></table-wrap><table-wrap id="Tab26"><label>Table 2.26</label><caption xml:lang="en"><p>Targets and effects of main microRNA species involved in atherosclerosis (<bold>Part 2</bold>; Source: [<xref ref-type="bibr" rid="CR183">396</xref>]; <italic>AT1R</italic> angiotensin-2 type-1 receptor, <italic>Col</italic> collagen, <italic>CKI</italic> cyclin-dependent kinase inhibitor, <italic>ELk</italic> ETS-like transcription factor, <italic>ETS</italic> E26 transformation-specific sequence transcription factor, <italic>IRAK</italic> interleukin-1 receptor-associated kinase, <italic>IRF</italic> interferon regulatory factor, <italic>KLF</italic> Krüppel-like factor, <italic>OSBPL</italic> oxysterol-binding protein-like protein, <italic>PTGS</italic> prostaglandin endoperoxide synthase [prostaglandin-G/H synthase and cyclooxygenase], <italic>ScaR</italic> scavenger receptor, <italic>SCFR</italic> stem cell factor receptor, <italic>TLR</italic> toll-like receptor, <italic>TOR</italic> target of rapamycin, <italic>TNFSF</italic> TNF superfamily member, <italic>TRAF</italic> TNFR-associated factor, <italic>vcam</italic> vascular cell adhesion molecule, <italic>VEGF</italic> vascular endothelial growth factor)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>microRNA</p></th><th align="left"><p>Main targets</p></th><th align="left"><p>Effects</p></th></tr></thead><tbody><tr><td align="left"><p>MiR100</p></td><td align="left"><p>Tor</p></td><td align="left"><p>Angiogenesis hindrance</p></td></tr><tr><td align="left"><p>MiR125a-5p</p></td><td align="left"><p>SCARB1/D1/E1,</p></td><td align="left"><p>Lipid uptake, oxLDL internalization,</p></td></tr><tr><td align="left"/><td align="left"><p>OSBPL9</p></td><td align="left"><p>cytokine production</p></td></tr><tr><td align="left"><p>MiR125b</p></td><td align="left"><p>Irf4</p></td><td align="left"><p>Inflammation by macrophages</p></td></tr><tr><td align="left"><p>MiR126</p></td><td align="left"><p>Tnfsf1, Vegf,</p></td><td align="left"><p>Endothelial dysfunction,</p></td></tr><tr><td align="left"/><td align="left"><p>VCAM1</p></td><td align="left"><p>vascular wall remodeling</p></td></tr><tr><td align="left"><p>MiR127</p></td><td align="left"><p>Tnfrsf5, Bcl6</p></td><td align="left"><p>Vascular inflammation, redox stress</p></td></tr><tr><td align="left"><p>MiR133a</p></td><td align="left"><p>Mmp9, Col1</p></td><td align="left"><p>VSMC proliferation, collagen synthesis</p></td></tr><tr><td align="left"><p>MiR143</p></td><td align="left"><p>PTGS2</p></td><td align="left"><p>Atherogenesis</p></td></tr><tr><td align="left"><p>MiR145</p></td><td align="left"><p>Klf4, Elk-1,</p></td><td align="left"><p>SMC differentiation,</p></td></tr><tr><td align="left"/><td align="left"/><td align="left"><p>SMC proliferation repression</p></td></tr><tr><td align="left"><p>MiR146a/b</p></td><td align="left"><p>Tlr4, Irak1,</p></td><td align="left"><p>Lipid accumulation and inflammation</p></td></tr><tr><td align="left"/><td align="left"><p>Traf6</p></td><td align="left"/></tr><tr><td align="left"><p>MiR155</p></td><td align="left"><p>Ets1, At1r</p></td><td align="left"><p>Protection against endothelial inflammation</p></td></tr><tr><td align="left"><p>MiR221/222</p></td><td align="left"><p>SCFR, CKI1B/C</p></td><td align="left"><p>SMC proliferation, contractile gene transcription</p></td></tr><tr><td align="left"><p>MiR223</p></td><td align="left"><p>Tissue factor</p></td><td align="left"><p>Atherogenesis, thrombosis</p></td></tr></tbody></table></table-wrap></p><p id="Par518">After a stroke, expression of Let7f, miR15b, miR126, miR142-3p, miR186, miR519e, miR768-5p, and miR1259 is downregulated [<xref ref-type="bibr" rid="CR183">396</xref>]. Circulating concentrations of miR21 and miR221 are higher in patients with stroke and carotid atherosclerosis than in healthy controls. Plasmatic concentrations of miR106b-5p and miR4306 increase after stroke, whereas those of miR320d and miR320e decline. In peripheral blood mononuclear cells (lymphocytes and monocytes) of patients with stroke, intracellular concentrations of Let7i, miR19a, miR122, miR148a, miR320d, and miR4429 are lower and those of miR363 and miR487b are elevated. Blood concentrations of miR151a-3p and miR140-5p increase, whereas that of miR18b-5p decreases. Concentrations of miR100, miR125a, miR127, miR133a, miR133b, miR145, and miR221 are higher in symptomatic than in asymptomatic plaques examined after endarterectomy. MiR145 concentration is higher in carotid plaques from hypertensive patients; plasmatic miR92a concentration is higher in hypertensive patients. Prognosis is better in patients with a high miR210 level in peripheral blood leukocytes, especially if measurement is combined with those of fibrin degradation product and IL-6 [<xref ref-type="bibr" rid="CR183">396</xref>]. An elevated miR17 concentration predicts early stroke recurrence. A high <index-term id="ITerm377"><term>Exosome</term></index-term>exosomal miR223 level in stroke patients is related to a poor outcome.</p><p id="Par519">Acute ischemic stroke is associated in a small sample of patients with abnormal blood concentrations of miR125a-5p, miR125b-5p, and miR143-3p, concentrations of which increase significantly, platelets rather than cerebral cells being the major source of these microRNAs [<xref ref-type="bibr" rid="CR184">397</xref>].</p></sec></sec><sec id="Sec37"><title>Circular RNAs</title><p id="Par520">Circular RNAs (circRNAs) can serve as miR sponges, which sequester miRs, and nuclear transcriptional regulators. They can be generated from back-spliced exons or intron-derived RNAs.</p><p id="Par521"><index-term id="ITerm378"><term>Platelet</term></index-term>Platelets and <index-term id="ITerm379"><term>RBC</term></index-term>RBCs contain large amounts of ubiquitous cell type-unspecific circular RNAs. Circular RNAs commonly derive from exons of protein-coding genes via backsplicing [<xref ref-type="bibr" rid="CR147">360</xref>]. On the other hand, some arise from intronic or intergenic regions via alternative splicing. They generally localize to the cytoplasm. RNA-binding proteins, such as quaking homolog and muscleblind-like protein, affect the amount of circRNA in cells, as the interaction of RNA-binding proteins and each RNA end facilitates the formation of a circle. Quaking elicits circRNA genesis.</p><p id="Par522">In the heart, highly expressed circRNAs correspond to key cardiac genes such as desmin (DES), dystrophin, four and a half LIM domain-containing protein-2 (FHL2), myoglobin (MB), cardiac myosin heavy chain-7 (MYH7), cardiac myosin regulatory light chain-2 (MYL2), cardiac ryanodine receptor-2 (RYR2), Na<sup>+</sup>–Ca<sup>2+</sup> exchanger NCX1 (SLC8A1), tropomyosin-1 (TPM1), titin (TTN), and cardiac type-2 troponin-T (TNNT2) [<xref ref-type="bibr" rid="CR185">398</xref>]. The longest human transcript TTN generates up to 415 different exonic circRNA isoforms.</p><p id="Par523">In vascular ECs, <index-term id="ITerm380"><term>Hypoxia</term></index-term>hypoxia upregulates many circRNAs, such as proangiogenic <index-term id="ITerm381"><term>cznf292</term></index-term>znf292,<xref ref-type="fn" rid="Fn94">94</xref><index-term id="ITerm382"><term>caff1</term></index-term>caff1,<xref ref-type="fn" rid="Fn95">95</xref><index-term id="ITerm383"><term>cdennd4c</term></index-term>cdennd4c,<xref ref-type="fn" rid="Fn96">96</xref> and slightly <index-term id="ITerm384"><term>csrsf4</term></index-term>csrsf4,<xref ref-type="fn" rid="Fn97">97</xref> but downregulates <index-term id="ITerm385"><term>cthsd1</term></index-term>cthsd1 [<xref ref-type="bibr" rid="CR186">399</xref>].<xref ref-type="fn" rid="Fn98">98</xref> Cznf292 promotes angiogenesis via AP1, E2F1, HIF1, NFκB, SP1, STAT3, and STAT5.</p><p id="Par529">In atherosclerotic plaques, the atheroprotective circANRIL regulates ribosome genesis in vSMCs and macrophages [<xref ref-type="bibr" rid="CR186">399</xref>].</p><p id="Par530"><index-term id="ITerm386"><term>atherosclerosis</term></index-term>Atherosclerosis and post-stenting restenosis are characterized by the dedifferentiation of vascular smooth myocytes and <index-term id="ITerm387"><term>Intimal hyperplasia</term></index-term>intimal hyperplasia. Differentiated vSMCs synthesize SMC-specific contractile proteins and related molecules, such as myosin heavy chain MHC11, actin Actα2, transgelin, and calponin, under control of the transcription factor serum response factor and its cofactor myocardin, which maintain SMC differentiation via the transcription factors and regulators Nkx3.1 and Nkx3.2, GATA4 and GATA6, SMADs, and Prx1, and the cysteine-rich LIM-only proteins, CRP1 and CRP2, which are associated with SRF and GATA proteins [<xref ref-type="bibr" rid="CR187">400</xref>]. PTen interacts with SRF in the nucleus to maintain the differentiated SMC phenotype. In addition, TGFβ, notch, RhoA, and P38MAPK promote SMC differentiation via transcriptional regulators that interact with SRF–myocardin. Furthermore, among epigenetic factors, histone modifications promote SMC contractile gene expression via SRF binding to genes, such as histone modifiers that acetylate (e.g., KAT3b) and methylate histones flanking CArG boxes in the MYH11 and ACTA2 genes. Short and long nonprotein-coding RNAs stimulate or preclude differentiated SMC phenotype. Components of the miR143–miR145 cluster target transcriptional repressors such as KLF4. On the other hand, miR21 and components of the miR221–miR222 cluster favor SMC dedifferentiation via growth repressors (e.g., PTen). Dedifferentiation of SMCs leads to a highly proliferative, migratory, and inflammatory phenotype characterized by the downregulated transcription of SMC-specific genes and upregulated production of inflammatory mediators and matrix components.</p><p id="Par531"><index-term id="ITerm388"><term>TGF</term></index-term>Transforming growth factor-β induces the formation and cleavage of transmembrane <index-term id="ITerm389"><term>Neuregulin</term></index-term>neuregulin-1.<xref ref-type="fn" rid="Fn99">99</xref> The extracellular EGF-like domain-containing domain (Nrg1<sup>ECD</sup>) binds to nearby receptors such as receptor protein Tyr kinases of the EGFR family, thereby acting as an auto- and paracrine messenger, in particular, during cardiovasculogenesis. Neuregulin-1, which has 11 isoforms, binds to HER3 and HER4 [<xref ref-type="bibr" rid="CR188">401</xref>]. Released soluble Nrg1 suppresses SMC proliferation via the HER receptor and then activates <index-term id="ITerm390"><term>ERK</term></index-term>ERK1 and ERK2 [<xref ref-type="bibr" rid="CR189">402</xref>].</p><p id="Par533">On the other hand, in response to TGFβ1, the intracellular domain of neuregulin-1 (Nrg1<sup>ICD</sup>) translocates to the nucleus and interacts with the transcription factor Ikaros family zinc finger protein IkZF1 (ZnFn1a1 or simply Ikaros) [<xref ref-type="bibr" rid="CR189">402</xref>].<xref ref-type="fn" rid="Fn100">100</xref> In the nucleus, the Nrg1<sup>ICD</sup>–IkZF1 complex binds to the first intron of the ACTA2 gene and launches the formation of the circRNA, <index-term id="ITerm391"><term>circActa2 lncRNA</term></index-term>circActa2, thereby promoting Actα2 production, as it operates as a sponge for miR548f-5p repressing Actα2 synthesis. <index-term id="ITerm392"><term>Intimal hyperplasia</term></index-term>In human intimal hyperplasia, expression of circActa2 decays and miR548f-5p dissociates from circActa2. On the other hand, PDGFbb decreases NRg1 expression.</p></sec><sec id="Sec38"><title><sup>Y</sup>RNAs</title><p id="Par536"><sup>Y</sup>RNAs are small RNA species, the size of which ranges from 112 (<sup>Y1</sup>RNA), 101 (<sup>Y3</sup>RNA), 98 (<sup>Y4</sup>RNA), to 84 nucleotides (<sup>Y5</sup>RNA). They originate from four genes (RNY1 and RNY3–RNY5) and about 900 pseudogenes [<xref ref-type="bibr" rid="CR147">360</xref>]. Full-length <sup>Y</sup>RNAs reside in the nucleus or cytoplasm. They are involved in the initiation of DNA replication and ribosomal RNA quality control. They are components of Ro ribonucleoproteins. Fragments of <sup>Y</sup>RNAs generated during cell stress or apoptosis circulate in the bloodstream, 5<italic>′</italic> fragments being much more abundant than 3<italic>′</italic> fragments for most RNY gene products.</p></sec><sec id="Sec39"><title>Long Nonprotein-Coding RNAs</title><p id="Par537"><index-term id="ITerm393"><term>lncRNA</term></index-term>In addition to proteins and microRNAs, long nonprotein-coding RNAs (lncRNAs; content&gt; 200 nt), lack significant open reading frames and hence a protein-coding potential. Nevertheless, lncRNAs can act as cofactors that permit the interaction of a transcription factor with a gene promoter, thereby regulating gene transcription. In addition, they can interact with histone modifiers to repress or activate gene expression.</p><p id="Par538">LncRNAs can be used as markers to identify and categorize individuals at risk for developing any type of cardiovascular pathological condition. They can hence support prevention, diagnosis, surveillance, and prognosis of cardiovascular maladies and help to adapt lifestyle and eventually optimize treatments.</p><p id="Par539">Numerous genes encoding lncRNAs have been identified [<xref ref-type="bibr" rid="CR163">376</xref>]. LncRNAs can be categorized into different groups of transcripts (Vol. 11, Chap. 2. Nonprotein-Coding Transcripts and Regulation of Protein-Coding Gene Transcription). <list list-type="order"><list-item><p id="Par540"><italic>Sense lncRNAs</italic> overlap exons or introns of messenger RNAs.</p></list-item><list-item><p id="Par541"><italic>Antisense lncRNAs</italic> originate from the opposite strand of protein-coding genes; their transcription start site localizes downstream from that of the coding gene; these RNAs transcribed in the antisense direction often display at least partial overlap with the coding sequence of the corresponding mRNA.</p></list-item><list-item><p id="Par542"><italic>Long intergenic ncRNAs</italic> are encoded between coding genes and do not overlap with exons of other genes; they are transcribed independently.</p></list-item><list-item><p id="Par543"><italic>Circular lncRNAs</italic> form closed loops derived from the splicing of protein-coding RNAs.</p></list-item><list-item><p id="Par544"><italic>Enhancer RNAs</italic> are located to genomic loci that activate gene expression.</p></list-item><list-item><p id="Par545"><italic>Bidirectional RNAs</italic> are transcribed from the same promoter as coding genes, but in the opposite direction.</p></list-item></list></p><p id="Par546">LncRNA genesis encompasses chromatin remodeling, lncrna gene transcription, and generally, but not always, transcript 5<italic>′</italic>-capping, polyadenylation, and alternative splicing [<xref ref-type="bibr" rid="CR74">287</xref>].</p><p id="Par547">Chromatin that packages DNA controls access to genetic information; it must be remodeled for gene transcription. Messenger RNAs, synthesized in the nucleus and packaged by RNA-binding proteins that form ribonucleoparticles, are exported to the cytoplasm.</p><p id="Par548">Certain enzymes change states of DNA methylation and histone modifications, whereas ATP-dependent chromatin-remodeling complexes modify nucleosome composition or positioning.</p><p id="Par549">LncRNAs contribute to the regulation of gene expression, as they are involved in epigenetic, transcriptional, or post-transcriptional regulation. They can partner with DNA- and histone-modifying enzymes, such as DNA methyltransferase DNMT1 and histone demethylase KDM1a, <index-term id="ITerm394"><term>PRC complex</term></index-term>polycomb repressive complex and <index-term id="ITerm395"><term>Trx complex</term></index-term>mixed lineage (myeloid–lymphoid) leukemia (MLL) factor <xref ref-type="fn" rid="Fn101">101</xref> activatory complex, in addition to nucleosome remodelers such as the <index-term id="ITerm396"><term>BAF (Swi/SNF) complex</term></index-term>Swi/SNF-like BAF complex [<xref ref-type="bibr" rid="CR191">404</xref>]. They can also serve as scaffolds.</p><p id="Par551">Nuclear lncRNAs are involved in epigenetic and transcriptional regulation of neighboring (in <italic>cis</italic>) or distant genes (in <italic>trans</italic>). Cis-acting lncRNAs can regulate lncRNA transcription. Trans-acting lncRNAs operate as recruiters or decoys of chromatin modifiers and transcription factors to activate or silence gene transcription. They can interact with RNA-binding proteins, such as members of the polycomb and trithorax groups. LncRNAs that recruit the polycomb repressive complex, a chromatin remodeler, provoke gene silencing. Other lncRNAs sequester RNA-binding proteins and transcription factors. On the other hand, some lncRNAs enhance protein-coding gene transcription. Activating nonprotein-coding RNAs have enhancer-like activity; they activate neighboring genes using a mechanism involving DNA looping between the lncRNA and its target gene [<xref ref-type="bibr" rid="CR74">287</xref>]. In addition, lncRNAs can bind to RNA polymerase-2, thereby regulating the transcriptional machinery.</p><p id="Par552">Cytoplasmic lncRNAs control mRNA splicing, translation, stability, and degradation, as they bind to mRNAs or proteic components of ribonucleoproteic complexes. Additionally, LncRNAs can act as decoys or sponges for proteins or microRNAs, preventing their activity, and they can serve as templates for small peptide synthesis. Some lncRNAs undergo a posttranscriptional processing. The lncRNA <index-term id="ITerm397"><term>neat2 lncRNA</term></index-term>neat1 men&#x01d716;<xref ref-type="fn" rid="Fn102">102</xref> and neat2 (malat1),<xref ref-type="fn" rid="Fn103">103</xref> which mainly localize to the nucleus, are processed into menRNA and mascRNA<xref ref-type="fn" rid="Fn104">104</xref> respectively, the latter lodging exclusively in the cytoplasm [<xref ref-type="bibr" rid="CR193">406</xref>]. Both neat2 and its product mascRNA serve as immunoregulators.</p><p id="Par557">Unlike microRNAs and <sup>Y</sup>RNA fragments, which mainly lodge in the cytosol, lncRNAs are predominantly retained in the nucleus. Whereas microRNAs and <sup>Y</sup>RNA fragments are secreted in microvesicles with cytoplasmic components, even in the absence of injury, lncRNAs are released upon cellular damage with nuclear material [<xref ref-type="bibr" rid="CR147">360</xref>]. In general, because their longer sequence is more vulnerable to cleavage and less protected by RNA-binding proteins, lncRNAs are more susceptible to ribonuclease than small ncRNAs.</p><p id="Par558">LncRNAs cross the plasma membrane, their egress being regulated by <index-term id="ITerm399"><term>ceramide</term></index-term>ceramide.<xref ref-type="fn" rid="Fn105">105</xref> They can thus reside in body fluids (e.g., blood, urine, and breast milk) [<xref ref-type="bibr" rid="CR163">376</xref>]. They are observed in <index-term id="ITerm400"><term>Exosome</term></index-term>exosomes, <index-term id="ITerm401"><term>Microvesicle</term></index-term>microvesicles, and <index-term id="ITerm402"><term>apoptotic body</term></index-term>apoptotic bodies and are linked to RNA-binding proteins, such as nucleolin, nucleophosmin NPm1, and argonaute protein Ago2, a factor of the RINC, LDLs, and HDLs. A substantial number of circulating ncRNAs are associated with ribonucleoproteins.</p><p id="Par560">Chromatin remodeling determines, at least partly, transcriptome programming during cardiogenesis and its reprogramming during pathogenesis. Improper re-organization of epigenetic marks leads to aberrant gene expression and organ dysfunction. LncRNAs participate in epigenetic regulation; they are designated <sup>Epi</sup>lncRNAs.</p><p id="Par561"><index-term id="ITerm403"><term>Hotair lncRNA</term></index-term>For example, HOX transcript antisense intergenic RNA (hotair) binds to PRC2 and promotes methylation of histone H3 at Lys27 trimethylation (H3K<sub>27</sub>me<sup>3</sup>) at the promoter region of target genes, causing gene silencing, in addition to the demethylase KDM1a that suppresses methylation of histone H3 at Lys4 (H3K4) carried out by the MLL complex [<xref ref-type="bibr" rid="CR194">407</xref>].</p><p id="Par562"><index-term id="ITerm404"><term>cdkn2bas lncRNA</term></index-term>Antisense long nonprotein-coding RNA in the CDKN2B gene locus in the chromosomal 9p21 region suppresses synthesis of the cell cycle regulator CKI2b. It is linked to AAA, myocardial infarction, and stroke [<xref ref-type="bibr" rid="CR195">408</xref>].</p><p id="Par563"><index-term id="ITerm405"><term>Hyperlnc</term></index-term>Hypoxia upregulates some lncRNAs. Hypoxia-induced endoplasmic reticulum stress (ERS)-regulating lncRNA (hyperlnc)<xref ref-type="fn" rid="Fn106">106</xref> enables expression of human pericyte markers, such as PDGFRβ, DES, α-smooth muscle actin, and neural and glial antigen NG2 [<xref ref-type="bibr" rid="CR196">409</xref>]. In addition, hyperlnc supports the connection between pericytes and ECs, thereby reducing endothelial permeability. On the other hand, hyperlnc deficiency favors ERS, ERS-related transcription factors being activated, and reduces the viability and proliferation of pericytes and primes their dedifferentiation. Therefore, hyperlnc modulates pericyte differentiation, proliferation, and recruitment to ECs.</p><p id="Par565">Pericytes stabilize the microvasculature (arterioles, venules, and lymphatics). They can be a source of regenerative cells that participate in the repair after injury and ischemia [<xref ref-type="bibr" rid="CR195">408</xref>]. A subset of pericytes can serve as a reservoir of multipotential mesenchymal stem cells that may replace lost CMCs or other cardiovascular cell types.</p><p id="Par566">Hyperlnc concentration is markedly reduced in the myocardium of failing hearts, which can be linked to abnormal microvasculature and fibrosis [<xref ref-type="bibr" rid="CR196">409</xref>]. In addition, hyperlnc expression correlates significantly with pericyte markers in human lungs from patients with idiopathic pulmonary arterial hypertension.</p><p id="Par567"><index-term id="ITerm406"><term>Lexis ncRNA</term></index-term>Liver-expressed LXR-induced sequence lncRNA (lexis) regulates cholesterol efflux and synthesis.</p><p id="Par568">The role played by 16401 lncRNAs was assessed in seven types of human cell lines (six transformed cell lines and one human-induced pluripotent stem cells) [<xref ref-type="bibr" rid="CR197">410</xref>]. The function of most of the tested lncRNAs was specific to a given cell type and often limited to a single cell type. A total of 499 lncRNAs influence cell proliferation, exclusively for a single cell type, among which 372 and 299 have loci distal from a protein-coding gene or mapped enhancer, respectively [<xref ref-type="bibr" rid="CR197">410</xref>].</p><p id="Par569">Endotheliocytes express relatively high concentrations of the lncRNAs <index-term id="ITerm407"><term>neat2 lncRNA</term></index-term>neat2,<xref ref-type="fn" rid="Fn107">107</xref><index-term id="ITerm409"><term>Tug1 lncRNA</term></index-term>tug1,<xref ref-type="fn" rid="Fn108">108</xref><index-term id="ITerm410"><term>meg3 lncRNA</term></index-term>meg3,<xref ref-type="fn" rid="Fn109">109</xref> linc00657, and linc00493 [<xref ref-type="bibr" rid="CR198">411</xref>]. Production of the lncRNAs neat2, tug1, meg3, and linc00657 increases in ECs exposed to <index-term id="ITerm411"><term>Hypoxia</term></index-term>hypoxia, but not that of linc00493. Neat2 controls both epigenetic gene regulation and RNA splicing. It promotes proliferation of ECs, but prevents their migration. It supports expression of endothelial cyclins CcnA2, CcnB1, and CcnB2 and hampers that of CKI1a and CKI1b. It interacts with CBx4,<xref ref-type="fn" rid="Fn110">110</xref> assisting recruitment of coactivators to the promoters of cell cycle control genes, which are linked to an increased number of transcriptionally active histone marks.</p><sec id="Sec40"><title>Endothelial Long Nonprotein-Coding RNAs</title><p id="Par575">Endotheliocytes respond to local and systemic stimuli and can change from quiescence to activation, then becoming a source of prooxidant, proinflammatory, vasoconstrictory, and clotting mediators. LncRNAs operate at the onset and after EC activation. The formation of 27 lncRNAs is markedly changed (two-fold), but among them, that of a single one, the PDZD2-206 transcript (ENST00000509256.1), which encodes PDZ domain-containing protein PDZD2,<xref ref-type="fn" rid="Fn111">111</xref> is downregulated [<xref ref-type="bibr" rid="CR199">412</xref>]. Many genes with a regulatory function are coexpressed with lncRNAs (e.g., CDK13, EIF3A, HNRNPH2, LHX2, PDSS2, SMEK2, RIF1, SPRY2, STAU2, Wdr20, and WDR42A [Dcaf8]).</p><p id="Par577">The proangiogenic lncRNA linc00323-003<xref ref-type="fn" rid="Fn112">112</xref> and mir503hg<xref ref-type="fn" rid="Fn113">113</xref> are induced in ECs subjected to <index-term id="ITerm412"><term>Hypoxia</term></index-term>hypoxia [<xref ref-type="bibr" rid="CR200">413</xref>]. However, linc00323-003 elicits tube formation, whereas mir503hg does not markedly affect tube formation.</p><p id="Par580"><index-term id="ITerm413"><term>meg3 lncRNA</term></index-term>The lncRNA meg3<xref ref-type="fn" rid="Fn114">114</xref> represses the production of VEGFa and VEGFR1 [<xref ref-type="bibr" rid="CR200">413</xref>]. Its expression increases in senescent ECs, precluding their angiogenic activity.</p><p id="Par582"><index-term id="ITerm414"><term>neat2 lncRNA</term></index-term>The lncRNA neat2<xref ref-type="fn" rid="Fn115">115</xref> is proangiogenic [<xref ref-type="bibr" rid="CR200">413</xref>]. It upregulates VEGF expression. In particular, it favors tumor angiogenesis, as it promotes FGF2 production in tumor-associated macrophages.</p><p id="Par584"><index-term id="ITerm415"><term>igf2as lncRNA</term></index-term>Formation of the lncRNA igf2as<xref ref-type="fn" rid="Fn116">116</xref> increases in myocardial microvascular ECs of <index-term id="ITerm416"><term>T2DM</term></index-term>T2DM rats, impeding cell proliferation via downregulation of IGF2 and VEGF expression [<xref ref-type="bibr" rid="CR200">413</xref>].</p><p id="Par586"><index-term id="ITerm417"><term>miat lncRNA</term></index-term>The lncRNA miat<xref ref-type="fn" rid="Fn117">117</xref> is an angiogenic activator [<xref ref-type="bibr" rid="CR200">413</xref>]. Hyperglycemia can launch miat formation in microvascular and retinal ECs.</p><p id="Par588"><index-term id="ITerm418"><term>mantis lncRNA</term></index-term>The epigenetically controlled endothelial nuclear lncRNA mantis,<xref ref-type="fn" rid="Fn118">118</xref> the gene of which lodges in the antisense strand of an intron of the gene encoding annexin-A4, is upregulated during angiogenesis; it maintains the endothelial angiogenic phenotype [<xref ref-type="bibr" rid="CR201">414</xref>]. Its synthesis is prevented by the histone demethylase KDM5b. Its production is downregulated in patients with idiopathic pulmonary arterial hypertension. It favors not only angiogenic sprouting, but also alignment of ECs subjected to hemodynamic stress. It interacts with SMARCa4 (BRG1), the catalytic subunit of the Swi/SNF-related, matrix-associated, actin-dependent regulator of chromatin, thereby promoting transcription of the NR2F2, Smad6, and SOX18 genes.</p><p id="Par590"><index-term id="ITerm419"><term>Sencr lncRNA</term></index-term>In ECs, the lncRNA sencr<xref ref-type="fn" rid="Fn119">119</xref> induces cell proliferation and migration in addition to differentiation (i.e., embryonic stem cell commitment into ECs) and hence <index-term id="ITerm420"><term>angiogenesis</term></index-term>angiogenesis [<xref ref-type="bibr" rid="CR202">415</xref>]. It stimulates EC migration, as it upregulates proangiogenic chemokines CCL5 and CX<sub>3</sub>CL1. It also governs the differentiation status of vascular smooth myocytes. This EC- and vSMC-enriched lncRNA exists in a full-length (sencr<sup>V1</sup>) and alternatively spliced variant (sencr<sup>V2</sup>).</p></sec><sec id="Sec41"><title>Long Nonprotein-Coding RNAs and Mitochondrial Function</title><p id="Par592"><index-term id="ITerm421"><term>Mitochondrion</term></index-term>Mitochondria serve as controllers of the cellular redox status and as stress sensors via proteins encoded by mitochondrial and nuclear DNA and integrators of stressors.<xref ref-type="fn" rid="Fn120">120</xref> These hubs also integrate cues from several metabolic pathways (ATP production and fatty acid and amino acid metabolism), modulating nuclear gene expression<xref ref-type="fn" rid="Fn121">121</xref> implicated in cell survival and growth [<xref ref-type="bibr" rid="CR155">368</xref>].</p><p id="Par595">Mitochondria and the nucleus mutually communicate to adapt their respective activities to the environment. The <italic>anterograde signaling</italic>, that is, the nuclear-to-mitochondrial control, modulates mitochondrial genesis and activity according to cellular needs. The nuclearly encoded mitochondrial proteome is regulated in a coordinated manner by transcription factors (e.g., NRF1–NRF2), among which are some nuclear receptors (e.g., ERRs and PPARs) and their cofactors (PGC1α–PGC1β). These effectors are regulated by sensors of changes in metabolic conditions.<xref ref-type="fn" rid="Fn122">122</xref> Under nuclear stress (e.g., DNA damage), the anterograde signaling lowers mitochondrial metabolism.<xref ref-type="fn" rid="Fn123">123</xref></p><p id="Par598">On the other hand, mitochondria signal their functional state and can trigger a compensatory cellular response. The <italic>retrograde signaling</italic> launches a metabolic reprogramming, ultimately leading to cell adaptation or death. In addition, when mitochondria are severely damaged, the retrograde signaling engages cellular stress responses without nuclear involvement, such as the intrinsic apoptotic pathway [<xref ref-type="bibr" rid="CR155">368</xref>].</p><p id="Par599">Mitochondrial function is monitored via their products, which act as signaling effectors that modulate the activity of regulators (e.g., sirtuins, HIF1α, AMPK, TOR, and calmodulin).<xref ref-type="fn" rid="Fn124">124</xref></p><p id="Par601"><index-term id="ITerm423"><term>Redox stress</term></index-term>Redox stress inactivates <index-term id="ITerm424"><term>TOR</term></index-term>TOR, the master cytosolic modulator of protein synthesis. In addition, TOR controls mitochondrial genesis and activity; this hub integrates antero- and retrograde signaling [<xref ref-type="bibr" rid="CR155">368</xref>].</p><p id="Par602">Nonprotein-coding RNAs act as messengers between the nucleus and mitochondria, hence contributing to the synchronization of cellular processes. The term <italic>mitolncRNAs</italic> (<sup>Mt</sup>lncRNAs) refers to lncRNAs lodging inside the mitochondrion, which are encoded either by the mitochondrial genome (category 1)<xref ref-type="fn" rid="Fn125">125</xref> or in the nucleus and subsequently enter the mitochondrion (category 2; Table <xref rid="Tab27" ref-type="table">2.27</xref>) [<xref ref-type="bibr" rid="CR155">368</xref>].<xref ref-type="fn" rid="Fn126">126</xref><table-wrap id="Tab27"><label>Table 2.27</label><caption xml:lang="en"><p>Long nonprotein-coding RNAs (lncRNAs) and mitochondrial function (Source: [<xref ref-type="bibr" rid="CR155">368</xref>]; <italic>GAS</italic> growth arrest-specific noncoding, single-stranded RNA, <italic>lipcar</italic> long intergenic noncoding RNA predicting cardiac remodeling, <italic>sammson</italic> survival-associated mitochondrial melanoma-specific oncogenic long intergenic noncoding RNA, <italic>sncmtRNA</italic> sense nonprotein-coding mitochondrial RNA)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>Type</p></th><th align="left"><p>Location</p></th><th align="left"><p>Targets</p></th><th align="left"><p>Effect</p></th></tr></thead><tbody><tr><td align="left"><p>GAS5</p></td><td align="left"><p>Ubiquitous</p></td><td align="left"><p>TOR (?)</p></td><td align="left"><p>Increases mitochondrial protein</p></td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"><p>synthesis and activity</p></td></tr><tr><td align="left"><p>Lincrnap21</p></td><td align="left"><p>Ubiquitous</p></td><td align="left"><p>HIF1α,</p></td><td align="left"><p>Increases HIF1α stability,</p></td></tr><tr><td align="left"/><td align="left"/><td align="left"><p>VHL</p></td><td align="left"><p>promotes glycolysis</p></td></tr><tr><td align="left"><p>Lipcar</p></td><td align="left"><p>Plasma</p></td><td align="left"><p>ND</p></td><td align="left"><p>ND</p></td></tr><tr><td align="left"><p>SncmtRNA</p></td><td align="left"><p>Proliferating</p></td><td align="left"><p><sup>Mt</sup>16S rRNA,</p></td><td align="left"><p>Cell proliferation</p></td></tr><tr><td align="left"/><td align="left"><p>cells</p></td><td align="left"><p>chromatin</p></td><td align="left"/></tr><tr><td align="left"><p>Sammson</p></td><td align="left"><p>Melanoma</p></td><td align="left"><p>C1qBP</p></td><td align="left"><p>Regulates mitochondrial protein</p></td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"><p>synthesis</p></td></tr></tbody></table><table-wrap-foot><p>Question mark (?) denotes denotes uncertainty</p></table-wrap-foot></table-wrap></p><p id="Par605">In addition to functioning as messengers, lncRNAs can also indirectly modulate mitochondrial function via regulation of metabolic components, such as <index-term id="ITerm426"><term>AMPK</term></index-term>AMPK, <index-term id="ITerm427"><term>TOR</term></index-term>TOR, <index-term id="ITerm428"><term>HIF</term></index-term>HIF1α, and sirtuins. The TOR kinase regulates synthesis of mitochondrial proteins encoded by the nuclear genes such as <sup>Mt</sup>TFa, components of <sup>ETC</sup>complex-<italic>I</italic> and -<italic>V</italic> , and mitochondrial ribosomal proteins. <index-term id="ITerm429"><term>gas5 lncRNA</term></index-term>The gas5 lncRNA promotes growth arrest upon TOR inhibition. <index-term id="ITerm430"><term>hif1as lncRNA</term></index-term>The hif1as lncRNA is associated with angiogenesis. <index-term id="ITerm431"><term>lincrnap21</term></index-term>The hypoxia-induced lincrnap21 disrupts the connection between VHL and HIF1α, hence impeding HIF1α ubiquitination and proteasomal degradation.</p></sec><sec id="Sec42"><title>Long Nonprotein-Coding RNAs in Adverse Cardiac Remodeling</title><p id="Par606">As CMCs are particularly enriched in mitochondria, mitochondrial lncRNAs are released during <index-term id="ITerm432"><term>Myocardial infarction</term></index-term>myocardial infarction [<xref ref-type="bibr" rid="CR147">360</xref>].</p><p id="Par607">Three lncRNAs, <index-term id="ITerm433"><term>CoroMarker lncRNA</term></index-term>CoroMarker,<xref ref-type="fn" rid="Fn127">127</xref> bat5,<xref ref-type="fn" rid="Fn128">128</xref> and <index-term id="ITerm434"><term>il21ras1 lncRNA</term></index-term>il21ras1,<xref ref-type="fn" rid="Fn129">129</xref> are CoAD markers (Table <xref rid="Tab28" ref-type="table">2.28</xref>) [<xref ref-type="bibr" rid="CR207">420</xref>]. In a population of patients suffering from chest pain, CoroMarker correlates with genes involved in atherosclerosis, such as IL15RA and ADORA1, which encode IL15 receptor-α and adenosine receptor-A1, respectively. On the other hand, CoroMarker correlates negatively with genes implicated in apoptosis and <index-term id="ITerm435"><term>Redox stress</term></index-term>redox stress, such as BAX and GSTT1, which encodes glutathione <sup>S</sup>transferase GSTθ1. CoroMarker plays an important role in inflammation involved in atherogenesis, as it favors expression of the proinflammatory cytokines IL1β, IL6, and TNFSF1 [<xref ref-type="bibr" rid="CR207">420</xref>]. <table-wrap id="Tab28"><label>Table 2.28</label><caption xml:lang="en"><p>Long nonprotein-coding RNA (lncRNA) markers in CVD (Source: [<xref ref-type="bibr" rid="CR163">376</xref>]; <italic>lipcar</italic> long intergenic ncRNA predicting cardiac remodeling, <italic>myheart</italic> myosin heavy-chain-associated RNA transcript, <italic>sencr</italic> smooth muscle and endothelial cell-enriched migration and differentiation-associated lncRNA, <italic>uca1</italic> urothelial carcinoma-associated lncRNA-1)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><p>LncRNA</p></th><th align="left"><p>Disease</p></th></tr></thead><tbody><tr><td align="left"><p>CoroMarker</p></td><td align="left"><p>Coronary atherosclerosis</p></td></tr><tr><td align="left"><p>Lipcar</p></td><td align="left"><p>Myocardial infarction</p></td></tr><tr><td align="left"><p>Myheart</p></td><td align="left"><p>Myocardial infarction</p></td></tr><tr><td align="left"><p>Lncpparδ</p></td><td align="left"><p>Coronary atherosclerosis</p></td></tr><tr><td align="left"><p>Sencr</p></td><td align="left"><p>Heart failure</p></td></tr><tr><td align="left"><p>Uc004cov4</p></td><td align="left"><p>Hypertrophic cardiomyopathy</p></td></tr><tr><td align="left"><p>Uc022bqu1</p></td><td align="left"><p>Hypertrophic cardiomyopathy</p></td></tr><tr><td align="left"><p>Uca1</p></td><td align="left"><p>Myocardial infarction</p></td></tr></tbody></table></table-wrap></p><p id="Par617">LncRNAs include regulators of CMC differentiation, such as braveheart and fendrr,<xref ref-type="fn" rid="Fn130">130</xref> and of cardiac remodeling, such as myheart or chast.<xref ref-type="fn" rid="Fn131">131</xref></p><p id="Par620"><index-term id="ITerm438"><term>Hypertrophic cardiomyopathy</term></index-term>In hypertrophic cardiomyopathy, BRG1,<xref ref-type="fn" rid="Fn132">132</xref> which interacts with multiple transcription regulators, in addition to several HDACs and poly<sup>ADP</sup>ribose polymerases, is activated. The epigenetic regulator BRG1 induces MYH7 gene transcription and represses that of the MYH6 gene, which encode fetal β- and adult α-myosin heavy chain, respectively.<xref ref-type="fn" rid="Fn133">133</xref> Pathological cardiac stress activates the BRG1–HDAC2–HDAC9–PARP1 chromatin repressor complex to complex on MYH6 and MYH7 promoters for antithetical control, thereby precluding transcription of <index-term id="ITerm439"><term>mhrt lncRNA</term></index-term>the lncRNA myheart (mhrt; myosin heavy chain [MYH7]-associated RNA transcript) in the heart, activating aberrant MYH7 gene expression and repressing MYH6 gene transcription, hence re-inducing fetal gene expression that is linked to maladaptive hypertrophy and that can evolve to HF.</p><p id="Par623"><index-term id="ITerm440"><term>chrf lncRNA</term></index-term>The lncRNA cardiac hypertrophy-related factor (chrf) regulates MYH7 expression, as it acts as a sponge for antihypertrophic miR489 [<xref ref-type="bibr" rid="CR171">384</xref>]. Whereas miR489 reduces adverse hypertrophy initiated by angiotensin-2 via MyD88, chrf downregulates miR489 expression [<xref ref-type="bibr" rid="CR210">423</xref>].</p><p id="Par624"><index-term id="ITerm441"><term>mhrt lncRNA</term></index-term>Cardiac-specific myheart, which abounds in adult CMCs, protects the heart from adverse remodeling. Its concentration is elevated after <index-term id="ITerm442"><term>Myocardial infarction</term></index-term>myocardial infarction [<xref ref-type="bibr" rid="CR163">376</xref>].</p><p id="Par625">The most abundant isoform. Mhrt779, is a potent inhibitor of adverse cardiac hypertrophy. Alternative splicing of MYH7 antisense transcripts engenders a cluster of Mhrts (size 709–1147 nucleotides) [<xref ref-type="bibr" rid="CR211">424</xref>]. The mhrt lncRNAs are linked to a transcriptional start site overlapping, but in the opposite direction, the MYH6 promoter, and the coding sequence extends into that of the MYH7 gene; hence, Mhrts correspond to both promoter-associated lncRNAs and antisense lncRNAs with respect to MYH6 and MYH7 respectively [<xref ref-type="bibr" rid="CR171">384</xref>]. In addition, these alternatively spliced antisense transcripts are implicated not only in cis-regulation at the MYH6–MYH7 locus, but also in the trans-regulation of other cardiac genes.</p><p id="Par626">The Mhrt splice variants abound in the adult myocardium (but in neither endo- nor the epicardium) [<xref ref-type="bibr" rid="CR211">424</xref>]. Cellular stress activates the BRG1–HDAC–PARP chromatin repressor complex and prevents Mhrt transcription, enabling cardiomyopathy development. In a given cell, the BRG1 complex inhibits both MYH6 and Mhrt and reactivates MYH7 expression. On the other hand, the Mhrt spliced isoforms tether to and antagonize the chromatin remodeler and helicase BRG1, which can connect to mhrt and chromatinized (but not naked) DNA, preventing cardiac adverse hypertrophic gene reprogramming. Mhrt directly interacts with BRG1 helicase domain [<xref ref-type="bibr" rid="CR211">424</xref>], as a decoy to regulate its chromatin remodeling activity, similar to braveheart, which operates as a decoy for the PRC2 complex [<xref ref-type="bibr" rid="CR170">383</xref>].</p><p id="Par627"><index-term id="ITerm443"><term>carl lncRNA</term></index-term>Cardiac apoptosis-related lncRNA, which was identified in CMCs exposed to anoxia, is another sponge for miR539 that regulates PHB2 expression [<xref ref-type="bibr" rid="CR212">425</xref>]. The prohibitin complex, with its two subunits (Phb1–Phb2), which localizes to the inner mitochondrial membrane, operates in mitochondrial genesis. In addition, Phb2 is an estrogen receptor-binding protein that represses gene transcription and a regulator of mitochondrial fission and fusion dynamics. Its production declines with the increased formation of miR539, causing mitochondrial fission and CMC apoptosis.</p><p id="Par628">In addition to carl and chrf, <index-term id="ITerm444"><term>hulc lncRNA</term></index-term>hulc<xref ref-type="fn" rid="Fn134">134</xref><index-term id="ITerm445"><term>lincMD1</term></index-term>lincMD1<xref ref-type="fn" rid="Fn135">135</xref><index-term id="ITerm446"><term>h19 lncRNA</term></index-term>LncRNA H19, which contributes to cardiofibroblast proliferation and <index-term id="ITerm447"><term>Cardiac fibrosis</term></index-term>fibrosis via repression of the DuSP5–ERK1/2 axis [<xref ref-type="bibr" rid="CR215">428</xref>], and <index-term id="ITerm448"><term>cdr1as lncRNA</term></index-term>the circular RNAs cdr1as<xref ref-type="fn" rid="Fn136">136</xref> also sequester miRs.</p><p id="Par632"><index-term id="ITerm449"><term>chaer lncRNA</term></index-term>The long nonprotein-coding RNA cardiac hypertrophy-associated epigenetic regulator (chaer) acts at the onset of <index-term id="ITerm450"><term>Cardiac hypertrophy</term></index-term>cardiac hypertrophy via a stress-induced transient interaction between chaer and the polycomb repressor complex PRC2, which depends on <index-term id="ITerm451"><term>TOR</term></index-term>TOR [<xref ref-type="bibr" rid="CR217">430</xref>]. Chaer recognizes the epigenetic modulator KTM6a, a PRC2 component, and sequesters PRC2, which forms repressive histone marks, thereby hampering histone H3 Lys27 methylation at the promoter regions of genes involved in cardiac hypertrophy and enabling prohypertrophic gene expression [<xref ref-type="bibr" rid="CR194">407</xref>]. Interaction between chaer and PRC2 is transiently induced after hormone or stress stimulation via <index-term id="ITerm452"><term>TORC1</term></index-term>TORC1, and causes epigenetic reprogramming.<xref ref-type="fn" rid="Fn137">137</xref> Inhibition of chaer production in the heart before, but not after, the onset of hypertension attenuates cardiac hypertrophy.</p><p id="Par635"><index-term id="ITerm455"><term>chast lncRNA</term></index-term>The cardiac hypertrophy-associated transcript chast is upregulated in maladaptive cardiac hypertrophy [<xref ref-type="bibr" rid="CR219">432</xref>]. Chast impedes the autophagy regulator PlekHm1<xref ref-type="fn" rid="Fn138">138</xref> impeding CMC autophagy.</p><p id="Par637"><index-term id="ITerm456"><term>Lipcar lincRNA</term></index-term>The mitochondrial long intergenic ncRNA predicting cardiac remodeling lipcarin (i.e., lncRNA lipcar or uc022bqs.1) is downregulated in an early phase after MI but is upregulated during later stages [<xref ref-type="bibr" rid="CR220">433</xref>]. It has a strong prognostic power for the future development of detrimental cardiac remodeling, <index-term id="ITerm457"><term>Heart failure</term></index-term>HF after MI, and death.</p><p id="Par638"><index-term id="ITerm458"><term>uca1 lncRNA</term></index-term>Concentration of urothelial carcinoma-associated transcript-1 (uca1), an indicator of <index-term id="ITerm459"><term>Cancer</term></index-term>pulmonary cancer, declines shortly after MI and increases 3 days after cardiac injury. Concentration of miR1, which may regulate uca1 expression, follows an opposite time course [<xref ref-type="bibr" rid="CR163">376</xref>].</p><p id="Par639"><index-term id="ITerm460"><term>Hypertrophic cardiomyopathy</term></index-term>Blood concentrations of uc004cov4 and uc022bqu1 are higher in hypertrophic obstructive cardiomyopathy than in hypertrophic non-obstructive cardiomyopathy and healthy subjects [<xref ref-type="bibr" rid="CR163">376</xref>].</p><p id="Par640"><index-term id="ITerm461"><term>Wisper lncRNA</term></index-term>The long nonprotein-coding RNAs wisper<xref ref-type="fn" rid="Fn139">139</xref> abounds in cardiofibroblasts and regulates their survival, proliferation, and migration in addition to extracellular matrix protein deposition and hence cardiac fibrosis after injury [<xref ref-type="bibr" rid="CR221">434</xref>]. Repression of wisper attenuates fibrosis after MI. Wisper cooperates with T-cell intracellular antigen TIA1-related protein (TIAR), an RNA-binding protein involved in the regulation of alternative pre-mRNA splicing, to control the expression of a profibrotic form of procollagen lysine 2-oxoglutarate 5-dioxygenase PLOD2,<xref ref-type="fn" rid="Fn140">140</xref> which is implicated in collagen crosslinking and stabilization of the matrix.</p></sec></sec><sec id="Sec43"><title>Ribosomal RNA</title><p id="Par643">Ribosomal RNA participates in protein synthesis. It is also detected in the blood circulation. It is released upon tissue damage and cell death.</p><p id="Par644">Extracellular ribosomal RNA may play several pathophysiological roles in <index-term id="ITerm462"><term>atherosclerosis</term></index-term>atherosclerotic plaques, as it can increase vascular permeability, initiate blood coagulation and hence thrombus formation, recruit leukocytes and support a proinflammatory phenotype of monocytes and macrophages, and favor CMC death [<xref ref-type="bibr" rid="CR163">376</xref>].</p></sec></sec><sec id="Sec44"><title>Clinical Types of Markers</title><p id="Par645">Markers of diseases can be classified into three main groups: <list list-type="order"><list-item><p id="Par646"><italic>Screening markers</italic> for individuals who have not yet developed any apparent disease (i.e., for early diagnosis and evolution prevention), as these markers modulate diet and activity in addition to potentially beneficial drug effects</p></list-item><list-item><p id="Par647"><italic>Diagnostic markers</italic> in subjects in whom advanced-stage disease is already suspected</p></list-item><list-item><p id="Par648"><italic>Prognostic markers</italic> in patients who have the disease</p></list-item></list></p><sec id="Sec45"><title>Screening</title><p id="Par649">Potential screening markers comprise molecules associated with [<xref ref-type="bibr" rid="CR222">435</xref>]: <list list-type="order"><list-item><p id="Par650"><italic>Inflammation</italic>, such as <index-term id="ITerm463"><term>CRP (Ptx1)</term></index-term>CRP (or pentraxin-1; Sects. <xref rid="Sec51" ref-type="sec">2.3.2.3</xref> and <ext-link xlink:href="10.1007/978-3-319-89315-0_5#Sec123" ext-link-type="doi">5.4.5.22</ext-link>), <index-term id="ITerm464"><term>Interleukin</term></index-term>IL-6 (Sect. <ext-link xlink:href="10.1007/978-3-319-89315-0_5#Sec126" ext-link-type="doi">5.4.5.25</ext-link>), and secreted and lipoprotein-associated <index-term id="ITerm465"><term>PLA</term></index-term>phospholipase-A2.</p></list-item><list-item><p id="Par651"><italic>Hemostasis</italic>, such as <index-term id="ITerm466"><term>Fibrinogen</term></index-term>fibrinogen and <index-term id="ITerm467"><term>PAI</term></index-term>plasminogen-activator inhibitor-1 (or serpin-E1)</p></list-item><list-item><p id="Par652"><italic>Neurohormonal control</italic>, such as <index-term id="ITerm468"><term>Renin</term></index-term>renin and <index-term id="ITerm469"><term>Natriuretic peptide</term></index-term>BNP</p></list-item><list-item><p id="Par653"><italic>Insulin resistance</italic>, such as <index-term id="ITerm470"><term>Insulin</term></index-term>insulin and hemoglobin-A1c.<xref ref-type="fn" rid="Fn141">141</xref></p></list-item><list-item><p id="Par655"><index-term id="ITerm471"><term>Endothelial dysfunction</term></index-term><italic>Endothelial dysfunction</italic>, such as <index-term id="ITerm472"><term>Homocysteine</term></index-term>homocysteine and albuminuria (urinary albumin).</p></list-item><list-item><p id="Par656"><italic>Myocardial damage</italic>, such as cardiac FABP (<sup>He</sup>FABP), which diffuses rapidly into the circulation after <index-term id="ITerm473"><term>CMC</term></index-term>CMC injury, and growth differentiation factor GDF15, which also rises sharply after <index-term id="ITerm474"><term>Ischemia</term></index-term>myocardial ischemia</p></list-item></list></p><p id="Par657">Screening tests incorporate two features: <italic>sensitivity</italic> and <italic>specificity</italic>. Sensitivity and specificity refer to the proportion of diseased persons with a positive test and to the proportion of healthy individuals with a negative test, respectively.</p><p id="Par658">Markers fulfill several criteria: <list list-type="bullet"><list-item><p id="Par659">Marker expression in the vascular tissue correlates with blood concentration.</p></list-item><list-item><p id="Par660">Marker blood level is related to structural and functional changes.</p></list-item><list-item><p id="Par661">Its method of identification is easy, reproducible, and has a low cost.</p></list-item><list-item><p id="Par662">The marker yields good sensitivity and specificity in detecting the pathological condition.</p></list-item></list></p><sec id="Sec46"><title>Hemostasis Factors</title><p id="Par663">Many components of hemostasis, such as fibrinogen, <sup>D</sup>dimer, coagulation factor-<italic>V</italic> <italic>III</italic>, plasmin–antiplasmin complexes, and <index-term id="ITerm475"><term>vWF</term></index-term>von Willebrand factor, in addition to <index-term id="ITerm476"><term>adamts</term></index-term>adamts13, correlate with an increased risk of coronary atherosclerosis complications, stroke, and mortality [<xref ref-type="bibr" rid="CR223">436</xref>].</p><p id="Par664">Von Willebrand factor (vWF) carries coagulation factor-<italic>V</italic> <italic>III</italic> and promotes <index-term id="ITerm477"><term>Platelet</term></index-term>platelet adhesion and aggregation at sites of vascular injury. Its activity depends on the metallopeptidase adamts13, which cleaves large and highly procoagulant vWF multimers into smaller and less procoagulant forms. Deficiency in vWF quantity or activity causes <index-term id="ITerm478"><term>von Willebrand disease</term></index-term> bleeding in von Willebrand disease. Severe deficiency in adamts13 engenders <index-term id="ITerm479"><term>Thrombocytopenic purpura</term></index-term>the clotting thrombocytopenic purpura. Elevated plasmatic vWF and reduced adamts13 concentrations provoke a procoagulant state, and hence the combination of the two is associated with an increased risk of <index-term id="ITerm480"><term>atherosclerosis</term></index-term>atherosclerosis complications [<xref ref-type="bibr" rid="CR224">437</xref>]. In addition, both vWF and adamts13 are dysregulated in <index-term id="ITerm481"><term>Inflammation</term></index-term>inflammation.</p></sec><sec id="Sec47"><title>Periodontitis</title><p id="Par665"><index-term id="ITerm482"><term>Periodontitis</term></index-term>Periodontitis is a chronic inflammatory disease caused by bacterial infections that destroy the tissue between the tooth surface and gingiva and provoke the loss of connective tissue attachment and teeth in addition to erosion of alveolar bone, which defines mild and moderate (radiographic bone loss 21–44%) or severe periodontitis (&lt; 66% remaining bone).</p><p id="Par666">Periodontitis is more commonly observed in patients with <index-term id="ITerm483"><term>atherosclerosis</term></index-term>atherosclerosis and its acute complications (MI and stroke) along with abdominal aortic <index-term id="ITerm484"><term>aneurysm</term></index-term>aneurysm [<xref ref-type="bibr" rid="CR225">438</xref>]. The risk for coronary atherosclerosis increases in these individuals.</p></sec></sec><sec id="Sec48"><title>Diagnosis</title><p id="Par667"><index-term id="ITerm485"><term>CRP (Ptx1)</term></index-term>CRP, <index-term id="ITerm486"><term>Natriuretic peptide</term></index-term>brain natriuretic peptide, <index-term id="ITerm487"><term>albumin</term></index-term>urinary albumin, <index-term id="ITerm488"><term>Renin</term></index-term>renin, and <index-term id="ITerm489"><term>Homocysteine</term></index-term>homocysteine are predictors of cardiovascular events with possible high death risk, but they moderately yield supplementary prediction in addition to known risk factors. In fact, <index-term id="ITerm490"><term>Marker</term></index-term>markers often provide information that correlates with known data.</p><sec id="Sec49"><title>Troponin, Myosin-Binding Protein-C, and CyR61</title><p id="Par668">In emergency departments, triage of patients with acute chest pain relies on the measurements in the blood circulation of cardiac troponins cTnnI or cTnnT, as only a small proportion of patients with acute myocardial infarction (AMI) have ST segment elevation on ECG trace. After the onset of myocardial ischemia, CMC death can occur within 15 min and necrosis within 4–6 h [<xref ref-type="bibr" rid="CR226">439</xref>].</p><p id="Par669">The fundamental contractile unit of the CMC, <italic>sarcomere</italic>, comprises thick (myosin) and thin filaments (actin; Vol. 5, Chap. 5. Cardiomyocytes). The thin filament is a helix of two filamentous actins, the groove of which contains TPM, to which troponin is attached. The troponin heterotrimer controls the Ca<sup>2+</sup>-dependent interaction of actin and myosin: <list list-type="order"><list-item><p id="Par670">Inhibitory cTnnI prevents actin–myosin cross-bridge formation in the absence of Ca<sup>2+</sup> ions.</p></list-item><list-item><p id="Par671">Tropomyosin-bound cTnnT links TPM on actin to the troponin complex.</p></list-item><list-item><p id="Par672">Calcium-binding cTnnC regulates activation of actin.</p></list-item></list></p><p id="Par673">Troponins are synthesized in fast- (ftTnns encoded by the TNNC2, TNNI2, and TNNT3 genes) and slow-twitch skeletal (stTnns encoded by the TNNC1, TNNI1, and TNNT1 genes) and cardiac myocytes (cTnns encoded by the TNNC1, TNNI3, and TNNT2 genes]). Hence, troponins TnnI and TnnT are selectively produced in the heart, but not TnnC, which is shared with the slow-twitch skeletal muscle. Both cTnnI and cTnnT are distinguished by regions of different amino acid sequences.</p><p id="Par674">The TNNT2 mRNA generates multiple alternatively spliced transcripts encoding different proteins (cTnnT1–cTnnT4), cTnnT3 being the dominant isoform in the normal adult heart [<xref ref-type="bibr" rid="CR226">439</xref>].</p><p id="Par675">During embryo- and fetogenesis, stTnnI is expressed in the heart instead of cTnnI. Troponin fetal isoforms, the expression of which is downregulated postnatally, can be re-expressed postnatally under certain pathological circumstances such as chronic HF. The cTnnT2 subtype is expressed to a greater extent than cTnnT3 in failing hearts.</p><p id="Par676">Cardiac troponins commonly serve as markers for acute myocardial necrosis. Both cTnnI and cTnnT are released in free forms and cleared by cardiac lymphatics. They are also liberated as noncovalent binary (cTnnI–cTnnT and predominantly cTnnI–cTnnC dimers) and ternary complexes (cTnnT–cTnnI–cTnnC trimer) [<xref ref-type="bibr" rid="CR226">439</xref>]. Moreover, all troponin isoforms undergo redox modifications and circulate as oxidized and reduced forms. Troponin is also released from the sarcomere both as intact proteins and degradation products after proteolysis by calpain-1, caspase, or MMP2 [<xref ref-type="bibr" rid="CR226">439</xref>]. These enzymes also reside in blood and the circulating cTnn complexes can also be degraded within blood.</p><p id="Par677">However, cTnn concentrations are commonly elevated in acute, reversible or irreversible, myocardial injury and are thus unrelated to necrosis linked to ACS, in addition to chronic diseases (e.g., chronic HF [myocardial strain], diabetes mellitus, pulmonary arterial hypertension, stable coronary artery disease, and chronic kidney disease, especially end-stage renal disease), along with extreme exercise [<xref ref-type="bibr" rid="CR226">439</xref>]. Cardiac troponins thus serve as organ-specific, disease-nonspecific markers.</p><p id="Par678">In addition, cTnnI and cTnnT are released slowly. <index-term id="ITerm491"><term>MyBPc</term></index-term>Cardiac myosin-binding protein-C (MyBPc3),<xref ref-type="fn" rid="Fn142">142</xref> another marker of cardiac injury, is more abundant than cardiac troponins and is released more rapidly after MI. Its blood concentration rises and falls more rapidly than those of cTnnT and cTnnI [<xref ref-type="bibr" rid="CR227">440</xref>].</p><p id="Par680"><index-term id="ITerm492"><term>Troponin</term></index-term>Known diagnostic markers include cardiac troponin-I and -T for <index-term id="ITerm493"><term>Myocardial infarction</term></index-term>MI and B-type natriuretic peptide for <index-term id="ITerm494"><term>Heart failure</term></index-term>HF.</p><p id="Par681">In mouse HF and human cardiomyopathies, accumulation of branched-chain α-keto acids (BCKAs) and associated defective catabolism of branched-chain amino acids (BCAAs) are markers of metabolic reprogramming [<xref ref-type="bibr" rid="CR228">441</xref>]. <index-term id="ITerm495"><term>KLF</term></index-term>The transcription factor KLF15 regulates BCAA catabolism in the heart. Impaired BCAA catabolism causes <index-term id="ITerm496"><term>Redox stress</term></index-term>redox stress in response to <index-term id="ITerm497"><term>Hypertension</term></index-term>hypertension. Elevated BCKA concentrations provoke superoxide production in mitochondria.</p><p id="Par682">Cardiac-specific troponins are characterized by better specificity and sensitivity than that of the cardiac marker <index-term id="ITerm498"><term>CK</term></index-term>CK-MB (which combines two isozymes <sup>SkM</sup>CK [muscle] and <sup>Br</sup>CK [brain]). Elevated troponin level is a CoAD diagnosis criterion that can require early revascularization. However, blood troponins are not necessarily augmented before 12 h after the onset of symptoms.<xref ref-type="fn" rid="Fn143">143</xref></p><p id="Par684"><index-term id="ITerm499"><term>MyBPc</term></index-term>Concentration of MyBPC3 is significantly higher in patients with acute myocardial necrosis than those without AMI [<xref ref-type="bibr" rid="CR227">440</xref>]. The discriminatory power of MyBPC3 (&gt; 10 ng/l) for AMI is similar to that of high-sensitivity troponins hscTnnT and hscTnnI, but higher than that of hscTnnT in patients with chest pain for less than 3 h (i.e., in early attenders to emergency departments).</p><p id="Par685"><index-term id="ITerm500"><term>CyR61 (CCN1)</term></index-term>In coronary thrombi of ACS patients, the amount of cysteine-rich angiogenic inducer CYR61 transcripts<xref ref-type="fn" rid="Fn144">144</xref> is elevated with respect to that in lymphocytes and monocytes [<xref ref-type="bibr" rid="CR229">442</xref>]. In a murine ischemia–reperfusion model, myocardial Cyr61 expression markedly rises. Concentration of CyR61 also significantly increases in STEMI with respect to non-STEMI, unstable angina, and stable CoAD, whether coronary thrombi are present or not. Therefore, soluble CyR61 can serve as a marker of ACS due to a thromboembolic event or acute myocardial injury. It can surpass the diagnostic potential of troponin [<xref ref-type="bibr" rid="CR229">442</xref>].</p></sec><sec id="Sec50"><title>Fatty Acid-Binding Proteins</title><p id="Par687">Fatty acid-binding proteins (FABPs) are small cytosolic widespread proteins that are members of the ILBP set<xref ref-type="fn" rid="Fn145">145</xref> (Sect. <ext-link xlink:href="10.1007/978-3-319-89315-0_5#Sec121" ext-link-type="doi">5.4.5.20</ext-link>). They reversibly bind to intracellular hydrophobic ligands, such as fatty acids and their acylCoA derivatives, with high affinity and broad specificity for transfer to various cellular compartments, (e.g., endoplasmic reticulum, nucleus, lipid droplets, peroxisomes, and mitochondria) for storage, oxidation, membrane synthesis, signaling, and activation of nuclear receptors, which are transcription factors, such as <index-term id="ITerm501"><term>PPAR (NR1c1/2/3)</term></index-term>peroxisome proliferator-activated receptors (PPARs [NR1c1–NR1c3]) [<xref ref-type="bibr" rid="CR232">445</xref>].</p><p id="Par689">Synthesis of FABPs is mostly regulated at the transcriptional level. The human genome encodes at least nine FABPs (Table <xref rid="Tab29" ref-type="table">2.29</xref>). These isoforms differ with regard to ligand affinity and specificity. <table-wrap id="Tab29"><label>Table 2.29</label><caption xml:lang="en"><p>Fatty acid-binding proteins (Source: [<xref ref-type="bibr" rid="CR232">445</xref>])</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><p>Protein names</p></th><th align="left"/></tr><tr><th align="left"><p>Gene</p></th><th align="left"><p>and aliases</p></th><th align="left"><p>Location</p></th></tr></thead><tbody><tr><td align="left"><p>Fabp1</p></td><td align="left"><p><sup>Li</sup>FABP (liver)</p></td><td align="left"><p>Liver, intestine, pancreas,</p></td></tr><tr><td align="left"/><td align="left"/><td align="left"><p>stomach, kidney, lung</p></td></tr><tr><td align="left"><p>Fabp2</p></td><td align="left"><p><sup>In</sup>FABP (intestine)</p></td><td align="left"><p>Intestine, liver</p></td></tr><tr><td align="left"><p>Fabp3</p></td><td align="left"><p><sup>He</sup>FABP (heart),</p></td><td align="left"><p>Cardiac and skeletal muscle,</p></td></tr><tr><td align="left"/><td align="left"><p>MDGI</p></td><td align="left"><p>brain, kidney, lung, stomach,</p></td></tr><tr><td align="left"/><td align="left"/><td align="left"><p>adrenal gland, brown adipose tissue,</p></td></tr><tr><td align="left"/><td align="left"/><td align="left"><p>mammary gland, placenta,</p></td></tr><tr><td align="left"/><td align="left"/><td align="left"><p>ovary, testis</p></td></tr><tr><td align="left"><p>Fabp4</p></td><td align="left"><p><sup>AdC</sup>FABP (adipocyte),</p></td><td align="left"><p>Adipocyte, macrophage,</p></td></tr><tr><td align="left"/><td align="left"><p>ALBP, aP2</p></td><td align="left"><p>dendrocyte, skeletal myocyte</p></td></tr><tr><td align="left"><p>Fabp5</p></td><td align="left"><p><sup>Ep</sup>FABP (epiderm),</p></td><td align="left"><p>Keratinocyte, adipocyte,</p></td></tr><tr><td align="left"/><td align="left"><p><sup>KC</sup>FABP,</p></td><td align="left"><p>macrophage, dendrocyte</p></td></tr><tr><td align="left"/><td align="left"><p>paFABP</p></td><td align="left"><p>Brain, lung, kidney, liver,</p></td></tr><tr><td align="left"/><td align="left"/><td align="left"><p>heart, skeletal muscle,</p></td></tr><tr><td align="left"/><td align="left"/><td align="left"><p>intestine, stomach, tongue, spleen,</p></td></tr><tr><td align="left"/><td align="left"/><td align="left"><p>retina, lens, testis,</p></td></tr><tr><td align="left"/><td align="left"/><td align="left"><p>mammary gland, placenta</p></td></tr><tr><td align="left"><p>Fabp6</p></td><td align="left"><p><sup>Il</sup>FABP (ileum),</p></td><td align="left"><p>Ileum, adrenal gland,</p></td></tr><tr><td align="left"/><td align="left"><p>gastrophin,</p></td><td align="left"><p>stomach,</p></td></tr><tr><td align="left"/><td align="left"><p><sup>In</sup>BABP</p></td><td align="left"><p>ovary</p></td></tr><tr><td align="left"><p>Fabp7</p></td><td align="left"><p><sup>Br</sup>FABP (brain),</p></td><td align="left"><p>Central nervous system,</p></td></tr><tr><td align="left"/><td align="left"><p>BLBP, MRG</p></td><td align="left"><p>retina, gliocyte,</p></td></tr><tr><td align="left"/><td align="left"/><td align="left"><p>mammary gland</p></td></tr><tr><td align="left"><p>Fabp8</p></td><td align="left"><p><sup>My</sup>FABP (myelin)</p></td><td align="left"><p>Peripheral nervous system,</p></td></tr><tr><td align="left"/><td align="left"><p>PMP2</p></td><td align="left"><p>Schwann cells</p></td></tr><tr><td align="left"><p>Fabp9</p></td><td align="left"><p><sup>Te</sup>FABP (testis)</p></td><td align="left"><p>Testis, salivary gland,</p></td></tr><tr><td align="left"/><td align="left"><p>TLBP, Perf, Perf15</p></td><td align="left"><p>mammary gland</p></td></tr></tbody></table><table-wrap-foot><p>These isoforms (FABP1–FABP9) were named according to the organ in which they were first identified or predominate. In fact, they have a widespread distribution in the organism (<italic>ALBP</italic> adipocyte lipid-binding protein, <italic>aP</italic> adipocyte protein, <italic>BABP</italic> bile acid-binding protein, <italic>BLBP</italic> brain lipid-binding protein, <italic>MDGI</italic> mammary gland-derived growth inhibitor, <italic>MRG</italic> MDRI-related gene product, <italic>paFABP</italic> psoriasis-associated-FABP, <italic>Perf</italic> perforatorial protein, <italic>PMP</italic> peripheral myelin protein, <italic>TLBP</italic> testis lipid-binding protein)</p></table-wrap-foot></table-wrap></p><p id="Par690">Circulating FABPs are markers of injury in the liver (FABP1), intestine (FABP2), myocardium (FABP3), kidney (FABP4), and brain (FABP7) [<xref ref-type="bibr" rid="CR9">167</xref>].</p><p id="Par691">Cardiac FABP3, which can be detected 1 h after acute coronary occlusion, is a more reliable early index of cardiac damage than MB [<xref ref-type="bibr" rid="CR233">446</xref>]. Moreover, it has a sensitivity superior to that of cardiac TNNT, but lacks specificity in detecting acute MI [<xref ref-type="bibr" rid="CR234">447</xref>].</p><p id="Par692">Plasmatic FABP4 concentration is correlated with atherosclerosis, insulin resistance, type-2 diabetes, obesity, hypertension, left ventricular hypertrophy, intimal hyperplasia, and endothelial and cardiac systolic and diastolic dysfunction [<xref ref-type="bibr" rid="CR9">167</xref>]. FABP4 is synthesized in adipocytes, macrophages, and ECs of capillaries and veins, but not arteries. However, ectopic production in and secretion of FABP4 from coronary arterial ECs contribute to neointima formation and restenosis after stenting [<xref ref-type="bibr" rid="CR235">448</xref>].</p><p id="Par693">Plasmatic FABP5 concentration is also associated with metabolic syndrome, although the correlation was not as strong as that of FABP4 [<xref ref-type="bibr" rid="CR9">167</xref>]. The metabolic syndrome results from interference between metabolic and inflammatory pathways, that is, <italic>metaflammation</italic> (Vol. 12, Chap. 3. Metabolic Syndrome).</p></sec><sec id="Sec51"><title>C-Reactive Protein (Pentraxin-1)</title><p id="Par694"><index-term id="ITerm502"><term>CRP (Ptx1)</term></index-term>The circulating pentameric molecule CRP<xref ref-type="fn" rid="Fn146">146</xref> (median concentration 0.8 mg/l in healthy young adults; half-life ∼19 h [<xref ref-type="bibr" rid="CR237">450</xref>]), a prototypical acute phase reactant,<xref ref-type="fn" rid="Fn147">147</xref> is the first identified <index-term id="ITerm503"><term>PRR</term></index-term>pattern recognition receptor. It binds to phosphocholine on the surface of dead or dying cells and some types of bacteria, thereby activating the complement system via the C1q complex.<xref ref-type="fn" rid="Fn148">148</xref></p><p id="Par698">It is synthesized mainly in the liver at a low rate in normal conditions. CRP isoforms have distinct functions. Its production increases, and it is secreted following tissue injury and inflammation, especially under the control of IL-6 released by immunocytes [<xref ref-type="bibr" rid="CR238">451</xref>]. Concentration of CRP hence rises in response to inflammation (&gt; 500 mg/l [<xref ref-type="bibr" rid="CR237">450</xref>]).</p><p id="Par699"><index-term id="ITerm504"><term>Pentraxin</term></index-term>C-reactive protein (CRP) pertains to the pentraxin family with pentraxin-2<xref ref-type="fn" rid="Fn149">149</xref> and pentraxin-3.<xref ref-type="fn" rid="Fn150">150</xref> Short monomeric, insoluble, tissue-associated, proinflammatory, pentraxin-1 (Ptx1) dissociates from pentameric CRP.</p><p id="Par702">Circulating pentameric CRP binds to activated <index-term id="ITerm505"><term>Platelet</term></index-term>platelets and microparticles enriched in lysophosphatidylcholine, which predominantly derive from activated cell membranes and carry <index-term id="ITerm506"><term>MicroRNA</term></index-term>microRNAs. On microparticles, the pentamer is converted into CRP monomers that reside on the microparticle surface [<xref ref-type="bibr" rid="CR239">452</xref>].</p><p id="Par703">In vitro, monomeric CRP provokes synthesis of chemokines in <index-term id="ITerm507"><term>Neutrophil</term></index-term>neutrophils and integrins in <index-term id="ITerm508"><term>Monocyte</term></index-term>monocytes, enhances neutrophil adhesion to <index-term id="ITerm509"><term>EC</term></index-term>ECs, and delays neutrophil apoptosis. Monomeric Ptx1 enhances <index-term id="ITerm510"><term>Platelet</term></index-term>platelet adhesion to ECs and supports formation of neutrophil–platelet aggregates.</p><p id="Par704">Pentraxin-1 can be detected in <index-term id="ITerm511"><term>atherosclerosis</term></index-term>atherosclerotic plaques and <index-term id="ITerm512"><term>Myocardial infarction</term></index-term>infarcted myocardium, where it colocalizes with inflammatory leukocytes.</p><p id="Par705">Plasmatic concentrations of CRP, nitrotyrosine, a molecular marker for NO-derived oxidants, and the CXCL8 chemokine (or IL-8) are predictors of acute cardiovascular events in patients with stable or unstable angina [<xref ref-type="bibr" rid="CR240">453</xref>]. Plasmatic CRP concentration is a stronger predictor of cardiovascular events than that of LDL<sup>CS</sup> [<xref ref-type="bibr" rid="CR238">451</xref>]. In women, 77% of cardiovascular events occur with LDL<sup>CS</sup> concentrations below 160 mg/dl (4.1 mmol/l) and 46% below 130 mg/dl (3.4 mmol/l) [<xref ref-type="bibr" rid="CR241">454</xref>]. Plasmatic CRP concentration rises in patients at moderate (1–3 μ g/ml [or mg/l]) and high risk (&gt; 3 μ g/ml) for future cardiovascular events [<xref ref-type="bibr" rid="CR241">454</xref>].</p><p id="Par706">Plasma concentration of pentraxin-3, which is highly expressed in the heart and mainly by <index-term id="ITerm513"><term>dendrocyte</term></index-term>dendrocytes, <index-term id="ITerm514"><term>Macrophage</term></index-term>macrophages, and <index-term id="ITerm515"><term>EC</term></index-term>ECs in response to inflammatory stimuli, reaches a peak approximately 7 h after MI. It also lodges in <index-term id="ITerm516"><term>atherosclerosis</term></index-term>atherosclerotic lesions and <index-term id="ITerm517"><term>Vasculitis</term></index-term>vasculitis in humans. It is induced by <index-term id="ITerm518"><term>oxLDL</term></index-term>oxidized LDLs in <index-term id="ITerm519"><term>vSMC</term></index-term>smooth myocytes. This acute phase protein, but neither Ptx1 nor other cardiac markers (<sub>NT</sub>proBNP, TNNT, and CK), predicts 3-month mortality [<xref ref-type="bibr" rid="CR242">455</xref>].</p></sec><sec id="Sec52"><title>Other Inflammatory Indices</title><p id="Par707">The <italic>neutrophil-to-lymphocyte ratio</italic> and <italic>monocyte-to-high-density lipoprotein ratio</italic> are used as indicators of <index-term id="ITerm520"><term>Inflammation</term></index-term>inflammation and <index-term id="ITerm521"><term>Redox stress</term></index-term>redox stress. These markers are related to adverse cardiovascular outcomes, especially after ACS treated by primary percutaneous coronary intervention (e.g., post-stenting <index-term id="ITerm522"><term>Restenosis</term></index-term>restenosis and altered cardiac rhythm such as atrial fibrillation). They are also associated with a bad prognosis in <index-term id="ITerm523"><term>Cancer</term></index-term>cancers, which is also linked to systemic inflammation (throughout the body).</p><p id="Par708"><index-term id="ITerm524"><term>Heart failure</term></index-term>In HF, neurohumoral processes are aimed at preserving contractile performance to compensate for a defective myocardium. <index-term id="ITerm525"><term>Sympathetic</term></index-term>However, sympathetic nervous system hyperactivity is associated with a poor prognosis in HF patients.</p><p id="Par709">Concentration of β ARs and GRK2 in circulating lymphocytes correlates with those in the myocardium, particularly in right atrial appendages of HF subjects [<xref ref-type="bibr" rid="CR243">456</xref>]. Moreover, after left ventricular assist device implantation, partial restoration of myocardial function and, in CMCs, of β AR signaling and attenuated GRK2 activity is associated with diminished GRK2 activity in lymphocytes. Therefore, lymphocytic GRK2 concentration may complement the blood concentration of <index-term id="ITerm526"><term>Natriuretic peptide</term></index-term><sub>NT</sub>proBNP to assess HF severity. Furthermore, lymphocyte GRK2 expression correlates significantly with age and left ventricular ejection fraction [<xref ref-type="bibr" rid="CR244">457</xref>]. The prognostic power of <sup>LC</sup>GRK2 concentration is similar to that of <sub>NT</sub>proBNP in HF patient surveillance, as <sup>LC</sup>GRK2 concentration independently predicts mortality.</p><p id="Par710">Inhibitors of the adrenergic and angiotensin signaling are used in HF patients. β-Adrenoceptor antagonists (β-blockers) that prevent CMC apoptosis and normalize inotropy are used in congestive heart failure and hypertension [<xref ref-type="bibr" rid="CR245">458</xref>]. Among them, carvedilol is a β-arrestin-based agonist of β-adrenoceptors that elicits GPCR phosphorylation by GRK, β-arrestin recruitment, β AR internalization, <index-term id="ITerm527"><term>ERK</term></index-term>ERK activation, and EGF receptor transactivation. Pepducins are lipidated peptides derived from the GPCR intracellular loop that can stimulate or inhibit downstream signaling from their cognate receptors. <sup>β2AR</sup>Pepducin operates in a similar manner to carvedilol, stabilizing the β2AR conformation used as a substrate for GRK-mediated phosphorylation and β-arrestin-1 binding, but induces CMC contraction, whereas carvedilol does not [<xref ref-type="bibr" rid="CR245">458</xref>]. Lymphocytic GRK2 concentration is not linked to therapy efficiency and does not predict mortality [<xref ref-type="bibr" rid="CR243">456</xref>].</p><p id="Par711"><index-term id="ITerm528"><term>GGT</term></index-term>Elevated plasmatic concentration of γ-glutamyl transferase (GGT)<xref ref-type="fn" rid="Fn151">151</xref> correlates with hypertension, diabetes, and vascular diseases, in addition to liver damage. GGT is an indicator for an early diagnosis and prognosis in HF patients [<xref ref-type="bibr" rid="CR246">459</xref>].</p><p id="Par713"><index-term id="ITerm529"><term>ectopic calcification</term></index-term>Cytokines released by inflammatory leukocytes cause vSMC apoptosis or transdifferentiation to an osteochondrogenic lineage, mineralizing <index-term id="ITerm530"><term>atherosclerosis</term></index-term>atherosclerotic plaques. Arterial wall calcification (Vol. 10, Chap. 3. Adverse Wall Remodeling), which is linked to altered stress field and phosphate metabolism in addition to hyperglycemia, hyperlipidemia, inflammation, and redox stress, is a frequent and severe complication of atherosclerosis [<xref ref-type="bibr" rid="CR247">460</xref>]. Calcium released in apoptotic bodies forms a nidus of microcalcification that can destabilize the lesion, but can also later fuse to form macrocalcification, which may protect against plaque rupture.</p><p id="Par714"><index-term id="ITerm531"><term>TNFSF</term></index-term>The cytokine TNFSF1 released primarily by macrophages not only primes apoptosis and hence the accumulation of apoptotic bodies but also activates osteogenic reprogramming in vSMCs via BMP2, Msx2, and Wnt [<xref ref-type="bibr" rid="CR248">461</xref>].</p><p id="Par715"><index-term id="ITerm532"><term>Rac</term></index-term>Signaling by GTPases of the Rac category influences the synthesis of growth factors and cytokines. In macrophages, Rac2 promotes VEGFa formation and hence arteriogenesis in response to ischemia [<xref ref-type="bibr" rid="CR248">461</xref>]. In addition, Rac2 precludes Rac1 activation. On the other hand, activated Rac1 supports <index-term id="ITerm533"><term>NFκB</term></index-term>NFκB signaling and <index-term id="ITerm534"><term>ROS</term></index-term>ROS production via <index-term id="ITerm535"><term>NOx</term></index-term>NOx and hence the action of NLRP3 inflammasome, which promotes IL1β maturation. Pattern recognition receptors and cholesterol crystals, which destabilize lysosomes, trigger the expression of IL1β via the Rac1–NFκB pathway.</p><p id="Par716"><index-term id="ITerm536"><term>IL</term></index-term>Interleukin-1β released by SMC-derived plaque macrophages also favors vascular calcification and can thus serve as a marker of advanced atherosclerotic plaque calcification. On the other hand, Rac2 hinders Rac1-mediated IL1β production in bone marrow-derived macrophages [<xref ref-type="bibr" rid="CR248">461</xref>]. In the late stages of atherosclerosis, the Rac2 concentration diminishes.</p></sec><sec id="Sec53"><title>Extracellular Vesicles</title><p id="Par717">Information is exchanged between cells using (1) short-distance signaling via intercellular contact, (2) mid-range intercellular transfer of paracrine messengers (autacoids) and <index-term id="ITerm537"><term>Microvesicle</term></index-term> EVs (size 50 nm–2 μ m), and (3) remote transmission of hormones, growth factors, and cytokines. Intercellular communication is fostered by juxta-, para-, and endocrine messengers (i.e., autacoids and endocrine regulators), which are secreted either as isolated messengers or contained in EVs.</p><p id="Par718">Once released, EVs travel to neighboring or relatively remote recipient cells, in which they can be incorporated via receptors or fusion of vesicle and target cell plasma membranes and subsequently enter the cytoplasm and even the nucleus.</p><p id="Par719">Extracellular vesicles of multiple cellular origin mediate intercellular communication in physiological and pathological conditions. Circulating EVs yield information on the disease state.</p><p id="Par720">Most cell types, in particular ECs, vascular smooth myocytes, CMCs, monocytes, macrophages, and platelets, release extracellular vesicles of different sizes, composition, and content, and hence subcellular origin. Extracellular vesicle composition and content are markers of cellular activation and injury.</p><p id="Par721">Extracellular vesicles originate from diverse subcellular compartments. They contain cytoplasmic and plasmalemmal components of source cells. Membrane-encapsulated extracellular particles are formed in different pathways, carry diverse cargos to target cells, and have distinct functions. They are detected in all bodily fluids (e.g., cerebrospinal fluid, saliva, and urine), especially in the blood circulation.</p><p id="Par722">A given cell type secretes various types of EVs characterized by their size, density, intracellular origin, and tetraspanin composition. In particular, cells release many types of nanovesicles with similar size, density, and surface markers.</p><p id="Par723">Extracellular vesicles are secreted under basal conditions and upon stress exposure, particularly in inflammatory sites [<xref ref-type="bibr" rid="CR249">462</xref>]. The origin, composition, and concentration of EVs can also be used as diagnostic and prognostic markers. Their composition, in particular the <index-term id="ITerm538"><term>MicroRNA</term></index-term>microRNA content, indeed signals cell activation and injury.</p><p id="Par724">Extracellular vesicles are covered by a lipid bilayer, which contains transmembrane proteins. They serve as containers of numerous soluble proteins (e.g., growth factors, cytokines, chemokines, receptors, and cell adhesion molecules) in addition to genetic information (DNA, mRNA, premature and mature microRNAs, long nonprotein-coding RNAs, and other nucleic acid species) and free ribonucleoprotein complexes.</p><p id="Par725">The vesicular content is transmitted to acceptors (e.g., ECs, monocytes, and platelets). The surface receptors of EVs allow their capture by neighboring recipient cells that can then incorporate proteic, lipidic, and RNA messengers. Extracellular vesicles that circulate in the extracellular space (including the blood) protect RNA from degradation by nucleases.</p><p id="Par726">Plasmatic concentrations of EVs result from the balance between production and rapid clearance by <index-term id="ITerm539"><term>Kupffer cell</term></index-term>Kupffer cells in the liver<xref ref-type="fn" rid="Fn152">152</xref> and <index-term id="ITerm540"><term>Macrophage</term></index-term>macrophages in the spleen and lung that renders the long-range transmission of information unlikely [<xref ref-type="bibr" rid="CR249">462</xref>].</p><p id="Par728">Red blood capsule-derived EVs undergo major uptake by the liver (∼45%), followed by bone (∼23%), skin (∼10%), muscle (∼6%), spleen (∼3%), kidney (∼3%), and lung (∼2%) [<xref ref-type="bibr" rid="CR251">464</xref>].</p><p id="Par729">The EV formation rate depends on the activation status of releasing cells. On the other hand, EVs are cleared using different mechanisms. Endothelial microvesicles are taken up by the endothelium owing to an annexin-5-phosphatidylserine receptor [<xref ref-type="bibr" rid="CR251">464</xref>]. Platelet-derived microvesicles are taken up by ECs via EDIL3<xref ref-type="fn" rid="Fn153">153</xref> in addition to macrophages via lactadherin<xref ref-type="fn" rid="Fn154">154</xref> Microvesicle clearance also implicate their uptake from the circulation by Kupffer cells and splenocytes. <index-term id="ITerm541"><term>Exosome</term></index-term>Exosome turnover relies on uptake via tetraspanins, integrins, and lactadherin [<xref ref-type="bibr" rid="CR251">464</xref>].</p><p id="Par732">Extracellular vesicles can be categorized into large, mid-size, and small particles. Small EVs can be further subdivided into subcategories according to proteic markers (e.g., Tspan28–Tspan30).</p><p id="Par733">Many subtypes of EVs are described in the literature, such as ectosomes, exosomes, microvesicles, microparticles, membrane particles, and apoptotic vesicles (Vol. 10, Chap. 1. Architecture and Structure of the Vasculature). Extracellular vesicles mainly comprise (Table <xref rid="Tab30" ref-type="table">2.30</xref>):
<table-wrap id="Tab30"><label>Table 2.30</label><caption xml:lang="en"><p>Characteristics of different types of extracellular vesicles, the size of vesicle subtype varying according to investigators (Source: [<xref ref-type="bibr" rid="CR249">462</xref>])</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><p>Exosomes</p></th><th align="left"><p>Microvesicles</p></th><th align="left"><p>Apoptotic bodies</p></th></tr></thead><tbody><tr><td align="left"><p>Caliber</p></td><td align="left"><p>30–150 nm</p></td><td align="left"><p>150–1000 nm</p></td><td align="left"><p>1–5 μm</p></td></tr><tr><td align="left"><p>Content</p></td><td align="left"><p>Proteins</p></td><td align="left"><p>Cell surface molecules</p></td><td align="left"><p>Organelles</p></td></tr><tr><td align="left"/><td align="left"><p>Cytosolic content:</p></td><td align="left"><p>RNA, miRs</p></td><td align="left"><p>Cytosolic content:</p></td></tr><tr><td align="left"/><td align="left"><p>proteins, lipids,</p></td><td align="left"/><td align="left"><p>proteins, lipids,</p></td></tr><tr><td align="left"/><td align="left"><p>RNA, miRs</p></td><td align="left"/><td align="left"><p>nucleic acids</p></td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"><p>(DNA, RNA, miRs)</p></td></tr><tr><td align="left"><p>Membrane</p></td><td align="left"><p>Impermeable</p></td><td align="left"><p>Impermeable</p></td><td align="left"><p>Permeable</p></td></tr><tr><td align="left"><p>Markers</p></td><td align="left"><p>Annexin-5</p></td><td align="left"><p>LAMP1, Tspan30,</p></td><td align="left"><p>Annexin-5,</p></td></tr><tr><td align="left"/><td align="left"><p>cell-specific markers</p></td><td align="left"><p>VPS23, lactadherin</p></td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Apoptotic bodies are formed during the late stage of apoptosis. Microvesicles (or microparticles) are smaller and created by membrane blebbing. They can be released from most cell types (e.g., circulating leukocytes, erythrocytes, and platelets, in addition to vascular cells and CMCs). Their number increases under stress. Exosomes are formed by the fusion of multivesicular bodies with the plasma membrane. Extracellular vesicles transfer their cargos to recipient cells by membrane fusion, endocytosis, or receptor-mediated binding. Microparticle-derived arachidonic acid, oxidized phospholipids, and chemokines may contribute to increased leukocyte adhesion on the vascular endothelium. Apoptotic bodies can prime IL-1α release by ECs. On the other hand, leukocyte-derived microparticles stimulate the secretion of anti-inflammatory cytokines</p></table-wrap-foot></table-wrap><list list-type="order"><list-item><p id="Par734"><index-term id="ITerm542"><term>Exosome</term></index-term>Exosomes (size 30–150 nm) originating from the endosomal circuit that are released upon fusion of multivesicular bodies with the plasma membrane</p></list-item><list-item><p id="Par735"><index-term id="ITerm543"><term>Microvesicle</term></index-term>Microvesicles (size 150 nm–1 μm) that are directly shed from the plasma membrane</p></list-item><list-item><p id="Par736"><index-term id="ITerm544"><term>apoptotic body</term></index-term>Apoptotic bodies (size 1–5 μm) that are released as blebs of apoptotic cells</p></list-item></list> Exosomes are permanently exported from cells, but microvesicles are released in response to cell activation or injury [<xref ref-type="bibr" rid="CR251">464</xref>].</p><p id="Par737">Extracellular vesicles formed and released from the plasma membrane are often called microparticles, shed microvesicles, or <italic>ectosomes</italic>. Their sizes range from a few tens of nanometers to a few micrometers.</p><p id="Par738">Intracellular vesicles generated in the endosomal and multivesicular compartment are secreted when they fuse with the plasma membrane. These endosome-derived vesicles released in the extracellular medium are named <italic>exosomes</italic>. Exosomes are defined by their size (&lt; 150 nm) and content (i.e., endosomal proteins).</p><p id="Par739">Extracellular vesicles, at least those from monocyte-derived <index-term id="ITerm545"><term>dendrocyte</term></index-term>dendrocytes, are categorized into large, medium-sized, and small vesicles [<xref ref-type="bibr" rid="CR253">466</xref>]. <list list-type="bullet"><list-item><p id="Par740">Large EVs contain HSP90b1 (endoplasmin) and possibly other endoplasmic reticulum-associated proteins.</p></list-item><list-item><p id="Par741">Large and medium-sized EVs possess actinin-4, mitofilin, and possibly other mitochondrial proteins, but not small EVs.</p></list-item><list-item><p id="Par742">Small EVs are characterized by the presence of flotillins, annexin-5, -6, and -11, syntenin-1, endosomal sorting complexes required for transport (ESCRT1) complex subunits TSG101, ChMP4a, ChMP4b, and VPS4b, <index-term id="ITerm546"><term>adam</term></index-term>ADAM10, ACE, and EHD4. Among them, syntenin-1 and TSG101 are specific to exosomes.</p></list-item></list></p><p id="Par743">Patients with risk factors, such as hypertension, metabolic syndrome, diabetes, and/or hypercholesterolemia, have elevated concentrations of circulating microvesicles derived from ECs and platelets [<xref ref-type="bibr" rid="CR251">464</xref>].</p><p id="Par744">In addition, microvesicular content changes. Diabetic patients have a reduced amount of endothelial miR26 and miR126-3p in circulating endothelial microvesicles [<xref ref-type="bibr" rid="CR251">464</xref>]. In EVs from smokers, the quantity of platelet-derived miR223 declines, whereas amounts of miR29b and type-2 U6 small nuclear RNA (RNU6-2) increase with respect to controls. Familial hypercholesterolemia is associated with higher numbers of platelet-derived microvesicles in addition to tissue factor-rich microvesicles, which have a procoagulant activity. Patients with low miR26a and miR126 levels are at a high risk for CoAD.</p><p id="Par745">In patients at a high CoAD risk, levels of circulating CD144+ endothelial microvesicles and/or CD31+ annexin-5+ microvesicles in addition to low concentrations of miR126-3p and miR199-5p predict future cardiovascular events [<xref ref-type="bibr" rid="CR251">464</xref>]. In patients with pulmonary hypertension, the circulating level of SelE+ endothelial microvesicles is related to a bad mid-term prognosis. Microvesicular cystatin-C (Cst3), an inhibitor of cysteine peptidases, serpin-F2, and CD14, a coreceptor for TLR2–TLR6 heterodimer and bacterial lipopolysaccharide, are related to an elevated risk for future vascular events.</p><sec id="Sec54"><title>Small Extracellular Vesicles</title><p id="Par746">Small EVs cross 220-nm pore filters. They incorporate subpopulations of <index-term id="ITerm547"><term>Exosome</term></index-term>exosomes and other types of extracellular vesicles.</p><p id="Par747"><index-term id="ITerm548"><term>Flotillin</term></index-term>Flotillin-1, <index-term id="ITerm549"><term>HSP</term></index-term>70-kDa heat shock proteins (inducible HSPa1 and constitutive HSPa8), and <index-term id="ITerm550"><term>MHC</term></index-term> MHC class-<italic>I</italic> and <italic>II</italic> proteins are present in all types of EVs, albeit to various extents [<xref ref-type="bibr" rid="CR253">466</xref>].</p><p id="Par748">Four subcategories of small extracellular vesicles (SECVs) can be defined according to the types of contained <index-term id="ITerm551"><term>Tetraspanin</term></index-term>tetraspanins among the three species used as markers (Tspan28–Tspan30) [<xref ref-type="bibr" rid="CR253">466</xref>]. <list list-type="order"><list-item><p id="Par749">SECVs enriched in Tspan28 to Tspan30 and endosomal markers are genuine exosomes.</p></list-item><list-item><p id="Par750">SECVs devoid of Tspan28 and Tspan30, but enriched in Tspan29 are linked to the plasma membrane and have an early endocytic signature. Tspan29+ small EVs have transmembrane proteins, integrin-α<sub>2B</sub>, and <index-term id="ITerm552"><term>MMP</term></index-term>MMP14.</p></list-item><list-item><p id="Par751">SECVs devoid of Tspan28 to Tspan30 are not associated with the endosomal route.</p></list-item><list-item><p id="Par752">SECVs enriched in matrix constituents (collagen, fibronectin, S100a18, and serpin-F1), complement (C3 and C4a), and serum-derived factors (prothrombin [coagulation factor F<italic>II</italic>] and albumin) are also not linked to the endosomal route.</p></list-item></list></p><p id="Par753"><index-term id="ITerm553"><term>Pulmonary arterial hypertension</term></index-term>Pulmonary arterial hypertension (PAHT) is characterized by hyperplasia and hypertrophy of vascular smooth myocytes and proliferation of ECs in small pulmonary arteries, increasing the mean pulmonary arterial pressure and hence right ventricle afterload. The severity of PAHT is associated with elevated amounts of circulating microvesicles released from stressed and apoptotic cells [<xref ref-type="bibr" rid="CR254">467</xref>].</p><p id="Par754">Circulating small vesicles from PAHT mouse models are heterogeneous in size (30–430 nm) and carry proteins characteristic of exosomes and microvesicles. Administration of lung- and plasma-derived vesicles from these mice to healthy mice increases right ventricular mass and pulmonary vascular wall thickness [<xref ref-type="bibr" rid="CR255">468</xref>]. Lung-derived small vesicles (LDSVs), but not plasma-derived small vesicles (PDSVs), contain high amounts of endothelial mRNAs. In addition, small vesicles from monocrotaline-treated mice possess altered levels of microRNAs, such as miR145, miR328, and miR451, which are involved in pulmonary arterial hypertensive remodeling. Furthermore, the concentration of phosphodiesterase-5 is augmented in both LDSVs and PDSVs.</p><p id="Par755">Extracellular vesicles from monocrotaline-treated mice induce differentiation of bone marrow cells into endothelial progenitor cells. When these cells are transplanted into healthy mice, they home to the lung, where they raise the muscularization of pulmonary arterial walls, thereby contributing to adverse pulmonary vascular remodeling; mobilization of bone marrow-derived progenitor cells and their recruitment to the pulmonary vasculature are also observed in experimental hypoxia-induced PAHT [<xref ref-type="bibr" rid="CR254">467</xref>]. Extracellular vesicles from monocrotaline-treated mice upregulate the activity of growth factor implicated in PAHT genesis from bone marrow-derived progenitor cells.</p></sec><sec id="Sec55"><title>Exosomes</title><p id="Par756"><index-term id="ITerm554"><term>Exosome</term></index-term>Exosomes are produced on the endosomal route from multivesicular bodies spontaneously or in response to external <index-term id="ITerm555"><term>Mechanical stress</term></index-term>mechanical and chemical cues (e.g., shear stress, <index-term id="ITerm556"><term>Hypoxia</term></index-term>hypoxia, cytokines, and chemotherapeutic agents), whereas larger vesicles are expelled from the plasma membrane.</p><p id="Par757">Exosomes contain membrane-anchored receptors, adhesion molecules, signaling mediators, and nucleic acids. They transfer their cargos to recipient cells, thereby affecting cell fate.</p><p id="Par758">Exosomes influence immune response and are involved in pathogenesis and in <index-term id="ITerm557"><term>Cancer</term></index-term>tumor growth. Cancerous cells exploit exosomes to favor tumor growth and control premetastatic niche formation [<xref ref-type="bibr" rid="CR256">469</xref>]. Exosomes can intervene in cancer growth, angiogenesis, metastasis, and immune surveillance.</p><p id="Par759"><index-term id="ITerm558"><term>Syntenin</term></index-term>Syntenin, a cytosolic adaptor that binds to the intracellular domain of <index-term id="ITerm559"><term>Syndecan</term></index-term>syndecans, is implicated in the genesis of a subset of exosomes. Syntenin also binds to programmed cell death-6-interacting protein (PdCD6IP), which is involved in endocytosis, multivesicular body genesis, membrane repair, cytokinesis, apoptosis, and maintenance of tight junction integrity. PdCD6IP connects the syntenin–syndecan complex to the ESCRT machinery, thereby operating in endosomal membrane budding and scission and generating intraluminal vesicles that are released as exosomes when multivesicular endosomes fuse with the plasma membrane [<xref ref-type="bibr" rid="CR256">469</xref>]. Regulators of these processes include, on the cytosolic side, the small GTPase ARF6 and its effector phospholipase-D2 and, on the luminal side, the endoglycosidase heparanase.</p><p id="Par760"><index-term id="ITerm560"><term>Src</term></index-term>The cytoplasmic protein Tyr kinase Src, which controls cell growth, proliferation, adhesion, and motility, and signal transduction induced by growth factors and integrins, stimulates the secretion of exosomes loaded with <index-term id="ITerm561"><term>Syntenin</term></index-term>syntenin and <index-term id="ITerm562"><term>Syndecan</term></index-term>syndecans [<xref ref-type="bibr" rid="CR256">469</xref>]. This regulator of exosomal communication phosphorylates syndecans and syntenin and stimulates syndecan internalization, endosomal genesis, and secretion of exosomes having promigratory activity on ECs. It operates in syndecan endocytosis and syntenin–syndecan endosomal budding upstream from the ArfGEF cytohesin-2, ARF6, and PLD2. Syntenin endosomal budding depends on interaction with phosphatidic acid, the PLD2 product [<xref ref-type="bibr" rid="CR256">469</xref>].</p><p id="Par761">Exosomes can cause <index-term id="ITerm563"><term>Pulmonary hypertension</term></index-term>pulmonary hypertension, but not microvesicles [<xref ref-type="bibr" rid="CR257">470</xref>]. Hypoxic lung-derived exosomes from patients with idiopathic pulmonary artery hypertension contain increased concentrations of <index-term id="ITerm564"><term>MicroRNA</term></index-term>miR19b, miR20a, miR20b, and miR145. On the other hand, <index-term id="ITerm565"><term>Stem cell</term></index-term>mesenchymal stem cell-derived exosomes have elevated concentrations of anti-inflammatory, antiproliferative, and antimigratory microRNAs (miR34a, miR122, miR124, and miR127),<xref ref-type="fn" rid="Fn155">155</xref> thereby preventing vascular remodeling and the development of hypoxic pulmonary hypertension. However, nonmesenchymal bone marrow stem and progenitor cells have no effect.</p><p id="Par763">Numerous microRNAs of mesenchymal stem cell-derived exosomes (e.g., miR101a, miR122, miR193, miR224, and miR302b) provoke apoptosis or suppress proliferation or migration of <index-term id="ITerm566"><term>Cancer</term></index-term>cancerous cells [<xref ref-type="bibr" rid="CR257">470</xref>].</p><p id="Par764">Adipose tissue macrophages (ATMφs) release exosomes containing <index-term id="ITerm567"><term>MicroRNA</term></index-term>microRNAs that modulate <index-term id="ITerm568"><term>Insulin</term></index-term>insulin sensitivity. MicroRNA-155 is differentially produced in ATMs in lean and obese rodents. Diet-induced obesity alters the amounts of various <index-term id="ITerm569"><term>MicroRNA</term></index-term>microRNAs in ATMφ-generated exosomes. In particular, the amount of miR155 rises. MicroRNA-155 diminishes glucose uptake and impedes insulin signaling [<xref ref-type="bibr" rid="CR258">471</xref>].</p><p id="Par765">In addition, <index-term id="ITerm570"><term>Leukotriene</term></index-term>macrophage-derived leukotriene-B<sub>4</sub>, which operates via its cognate receptor LTb<sub>4</sub>R,<xref ref-type="fn" rid="Fn156">156</xref> participates in metabolic dysfunction; it can reduce insulin signaling in hepatocytes and myocytes [<xref ref-type="bibr" rid="CR259">472</xref>]. It supports macrophage chemotaxis, elicits inflammatory phenotype in macrophages, promotes hepatic lipogenesis, decreases insulin-stimulated glucose uptake in myocytes, increases gluconeogenesis, and alters insulin-mediated suppression of glucose output in hepatocytes, as it reduces insulin-primed Gi- and JNK-dependent <index-term id="ITerm571"><term>PKB</term></index-term>PKB phosphorylation and augments <index-term id="ITerm572"><term>IRS</term></index-term>IRS1 and IRS2 phosphorylation [<xref ref-type="bibr" rid="CR259">472</xref>].</p><p id="Par767"><index-term id="ITerm573"><term>Galectin</term></index-term>Galectin-3 (GaL3), a β-galactoside-binding lectin on monocytes and macrophages, the concentration of which rises progressively during differentiation of monocytes into macrophages, is a macrophage-secreted molecule that can promote inflammation and inhibit insulin receptor. Galectin-3 serves as a chemoattractant for monocytes and macrophages. Intracellular GaL3 participates in cell migration and apoptosis. Extracellular GaL3 mediates cellular adhesion and cytokine production. Homocysteine, which is produced by methionine processing, stimulates activity of the GaL3 inducer, NFκB. Galectin-3 contributes to macrophage activation, especially in atherosclerotic plaques [<xref ref-type="bibr" rid="CR260">473</xref>]. Hyperhomocysteinemia is observed in patients with unstable CoAD. In monocytes, it participates in the production of superoxide and cooperates with ROS in exosome formation. Galectin-3 is thus involved in inflammation, redox stress, and cardiac fibrosis.</p><p id="Par768">ATMφ-derived TSG101+ ,<xref ref-type="fn" rid="Fn157">157</xref> syntenin-1+ ,<xref ref-type="fn" rid="Fn158">158</xref> TSpan29+ , and TSpan30+ exosomes are taken up by adipocytes, hepatocytes, and skeletal myocytes, the major insulin target cells [<xref ref-type="bibr" rid="CR258">471</xref>]. In particular, neighboring adipocytes take up exosomes containing myeloid cell-specific microRNAs. MicroRNA-155 contributes to insulin resistance in obesity. MicroRNA-155 released by proinflammatory macrophages targets the ligand-activated transcription factor, nuclear receptor <index-term id="ITerm574"><term>PPAR (NR1c1/2/3)</term></index-term>NR1c3 (PPARγ) [<xref ref-type="bibr" rid="CR258">471</xref>]. However, other exosomal microRNAs contribute to the modulation of insulin sensitivity. ATMφ-derived exosomal miRs from obese mice impair cellular insulin sensitivity. On the other hand, ATMφ-derived exosomal miRs from lean mice attenuate obesity-induced insulin resistance. Lean mice receiving ATMφ-derived exosomes from obese mice develop glucose intolerance and <index-term id="ITerm575"><term>Insulin resistance</term></index-term>insulin resistance. Conversely, in obese mice, injection of ATMφ-engendered exosomes from lean mice normalizes insulin signaling.</p><p id="Par771">Exosomes mediate intercellular communication among <index-term id="ITerm576"><term>Cancer</term></index-term>tumoral cells and between them and their surrounding stroma. Sunitinib-resistant renal carcinoma cells<xref ref-type="fn" rid="Fn159">159</xref> transfer the <index-term id="ITerm577"><term>lncarsr</term></index-term>long nonprotein-coding RNA activated in renal cell carcinoma with sunitinib resistance (lncarsr) to sensitive cells via exosomes. Lncarsr competitively connects to tumor-suppressive microRNAs miR34 and miR449 and raises amounts of receptor protein Tyr kinases <index-term id="ITerm578"><term>Axl (RTK)</term></index-term>Axl and <index-term id="ITerm579"><term>HGFR</term></index-term>hepatocyte growth factor receptor in recipient cells [<xref ref-type="bibr" rid="CR262">475</xref>]. Lncarsr packaging into exosomes involved the ribonucleoprotein hnRNPa2b1. Inhibitors of both Axl and HGFR resensitize lncarsr+ cells to sunitinib.</p></sec><sec id="Sec56"><title>Microvesicles</title><p id="Par773"><index-term id="ITerm580"><term>Microvesicle</term></index-term>Plasmatic concentration of endothelial microvesicles is a marker of <index-term id="ITerm581"><term>Endothelial dysfunction</term></index-term>endothelial dysfunction. Plasmatic concentration of <index-term id="ITerm582"><term>Platelet</term></index-term>platelet and leukocyte microparticles rises in <index-term id="ITerm583"><term>Heart failure</term></index-term>HF and cardiac valvulopathies [<xref ref-type="bibr" rid="CR249">462</xref>].</p><p id="Par774">Phosphatidylserine+ microvesicles of different cellular origin bind to the platelet <index-term id="ITerm584"><term>ScaR</term></index-term>scavenger receptor ScaRb3 and increase ADP-dependent platelet activation, thereby facilitating <index-term id="ITerm585"><term>Thrombosis</term></index-term>thrombosis. On the other hand, phosphatidylserine of endothelial microvesicles can interact with endothelial phosphatidylserine receptor in an annexin-1-dependent manner to prevent apoptosis [<xref ref-type="bibr" rid="CR249">462</xref>]. Lactadherin<xref ref-type="fn" rid="Fn160">160</xref> allows the clearance of circulating PSer+ microvesicles by <index-term id="ITerm586"><term>Macrophage</term></index-term>macrophages in the spleen and liver.</p><p id="Par776">Microvesicles contain <index-term id="ITerm587"><term>MMP</term></index-term> MMP2, MMP3, MMP7, and MMP13, which can assist crossing of the extracellular matrix to reach target neighboring cells (mainly) or blood circulation [<xref ref-type="bibr" rid="CR249">462</xref>].<xref ref-type="fn" rid="Fn161">161</xref> Microvesicles derived from <index-term id="ITerm588"><term>atherosclerosis</term></index-term>atherosclerotic plaques possess the <index-term id="ITerm589"><term>adam</term></index-term>adamalysin ADAM17. Microvesicles can also engender <index-term id="ITerm590"><term>ROS</term></index-term>ROS production.</p><p id="Par778"><index-term id="ITerm591"><term>Senescence</term></index-term>Exposure of ECs to microvesicles shed from senescent ECs or circulating endothelial microvesicles from ACS patients provokes premature aging, elevated β-galactosidase activity, redox stress, abnormal phosphorylation of <index-term id="ITerm592"><term>MAPK</term></index-term>MAPK and <index-term id="ITerm593"><term>PKB</term></index-term>PKB, and upregulation of P53, CKI1a, and CKI2a [<xref ref-type="bibr" rid="CR263">476</xref>]. Endotheliocyte senescence is associated with a progressive shedding of procoagulant microvesicles, augmented tissue factor activity, attenuated NOS3 activity and hence NO-mediated inhibition of platelet aggregation. These microvesicles are endowed with an angiotensin convertase activity and AT<sub>1</sub> receptors. Inhibitors of AT<sub>1</sub>, MAPK, or PKB prevent microvesicle-primed endothelial senescence. Premature endothelial senescence and thrombogenicity result from angiotensin-2-induced redox-sensitive activation of the MAPK module and <index-term id="ITerm594"><term>PKB</term></index-term>PKB.</p></sec></sec><sec id="Sec57"><title>Genomic Loci and Variants</title><p id="Par779">New markers can be found from reproducible variants in genes, RNAs, and metabolites associated with the investigated disease. Current technology allows the examination of hundreds to thousands of <index-term id="ITerm595"><term>Single-nucleotide polymorphism</term></index-term>single-nucleotide polymorphisms to search for significant associations with any disease (Chap. <ext-link xlink:href="10.1007/978-3-319-89315-0_7" ext-link-type="doi">7</ext-link>).</p><p id="Par780">For example, a locus on chromosome 9p21 that does not contain genes linked to established CoAD risk factors, but near genes encoding cyclin-dependent kinase inhibitors CKI2a and CKI2b implicated in cellular <index-term id="ITerm596"><term>Senescence</term></index-term>senescence and apoptosis, is associated with the early onset of myocardial infarction [<xref ref-type="bibr" rid="CR222">435</xref>].</p></sec></sec><sec id="Sec58"><title>Prognosis</title><p id="Par781">Prognosis<xref ref-type="fn" rid="Fn162">162</xref> predicting the likely outcome of a disease, upon treatment or not. In addition, appropriate use of markers can optimize treatment [<xref ref-type="bibr" rid="CR264">477</xref>]. Prognostic indicators and estimators can be used to assess the disease evolution.</p><sec id="Sec59"><title>Renin</title><p id="Par783"><index-term id="ITerm597"><term>Renin</term></index-term>Reninemia (blood [plasmatic] concentration of renin) is inversely related to oral sodium intake. Reninemia can serve as a prognostic index for the cardiovascular event risk, independently of the blood pressure value [<xref ref-type="bibr" rid="CR265">478</xref>].</p></sec><sec id="Sec60"><title>IL1RL1 (ST2 Marker of Cardiac Stress)</title><p id="Par784"><index-term id="ITerm598"><term>IL receptor</term></index-term>Membrane-bound receptor <sub>m</sub>IL1RL1<xref ref-type="fn" rid="Fn163">163</xref> also exists as a soluble truncated form (<inline-formula id="IEq2"><alternatives><mml:math id="IEq2_Math"><mml:msubsup><mml:mrow/><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:msubsup></mml:math><tex-math id="IEq2_TeX">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}
$${ }_{\mathrm {t}}^{\mathrm {S}}$$
\end{document}</tex-math><inline-graphic specific-use="web" mime-subtype="GIF" xlink:href="460479_1_En_2_Chapter_IEq2.gif"/></alternatives></inline-formula>IL1RL1 or ST2), which is secreted into the bloodstream. The messenger RNA of IL33 is markedly upregulated in cultured <index-term id="ITerm599"><term>CMC</term></index-term>CMCs exposed to <index-term id="ITerm600"><term>Hypertension</term></index-term>hypertension. Binding of IL33 to IL1RL1 ensures cardioprotection. However, IL33 connects competitively to <inline-formula id="IEq3"><alternatives><mml:math id="IEq3_Math"><mml:msubsup><mml:mrow/><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:msubsup></mml:math><tex-math id="IEq3_TeX">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}
$${ }_{\mathrm {t}}^{\mathrm {S}}$$
\end{document}</tex-math><inline-graphic specific-use="web" mime-subtype="GIF" xlink:href="460479_1_En_2_Chapter_IEq3.gif"/></alternatives></inline-formula>IL1RL1 and is then unavailable for its IL1RL1 receptor, hence functioning as a decoy receptor for the IL33 cytokine. The soluble truncated IL1RL1 can be used to estimate the severity of adverse cardiac remodeling; elevated blood concentration in <inline-formula id="IEq4"><alternatives><mml:math id="IEq4_Math"><mml:msubsup><mml:mrow/><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi></mml:mrow></mml:msubsup></mml:math><tex-math id="IEq4_TeX">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym}
				\usepackage{amsfonts}
				\usepackage{amssymb}
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}
$${ }_{\mathrm {t}}^{\mathrm {S}}$$
\end{document}</tex-math><inline-graphic specific-use="web" mime-subtype="GIF" xlink:href="460479_1_En_2_Chapter_IEq4.gif"/></alternatives></inline-formula>IL1RL1 can then predict outcomes in <index-term id="ITerm601"><term>Heart failure</term></index-term>HF patients [<xref ref-type="bibr" rid="CR266">479</xref>, <xref ref-type="bibr" rid="CR267">480</xref>].</p></sec><sec id="Sec61"><title>S100</title><p id="Par786"><index-term id="ITerm602"><term>S100</term></index-term>The secreted calcium-binding protein S100a9<xref ref-type="fn" rid="Fn164">164</xref> is a discriminator between stable and unstable CoAD. Other proteins can be targeted using nuclear magnetic resonance spectroscopy and tandem mass spectrometry coupled with chromatography, but generally their amounts are low, as they are within nanomolar (e.g., troponin), picomolar (e.g., insulin), or femtomolar (e.g., tumor-necrosis factor) ranges [<xref ref-type="bibr" rid="CR222">435</xref>].</p></sec><sec id="Sec62"><title>Quinones</title><p id="Par788"><index-term id="ITerm603"><term>Quinone</term></index-term>Quinones are metabolic intermediates of several endogenous and dietary molecules that can form stable adducts with DNA and proteins, which can be toxic products. The most common quinones are derivatives of hormones and neurotransmitters, such as catecholamines (adrenaline, noradrenaline, and dopamine). Others are produced in the human organism from tea catechins and other vegetable-derived flavonoids (with anti-inflammatory, -oxidant, and -carcinogenic effects) in addition to environmental pollutants such as pesticides. Molecular sources share a catechol (1,2)-dihydroxy benzene group that is generally metabolized to a quinone moiety. Moreover, quinones can also be generated during <index-term id="ITerm604"><term>Redox stress</term></index-term>redox stress, as they can be produced from catechol-containing molecules by reaction with free radicals and other reactive species.</p><p id="Par789">Quinones are involved in the onset of several pathological conditions. Systematic analysis of the reactivity of quinone derivatives with amino acids and DNA bases based on computational chemistry techniques is aimed at addressing the formation and stability of quinone adducts to predict the most reactive quinones and their adducts with biological and pathophysiological relevance. Computational results can then be used to guide experiments to validate the identification of reliable markers in the early detection and prognosis evaluation of pathological conditions.</p></sec><sec id="Sec63"><title>Rock</title><p id="Par790"><index-term id="ITerm605"><term>Rock</term></index-term>Two isoforms of rock kinases (rock1–rock2) are effectors of small GTPases of the RHOA subfamily that have different functions in the vascular circuit. Hence, rock is an effector of the small RhoA, RhoB, and RhoC GTPases [<xref ref-type="bibr" rid="CR268">481</xref>].</p><p id="Par791">The RhoA–rock pathway is implicated in cell contraction (and hence vasospasm and systemic and pulmonary <index-term id="ITerm606"><term>Hypertension</term></index-term>hypertension), motility, proliferation, and apoptosis.</p><p id="Par792">Its major substrates include PP1<sub>r12a</sub> (Thr697, Ser854, and Thr855, attenuating MLCP activity), PP1<sub>r14a</sub> (at Thr38), MLC2, LIMKs (LIMK1–LIMK2, which phosphorylate [inhibit] cofilin, hence impeding actin depolymerization), the plasma membrane–actin filament crosslinkers ezrin, radixin, and moesin (phosphorylated in response to vasoconstrictors signaling via PKC and rock), and adducin. These substrates are also phosphorylated by MLCK, PKA, PKC, and PKG [<xref ref-type="bibr" rid="CR269">482</xref>].</p><p id="Par793">The kinase rock participates in organizing the actin cytoskeleton and controlling its dynamics and hence stress fiber formation, using the contraction-mediating rock–PP1<sub>r12a</sub>–MLC and actin-stabilizing rock–LIMK–cofilin pathways. It is thus involved in cell contraction, adhesion, migration, proliferation, and apoptosis, in addition to remodeling of the extracellular matrix. Its activity is modulated by interaction with lipid mediators (e.g., arachidonic acid and sphingosylphosphorylcholine), mechanical stress, autophosphorylation, and proteolytic cleavage of its inhibitory C-terminus.</p><p id="Par794">Because rock stabilizes PTen, the RhoA–rock–PTen pathway antagonizes the PI3K–PKB pathway. Rock also phosphorylates IRS1 and IRS2, thereby improving or impairing <index-term id="ITerm607"><term>Insulin</term></index-term>insulin signaling according to the context.</p><p id="Par795">Its ubiquitous isoforms, rock1 and rock2, are functionally redundant. They both homodimerize. The autoinhibitory domain obviates constitutive activation; activation by Rho<sup>GTP</sup> thus relies on derepression. Rock activity does not depend on autophosphorylation. Full catalytic rock2 activity relies on several phosphorylation sites (PLK1 targets Thr967, Ser1099, Ser1133, and Ser1374).</p><p id="Par796">Cytosolic ubiquitous rock1 is linked to the plasma membrane, centrosome, cellular adhesion sites, and vesicles [<xref ref-type="bibr" rid="CR268">481</xref>]. Cytosolic and nuclear rock2, which abounds in the brain, heart, muscle, lung, and placenta, localizes to the centrosome and colocalizes with actin and vimentin filaments, in addition to the intercalated and Z discs of striated myocytes. In the myocardium and skeletal muscles, a unique rock2 splice variant exists (<sup>SkM</sup>rock2) [<xref ref-type="bibr" rid="CR268">481</xref>]. Both rock1 and rock2 are cleaved and activated by peptidases.</p><p id="Par797">Only rock2 binds directly to and phosphorylates PP1<sub>r12a</sub> [<xref ref-type="bibr" rid="CR269">482</xref>]. In addition, rock2 tethers to PIP<sub>3</sub> and PI(4,5)P<sub>2</sub>, but not rock1 [<xref ref-type="bibr" rid="CR268">481</xref>]. Rock1, but not rock2, phosphorylates RhoE, a rock-specific substrate [<xref ref-type="bibr" rid="CR268">481</xref>].</p><p id="Par798">In the vasculature, The RhoA–rock pathway is implicated in vasoconstriction, using the rock–PP1<sub>r12a</sub>–MLC2 pathway, and inflammatory cell recruitment, in addition to endothelial dysfunction and vascular and cardiac remodeling [<xref ref-type="bibr" rid="CR269">482</xref>]. It is involved in vascular effects of redox stress (ROS production by NOxs) and various vasoconstrictors, in particular the renin–angiotensin–aldosterone axis, and hence hypertension.</p><p id="Par799">The rock is also involved in transcriptional regulation, especially in <index-term id="ITerm608"><term>SRF</term></index-term>SRF activity [<xref ref-type="bibr" rid="CR269">482</xref>]. <index-term id="ITerm609"><term>Myocardin</term></index-term>Myocardin and <index-term id="ITerm610"><term>MRTF</term></index-term>myocardin-related transcription factors MRTFa and MRTFb are SRF coactivators, the nuclear translocation of which depends on actin dynamics. It can thus regulate MRTFa-mediated myofibroblast activation in <index-term id="ITerm611"><term>Cardiac fibrosis</term></index-term>cardiac fibrosis.</p><p id="Par800">In addition, rock mediates CMC hypertrophy caused by angiotensin-2, endothelin-1, and α-adrenoceptor [<xref ref-type="bibr" rid="CR269">482</xref>]. In fact, rock1 and rock2 operates in cardiac fibrosis and hypertrophy, respectively [<xref ref-type="bibr" rid="CR268">481</xref>].</p><p id="Par801">The rock also favors inflammation, as it can induce expression of proinflammatory cytokines and adhesion molecules in endothelial and smooth muscle cells. It stimulates several molecules involved in <index-term id="ITerm612"><term>Inflammation</term></index-term>inflammation, <index-term id="ITerm613"><term>Fibrosis</term></index-term>fibrosis, and <index-term id="ITerm614"><term>Thrombosis</term></index-term>thrombosis. Activity of the rock in circulating leukocytes serves as a marker for the assessment of disease severity and therapeutic response [<xref ref-type="bibr" rid="CR270">483</xref>].</p><p id="Par802">Myosin light chain (MLC) is phosphorylated by Ca<sup>2+</sup>–Cam-activated MLC kinase (MLCK) and is dephosphorylated by MLC phosphatase (MLCP),<xref ref-type="fn" rid="Fn165">165</xref> hence causing <index-term id="ITerm615"><term>vSMC</term></index-term>vSMC contraction and relaxation, respectively. In vascular smooth myocytes, the RhoA–rock axis leads to MLC phosphorylation directly and via PP1<sub>r12a</sub> inhibition. The substrates of rock include not only MLC and MLCP, but also the members of the ERM (ezrin–radixin–moesin) family, adducin, PTen phosphatase, and LIM kinases [<xref ref-type="bibr" rid="CR270">483</xref>].</p><p id="Par804">The vascular effect of the rock is augmented by <index-term id="ITerm616"><term>Mechanical stress</term></index-term>mechanical stress, <index-term id="ITerm617"><term>Hypoxia</term></index-term>hypoxia, growth factors (e.g., PDGF), and some vasoactive agents (e.g., angiotensin-2, thrombin, thromboxanes, extracellular nucleotides, and urotensin) [<xref ref-type="bibr" rid="CR270">483</xref>]. The rock upregulates <index-term id="ITerm618"><term>NOx</term></index-term>NADPH oxidase expression.</p><p id="Par805">The rock participates in interactions between vascular <index-term id="ITerm619"><term>EC</term></index-term>endothelial and <index-term id="ITerm620"><term>vSMC</term></index-term>vSMCs. Endotheliocytes release vasodilators, such as NO and prostacyclin, and endothelium-derived hyperpolarizing factors such as hydrogen peroxide. <index-term id="ITerm621"><term>Hydrogen peroxide</term></index-term>Hydrogen peroxide transmitted through myoendothelial junctions rapidly cause <index-term id="ITerm622"><term>Vasodilation</term></index-term>vasodilation via PGhS (cyclooxygenase), cAMP, and the cGMP–PKG1α–K<sub>Ca</sub> pathway (vSMC membrane hyperpolarization) [<xref ref-type="bibr" rid="CR270">483</xref>].</p><p id="Par806">In ECs, the RhoA–rock axis prevents <index-term id="ITerm623"><term>Nitric oxide</term></index-term>nitric oxide synthesis. It also supports actin–myosin contractility, hence disrupting the endothelial barrier and raising endothelial permeability.</p><p id="Par807">In addition, activated rock enhances transcriptional regulation of <index-term id="ITerm624"><term>SRF</term></index-term>SRF, provoking <index-term id="ITerm625"><term>Stress fiber</term></index-term>stress fiber formation and vSMC contraction. It also mediates vSMC contraction elicited by vasoconstrictory GPCR ligands sent by ECs.</p><p id="Par808"><index-term id="ITerm626"><term>Cyclophilin</term></index-term>Cyclophilin-A mediates <index-term id="ITerm627"><term>Redox stress</term></index-term>redox stress. Reactive oxygen species and the RhoA–rock axis promote cyclophilin-A secretion via VAMP2+ <xref ref-type="fn" rid="Fn166">166</xref> vesicle formation and actin–myosin-2 cytoskeletal dynamics [<xref ref-type="bibr" rid="CR270">483</xref>].</p><p id="Par810">In ECs, released cyclophilin-A decreases <index-term id="ITerm628"><term>NOS</term></index-term>NOS3 activity. In addition, it stimulates expression of E-selectin and vcam1 on vECs. It is also a chemoattractant for inflammatory leukocytes and activates MMPs.</p><p id="Par811">In vascular smooth myocytes, extracellular cyclophilin-A activates <index-term id="ITerm629"><term>ERK</term></index-term>ERK1, ERK2, <index-term id="ITerm630"><term>PKB</term></index-term>PKB, and <index-term id="ITerm631"><term>JaK</term></index-term>JaK, contributing to <index-term id="ITerm632"><term>ROS</term></index-term>ROS production. Reactive oxygen species foster vSMC proliferation in an auto- and paracrine manner.</p><p id="Par812">The rock is active not only in vascular cells, but also in leukocytes. It inhibits reverse cholesterol transport in macrophages, thereby promoting foam cell formation [<xref ref-type="bibr" rid="CR271">484</xref>].</p><p id="Par813">Extracellular cyclophilin-A also activates <index-term id="ITerm633"><term>Platelet</term></index-term>platelets via basigin and the <index-term id="ITerm634"><term>PKB</term></index-term>PI3K–PKB axis, enhancing their adhesion and <index-term id="ITerm635"><term>Thrombus</term></index-term>thrombus formation.</p><p id="Par814">Platelets are not only involved in hemostasis but also in inflammation and immunity. Platelet activation results from signaling initiated and then amplified by plasmalemmal receptors and involves re-organization of the actin cytoskeleton for the secretion of granule content, adhesion, spreading, aggregation, and blood clot retraction, and hence monomeric GTPases of the RHO superfamily (RhoA, Rac1, and CDC42). RhoA is implicated in platelet contractility and thrombus stability, Rac1 in lamellipodium formation, and CDC42 in filopodium formation and granule secretion [<xref ref-type="bibr" rid="CR271">484</xref>].</p><p id="Par815">Platelet activators such as thrombin connect to their cognate GPCRs and launch RhoA–rock2 signaling. In addition, RhoA and Rock2 regulate platelet formation from megakaryocytes, albeit to a considerably lesser extent than Rac1 and CDC42 [<xref ref-type="bibr" rid="CR271">484</xref>].</p><p id="Par816">Rock2 operates in platelet activation and thrombosis. It promotes α<sub>2B</sub>β<sub>3</sub>-integrin binding to fibrinogen and expression of P-selectin, which elicits hetero- (platelet–leukocyte) and homotypic aggregates [<xref ref-type="bibr" rid="CR272">485</xref>]. Rock2 does not influence expression of plasmalemmal receptors, but their activation and function, as binding of fibrinogen to α<sub>2B</sub>β<sub>3</sub>Itg relies on its structural changes to bind to fibrinogen. Rock2 is necessary for initial activation of α<sub>2B</sub>β<sub>3</sub>Itg, but not for the maintenance of of activation. α-Granules contain P-selectin. Upon platelet activation, P-selectin lodges on the plasma membrane. Rock2 is necessary for the initial release of granules at low thrombin concentration, but not for release maintenance at a higher thrombin concentration.</p><p id="Par817">Rock2 influences blood clot formation, but not its growth. In platelets, rock2 may also regulate rock1 concentration. Rock2 deficiency does indeed mildly reduce rock1 concentration [<xref ref-type="bibr" rid="CR272">485</xref>].</p><p id="Par818">Coronary microvascular resistance is controlled by numerous myogenic, metabolic, neurohumoral, and endothelium-derived factors to adjust myocardial nutrient oxygen delivery to its metabolism. Microvascular dysfunction is generally characterized by the decreased production of vasodilators (NO, hydrogen peroxide, prostacyclin, and endothelium-derived hyperpolarizing factors) and increased formation of vasoconstrictors (endothelin, thromboxane-A2, and superoxide). Adverse remodeling and hypoperfusion perpetuate cardiac dysfunction. Activation of the RhoA–rock axis and redox stress in different cardiac cell types alters cardiac function either directly via hypertrophy and fibrosis or indirectly via hypoperfusion, that is, whether abnormal activation of the RhoA–rock axis and redox stress occur in cardiac myocytes and fibroblasts or in arteriolar endothelial and smooth muscle cells [<xref ref-type="bibr" rid="CR273">486</xref>].</p><p id="Par819">Hypertensive cardiac hypertrophy is associated with reduced coronary flow reserve. In hypertension, rock1 and rock2 cause NO deficiency, augment ET activity, and increase superoxide production, thereby provoking redox stress and contributing to coronary arteriolar dysfunction, that is, the inability to increase blood flow in response to metabolic stimulation. Myocardial and microvascular redox stress, elevated vasoconstriction, perivascular fibrosis, and CMC hypertrophy are attenuated by rock inhibition [<xref ref-type="bibr" rid="CR274">487</xref>]. Expression of both rock isoforms is significantly upregulated in the coronary arterioles of hypertensive mice. In mice, deletion of rock1 reduces fibrogenesis, but not ventricular hypertrophy, although it improves cardiac contractility. On the other hand, rock2 deletion reduces cardiac cell apoptosis and ventricular fibrosis and hypertrophy. In addition, rock inhibition improves aortic endothelial and cardiac function in rat models of streptozotocin-induced diabetes [<xref ref-type="bibr" rid="CR273">486</xref>].</p></sec></sec></sec></body><back><ref-list id="Bib1" specific-use="web-only"><title>References</title><ref-list><ref id="CR1"><label>30.</label><mixed-citation publication-type="other">Mendis S, Puska P, Norrving B (Eds) (2011) Global atlas on cardiovascular disease prevention and control. Policies, strategies and interventions. World Health Organization in collaboration with the World Heart Federation and World Stroke Organization, Geneva</mixed-citation></ref><ref id="CR2"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rawshani</surname><given-names>A</given-names></name><name><surname>Rawshani</surname><given-names>A</given-names></name><name><surname>Franzén</surname><given-names>S</given-names></name><name><surname>Eliasson</surname><given-names>B</given-names></name><name><surname>Svensson</surname><given-names>AM</given-names></name><name><surname>Miftaraj</surname><given-names>M</given-names></name><name><surname>McGuire</surname><given-names>DK</given-names></name><name><surname>Sattar</surname><given-names>N</given-names></name><name><surname>Rosengren</surname><given-names>A</given-names></name><name><surname>Gudbjörnsdottir</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Range of risk factor levels. Control, mortality, and cardiovascular outcomes in type 1 diabetes mellitus</article-title><source>Circulation</source><year>2017</year><volume>135</volume><fpage>1522</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.025961</pub-id></mixed-citation></ref><ref id="CR3"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Touyz</surname><given-names>RM</given-names></name><name><surname>Anagnostopoulou</surname><given-names>A</given-names></name><name><surname>de Lucca</surname><given-names>Camargo L</given-names></name><name><surname>Montezano</surname><given-names>AC</given-names></name></person-group><article-title xml:lang="en">Novel biosensors reveal a shift in the redox paradigm from oxidative to reductive stress in heart disease</article-title><source>Circ Res</source><year>2016</year><volume>119</volume><fpage>969</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309854</pub-id></mixed-citation></ref><ref id="CR4"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cervantes Gracia</surname><given-names>K</given-names></name><name><surname>Llanas-Cornejo</surname><given-names>D</given-names></name><name><surname>Husi</surname><given-names>H</given-names></name></person-group><article-title xml:lang="en">CVD and oxidative stress</article-title><source>J Clin Med</source><year>2017</year><volume>6</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.3390/jcm6020022</pub-id></mixed-citation></ref><ref id="CR5"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>E</given-names></name><name><surname>Karimi Galougahi</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>CC</given-names></name><name><surname>Bhindi</surname><given-names>R</given-names></name><name><surname>Figtree</surname><given-names>GA</given-names></name></person-group><article-title xml:lang="en">Biological markers of oxidative stress: applications to cardiovascular research and practice</article-title><source>Redox Biol</source><year>2013</year><volume>1</volume><fpage>483</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1016/j.redox.2013.07.006</pub-id></mixed-citation></ref><ref id="CR6"><label>107.</label><mixed-citation publication-type="other">Hoffmann R, Valencia A (2004) A gene network for navigating the literature. Nat Genet 36:664. (Information Hyperlinked over Proteins (<ext-link xlink:href="http://www.ihop-net.org" ext-link-type="uri">www.ihop-net.org</ext-link>)</mixed-citation></ref><ref id="CR7"><label>108.</label><mixed-citation publication-type="other">Universal Protein Resource (UniProt) Consortium (2002–2016) European Bioinformatics Institute, Swiss Institute of Bioinformatics, and Protein Information Resource (<ext-link xlink:href="http://www.uniprot.org" ext-link-type="uri">www.uniprot.org</ext-link>)</mixed-citation></ref><ref id="CR8"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>P</given-names></name><name><surname>Leong</surname><given-names>D</given-names></name><name><surname>McKee</surname><given-names>M</given-names></name><name><surname>Anand</surname><given-names>SS</given-names></name><name><surname>Schwalm</surname><given-names>JD</given-names></name><name><surname>Teo</surname><given-names>K</given-names></name><name><surname>Mente</surname><given-names>A</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Reducing the global burden of cardiovascular disease. I. the epidemiology and risk factors</article-title><source>Circ Res</source><year>2017</year><volume>121</volume><fpage>677</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.308903</pub-id></mixed-citation></ref><ref id="CR9"><label>167.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuhashi</surname><given-names>M</given-names></name><name><surname>Saitoh</surname><given-names>S</given-names></name><name><surname>Shimamoto</surname><given-names>K</given-names></name><name><surname>Miura</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases</article-title><source>Clin Med Insights Cardiol</source><year>2014</year><volume>8</volume><fpage>23</fpage><lpage>33</lpage></mixed-citation></ref><ref id="CR10"><label>194.</label><mixed-citation publication-type="other">Online Mendelian Inheritance in Man—An Online Catalog of Human Genes and Genetic Disorders (1966–2016) McKusick–Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine (<ext-link xlink:href="http://www.omim.org" ext-link-type="uri">www.omim.org</ext-link>)</mixed-citation></ref><ref id="CR11"><label>223.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>de Lubac</surname><given-names>H</given-names></name></person-group><source>Paradoxes, Œuvres Complètes, [Paradoxes, Complete Works] vol XXX1</source><year>1999</year><publisher-loc>Paris</publisher-loc><publisher-name>CERF</publisher-name></mixed-citation></ref><ref id="CR12"><label>224.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lloyd-Jones</surname><given-names>DM</given-names></name></person-group><article-title xml:lang="en">Cardiovascular health and protection against CVD. More than the sum of the parts?</article-title><source>Circulation</source><year>2014</year><volume>130</volume><fpage>1671</fpage><lpage>1673</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.012869</pub-id></mixed-citation></ref><ref id="CR13"><label>225.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ference</surname><given-names>BA</given-names></name><name><surname>Ginsberg</surname><given-names>HN</given-names></name><name><surname>Kausik</surname><given-names>IG</given-names></name><name><surname>Chris</surname><given-names>KR</given-names></name><name><surname>Bruckert</surname><given-names>JPE</given-names></name><name><surname>Hegele</surname><given-names>RA</given-names></name><name><surname>Krauss</surname><given-names>RM</given-names></name><name><surname>Raal</surname><given-names>FJ</given-names></name><name><surname>Schunkert</surname><given-names>H</given-names></name><name><surname>Watts</surname><given-names>GF</given-names></name><name><surname>Borén</surname><given-names>J</given-names></name><name><surname>Fazio</surname><given-names>S</given-names></name><name><surname>Horton</surname><given-names>JD</given-names></name><name><surname>Masana</surname><given-names>L</given-names></name><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name><name><surname>van de Sluis</surname><given-names>B</given-names></name><name><surname>Taskinen</surname><given-names>MR</given-names></name><name><surname>Tokgözoğlu</surname><given-names>L</given-names></name><name><surname>Landmesser</surname><given-names>U</given-names></name><name><surname>Laufs</surname><given-names>U</given-names></name><name><surname>Wiklund</surname><given-names>O</given-names></name><name><surname>Stock</surname><given-names>JK</given-names></name><name><surname>Chapman</surname><given-names>MJ</given-names></name><name><surname>Catapano</surname><given-names>AL</given-names></name></person-group><article-title xml:lang="en">Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><fpage>2459</fpage><lpage>2472</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx144</pub-id></mixed-citation></ref><ref id="CR14"><label>226.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Pasternak</surname><given-names>R</given-names></name><name><surname>Greenland</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name></person-group><article-title xml:lang="en">Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology</article-title><source>Circulation</source><year>1999</year><volume>100</volume><fpage>1481</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.100.13.1481</pub-id></mixed-citation></ref><ref id="CR15"><label>227.</label><mixed-citation publication-type="other">Vidal-Petiot E, Stebbins A, Chiswell K, Ardissino D, Aylward PE, Cannon CP, Ramos Corrales MA, Held C, López-Sendón JL, Stewart RAH, Wallentin L, White HD, Steg PG: STABILITY Investigators (2017) Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. Eur Heart J 38:2813–2822</mixed-citation></ref><ref id="CR16"><label>228.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>MA</given-names></name></person-group><article-title xml:lang="en">Blood pressure variability and cardiovascular prognosis: implications for clinical practice</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><fpage>2823</fpage><lpage>2826</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx322</pub-id></mixed-citation></ref><ref id="CR17"><label>229.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambale-Venkatesh</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>CO</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Hundley</surname><given-names>WG</given-names></name><name><surname>McClelland</surname><given-names>R</given-names></name><name><surname>Gomes</surname><given-names>AS</given-names></name><name><surname>Folsom</surname><given-names>AR</given-names></name><name><surname>Shea</surname><given-names>S</given-names></name><name><surname>Guallar</surname><given-names>E</given-names></name><name><surname>Bluemke</surname><given-names>DA</given-names></name><name><surname>Lima</surname><given-names>JAC</given-names></name></person-group><article-title xml:lang="en">Cardiovascular event prediction by machine learning. The multi-ethnic study of atherosclerosis</article-title><source>Circ Res</source><year>2017</year><volume>121</volume><fpage>1092</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.311312</pub-id></mixed-citation></ref><ref id="CR18"><label>230.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boehme</surname><given-names>AK</given-names></name><name><surname>Esenwa</surname><given-names>C</given-names></name><name><surname>Elkind</surname><given-names>MSV</given-names></name></person-group><article-title xml:lang="en">Stroke risk factors, genetics, and prevention</article-title><source>Circ Res</source><year>2017</year><volume>120</volume><fpage>472</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.308398</pub-id></mixed-citation></ref><ref id="CR19"><label>231.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>DPJ</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Fairhead</surname><given-names>JF</given-names></name><name><surname>Hands</surname><given-names>L</given-names></name><name><surname>Silver</surname><given-names>LE</given-names></name><name><surname>Rothwell</surname><given-names>PM</given-names></name><collab>on behalf of the Oxford Vascular Study</collab></person-group><article-title xml:lang="en">Population-based study of incidence, risk factors, outcome, and prognosis of ischemic peripheral arterial events</article-title><source>Implications for prevention. Circulation</source><year>2015</year><volume>132</volume><fpage>1805</fpage><lpage>1815</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.016424</pub-id></mixed-citation></ref><ref id="CR20"><label>232.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chasman</surname><given-names>DI</given-names></name><name><surname>Lawler</surname><given-names>PR</given-names></name></person-group><article-title xml:lang="en">Understanding AAA pathobiology. A GWAS leads the way</article-title><source>Circ Res</source><year>2017</year><volume>120</volume><fpage>259</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.310395</pub-id></mixed-citation></ref><ref id="CR21"><label>233.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seidah</surname><given-names>NG</given-names></name><name><surname>Abifadel</surname><given-names>M</given-names></name><name><surname>Prost</surname><given-names>S</given-names></name><name><surname>Boileau</surname><given-names>C</given-names></name><name><surname>Prat</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin/kexin 9</article-title><source>Pharmacol Rev</source><year>2017</year><volume>69</volume><fpage>33</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1124/pr.116.012989</pub-id></mixed-citation></ref><ref id="CR22"><label>234.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leander</surname><given-names>K</given-names></name><name><surname>Mälarstig</surname><given-names>A</given-names></name><name><surname>Van’t Hooft</surname><given-names>FM</given-names></name><name><surname>Hyde</surname><given-names>C</given-names></name><name><surname>Hellénius</surname><given-names>ML</given-names></name><name><surname>Troutt</surname><given-names>JS</given-names></name><name><surname>Konrad</surname><given-names>RJ</given-names></name><name><surname>Öhrvik</surname><given-names>J</given-names></name><name><surname>Hamsten</surname><given-names>A</given-names></name><name><surname>de Faire</surname><given-names>U</given-names></name></person-group><article-title xml:lang="en">Circulating PCSK9 predicts future risk of cardiovascular events independently of established risk factors</article-title><source>Circulation</source><year>2016</year><volume>133</volume><fpage>1230</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.018531</pub-id></mixed-citation></ref><ref id="CR23"><label>235.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xanthakis</surname><given-names>V</given-names></name><name><surname>Enserro</surname><given-names>DM</given-names></name><name><surname>Murabito</surname><given-names>JM</given-names></name><name><surname>Polak</surname><given-names>JF</given-names></name><name><surname>Wollert</surname><given-names>KC</given-names></name><name><surname>Januzzi</surname><given-names>JL</given-names></name><name><surname>Wang</surname><given-names>TJ</given-names></name><name><surname>Tofler</surname><given-names>G</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name></person-group><article-title xml:lang="en">Ideal cardiovascular health: associations with biomarkers and subclinical disease, and impact on incidence of cardiovascular disease in the Framingham offspring study</article-title><source>Circulation</source><year>2014</year><volume>130</volume><fpage>1676</fpage><lpage>1683</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.009273</pub-id></mixed-citation></ref><ref id="CR24"><label>236.</label><mixed-citation publication-type="other">Wei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, Groshen S, Mack WJ, Guen E, Di Biase S, Cohen P, Morgan TE, Dorff T, Hong K, Michalsen A, Laviano A, Longo VD (2017) Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med 9:eaai8700</mixed-citation></ref><ref id="CR25"><label>237.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabrhel</surname><given-names>C</given-names></name><name><surname>Mark Courtney</surname><given-names>D</given-names></name><name><surname>Camargo</surname><given-names>CA</given-names><suffix>Jr</suffix></name><name><surname>Plewa</surname><given-names>MC</given-names></name><name><surname>Nordenholz</surname><given-names>KE</given-names></name><name><surname>Moore</surname><given-names>CL</given-names></name><name><surname>Richman</surname><given-names>PB</given-names></name><name><surname>Smithline</surname><given-names>HA</given-names></name><name><surname>Beam</surname><given-names>DM</given-names></name><name><surname>Kline</surname><given-names>JA</given-names></name></person-group><article-title xml:lang="en">Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism</article-title><source>Acad Emerg Med</source><year>2010</year><volume>17</volume><fpage>589</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1111/j.1553-2712.2010.00765.x</pub-id></mixed-citation></ref><ref id="CR26"><label>238.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>MR</given-names></name><name><surname>Lip</surname><given-names>GYH</given-names></name></person-group><article-title xml:lang="en">Novel risk markers and risk assessments for cardiovascular disease</article-title><source>Circ Res</source><year>2017</year><volume>120</volume><fpage>133</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309955</pub-id></mixed-citation></ref><ref id="CR27"><label>239.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puri</surname><given-names>R</given-names></name><name><surname>Nissen</surname><given-names>SE</given-names></name><name><surname>Shao</surname><given-names>M</given-names></name><name><surname>Elshazly</surname><given-names>MB</given-names></name><name><surname>Kataoka</surname><given-names>Y</given-names></name><name><surname>Kapadia</surname><given-names>SR</given-names></name><name><surname>Tuzcu</surname><given-names>EM</given-names></name><name><surname>Nicholls</surname><given-names>SJ</given-names></name></person-group><article-title xml:lang="en">Non-HDL cholesterol and triglycerides. Implications for coronary atheroma progression and clinical events</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2016</year><volume>36</volume><fpage>2220</fpage><lpage>2228</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.116.307601</pub-id></mixed-citation></ref><ref id="CR28"><label>240.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lew</surname><given-names>J</given-names></name><name><surname>Sanghavi</surname><given-names>M</given-names></name><name><surname>Ayers</surname><given-names>CR</given-names></name><name><surname>McGuire</surname><given-names>DK</given-names></name><name><surname>Omland</surname><given-names>T</given-names></name><name><surname>Atzler</surname><given-names>D</given-names></name><name><surname>Gore</surname><given-names>MO</given-names></name><name><surname>Neeland</surname><given-names>I</given-names></name><name><surname>Berry</surname><given-names>JD</given-names></name><name><surname>Khera</surname><given-names>A</given-names></name><name><surname>Rohatgi</surname><given-names>A</given-names></name><name><surname>de Lemos</surname><given-names>JA</given-names></name></person-group><article-title xml:lang="en">Sex-based differences in cardiometabolic biomarkers</article-title><source>Circulation</source><year>2017</year><volume>135</volume><fpage>544</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.023005</pub-id></mixed-citation></ref><ref id="CR29"><label>241.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann-Werman</surname><given-names>R</given-names></name><name><surname>Neiman</surname><given-names>D</given-names></name><name><surname>Zemmour</surname><given-names>H</given-names></name><name><surname>Moss</surname><given-names>J</given-names></name><name><surname>Magenheim</surname><given-names>J</given-names></name><name><surname>Vaknin-Dembinsky</surname><given-names>A</given-names></name><name><surname>Rubertsson</surname><given-names>S</given-names></name><name><surname>Nellgård</surname><given-names>B</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Spalding</surname><given-names>K</given-names></name><name><surname>Haller</surname><given-names>MJ</given-names></name><name><surname>Wasserfall</surname><given-names>CH</given-names></name><name><surname>Schatz</surname><given-names>DA</given-names></name><name><surname>Greenbaum</surname><given-names>CJ</given-names></name><name><surname>Dorrell</surname><given-names>C</given-names></name><name><surname>Grompe</surname><given-names>M</given-names></name><name><surname>Zick</surname><given-names>A</given-names></name><name><surname>Hubert</surname><given-names>A</given-names></name><name><surname>Maoz</surname><given-names>M</given-names></name><name><surname>Fendrich</surname><given-names>V</given-names></name><name><surname>Bartsch</surname><given-names>DK</given-names></name><name><surname>Golan</surname><given-names>T</given-names></name><name><surname>Ben Sasson</surname><given-names>SA</given-names></name><name><surname>Zamir</surname><given-names>G</given-names></name><name><surname>Razin</surname><given-names>A</given-names></name><name><surname>Cedar</surname><given-names>H</given-names></name><name><surname>Shapiro</surname><given-names>AM</given-names></name><name><surname>Glaser</surname><given-names>B</given-names></name><name><surname>Shemer</surname><given-names>R</given-names></name><name><surname>Dor</surname><given-names>Y</given-names></name></person-group><article-title xml:lang="en">Identification of tissue-specific cell death using methylation patterns of circulating DNA</article-title><source>Proc Natl Acad Sci USA</source><year>2016</year><volume>113</volume><fpage>E1826</fpage><lpage>E1834</lpage><pub-id pub-id-type="doi">10.1073/pnas.1519286113</pub-id></mixed-citation></ref><ref id="CR30"><label>242.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>D</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>Kuhn</surname><given-names>E</given-names></name><name><surname>Keyes</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Benson</surname><given-names>MD</given-names></name><name><surname>O’Sullivan</surname><given-names>JF</given-names></name><name><surname>Keshishian</surname><given-names>H</given-names></name><name><surname>Farrell</surname><given-names>L</given-names></name><name><surname>Fifer</surname><given-names>MA</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name><name><surname>Sabatine</surname><given-names>M</given-names></name><name><surname>Larson</surname><given-names>MG</given-names></name><name><surname>Carr</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>TJ</given-names></name><name><surname>Gerszten</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Aptamer-based proteomic profiling reveals novel candidate biomarkers and pathways in cardiovascular disease</article-title><source>Circulation</source><year>2016</year><volume>134</volume><fpage>270</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.021803</pub-id></mixed-citation></ref><ref id="CR31"><label>243.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velasquez</surname><given-names>MT</given-names></name><name><surname>Ramezani</surname><given-names>A</given-names></name><name><surname>Manal</surname><given-names>A</given-names></name><name><surname>Raj</surname><given-names>DS</given-names></name></person-group><article-title xml:lang="en">Trimethylamine N-oxide: the good, the bad and the unknown</article-title><source>Toxins</source><year>2016</year><volume>8</volume><fpage>326</fpage><pub-id pub-id-type="doi">10.3390/toxins8110326</pub-id></mixed-citation></ref><ref id="CR32"><label>244.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiattarella</surname><given-names>GG</given-names></name><name><surname>Sannino</surname><given-names>A</given-names></name><name><surname>Toscano</surname><given-names>E</given-names></name><name><surname>Giugliano</surname><given-names>G</given-names></name><name><surname>Gargiulo</surname><given-names>G</given-names></name><name><surname>Franzone</surname><given-names>A</given-names></name><name><surname>Trimarco</surname><given-names>B</given-names></name><name><surname>Esposito</surname><given-names>G</given-names></name><name><surname>Perrino</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><fpage>2948</fpage><lpage>2956</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx342</pub-id></mixed-citation></ref><ref id="CR33"><label>245.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>S</given-names></name><name><surname>Michikawa</surname><given-names>T</given-names></name><name><surname>Ueda</surname><given-names>K</given-names></name><name><surname>Sakamoto</surname><given-names>T</given-names></name><name><surname>Matsui</surname><given-names>K</given-names></name><name><surname>Kojima</surname><given-names>T</given-names></name><name><surname>Tsujita</surname><given-names>K</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Nitta</surname><given-names>H</given-names></name><name><surname>Takami</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">Asian dust exposure triggers acute myocardial infarction</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><fpage>3202</fpage><lpage>3208</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx509</pub-id></mixed-citation></ref><ref id="CR34"><label>246.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>NL</given-names></name><name><surname>Donaldson</surname><given-names>K</given-names></name><name><surname>Hadoke</surname><given-names>PW</given-names></name><name><surname>Boon</surname><given-names>NA</given-names></name><name><surname>MacNee</surname><given-names>W</given-names></name><name><surname>Cassee</surname><given-names>FR</given-names></name><name><surname>Sandström</surname><given-names>T</given-names></name><name><surname>Blomberg</surname><given-names>A</given-names></name><name><surname>Newby</surname><given-names>DE</given-names></name></person-group><article-title xml:lang="en">Adverse cardiovascular effects of air pollution</article-title><source>Nat Clin Pract Cardiovasc Med</source><year>2008</year><volume>6</volume><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/ncpcardio1399</pub-id></mixed-citation></ref><ref id="CR35"><label>247.</label><mixed-citation publication-type="other">Brook RD, Rajagopalan S, Pope CA, Brook JR, Bhatnagar A, Diez-Roux AV, Holguin F, Hong Y, Luepker RV, Mittleman MA, Peters A, Siscovick D, Smith SC Jr, Whitsel L, Kaufman JD; American Heart Association Council on Epidemiology and Prevention, Council on the Kidney in Cardiovascular Disease, and Council on Nutrition, Physical Activity and Metabolism (2010) Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation 121:2331–2378</mixed-citation></ref><ref id="CR36"><label>248.</label><mixed-citation publication-type="other">Newby DE, Mannucci PM, Tell GS, Baccarelli AA, Brook RD, Donaldson K, Forastiere F, Franchini M, Franco OH, Graham I, Hoek G, Hoffmann B, Hoylaerts MF, Künzli N, Mills N, Pekkanen J, Peters A, Piepoli MF, Rajagopalan S, Storey RF; on behalf of ESC Working Group on Thrombosis, European Association for Cardiovascular Prevention and Rehabilitation and ESC Heart Failure Association (2015) Expert position paper on air pollution and cardiovascular disease. Eur Heart J 36:83–93</mixed-citation></ref><ref id="CR37"><label>249.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Moran</surname><given-names>AE</given-names></name><name><surname>Coxson</surname><given-names>PG</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Goldman</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Kinney</surname><given-names>PL</given-names></name><name><surname>Gu</surname><given-names>D</given-names></name></person-group><article-title xml:lang="en">Potential cardiovascular and total mortality benefits of air pollution control in urban china</article-title><source>Circulation</source><year>2017</year><volume>136</volume><fpage>1575</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.026487</pub-id></mixed-citation></ref><ref id="CR38"><label>250.</label><mixed-citation publication-type="other">Ambient (outdoor) air quality and health (2014) Fact sheet 313. World Health Organization (<ext-link xlink:href="http://www.who.int/mediacentre/factsheets/fs313/en" ext-link-type="uri">www.who.int/mediacentre/factsheets/fs313/en</ext-link>)</mixed-citation></ref><ref id="CR39"><label>251.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pope</surname><given-names>CA</given-names></name><name><surname>Bhatnagar</surname><given-names>A</given-names></name><name><surname>McCracken</surname><given-names>JP</given-names></name><name><surname>Abplanalp</surname><given-names>W</given-names></name><name><surname>Conklin</surname><given-names>DJ</given-names></name><name><surname>O’Toole</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Exposure to fine particulate air pollution is associated with endothelial injury and systemic inflammation</article-title><source>Circ Res</source><year>2016</year><volume>119</volume><fpage>1204</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309279</pub-id></mixed-citation></ref><ref id="CR40"><label>252.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vora</surname><given-names>R</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name><name><surname>Utell</surname><given-names>MJ</given-names></name><name><surname>Pietropaoli</surname><given-names>AP</given-names></name><name><surname>Chalupa</surname><given-names>D</given-names></name><name><surname>Little</surname><given-names>EL</given-names></name><name><surname>Oakes</surname><given-names>D</given-names></name><name><surname>Bausch</surname><given-names>J</given-names></name><name><surname>Wiltshire</surname><given-names>J</given-names></name><name><surname>Frampton</surname><given-names>MW</given-names></name></person-group><article-title xml:lang="en">Inhalation of ultrafine carbon particles alters heart rate and heart rate variability in people with type 2 diabetes</article-title><source>Part Fibre Toxicol</source><year>2014</year><volume>11</volume><fpage>31</fpage><pub-id pub-id-type="doi">10.1186/s12989-014-0031-y</pub-id></mixed-citation></ref><ref id="CR41"><label>253.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>A</given-names></name><name><surname>Hampel</surname><given-names>R</given-names></name><name><surname>Cyrys</surname><given-names>J</given-names></name><name><surname>Breitner</surname><given-names>S</given-names></name><name><surname>Geruschkat</surname><given-names>U</given-names></name><name><surname>Kraus</surname><given-names>U</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name><name><surname>Schneider</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">Elevated particle number concentrations induce immediate changes in heart rate variability: a panel study in individuals with impaired glucose metabolism or diabetes</article-title><source>Part Fibre Toxicol</source><year>2015</year><volume>12</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s12989-015-0083-7</pub-id></mixed-citation></ref><ref id="CR42"><label>254.</label><mixed-citation publication-type="other">World Health Report: Research for Universal Health Coverage (2013) World Health Organization, Geneva, Switzerland</mixed-citation></ref><ref id="CR43"><label>255.</label><mixed-citation publication-type="other">Monographs on the Evaluation of Carcinogenic Risks to Humans (2012) World Health Organization, International Agency for Research on Cancer (IARC), Lyon</mixed-citation></ref><ref id="CR44"><label>256.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Maiseyeu</surname><given-names>A</given-names></name><name><surname>Gopalakrishnan</surname><given-names>B</given-names></name><name><surname>Villamena</surname><given-names>FA</given-names></name><name><surname>Chen</surname><given-names>LC</given-names></name><name><surname>Harkema</surname><given-names>JR</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Rajagopalan</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">CD36-dependent 7-ketocholesterol accumulation in macrophages mediates progression of atherosclerosis in response to chronic air pollution exposure</article-title><source>Circ Res</source><year>2014</year><volume>115</volume><fpage>770</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.304666</pub-id></mixed-citation></ref><ref id="CR45"><label>257.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olfert</surname><given-names>J</given-names></name><name><surname>Collings</surname><given-names>N</given-names></name></person-group><article-title xml:lang="en">New method for particle mass classification</article-title><source>The Couette centrifugal particle mass analyzer. J Aerosol Sci</source><year>2005</year><volume>36</volume><fpage>1338</fpage><lpage>1352</lpage></mixed-citation></ref><ref id="CR46"><label>258.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavakoli</surname><given-names>F</given-names></name><name><surname>Olfert</surname><given-names>JS</given-names></name></person-group><article-title xml:lang="en">An instrument for the classification of aerosols by particle relaxation time: theoretical models of the aerodynamic aerosol classifier</article-title><source>Aerosp Sci Technol</source><year>2013</year><volume>47</volume><fpage>916</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1080/02786826.2013.802761</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2013AerST..47..916T</pub-id></mixed-citation></ref><ref id="CR47"><label>259.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Givehchi</surname><given-names>R</given-names></name><name><surname>Tan</surname><given-names>Z</given-names></name></person-group><article-title xml:lang="en">An overview of airborne nanoparticle filtration and thermal rebound theory</article-title><source>Aerosol Air Qual Res</source><year>2014</year><volume>14</volume><fpage>45</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.4209/aaqr.2013.07.0239</pub-id></mixed-citation></ref><ref id="CR48"><label>260.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostofi</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Haghighat</surname><given-names>F</given-names></name><name><surname>Bahloul</surname><given-names>A</given-names></name><name><surname>Lara</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en">Performance of mechanical filters and respirators for capturing nanoparticles—limitations and future direction</article-title><source>Ind Health</source><year>2010</year><volume>48</volume><fpage>296</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.2486/indhealth.48.296</pub-id></mixed-citation></ref><ref id="CR49"><label>261.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Ying</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hao</surname><given-names>K</given-names></name><name><surname>Kinney</surname><given-names>PL</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Kan</surname><given-names>H</given-names></name></person-group><article-title xml:lang="en">Particulate matter exposure and stress hormone levels. A randomized, double-blind, crossover trial of air purification</article-title><source>Circulation</source><year>2017</year><volume>136</volume><fpage>618</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.026796</pub-id></mixed-citation></ref><ref id="CR50"><label>262.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Cayir</surname><given-names>A</given-names></name><name><surname>Trevisi</surname><given-names>L</given-names></name><name><surname>Sanchez-Guerra</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Bind</surname><given-names>MA</given-names></name><name><surname>Prada</surname><given-names>D</given-names></name><name><surname>Laue</surname><given-names>H</given-names></name><name><surname>Brennan</surname><given-names>KJ</given-names></name><name><surname>Dereix</surname><given-names>A</given-names></name><name><surname>Sparrow</surname><given-names>D</given-names></name><name><surname>Vokonas</surname><given-names>P</given-names></name><name><surname>Schwartz</surname><given-names>J</given-names></name><name><surname>Baccarelli</surname><given-names>AA</given-names></name></person-group><article-title xml:lang="en">Traffic-related air pollution, blood pressure, and adaptive response of mitochondrial abundance</article-title><source>Circulation</source><year>2016</year><volume>133</volume><fpage>378</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.018802</pub-id></mixed-citation></ref><ref id="CR51"><label>263.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wauters</surname><given-names>A</given-names></name><name><surname>Vicenzi</surname><given-names>M</given-names></name><name><surname>De Becker</surname><given-names>B</given-names></name><name><surname>Riga</surname><given-names>JP</given-names></name><name><surname>Esmaeilzadeh</surname><given-names>F</given-names></name><name><surname>Faoro</surname><given-names>V</given-names></name><name><surname>Vachiéry</surname><given-names>JL</given-names></name><name><surname>van de Borne</surname><given-names>P</given-names></name><name><surname>Argacha</surname><given-names>JF</given-names></name></person-group><article-title xml:lang="en">At high cardiac output, diesel exhaust exposure increases pulmonary vascular resistance and decreases distensibility of pulmonary resistive vessels</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2015</year><volume>309</volume><fpage>H2137</fpage><lpage>H2144</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00149.2015</pub-id></mixed-citation></ref><ref id="CR52"><label>264.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaziri</surname><given-names>ND</given-names></name></person-group><article-title xml:lang="en">Mechanisms of lead-induced hypertension and cardiovascular disease</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2008</year><volume>295</volume><fpage>H454</fpage><lpage>H465</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00158.2008</pub-id></mixed-citation></ref><ref id="CR53"><label>265.</label><mixed-citation publication-type="other">Cai Y, Hansell AL, Blangiardo M, Burton PR, BioSHaRE, de Hoogh K, Doiron D, Fortier I, Gulliver J, Hveem K, Mbatchou S, Morley DW, Stolk RP, Zijlema WL, Elliott P, Hodgson S (2017) Long-term exposure to road traffic noise, ambient air pollution, and cardiovascular risk factors in the HUNT and lifelines cohorts. Eur Heart J 38:2290–2296</mixed-citation></ref><ref id="CR54"><label>266.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzik</surname><given-names>TJ</given-names></name><name><surname>Channon</surname><given-names>KM</given-names></name></person-group><article-title xml:lang="en">Linking noise to cardiovascular disease pathogenesis</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><fpage>2850</fpage><lpage>2852</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx217</pub-id></mixed-citation></ref><ref id="CR55"><label>267.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Münzel</surname><given-names>T</given-names></name><name><surname>Daiber</surname><given-names>A</given-names></name><name><surname>Steven</surname><given-names>S</given-names></name><name><surname>Tran</surname><given-names>LP</given-names></name><name><surname>Ullmann</surname><given-names>E</given-names></name><name><surname>Kossmann</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>FP</given-names></name><name><surname>Oelze</surname><given-names>M</given-names></name><name><surname>Xia</surname><given-names>N</given-names></name><name><surname>Pinto</surname><given-names>HLA</given-names></name><name><surname>Wild</surname><given-names>P</given-names></name><name><surname>Pies</surname><given-names>K</given-names></name><name><surname>Schmidt</surname><given-names>ER</given-names></name><name><surname>Rapp</surname><given-names>S</given-names></name><name><surname>Kröller-Schön</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Effects of noise on vascular function, oxidative stress, and inflammation: mechanistic insight from studies in mice</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><fpage>2838</fpage><lpage>2849</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx081</pub-id></mixed-citation></ref><ref id="CR56"><label>268.</label><mixed-citation publication-type="other">Nelson JW, Breaker RR (2017) The lost language of the RNA world. Sci Signal 10:eaam8812</mixed-citation></ref><ref id="CR57"><label>269.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>YLJ</given-names></name><name><surname>Poruri</surname><given-names>K</given-names></name><name><surname>Martinis</surname><given-names>SA</given-names></name></person-group><article-title xml:lang="en">tRNA synthetase: tRNA aminoacylation and beyond</article-title><source>Wiley Interdiscip Rev RNA</source><year>2014</year><volume>5</volume><fpage>461</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1002/wrna.1224</pub-id></mixed-citation></ref><ref id="CR58"><label>270.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Liljas</surname><given-names>A</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Brenner</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>JH</given-names></name></person-group><article-title xml:lang="en">Consensus sequence</article-title><source>Encyclopedia of genetics</source><year>2002</year><publisher-loc>San Diego, CA</publisher-loc><publisher-name>Academic/Elsevier</publisher-name><fpage>457</fpage><lpage>458</lpage></mixed-citation></ref><ref id="CR59"><label>271.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirando</surname><given-names>AC</given-names></name><name><surname>Francklyn</surname><given-names>CS</given-names></name><name><surname>Lounsbury</surname><given-names>KM</given-names></name></person-group><article-title xml:lang="en">Regulation of angiogenesis by aminoacyl–tRNA synthetases</article-title><source>Int J Mol Sci</source><year>2014</year><volume>15</volume><fpage>23725</fpage><lpage>23748</lpage><pub-id pub-id-type="doi">10.3390/ijms151223725</pub-id></mixed-citation></ref><ref id="CR60"><label>272.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lounsbury</surname><given-names>KM</given-names></name><name><surname>Francklyn</surname><given-names>CS</given-names></name></person-group><article-title xml:lang="en">Aminoacyl–transfer RNA synthetases: connecting nutrient status to angiogenesis through the unfolded protein response</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2016</year><volume>36</volume><fpage>582</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.116.307193</pub-id></mixed-citation></ref><ref id="CR61"><label>273.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castranova</surname><given-names>D</given-names></name><name><surname>Davis</surname><given-names>AE</given-names></name><name><surname>Lo</surname><given-names>BD</given-names></name><name><surname>Miller</surname><given-names>MF</given-names></name><name><surname>Paukstelis</surname><given-names>PJ</given-names></name><name><surname>Swift</surname><given-names>MR</given-names></name><name><surname>Pham</surname><given-names>VN</given-names></name><name><surname>Torres-Vázquez</surname><given-names>J</given-names></name><name><surname>Bell</surname><given-names>K</given-names></name><name><surname>Shaw</surname><given-names>KM</given-names></name><name><surname>Kamei</surname><given-names>M</given-names></name><name><surname>Weinstein</surname><given-names>BM</given-names></name></person-group><article-title xml:lang="en">Aminoacyl–transfer RNA synthetase deficiency promotes angiogenesis via the unfolded protein response pathway</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2016</year><volume>36</volume><fpage>655</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.115.307087</pub-id></mixed-citation></ref><ref id="CR62"><label>274.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boeckel</surname><given-names>JN</given-names></name><name><surname>Derlet</surname><given-names>A</given-names></name><name><surname>Glaser</surname><given-names>SF</given-names></name><name><surname>Luczak</surname><given-names>A</given-names></name><name><surname>Lucas</surname><given-names>T</given-names></name><name><surname>Heumüller</surname><given-names>AW</given-names></name><name><surname>Krüger</surname><given-names>M</given-names></name><name><surname>Zehendner</surname><given-names>CM</given-names></name><name><surname>Kaluza</surname><given-names>D</given-names></name><name><surname>Doddaballapur</surname><given-names>A</given-names></name><name><surname>Ohtani</surname><given-names>K</given-names></name><name><surname>Treguer</surname><given-names>K</given-names></name><name><surname>Dimmeler</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">JMJD8 regulates angiogenic sprouting and cellular metabolism by interacting with pyruvate kinase M2 in endothelial cells</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2016</year><volume>36</volume><fpage>1425</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.116.307695</pub-id></mixed-citation></ref><ref id="CR63"><label>275.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>KC</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><article-title xml:lang="en">Molecular mechanisms of long noncoding RNAs</article-title><source>Mol Cell</source><year>2011</year><volume>43</volume><fpage>904</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2011.08.018</pub-id></mixed-citation></ref><ref id="CR64"><label>276.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langley</surname><given-names>AR</given-names></name><name><surname>Chambers</surname><given-names>H</given-names></name><name><surname>Christov</surname><given-names>CP</given-names></name><name><surname>Krude</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Ribonucleoprotein particles containing non-coding Y RNAs, Ro60, La and nucleolin are not required for Y RNA function in DNA replication</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0013673</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2010PLoSO...513673L</pub-id></mixed-citation></ref><ref id="CR65"><label>277.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrick</surname><given-names>JP</given-names></name><name><surname>Wolin</surname><given-names>SL</given-names></name><name><surname>Rinke</surname><given-names>J</given-names></name><name><surname>Lerner</surname><given-names>MR</given-names></name><name><surname>Steitz</surname><given-names>JA</given-names></name></person-group><article-title xml:lang="en">Ro small cytoplasmic ribonucleoproteins are a subclass of La ribonucleoproteins: further characterization of the Ro and La small ribonucleoproteins from uninfected mammalian cells</article-title><source>Mol Cell Biol</source><year>1981</year><volume>1</volume><fpage>1138</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1128/MCB.1.12.1138</pub-id></mixed-citation></ref><ref id="CR66"><label>278.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>P</given-names></name><name><surname>Lingappa</surname><given-names>VR</given-names></name></person-group><article-title xml:lang="en">Mechanism of protein translocation across the endoplasmic reticulum membrane</article-title><source>Annu Rev Cell Biol</source><year>1986</year><volume>2</volume><fpage>499</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1146/annurev.cb.02.110186.002435</pub-id></mixed-citation></ref><ref id="CR67"><label>279.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinger</surname><given-names>ME</given-names></name><name><surname>Pang</surname><given-names>KC</given-names></name><name><surname>Mercer</surname><given-names>TR</given-names></name><name><surname>Mattick</surname><given-names>JS</given-names></name></person-group><article-title xml:lang="en">Differentiating protein-coding and noncoding RNA: challenges and ambiguities</article-title><source>PLoS Comput Biol</source><year>2008</year><volume>4</volume><pub-id pub-id-type="doi">10.1371/journal.pcbi.1000176</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2008PLSCB...4E0176D</pub-id></mixed-citation></ref><ref id="CR68"><label>281.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chooniedass-Kothari</surname><given-names>S</given-names></name><name><surname>Emberley</surname><given-names>E</given-names></name><name><surname>Hamedani</surname><given-names>MK</given-names></name><name><surname>Troup</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Czosnek</surname><given-names>A</given-names></name><name><surname>Hube</surname><given-names>F</given-names></name><name><surname>Mutawe</surname><given-names>M</given-names></name><name><surname>Watson</surname><given-names>PH</given-names></name><name><surname>Leygue</surname><given-names>E</given-names></name></person-group><article-title xml:lang="en">The steroid receptor RNA activator is the first functional RNA encoding a protein</article-title><source>FEBS Lett</source><year>2004</year><volume>566</volume><fpage>43</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2004.03.104</pub-id></mixed-citation></ref><ref id="CR69"><label>282.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>JW</given-names></name><name><surname>Choi</surname><given-names>SW</given-names></name><name><surname>You</surname><given-names>BH</given-names></name></person-group><article-title xml:lang="en">Incredible RNA: dual functions of coding and noncoding</article-title><source>Mol Cells</source><year>2016</year><volume>39</volume><fpage>367</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.14348/molcells.2016.0039</pub-id></mixed-citation></ref><ref id="CR70"><label>283.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>TM</given-names></name><name><surname>Tsai</surname><given-names>M</given-names></name><name><surname>Tian</surname><given-names>B</given-names></name><name><surname>Mathews</surname><given-names>MB</given-names></name><name><surname>Pe’ery</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Cellular mRNA activates transcription elongation by displacing 7SK RNA</article-title><source>PLoS One</source><year>2007</year><volume>2</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0001010</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2007PLoSO...2.1010Y</pub-id></mixed-citation></ref><ref id="CR71"><label>284.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quévillon Huberdeau</surname><given-names>M</given-names></name><name><surname>Zeitler</surname><given-names>DM</given-names></name><name><surname>Hauptmann</surname><given-names>J</given-names></name><name><surname>Bruckmann</surname><given-names>A</given-names></name><name><surname>Fressigné</surname><given-names>L</given-names></name><name><surname>Danner</surname><given-names>J</given-names></name><name><surname>Piquet</surname><given-names>S</given-names></name><name><surname>Strieder</surname><given-names>N</given-names></name><name><surname>Engelmann</surname><given-names>JC</given-names></name><name><surname>Jannot</surname><given-names>G</given-names></name><name><surname>Deutzmann</surname><given-names>R</given-names></name><name><surname>Simard</surname><given-names>MJ</given-names></name><name><surname>Meister</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">Phosphorylation of Argonaute proteins affects mRNA binding and is essential for microRNA-guided gene silencing in vivo</article-title><source>EMBO J</source><year>2017</year><volume>36</volume><fpage>2088</fpage><lpage>2106</lpage><pub-id pub-id-type="doi">10.15252/embj.201696386</pub-id></mixed-citation></ref><ref id="CR72"><label>285.</label><mixed-citation publication-type="other">Bublik DR, Bursać S, Sheffer M, Oršolić I, Shalit T, Tarcic O, Kotler E, Mouhadeb O, Hoffman Y, Fuchs G, Levin Y, Volarević S, Oren M5 (2017) Regulatory module involving FGF13, miR-504, and p53 regulates ribosomal biogenesis and supports cancer cell survival. Proc Natl Acad Sci USA 114:E496–E505</mixed-citation></ref><ref id="CR73"><label>286.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dron</surname><given-names>JS</given-names></name><name><surname>Ho</surname><given-names>R</given-names></name><name><surname>Hegele</surname><given-names>RA</given-names></name></person-group><article-title xml:lang="en">Recent advances in the genetics of atherothrombotic disease and its determinants</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2017</year><volume>37</volume><fpage>e158</fpage><lpage>e166</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.117.309934</pub-id></mixed-citation></ref><ref id="CR74"><label>287.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheuermann</surname><given-names>JC</given-names></name><name><surname>Boyer</surname><given-names>LA</given-names></name></person-group><article-title xml:lang="en">Getting to the heart of the matter: long non-coding RNAs in cardiac development and disease</article-title><source>EMBO J</source><year>2013</year><volume>32</volume><fpage>1805</fpage><lpage>1816</lpage><pub-id pub-id-type="doi">10.1038/emboj.2013.134</pub-id></mixed-citation></ref><ref id="CR75"><label>288.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magenta</surname><given-names>A</given-names></name><name><surname>Greco</surname><given-names>S</given-names></name><name><surname>Gaetano</surname><given-names>C</given-names></name><name><surname>Martelli</surname><given-names>F</given-names></name></person-group><article-title xml:lang="en">Oxidative stress and microRNAs in vascular diseases</article-title><source>Int J Mol Sci</source><year>2013</year><volume>14</volume><fpage>17319</fpage><lpage>17346</lpage><pub-id pub-id-type="doi">10.3390/ijms140917319</pub-id></mixed-citation></ref><ref id="CR76"><label>289.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magenta</surname><given-names>A</given-names></name><name><surname>Ciarapica</surname><given-names>R</given-names></name><name><surname>Capogrossi</surname><given-names>MC</given-names></name></person-group><article-title xml:lang="en">The emerging role of miR-200 family in cardiovascular diseases</article-title><source>Circ Res</source><year>2017</year><volume>120</volume><fpage>1399</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.310274</pub-id></mixed-citation></ref><ref id="CR77"><label>290.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magenta</surname><given-names>A</given-names></name><name><surname>Cencioni</surname><given-names>C</given-names></name><name><surname>Fasanaro</surname><given-names>P</given-names></name><name><surname>Zaccagnini</surname><given-names>G</given-names></name><name><surname>Greco</surname><given-names>S</given-names></name><name><surname>Sarra-Ferraris</surname><given-names>G</given-names></name><name><surname>Antonini</surname><given-names>A</given-names></name><name><surname>Martelli</surname><given-names>F</given-names></name><name><surname>Capogrossi</surname><given-names>MC</given-names></name></person-group><article-title xml:lang="en">MiR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition</article-title><source>Cell Death Differ</source><year>2011</year><volume>18</volume><fpage>1628</fpage><lpage>1639</lpage><pub-id pub-id-type="doi">10.1038/cdd.2011.42</pub-id></mixed-citation></ref><ref id="CR78"><label>291.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korpal</surname><given-names>M</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name></person-group><article-title xml:lang="en">The emerging role of miR-200 family of microRNAs in epithelial–mesenchymal transition and cancer metastasis</article-title><source>RNA Biol</source><year>2008</year><volume>5</volume><fpage>115</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.4161/rna.5.3.6558</pub-id></mixed-citation></ref><ref id="CR79"><label>292.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Shang</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Bian</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial–mesenchymal transition (EMT)</article-title><source>Cancer Lett</source><year>2017</year><volume>392</volume><fpage>26</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2017.01.039</pub-id></mixed-citation></ref><ref id="CR80"><label>293.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perdigão-Henriques</surname><given-names>R</given-names></name><name><surname>Petrocca</surname><given-names>F</given-names></name><name><surname>Altschuler</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>MP</given-names></name><name><surname>Le</surname><given-names>MTN</given-names></name><name><surname>Tan</surname><given-names>SM</given-names></name><name><surname>Hide</surname><given-names>W</given-names></name><name><surname>Lieberman</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en">MiR-200 promotes the mesenchymal to epithelial transition by suppressing multiple members of the Zeb2 and Snail1 transcriptional repressor complexes</article-title><source>Oncogene</source><year>2016</year><volume>35</volume><fpage>158</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1038/onc.2015.69</pub-id></mixed-citation></ref><ref id="CR81"><label>294.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DY</given-names></name><name><surname>Lin</surname><given-names>TE</given-names></name><name><surname>Lee</surname><given-names>CI</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>PL</given-names></name><name><surname>Shih</surname><given-names>YT</given-names></name><name><surname>Chien</surname><given-names>S</given-names></name><name><surname>Chiu</surname><given-names>JJ</given-names></name></person-group><article-title xml:lang="en">MicroRNA-10a is crucial for endothelial response to different flow patterns via interaction of retinoid acid receptors and histone deacetylases</article-title><source>Proc Natl Acad Sci USA</source><year>2017</year><volume>114</volume><fpage>2072</fpage><lpage>2077</lpage><pub-id pub-id-type="doi">10.1073/pnas.1621425114</pub-id></mixed-citation></ref><ref id="CR82"><label>295.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>JJ</given-names></name><name><surname>Liu</surname><given-names>YF</given-names></name><name><surname>Zhang</surname><given-names>YP</given-names></name><name><surname>Zhao</surname><given-names>CR</given-names></name><name><surname>Yao</surname><given-names>WJ</given-names></name><name><surname>Li</surname><given-names>YS</given-names></name><name><surname>Wang</surname><given-names>KC</given-names></name><name><surname>Huang</surname><given-names>TS</given-names></name><name><surname>Pang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>XF</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chien</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en">VAMP3 and SNAP23 mediate the disturbed flow-induced endothelial microRNA secretion and smooth muscle hyperplasia</article-title><source>Proc Natl Acad Sci USA</source><year>2017</year><volume>114</volume><fpage>8271</fpage><lpage>8276</lpage><pub-id pub-id-type="doi">10.1073/pnas.1700561114</pub-id></mixed-citation></ref><ref id="CR83"><label>296.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudijanto</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis</article-title><source>Acta Med Indones</source><year>2007</year><volume>39</volume><fpage>86</fpage><lpage>93</lpage></mixed-citation></ref><ref id="CR84"><label>297.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>JH</given-names></name><name><surname>Rennick</surname><given-names>RE</given-names></name><name><surname>Kalevitch</surname><given-names>SG</given-names></name><name><surname>Campbell</surname><given-names>GR</given-names></name></person-group><article-title xml:lang="en">Heparan sulfate-degrading enzymes induce modulation of smooth muscle phenotype</article-title><source>Exp Cell Res</source><year>1992</year><volume>200</volume><fpage>156</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/S0014-4827(05)80084-9</pub-id></mixed-citation></ref><ref id="CR85"><label>298.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maegdefessel</surname><given-names>L</given-names></name><name><surname>Rayner</surname><given-names>KJ</given-names></name><name><surname>Leeper</surname><given-names>NJ</given-names></name></person-group><article-title xml:lang="en">MicroRNA regulation of vascular smooth muscle function and phenotype: early career committee contribution</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2015</year><volume>35</volume><fpage>2</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.114.304877</pub-id></mixed-citation></ref><ref id="CR86"><label>299.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sala-Newby</surname><given-names>GB</given-names></name><name><surname>George</surname><given-names>SJ</given-names></name><name><surname>Bond</surname><given-names>M</given-names></name><name><surname>Dhoot</surname><given-names>GK</given-names></name><name><surname>Newby</surname><given-names>AC</given-names></name></person-group><article-title xml:lang="en">Regulation of vascular smooth muscle cell proliferation, migration and death by heparan sulfate 6-O-endosulfatase1</article-title><source>FEBS Lett</source><year>2005</year><volume>579</volume><fpage>6493</fpage><lpage>6498</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2005.10.026</pub-id></mixed-citation></ref><ref id="CR87"><label>300.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanimura</surname><given-names>S</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name></person-group><article-title xml:lang="en">ERK signalling as a regulator of cell motility</article-title><source>J Biochem</source><year>2017</year><volume>162</volume><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1093/jb/mvx048</pub-id></mixed-citation></ref><ref id="CR88"><label>301.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanimura</surname><given-names>S</given-names></name><name><surname>Hashizume</surname><given-names>J</given-names></name><name><surname>Arichika</surname><given-names>N</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Ohyama</surname><given-names>K</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Kohno</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">ERK signaling promotes cell motility by inducing the localization of myosin 1E to lamellipodial tips</article-title><source>J Cell Biol</source><year>2016</year><volume>214</volume><fpage>475</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1083/jcb.201503123</pub-id></mixed-citation></ref><ref id="CR89"><label>302.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai-Kowase</surname><given-names>K</given-names></name><name><surname>Owens</surname><given-names>GK</given-names></name></person-group><article-title xml:lang="en">Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells</article-title><source>Am J Physiol Cell Physiol</source><year>2007</year><volume>292</volume><fpage>C59</fpage><lpage>C69</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00394.2006</pub-id></mixed-citation></ref><ref id="CR90"><label>303.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anholt</surname><given-names>RRH</given-names></name></person-group><article-title xml:lang="en">Olfactomedin proteins: central players in development and disease</article-title><source>Front Cell Dev Biol</source><year>2014</year><volume>2</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.3389/fcell.2014.00006</pub-id></mixed-citation></ref><ref id="CR91"><label>304.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomarev</surname><given-names>SI</given-names></name><name><surname>Nakaya</surname><given-names>N</given-names></name></person-group><article-title xml:lang="en">Olfactomedin domain-containing proteins: possible mechanisms of action and functions in normal development and pathology</article-title><source>Mol Neurobiol</source><year>2009</year><volume>40</volume><fpage>122</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1007/s12035-009-8076-x</pub-id></mixed-citation></ref><ref id="CR92"><label>305.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Rubin</surname><given-names>JS</given-names></name><name><surname>Tomarev</surname><given-names>SI</given-names></name></person-group><article-title xml:lang="en">Myocilin is a modulator of Wnt signaling</article-title><source>Mol Cell Biol</source><year>2009</year><volume>29</volume><fpage>2139</fpage><lpage>2154</lpage><pub-id pub-id-type="doi">10.1128/MCB.01274-08</pub-id></mixed-citation></ref><ref id="CR93"><label>306.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joe</surname><given-names>MK</given-names></name><name><surname>Kee</surname><given-names>C</given-names></name><name><surname>Tomarev</surname><given-names>SI</given-names></name></person-group><article-title xml:lang="en">Myocilin interacts with syntrophins and is member of dystrophin-associated protein complex</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>13216</fpage><lpage>13227</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.224063</pub-id></mixed-citation></ref><ref id="CR94"><label>307.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>CX</given-names></name><name><surname>Cui</surname><given-names>XB</given-names></name><name><surname>Tomarev</surname><given-names>SI</given-names></name><name><surname>Chen</surname><given-names>SY</given-names></name></person-group><article-title xml:lang="en">Olfactomedin 2 regulates smooth muscle phenotypic modulation and vascular remodeling through mediating Runt-related transcription factor 2 binding to serum response factor</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2017</year><volume>37</volume><fpage>446</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.116.308606</pub-id></mixed-citation></ref><ref id="CR95"><label>308.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>SenBanerjee</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Atkins</surname><given-names>GB</given-names></name><name><surname>Greif</surname><given-names>DM</given-names></name><name><surname>Rao</surname><given-names>RM</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Feinberg</surname><given-names>MW</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Simon</surname><given-names>DI</given-names></name><name><surname>Luscinskas</surname><given-names>FW</given-names></name><name><surname>Michel</surname><given-names>TM</given-names></name><name><surname>Gimbrone</surname><given-names>MA</given-names><suffix>Jr</suffix></name><name><surname>García-Cardeña</surname><given-names>G</given-names></name><name><surname>Jain</surname><given-names>MK</given-names></name></person-group><article-title xml:lang="en">KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation</article-title><source>J Exp Med</source><year>2004</year><volume>199</volume><fpage>1305</fpage><lpage>1315</lpage><pub-id pub-id-type="doi">10.1084/jem.20031132</pub-id></mixed-citation></ref><ref id="CR96"><label>309.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Wen</surname><given-names>JK</given-names></name></person-group><article-title xml:lang="en">Role of Krüppel-like factor 4 in phenotypic switching and proliferation of vascular smooth muscle cells</article-title><source>IUBMB Life</source><year>2010</year><volume>62</volume><fpage>132</fpage><lpage>139</lpage></mixed-citation></ref><ref id="CR97"><label>310.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamik</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Balcells</surname><given-names>M</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Katz</surname><given-names>J</given-names></name><name><surname>Feinberg</surname><given-names>MW</given-names></name><name><surname>Gerzsten</surname><given-names>RE</given-names></name><name><surname>Edelman</surname><given-names>ER</given-names></name><name><surname>Jain</surname><given-names>MK</given-names></name></person-group><article-title xml:lang="en">Krüppel-like factor 4 regulates endothelial inflammation</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>13769</fpage><lpage>13779</lpage><pub-id pub-id-type="doi">10.1074/jbc.M700078200</pub-id></mixed-citation></ref><ref id="CR98"><label>311.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>HY</given-names></name><name><surname>Bai</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Maurya</surname><given-names>MR</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Sangwung</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>YJ</given-names></name><name><surname>Lei</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>HD</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Jain</surname><given-names>MK</given-names></name><name><surname>Subramaniam</surname><given-names>S</given-names></name><name><surname>Shyy</surname><given-names>JYJ</given-names></name></person-group><article-title xml:lang="en">Krüppel-like factor 4 regulation of cholesterol-25-hydroxylase and liver X receptor mitigates atherosclerosis susceptibility</article-title><source>Circulation</source><year>2017</year><volume>136</volume><fpage>1315</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.027462</pub-id></mixed-citation></ref><ref id="CR99"><label>312.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garvey</surname><given-names>SM</given-names></name><name><surname>Sinden</surname><given-names>DS</given-names></name><name><surname>Schoppee Bortz</surname><given-names>PD</given-names></name><name><surname>Wamhoff</surname><given-names>BR</given-names></name></person-group><article-title xml:lang="en">Cyclosporine up-regulates Krüppel-like factor-4 (KLF4) in vascular smooth muscle cells and drives phenotypic modulation in vivo</article-title><source>J Pharmacol Exp Ther</source><year>2010</year><volume>333</volume><fpage>34</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1124/jpet.109.163949</pub-id></mixed-citation></ref><ref id="CR100"><label>313.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>SF</given-names></name><name><surname>Zahradka</surname><given-names>P</given-names></name></person-group><article-title xml:lang="en">Vascular smooth muscle cell motility: from migration to invasion</article-title><source>Exp Clin Cardiol</source><year>2010</year><volume>15</volume><fpage>e75</fpage><lpage>e85</lpage></mixed-citation></ref><ref id="CR101"><label>314.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname><given-names>N</given-names></name><name><surname>Kinsella</surname><given-names>MG</given-names></name><name><surname>Wight</surname><given-names>TN</given-names></name><name><surname>Hedin</surname><given-names>U</given-names></name><name><surname>Clowes</surname><given-names>AW</given-names></name></person-group><article-title xml:lang="en">Heparan sulfate proteoglycans mediate a potent inhibitory signal for migration of vascular smooth muscle cells</article-title><source>Circ Res</source><year>1998</year><volume>83</volume><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1161/01.RES.83.3.305</pub-id></mixed-citation></ref><ref id="CR102"><label>315.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Jo</surname><given-names>EK</given-names></name><name><surname>Kim</surname><given-names>YW</given-names></name><name><surname>Kwon</surname><given-names>JS</given-names></name><name><surname>Bae</surname><given-names>SS</given-names></name><name><surname>Sung</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>SG</given-names></name><name><surname>Kim</surname><given-names>JT</given-names></name><name><surname>Suh</surname><given-names>W</given-names></name></person-group><article-title xml:lang="en">Fibroblast growth factor 12 is a novel regulator of vascular smooth muscle cell plasticity and fate</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2016</year><volume>36</volume><fpage>1928</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.116.308017</pub-id></mixed-citation></ref><ref id="CR103"><label>316.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>PY</given-names></name><name><surname>Qin</surname><given-names>LF</given-names></name><name><surname>Li</surname><given-names>GX</given-names></name><name><surname>Tellides</surname><given-names>G</given-names></name><name><surname>Simons</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">Fibroblast growth factor (FGF) signaling regulates transforming growth factor β(TGFβ)-dependent smooth muscle cell phenotype modulation</article-title><source>Sci Report</source><year>2016</year><volume>6</volume><fpage>33407</fpage><pub-id pub-id-type="doi">10.1038/srep33407</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2016NatSR...633407C</pub-id></mixed-citation></ref><ref id="CR104"><label>317.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>S</given-names></name><name><surname>Hollenbeck</surname><given-names>ST</given-names></name><name><surname>Ryer</surname><given-names>EJ</given-names></name><name><surname>Edlin</surname><given-names>R</given-names></name><name><surname>Yamanouchi</surname><given-names>D</given-names></name><name><surname>Kundi</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Kent</surname><given-names>KC</given-names></name></person-group><article-title xml:lang="en">TGF-β through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2009</year><volume>297</volume><fpage>H540</fpage><lpage>H549</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.91478.2007</pub-id></mixed-citation></ref><ref id="CR105"><label>318.</label><mixed-citation publication-type="other">Li J, Zhao L, Yang T, Zeng YJ, Yang K (2014) c-Ski inhibits autophagy of vascular smooth muscle cells induced by oxLDL and PDGF. PLoS One 9:e98902</mixed-citation></ref><ref id="CR106"><label>319.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name></person-group><article-title xml:lang="en">MiR-21 inhibits c-Ski signaling to promote the proliferation of rat vascular smooth muscle cells</article-title><source>Cell Signal</source><year>2014</year><volume>26</volume><fpage>724</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2013.12.013</pub-id></mixed-citation></ref><ref id="CR107"><label>320.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name></person-group><article-title xml:lang="en">Vascular smooth muscle cell glycocalyx modulates shear-induced proliferation, migration, and NO* production responses</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2011</year><volume>300</volume><fpage>H76</fpage><lpage>H83</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00905.2010</pub-id></mixed-citation></ref><ref id="CR108"><label>321.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueba</surname><given-names>H</given-names></name><name><surname>Kawakami</surname><given-names>M</given-names></name><name><surname>Yaginuma</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Shear stress as an inhibitor of vascular smooth muscle cell proliferation. Role of transforming growth factorβ 1 and tissue-type plasminogen activator</article-title><source>Arterioscler Thromb Vasc Biol</source><year>1997</year><volume>17</volume><fpage>1512</fpage><lpage>1516</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.17.8.1512</pub-id></mixed-citation></ref><ref id="CR109"><label>322.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palumbo</surname><given-names>R</given-names></name><name><surname>Gaetano</surname><given-names>C</given-names></name><name><surname>Melillo</surname><given-names>G</given-names></name><name><surname>Toschi</surname><given-names>E</given-names></name><name><surname>Remuzzi</surname><given-names>A</given-names></name><name><surname>Capogrossi</surname><given-names>MC</given-names></name></person-group><article-title xml:lang="en">Shear stress downregulation of platelet-derived growth factor receptor-β and matrix metalloprotease-2 is associated with inhibition of smooth muscle cell invasion and migration</article-title><source>Circulation</source><year>2000</year><volume>102</volume><fpage>225</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.102.2.225</pub-id></mixed-citation></ref><ref id="CR110"><label>323.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garanich</surname><given-names>JS</given-names></name><name><surname>Pahakis</surname><given-names>M</given-names></name><name><surname>Tarbell</surname><given-names>JM</given-names></name></person-group><article-title xml:lang="en">Shear stress inhibits smooth muscle cell migration via nitric oxide-mediated downregulation of matrix metalloproteinase-2 activity</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2005</year><volume>288</volume><fpage>H2244</fpage><lpage>H2252</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00428.2003</pub-id></mixed-citation></ref><ref id="CR111"><label>324.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JH</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>YF</given-names></name><name><surname>Haslam</surname><given-names>J</given-names></name><name><surname>Elvis</surname><given-names>ON</given-names></name><name><surname>Mao</surname><given-names>L</given-names></name><name><surname>Xia</surname><given-names>YP</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name></person-group><article-title xml:lang="en">Semaphorin-3E attenuates neointimal formation via suppressing VSMCs migration and proliferation</article-title><source>Cardiovasc Res</source><year>2017</year><volume>113</volume><fpage>1763</fpage><lpage>1775</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvx190</pub-id></mixed-citation></ref><ref id="CR112"><label>325.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbert</surname><given-names>JM</given-names></name><name><surname>Clowes</surname><given-names>M</given-names></name><name><surname>Lea</surname><given-names>HJ</given-names></name><name><surname>Pascal</surname><given-names>M</given-names></name><name><surname>Clowes</surname><given-names>AW</given-names></name></person-group><article-title xml:lang="en">Protein kinase C α expression is required for heparin inhibition of rat smooth muscle cell proliferation in vitro and in vivo</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>25928</fpage><lpage>25935</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.42.25928</pub-id></mixed-citation></ref><ref id="CR113"><label>326.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fetalvero</surname><given-names>KM</given-names></name><name><surname>Shyu</surname><given-names>M</given-names></name><name><surname>Nomikos</surname><given-names>AP</given-names></name><name><surname>Chiu</surname><given-names>YF</given-names></name><name><surname>Wagner</surname><given-names>RJ</given-names></name><name><surname>Powell</surname><given-names>RJ</given-names></name><name><surname>Hwa</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>KA</given-names></name></person-group><article-title xml:lang="en">The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2006</year><volume>290</volume><fpage>H1337</fpage><lpage>H1346</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00936.2005</pub-id></mixed-citation></ref><ref id="CR114"><label>327.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Nickel</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Gilbertsen</surname><given-names>A</given-names></name><name><surname>Geng</surname><given-names>Z</given-names></name><name><surname>Johnson</surname><given-names>C</given-names></name><name><surname>Young</surname><given-names>B</given-names></name><name><surname>Henke</surname><given-names>C</given-names></name><name><surname>Gourley</surname><given-names>GR</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en">Lactate promotes synthetic phenotype in vascular smooth muscle cells</article-title><source>Circ Res</source><year>2017</year><volume>121</volume><fpage>1251</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.311819</pub-id></mixed-citation></ref><ref id="CR115"><label>328.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Ostriker</surname><given-names>AC</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>MY</given-names></name><name><surname>Leslie</surname><given-names>KL</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sessa</surname><given-names>WC</given-names></name><name><surname>Hwa</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>KA</given-names></name></person-group><article-title xml:lang="en">Opposing actions of AKT (protein kinase B) isoforms in vascular smooth muscle injury and therapeutic response</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2017</year><volume>37</volume><fpage>2311</fpage><lpage>2321</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.117.310053</pub-id></mixed-citation></ref><ref id="CR116"><label>329.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Schnackenberg</surname><given-names>L</given-names></name><name><surname>Khaidakov</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Singla</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Mehta</surname><given-names>JL</given-names></name></person-group><article-title xml:lang="en">Regulation of autophagy and apoptosis in response to ox-LDL in vascular smooth muscle cells, and the modulatory effects of the microRNA hsa-let-7g</article-title><source>Int J Cardiol</source><year>2013</year><volume>168</volume><fpage>1378</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2012.12.045</pub-id></mixed-citation></ref><ref id="CR117"><label>330.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Radhakrishnan</surname><given-names>SK</given-names></name><name><surname>Huang</surname><given-names>ZP</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Kilsdonk</surname><given-names>EP</given-names></name><name><surname>Gui</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>DZ</given-names></name><name><surname>Zheng</surname><given-names>XL</given-names></name></person-group><article-title xml:lang="en">Induction of microRNA-1 by myocardin in smooth muscle cells inhibits cell proliferation</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2011</year><volume>31</volume><fpage>368</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.110.218149</pub-id></mixed-citation></ref><ref id="CR118"><label>331.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Schober</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">Pathogenic arterial remodeling: the good and bad of microRNAs</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2013</year><volume>304</volume><fpage>H1050</fpage><lpage>H1059</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00267.2012</pub-id></mixed-citation></ref><ref id="CR119"><label>332.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">MicroRNA-31 regulated by the extracellular-regulated kinase is involved in vascular smooth muscle cell growth via large tumor suppressor homolog 2</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>42371</fpage><lpage>42380</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.261065</pub-id></mixed-citation></ref><ref id="CR120"><label>333.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takada</surname><given-names>S</given-names></name><name><surname>Berezikov</surname><given-names>E</given-names></name><name><surname>Choi</surname><given-names>YL</given-names></name><name><surname>Yamashita</surname><given-names>Y</given-names></name><name><surname>Mano</surname><given-names>H</given-names></name></person-group><article-title xml:lang="en">Potential role of miR-29b in modulation of Dnmt3a and Dnmt3b expression in primordial germ cells of female mouse embryos</article-title><source>RNA</source><year>2009</year><volume>15</volume><fpage>1507</fpage><lpage>1514</lpage><pub-id pub-id-type="doi">10.1261/rna.1418309</pub-id></mixed-citation></ref><ref id="CR121"><label>334.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>KC</given-names></name><name><surname>Wang</surname><given-names>YS</given-names></name><name><surname>Hu</surname><given-names>CY</given-names></name><name><surname>Chang</surname><given-names>WC</given-names></name><name><surname>Liao</surname><given-names>YC</given-names></name><name><surname>Dai</surname><given-names>CY</given-names></name><name><surname>Juo</surname><given-names>SH</given-names></name></person-group><article-title xml:lang="en">OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases</article-title><source>FASEB J</source><year>2011</year><volume>25</volume><fpage>1718</fpage><lpage>1728</lpage><pub-id pub-id-type="doi">10.1096/fj.10-174904</pub-id></mixed-citation></ref><ref id="CR122"><label>335.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Qin</surname><given-names>G</given-names></name><name><surname>Weintraub</surname><given-names>NL</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name></person-group><article-title xml:lang="en">MiR-92a inhibits vascular smooth muscle cell apoptosis: role of the MKK4–JNK pathway</article-title><source>Apoptosis</source><year>2014</year><volume>19</volume><fpage>975</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1007/s10495-014-0987-y</pub-id></mixed-citation></ref><ref id="CR123"><label>336.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name></person-group><article-title xml:lang="en">MicroRNA-124 controls human vascular smooth muscle cell phenotypic switch via Sp1</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2017</year><volume>313</volume><fpage>H641</fpage><lpage>H649</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00660.2016</pub-id></mixed-citation></ref><ref id="CR124"><label>337.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villeneuve</surname><given-names>LM</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Reddy</surname><given-names>MA</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Lanting</surname><given-names>L</given-names></name><name><surname>Natarajan</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1</article-title><source>Diabetes</source><year>2010</year><volume>59</volume><fpage>2904</fpage><lpage>2915</lpage><pub-id pub-id-type="doi">10.2337/db10-0208</pub-id></mixed-citation></ref><ref id="CR125"><label>338.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>YS</given-names></name><name><surname>Nguyen</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>KC</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name><name><surname>Kuo</surname><given-names>YC</given-names></name><name><surname>Chiu</surname><given-names>JJ</given-names></name><name><surname>Shyy</surname><given-names>JY</given-names></name><name><surname>Chien</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Regulation of vascular smooth muscle cell turnover by endothelial cell-secreted microRNA-126: role of shear stress</article-title><source>Circ Res</source><year>2013</year><volume>113</volume><fpage>40</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.113.280883</pub-id></mixed-citation></ref><ref id="CR126"><label>339.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Reddy</surname><given-names>MA</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Putta</surname><given-names>S</given-names></name><name><surname>Lanting</surname><given-names>L</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>JT</given-names></name><name><surname>Chandra</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Tangirala</surname><given-names>RK</given-names></name><name><surname>Natarajan</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Small RNA sequencing reveals microRNAs that modulate angiotensin II effects in vascular smooth muscle cells</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>15672</fpage><lpage>15683</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.322669</pub-id></mixed-citation></ref><ref id="CR127"><label>340.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torella</surname><given-names>D</given-names></name><name><surname>Iaconetti</surname><given-names>C</given-names></name><name><surname>Catalucci</surname><given-names>D</given-names></name><name><surname>Ellison</surname><given-names>GM</given-names></name><name><surname>Leone</surname><given-names>A</given-names></name><name><surname>Waring</surname><given-names>CD</given-names></name><name><surname>Bochicchio</surname><given-names>A</given-names></name><name><surname>Vicinanza</surname><given-names>C</given-names></name><name><surname>Aquila</surname><given-names>I</given-names></name><name><surname>Curcio</surname><given-names>A</given-names></name><name><surname>Condorelli</surname><given-names>G</given-names></name><name><surname>Indolfi</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo</article-title><source>Circ Res</source><year>2011</year><volume>109</volume><fpage>880</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.240150</pub-id></mixed-citation></ref><ref id="CR128"><label>341.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis-Dusenbery</surname><given-names>BN</given-names></name><name><surname>Chan</surname><given-names>MC</given-names></name><name><surname>Reno</surname><given-names>KE</given-names></name><name><surname>Weisman</surname><given-names>AS</given-names></name><name><surname>Layne</surname><given-names>MD</given-names></name><name><surname>Lagna</surname><given-names>G</given-names></name><name><surname>Hata</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">Down-regulation of Krüppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-β and bone morphogenetic protein 4</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>28097</fpage><lpage>28110</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.236950</pub-id></mixed-citation></ref><ref id="CR129"><label>342.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>SG</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Fang</surname><given-names>XM</given-names></name><name><surname>Li</surname><given-names>HX</given-names></name><name><surname>Miao</surname><given-names>SB</given-names></name><name><surname>Su</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>HJ</given-names></name><name><surname>Wen</surname><given-names>JK</given-names></name></person-group><article-title xml:lang="en">miR-146a and Krüppel-like factor 4 form a feedback loop to participate in vascular smooth muscle cell proliferation</article-title><source>EMBO Rep</source><year>2011</year><volume>12</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1038/embor.2010.172</pub-id></mixed-citation></ref><ref id="CR130"><label>343.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>RN</given-names></name><name><surname>Wu</surname><given-names>XL</given-names></name><name><surname>Wen</surname><given-names>JK</given-names></name></person-group><article-title xml:lang="en">MiR-155-dependent regulation of mammalian sterile 20-like kinase 2 (MST2) coordinates inflammation, oxidative stress and proliferation in vascular smooth muscle cells</article-title><source>Biochim Biophys Acta Mol Basis Dis</source><year>2015</year><volume>1852</volume><fpage>1477</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2015.04.012</pub-id></mixed-citation></ref><ref id="CR131"><label>344.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Yin</surname><given-names>WN</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>LL</given-names></name><name><surname>Jin</surname><given-names>LS</given-names></name><name><surname>Zhan</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>JS</given-names></name><name><surname>Wen</surname><given-names>JK</given-names></name></person-group><article-title xml:lang="en">Exosome-mediated miR-155 transfer from smooth muscle cells to endothelial cells induces endothelial injury and promotes atherosclerosis</article-title><source>Mol Ther</source><year>2017</year><volume>25</volume><fpage>1279</fpage><lpage>1294</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.03.031</pub-id></mixed-citation></ref><ref id="CR132"><label>345.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Lv</surname><given-names>B</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name></person-group><article-title xml:lang="en">MicroRNA-182 prevents vascular smooth muscle cell dedifferentiation via FGF9/PDGFRβ signaling</article-title><source>Int J Mol Med</source><year>2017</year><volume>39</volume><fpage>791</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2017.2905</pub-id></mixed-citation></ref><ref id="CR133"><label>346.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frontini</surname><given-names>MJ</given-names></name><name><surname>Nong</surname><given-names>Z</given-names></name><name><surname>Gros</surname><given-names>R</given-names></name><name><surname>Drangova</surname><given-names>M</given-names></name><name><surname>O’Neil</surname><given-names>C</given-names></name><name><surname>Rahman</surname><given-names>MN</given-names></name><name><surname>Akawi</surname><given-names>O</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Ellis</surname><given-names>CG</given-names></name><name><surname>Pickering</surname><given-names>JG</given-names></name></person-group><article-title xml:lang="en">Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells</article-title><source>Nat Biotechnol</source><year>2011</year><volume>29</volume><fpage>421</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1038/nbt.1845</pub-id></mixed-citation></ref><ref id="CR134"><label>347.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>He</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>P</given-names></name><name><surname>Du</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">Oncological miR-182-3p, a novel smooth muscle cell phenotype modulator, evidences from model rats and patients</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2016</year><volume>36</volume><fpage>1386</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.115.307412</pub-id></mixed-citation></ref><ref id="CR135"><label>348.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiesow</surname><given-names>K</given-names></name><name><surname>Bennewitz</surname><given-names>K</given-names></name><name><surname>Gutierrez Miranda</surname><given-names>L</given-names></name><name><surname>Stoll</surname><given-names>SJ</given-names></name><name><surname>Hartenstein</surname><given-names>B</given-names></name><name><surname>Angel</surname><given-names>P</given-names></name><name><surname>Kroll</surname><given-names>J</given-names></name><name><surname>Schorpp-Kistner</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">Junb controls lymphatic vascular development in zebrafish via miR-182</article-title><source>Sci Report</source><year>2015</year><volume>5</volume><fpage>15007</fpage><pub-id pub-id-type="doi">10.1038/srep15007</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2015NatSR...515007K</pub-id></mixed-citation></ref><ref id="CR136"><label>349.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YS</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Liao</surname><given-names>YC</given-names></name><name><surname>Tsai</surname><given-names>PC</given-names></name><name><surname>Chen</surname><given-names>KC</given-names></name><name><surname>Cheng</surname><given-names>HY</given-names></name><name><surname>Lin</surname><given-names>RT</given-names></name><name><surname>Juo</surname><given-names>SH</given-names></name></person-group><article-title xml:lang="en">MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation</article-title><source>Cardiovasc Res</source><year>2012</year><volume>95</volume><fpage>517</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvs223</pub-id></mixed-citation></ref><ref id="CR137"><label>350.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Imbrie</surname><given-names>GA</given-names></name><name><surname>Baur</surname><given-names>WE</given-names></name><name><surname>Iyer</surname><given-names>LK</given-names></name><name><surname>Aronovitz</surname><given-names>MJ</given-names></name><name><surname>Kershaw</surname><given-names>TB</given-names></name><name><surname>Haselmann</surname><given-names>GM</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Karas</surname><given-names>RH</given-names></name></person-group><article-title xml:lang="en">Estrogen receptor-mediated regulation of microRNA inhibits proliferation of vascular smooth muscle cells</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2013</year><volume>33</volume><fpage>257</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.112.300200</pub-id></mixed-citation></ref><ref id="CR138"><label>351.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>A</given-names></name><name><surname>Trac</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Lanting</surname><given-names>L</given-names></name><name><surname>Akbany</surname><given-names>A</given-names></name><name><surname>Sætrom</surname><given-names>P</given-names></name><name><surname>Schones</surname><given-names>DE</given-names></name><name><surname>Natarajan</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Novel long noncoding RNAs are regulated by angiotensin II in vascular smooth muscle cells</article-title><source>Circ Res</source><year>2013</year><volume>113</volume><fpage>266</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.112.300849</pub-id></mixed-citation></ref><ref id="CR139"><label>352.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">FAM3B mediates high glucose-induced vascular smooth muscle cell proliferation and migration via inhibition of miR-322-5p</article-title><source>Sci Report</source><year>2017</year><volume>7</volume><fpage>2298</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-02683-3</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2017NatSR...7.2298Z</pub-id></mixed-citation></ref><ref id="CR140"><label>353.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merlet</surname><given-names>E</given-names></name><name><surname>Atassi</surname><given-names>F</given-names></name><name><surname>Motiani</surname><given-names>RK</given-names></name><name><surname>Mougenot</surname><given-names>N</given-names></name><name><surname>Jacquet</surname><given-names>A</given-names></name><name><surname>Nadaud</surname><given-names>S</given-names></name><name><surname>Capiod</surname><given-names>T</given-names></name><name><surname>Trebak</surname><given-names>M</given-names></name><name><surname>Lompré</surname><given-names>AM</given-names></name><name><surname>Marchand</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">MiR-424/322 regulates vascular smooth muscle cell phenotype and neointimal formation in the rat</article-title><source>Cardiovasc Res</source><year>2013</year><volume>98</volume><fpage>458</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvt045</pub-id></mixed-citation></ref><ref id="CR141"><label>354.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Ham</surname><given-names>O</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Choi</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>CY</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Seo</surname><given-names>HH</given-names></name><name><surname>Seung</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>E</given-names></name><name><surname>Min</surname><given-names>PK</given-names></name><name><surname>Hwang</surname><given-names>KC</given-names></name></person-group><article-title xml:lang="en">MicroRNA-365 inhibits the proliferation of vascular smooth muscle cells by targeting cyclin D1</article-title><source>J Cell Biochem</source><year>2014</year><volume>115</volume><fpage>1752</fpage><lpage>1761</lpage><pub-id pub-id-type="doi">10.1002/jcb.24841</pub-id></mixed-citation></ref><ref id="CR142"><label>355.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title xml:lang="en">MiR-490-3p modulates the proliferation of vascular smooth muscle cells induced by ox-LDL through targeting PAPP-A</article-title><source>Cardiovasc Res</source><year>2013</year><volume>100</volume><fpage>272</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvt172</pub-id></mixed-citation></ref><ref id="CR143"><label>356.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>MA</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Zhuo</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Lanting</surname><given-names>L</given-names></name><name><surname>Natarajan</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Regulation of vascular smooth muscle cell dysfunction under diabetic conditions by miR-504</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2016</year><volume>36</volume><fpage>864</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.115.306770</pub-id></mixed-citation></ref><ref id="CR144"><label>357.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">MiR-599 inhibits vascular smooth muscle cell proliferation and migration by targeting TGFB2</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0141512</pub-id></mixed-citation></ref><ref id="CR145"><label>358.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuylen</surname><given-names>S</given-names></name><name><surname>Blaukopf</surname><given-names>C</given-names></name><name><surname>Politi</surname><given-names>AZ</given-names></name><name><surname>Müller-Reichert</surname><given-names>T</given-names></name><name><surname>Neumann</surname><given-names>B</given-names></name><name><surname>Poser</surname><given-names>I</given-names></name><name><surname>Ellenberg</surname><given-names>J</given-names></name><name><surname>Hyman</surname><given-names>AA</given-names></name><name><surname>Gerlich</surname><given-names>DW</given-names></name></person-group><article-title xml:lang="en">Ki-67 acts as a biological surfactant to disperse mitotic chromosomes</article-title><source>Nature</source><year>2016</year><volume>535</volume><fpage>308</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1038/nature18610</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2016Natur.535..308C</pub-id></mixed-citation></ref><ref id="CR146"><label>359.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yi</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>You</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Summer</surname><given-names>R</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en">MicroRNA-638 is highly expressed in human vascular smooth muscle cells and inhibits PDGF-BB-induced cell proliferation and migration through targeting orphan nuclear receptor NOR1</article-title><source>Cardiovasc Res</source><year>2013</year><volume>99</volume><fpage>185</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvt082</pub-id></mixed-citation></ref><ref id="CR147"><label>360.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunderland</surname><given-names>N</given-names></name><name><surname>Skroblin</surname><given-names>P</given-names></name><name><surname>Barwari</surname><given-names>T</given-names></name><name><surname>Huntley</surname><given-names>RP</given-names></name><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Joshi</surname><given-names>A</given-names></name><name><surname>Lovering</surname><given-names>RC</given-names></name><name><surname>Mayr</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">MicroRNA biomarkers and platelet reactivity—the clot thickens</article-title><source>Circ Res</source><year>2017</year><volume>120</volume><fpage>418</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309303</pub-id></mixed-citation></ref><ref id="CR148"><label>361.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willeit</surname><given-names>P</given-names></name><name><surname>Skroblin</surname><given-names>P</given-names></name><name><surname>Kiechl</surname><given-names>S</given-names></name><name><surname>Fernández-Hernando</surname><given-names>C</given-names></name><name><surname>Mayr</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?</article-title><source>Eur Heart J</source><year>2016</year><volume>37</volume><fpage>3260</fpage><lpage>3266</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehw146</pub-id></mixed-citation></ref><ref id="CR149"><label>362.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dávalos</surname><given-names>A</given-names></name><name><surname>Goedeke</surname><given-names>L</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name><name><surname>Ramírez</surname><given-names>CM</given-names></name><name><surname>Warrier</surname><given-names>NP</given-names></name><name><surname>Andreo</surname><given-names>U</given-names></name><name><surname>Cirera-Salinas</surname><given-names>D</given-names></name><name><surname>Rayner</surname><given-names>K</given-names></name><name><surname>Suresh</surname><given-names>U</given-names></name><name><surname>Pastor-Pareja</surname><given-names>JC</given-names></name><name><surname>Esplugues</surname><given-names>E</given-names></name><name><surname>Fisher</surname><given-names>EA</given-names></name><name><surname>Penalva</surname><given-names>LO</given-names></name><name><surname>Moore</surname><given-names>KJ</given-names></name><name><surname>Suárez</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>EC</given-names></name><name><surname>Fernández-Hernando</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">MiR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><fpage>9232</fpage><lpage>9237</lpage><pub-id pub-id-type="doi">10.1073/pnas.1102281108</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2011PNAS..108.9232D</pub-id></mixed-citation></ref><ref id="CR150"><label>363.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horie</surname><given-names>T</given-names></name><name><surname>Nishino</surname><given-names>T</given-names></name><name><surname>Baba</surname><given-names>O</given-names></name><name><surname>Kuwabara</surname><given-names>Y</given-names></name><name><surname>Nakao</surname><given-names>T</given-names></name><name><surname>Nishiga</surname><given-names>M</given-names></name><name><surname>Usami</surname><given-names>S</given-names></name><name><surname>Izuhara</surname><given-names>M</given-names></name><name><surname>Sowa</surname><given-names>N</given-names></name><name><surname>Yahagi</surname><given-names>N</given-names></name><name><surname>Shimano</surname><given-names>H</given-names></name><name><surname>Matsumura</surname><given-names>S</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Marusawa</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Kume</surname><given-names>N</given-names></name><name><surname>Yokode</surname><given-names>M</given-names></name><name><surname>Kita</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Ono</surname><given-names>K</given-names></name></person-group><article-title xml:lang="en">MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice</article-title><source>Nat Commun</source><year>2013</year><volume>4</volume><fpage>2883</fpage><pub-id pub-id-type="doi">10.1038/ncomms3883</pub-id></mixed-citation></ref><ref id="CR151"><label>364.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Fernández-Hernando</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">MiR-33 regulation of adaptive fibrotic response in cardiac remodeling</article-title><source>Circ Res</source><year>2017</year><volume>120</volume><fpage>753</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.310575</pub-id></mixed-citation></ref><ref id="CR152"><label>365.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vickers</surname><given-names>KC</given-names></name><name><surname>Landstreet</surname><given-names>SR</given-names></name><name><surname>Levin</surname><given-names>MG</given-names></name><name><surname>Shoucri</surname><given-names>BM</given-names></name><name><surname>Toth</surname><given-names>CL</given-names></name><name><surname>Taylor</surname><given-names>RC</given-names></name><name><surname>Palmisano</surname><given-names>BT</given-names></name><name><surname>Tabet</surname><given-names>F</given-names></name><name><surname>Cui</surname><given-names>HL</given-names></name><name><surname>Rye</surname><given-names>KA</given-names></name><name><surname>Sethupathy</surname><given-names>P</given-names></name><name><surname>Remaley</surname><given-names>AT</given-names></name></person-group><article-title xml:lang="en">MicroRNA-223 coordinates cholesterol homeostasis</article-title><source>Proc Natl Acad Sci USA</source><year>2014</year><volume>111</volume><fpage>14518</fpage><lpage>14523</lpage><pub-id pub-id-type="doi">10.1073/pnas.1215767111</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2014PNAS..11114518V</pub-id></mixed-citation></ref><ref id="CR153"><label>366.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Hussain</surname><given-names>MM</given-names></name></person-group><article-title xml:lang="en">Human microRNA-548p decreases hepatic apolipoprotein B secretion and lipid synthesis</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2017</year><volume>37</volume><fpage>786</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.117.309247</pub-id></mixed-citation></ref><ref id="CR154"><label>367.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinti</surname><given-names>MV</given-names></name><name><surname>Hathaway</surname><given-names>QA</given-names></name><name><surname>Hollander</surname><given-names>JM</given-names></name></person-group><article-title xml:lang="en">Role of microRNA in metabolic shift during heart failure</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2017</year><volume>312</volume><fpage>H33</fpage><lpage>H45</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00341.2016</pub-id></mixed-citation></ref><ref id="CR155"><label>368.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vendramin</surname><given-names>R</given-names></name><name><surname>Marine</surname><given-names>JC</given-names></name><name><surname>Leucci</surname><given-names>E</given-names></name></person-group><article-title xml:lang="en">Non-coding RNAs: the dark side of nuclear-mitochondrial communication</article-title><source>EMBO J</source><year>2017</year><volume>36</volume><fpage>1123</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.15252/embj.201695546</pub-id></mixed-citation></ref><ref id="CR156"><label>369.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollander</surname><given-names>JM</given-names></name><name><surname>Baseler</surname><given-names>WA</given-names></name><name><surname>Dabkowski</surname><given-names>ER</given-names></name></person-group><article-title xml:lang="en">Proteomic remodeling of mitochondria in heart failure</article-title><source>Congest Heart Fail</source><year>2011</year><volume>17</volume><fpage>262</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1111/j.1751-7133.2011.00254.x</pub-id></mixed-citation></ref><ref id="CR157"><label>370.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopert</surname><given-names>P</given-names></name><name><surname>Patel</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">Nicotinamide nucleotide transhydrogenase (Nnt) links the substrate requirement in brain mitochondria for hydrogen peroxide removal to the thioredoxin/peroxiredoxin (Trx/Prx) system</article-title><source>J Biol Chem</source><year>2014</year><volume>289</volume><fpage>15611</fpage><lpage>15620</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.533653</pub-id></mixed-citation></ref><ref id="CR158"><label>371.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nickel</surname><given-names>AG</given-names></name><name><surname>von Hardenberg</surname><given-names>A</given-names></name><name><surname>Hohl</surname><given-names>M</given-names></name><name><surname>Löffler</surname><given-names>JR</given-names></name><name><surname>Kohlhaas</surname><given-names>M</given-names></name><name><surname>Becker</surname><given-names>J</given-names></name><name><surname>Reil</surname><given-names>JC</given-names></name><name><surname>Kazakov</surname><given-names>A</given-names></name><name><surname>Bonnekoh</surname><given-names>J</given-names></name><name><surname>Stadelmaier</surname><given-names>M</given-names></name><name><surname>Puhl</surname><given-names>SL</given-names></name><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Bogeski</surname><given-names>I</given-names></name><name><surname>Cortassa</surname><given-names>S</given-names></name><name><surname>Kappl</surname><given-names>R</given-names></name><name><surname>Pasieka</surname><given-names>B</given-names></name><name><surname>Lafontaine</surname><given-names>M</given-names></name><name><surname>Lancaster</surname><given-names>CR</given-names></name><name><surname>Blacker</surname><given-names>TS</given-names></name><name><surname>Hall</surname><given-names>AR</given-names></name><name><surname>Duchen</surname><given-names>MR</given-names></name><name><surname>Kästner</surname><given-names>L</given-names></name><name><surname>Lipp</surname><given-names>P</given-names></name><name><surname>Zeller</surname><given-names>T</given-names></name><name><surname>Müller</surname><given-names>C</given-names></name><name><surname>Knopp</surname><given-names>A</given-names></name><name><surname>Laufs</surname><given-names>U</given-names></name><name><surname>Böhm</surname><given-names>M</given-names></name><name><surname>Hoth</surname><given-names>M</given-names></name><name><surname>Maack</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">Reversal of mitochondrial transhydrogenase causes oxidative stress in heart failure</article-title><source>Cell Metab</source><year>2015</year><volume>22</volume><fpage>472</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2015.07.008</pub-id></mixed-citation></ref><ref id="CR159"><label>372.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharer</surname><given-names>JD</given-names></name><name><surname>Shern</surname><given-names>JF</given-names></name><name><surname>van Valkenburgh</surname><given-names>H</given-names></name><name><surname>Wallace</surname><given-names>DC</given-names></name><name><surname>Kahn</surname><given-names>RA</given-names></name></person-group><article-title xml:lang="en">ARL2 and BART enter mitochondria and bind the adenine nucleotide transporter</article-title><source>Mol Biol Cell</source><year>2002</year><volume>13</volume><fpage>71</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1091/mbc.01-05-0245</pub-id></mixed-citation></ref><ref id="CR160"><label>373.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swain</surname><given-names>L</given-names></name><name><surname>Kesemeyer</surname><given-names>A</given-names></name><name><surname>Meyer-Roxlau</surname><given-names>S</given-names></name><name><surname>Vettel</surname><given-names>C</given-names></name><name><surname>Zieseniss</surname><given-names>A</given-names></name><name><surname>Güntsch</surname><given-names>A</given-names></name><name><surname>Jatho</surname><given-names>A</given-names></name><name><surname>Becker</surname><given-names>A</given-names></name><name><surname>Nanadikar</surname><given-names>MS</given-names></name><name><surname>Morgan</surname><given-names>B</given-names></name><name><surname>Dennerlein</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>AM</given-names></name><name><surname>El-Armouche</surname><given-names>A</given-names></name><name><surname>Nikolaev</surname><given-names>VO</given-names></name><name><surname>Katschinski</surname><given-names>DM</given-names></name></person-group><article-title xml:lang="en">Redox imaging using cardiac myocyte-specific transgenic biosensor mice</article-title><source>Circ Res</source><year>2016</year><volume>119</volume><fpage>1004</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309551</pub-id></mixed-citation></ref><ref id="CR161"><label>374.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>CV</given-names></name></person-group><article-title xml:lang="en">C-MYC mRNA tail tale about glutamine control of transcription</article-title><source>EMBO J</source><year>2017</year><volume>36</volume><fpage>1806</fpage><lpage>1808</lpage><pub-id pub-id-type="doi">10.15252/embj.201796999</pub-id></mixed-citation></ref><ref id="CR162"><label>375.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejure</surname><given-names>FR</given-names></name><name><surname>Royla</surname><given-names>N</given-names></name><name><surname>Herold</surname><given-names>S</given-names></name><name><surname>Kalb</surname><given-names>J</given-names></name><name><surname>Walz</surname><given-names>S</given-names></name><name><surname>Ade</surname><given-names>CP</given-names></name><name><surname>Mastrobuoni</surname><given-names>G</given-names></name><name><surname>Vanselow</surname><given-names>JT</given-names></name><name><surname>Schlosser</surname><given-names>A</given-names></name><name><surname>Wolf</surname><given-names>E</given-names></name><name><surname>Kempa</surname><given-names>S</given-names></name><name><surname>Eilers</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">The MYC mRNA 3<italic>′</italic>-UTR couples RNA polymerase II function to glutamine and ribonucleotide levels</article-title><source>EMBO J</source><year>2017</year><volume>36</volume><fpage>1854</fpage><lpage>1868</lpage><pub-id pub-id-type="doi">10.15252/embj.201796662</pub-id></mixed-citation></ref><ref id="CR163"><label>376.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viereck</surname><given-names>J</given-names></name><name><surname>Thum</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Circulating noncoding RNAs as biomarkers of cardiovascular disease and injury</article-title><source>Circ Res</source><year>2017</year><volume>120</volume><fpage>381</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.308434</pub-id></mixed-citation></ref><ref id="CR164"><label>377.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pokhrel</surname><given-names>S</given-names></name><name><surname>Guotian</surname><given-names>Y</given-names></name></person-group><article-title xml:lang="en">MicroRNA and its role in cardiovascular disease</article-title><source>World J Cardiovasc Dis</source><year>2017</year><volume>7</volume><fpage>340</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.4236/wjcd.2017.710032</pub-id></mixed-citation></ref><ref id="CR165"><label>378.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiga</surname><given-names>M</given-names></name><name><surname>Horie</surname><given-names>T</given-names></name><name><surname>Kuwabara</surname><given-names>Y</given-names></name><name><surname>Nagao</surname><given-names>K</given-names></name><name><surname>Baba</surname><given-names>O</given-names></name><name><surname>Nakao</surname><given-names>T</given-names></name><name><surname>Nishino</surname><given-names>T</given-names></name><name><surname>Hakuno</surname><given-names>D</given-names></name><name><surname>Nakashima</surname><given-names>Y</given-names></name><name><surname>Nishi</surname><given-names>H</given-names></name><name><surname>Nakazeki</surname><given-names>F</given-names></name><name><surname>Ide</surname><given-names>Y</given-names></name><name><surname>Koyama</surname><given-names>S</given-names></name><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Hanada</surname><given-names>R</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Inada</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Conway</surname><given-names>SJ</given-names></name><name><surname>Kita</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Ono</surname><given-names>K</given-names></name></person-group><article-title xml:lang="en">MicroRNA-33 controls adaptive fibrotic response in the remodeling heart by preserving lipid raft cholesterol</article-title><source>Circ Res</source><year>2017</year><volume>120</volume><fpage>835</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309528</pub-id></mixed-citation></ref><ref id="CR166"><label>379.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YC</given-names></name><name><surname>Park</surname><given-names>MJ</given-names></name><name><surname>Ye</surname><given-names>SK</given-names></name><name><surname>Kim</surname><given-names>CW</given-names></name><name><surname>Kim</surname><given-names>YN</given-names></name></person-group><article-title xml:lang="en">Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents</article-title><source>Am J Pathol</source><year>2006</year><volume>168</volume><fpage>1107</fpage><lpage>1118</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2006.050959</pub-id></mixed-citation></ref><ref id="CR167"><label>380.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reis-Sobreiro</surname><given-names>M</given-names></name><name><surname>Roué</surname><given-names>G</given-names></name><name><surname>Moros</surname><given-names>A</given-names></name><name><surname>Gajate</surname><given-names>C</given-names></name><name><surname>de la Iglesia-Vicente</surname><given-names>J</given-names></name><name><surname>Colomer</surname><given-names>D</given-names></name><name><surname>Mollinedo</surname><given-names>F</given-names></name></person-group><article-title xml:lang="en">Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma</article-title><source>Blood Cancer J</source><year>2013</year><volume>3</volume><pub-id pub-id-type="doi">10.1038/bcj.2013.15</pub-id></mixed-citation></ref><ref id="CR168"><label>381.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liew</surname><given-names>OW</given-names></name><name><surname>Richards</surname><given-names>AM</given-names></name><name><surname>Chen</surname><given-names>YT</given-names></name></person-group><article-title xml:lang="en">Overview of microRNAs in cardiac hypertrophy, fibrosis, and apoptosis</article-title><source>Int J Mol Sci</source><year>2016</year><volume>17</volume><fpage>749</fpage><pub-id pub-id-type="doi">10.3390/ijms17050749</pub-id></mixed-citation></ref><ref id="CR169"><label>382.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leistner</surname><given-names>DM</given-names></name><name><surname>Boeckel</surname><given-names>JN</given-names></name><name><surname>Reis</surname><given-names>SM</given-names></name><name><surname>Thome</surname><given-names>CE</given-names></name><name><surname>De Rosa</surname><given-names>R</given-names></name><name><surname>Keller</surname><given-names>T</given-names></name><name><surname>Palapies</surname><given-names>L</given-names></name><name><surname>Fichtlscherer</surname><given-names>S</given-names></name><name><surname>Dimmeler</surname><given-names>S</given-names></name><name><surname>Zeiher</surname><given-names>AM</given-names></name></person-group><article-title xml:lang="en">Transcoronary gradients of vascular miRNAs and coronary atherosclerotic plaque characteristics</article-title><source>Eur Heart J</source><year>2016</year><volume>37</volume><fpage>1738</fpage><lpage>1749</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehw047</pub-id></mixed-citation></ref><ref id="CR170"><label>383.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>DZ</given-names></name></person-group><article-title xml:lang="en">An epigenetic “LINK(RNA)” to pathological cardiac hypertrophy</article-title><source>Cell Metab</source><year>2014</year><volume>20</volume><fpage>555</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2014.09.011</pub-id></mixed-citation></ref><ref id="CR171"><label>384.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title xml:lang="en">Dawn of the Epi-lncRNAs: new path from myheart</article-title><source>Circ Res</source><year>2015</year><volume>116</volume><fpage>235</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.305490</pub-id></mixed-citation></ref><ref id="CR172"><label>385.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heggermont</surname><given-names>WA</given-names></name><name><surname>Papageorgiou</surname><given-names>AP</given-names></name><name><surname>Quaegebeur</surname><given-names>A</given-names></name><name><surname>Deckx</surname><given-names>S</given-names></name><name><surname>Carai</surname><given-names>P</given-names></name><name><surname>Verhesen</surname><given-names>W</given-names></name><name><surname>Eelen</surname><given-names>G</given-names></name><name><surname>Schoors</surname><given-names>S</given-names></name><name><surname>van Leeuwen</surname><given-names>R</given-names></name><name><surname>Alekseev</surname><given-names>S</given-names></name><name><surname>Elzenaar</surname><given-names>I</given-names></name><name><surname>Vinckier</surname><given-names>S</given-names></name><name><surname>Pokreisz</surname><given-names>P</given-names></name><name><surname>Walravens</surname><given-names>AS</given-names></name><name><surname>Gijsbers</surname><given-names>R</given-names></name><name><surname>van den Haute</surname><given-names>C</given-names></name><name><surname>Nickel</surname><given-names>A</given-names></name><name><surname>Schroen</surname><given-names>B</given-names></name><name><surname>van Bilsen</surname><given-names>M</given-names></name><name><surname>Janssens</surname><given-names>S</given-names></name><name><surname>Maack</surname><given-names>C</given-names></name><name><surname>Pinto</surname><given-names>Y</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name><name><surname>Heymans</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Inhibition of microRNA-146a and overexpression of its target dihydrolipoyl succinyltransferase protect against pressure overload-induced cardiac hypertrophy and dysfunction</article-title><source>Circulation</source><year>2017</year><volume>136</volume><fpage>747</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.024171</pub-id></mixed-citation></ref><ref id="CR173"><label>386.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demkes</surname><given-names>CJ</given-names></name><name><surname>van Rooij</surname><given-names>E</given-names></name></person-group><article-title xml:lang="en">MicroRNA-146a as a regulator of cardiac energy metabolism</article-title><source>Circulation</source><year>2017</year><volume>136</volume><fpage>762</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.029703</pub-id></mixed-citation></ref><ref id="CR174"><label>387.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>BH</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>YY</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>SJ</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Zhang</surname><given-names>SH</given-names></name><name><surname>Wu</surname><given-names>JH</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>B</given-names></name></person-group><article-title xml:lang="en">Circular noncoding RNA HIPK3 mediates retinal vascular dysfunction in diabetes mellitus</article-title><source>Circulation</source><year>2017</year><volume>136</volume><fpage>1629</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.029004</pub-id></mixed-citation></ref><ref id="CR175"><label>388.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Widmer</surname><given-names>RJ</given-names></name><name><surname>Lerman</surname><given-names>LO</given-names></name><name><surname>Lerman</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">MicroRNAs: small molecule, big potential for coronary artery disease</article-title><source>Eur Heart J</source><year>2016</year><volume>37</volume><fpage>1750</fpage><lpage>1752</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehw067</pub-id></mixed-citation></ref><ref id="CR176"><label>389.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navickas</surname><given-names>R</given-names></name><name><surname>Gal</surname><given-names>D</given-names></name><name><surname>Laucevičius</surname><given-names>A</given-names></name><name><surname>Taparauskaité</surname><given-names>A</given-names></name><name><surname>Zdanyté</surname><given-names>M</given-names></name><name><surname>Holvoet</surname><given-names>P</given-names></name></person-group><article-title xml:lang="en">Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review</article-title><source>Cardiovasc Res</source><year>2016</year><volume>111</volume><fpage>322</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvw174</pub-id></mixed-citation></ref><ref id="CR177"><label>390.</label><mixed-citation publication-type="other">Italiani P, Boraschi D (2014) From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol 5:514</mixed-citation></ref><ref id="CR178"><label>391.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sluijter</surname><given-names>JPG</given-names></name><name><surname>Pasterkamp</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">MicroRNAs. The swing voters in vascular disease waiting for a program</article-title><source>Circ Res</source><year>2017</year><volume>120</volume><fpage>5</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.310215</pub-id></mixed-citation></ref><ref id="CR179"><label>392.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Gregoli</surname><given-names>K</given-names></name><name><surname>Mohamad Anuar</surname><given-names>NN</given-names></name><name><surname>Bianco</surname><given-names>R</given-names></name><name><surname>White</surname><given-names>SJ</given-names></name><name><surname>Newby</surname><given-names>AC</given-names></name><name><surname>George</surname><given-names>SJ</given-names></name><name><surname>Johnson</surname><given-names>JL</given-names></name></person-group><article-title xml:lang="en">MicroRNA-181b controls atherosclerosis and aneurysms through regulation of TIMP-3 and elastin</article-title><source>Circ Res</source><year>2017</year><volume>120</volume><fpage>49</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309321</pub-id></mixed-citation></ref><ref id="CR180"><label>393.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>An</surname><given-names>TH</given-names></name><name><surname>He</surname><given-names>QW</given-names></name><name><surname>Xia</surname><given-names>YP</given-names></name><name><surname>Chen</surname><given-names>SC</given-names></name><name><surname>Baral</surname><given-names>S</given-names></name><name><surname>Mao</surname><given-names>L</given-names></name><name><surname>Jin</surname><given-names>HJ</given-names></name><name><surname>Li</surname><given-names>YN</given-names></name><name><surname>Wang</surname><given-names>MD</given-names></name><name><surname>Chen</surname><given-names>JG</given-names></name><name><surname>Zhu</surname><given-names>LQ</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name></person-group><source>MiR-181b antagonizes atherosclerotic plaque vulnerability through modulating macrophage polarization by directly targeting Notch1</source><year>2016</year><comment>Mol Neurobiol, https://doi.org/10.1007/s12035-016-0163-1</comment></mixed-citation></ref><ref id="CR181"><label>394.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henao-Mejia</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Goff</surname><given-names>LA</given-names></name><name><surname>Staron</surname><given-names>M</given-names></name><name><surname>Licona-Limón</surname><given-names>P</given-names></name><name><surname>Kaech</surname><given-names>SM</given-names></name><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group><article-title xml:lang="en">The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis</article-title><source>Immunity</source><year>2013</year><volume>38</volume><fpage>984</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.02.021</pub-id></mixed-citation></ref><ref id="CR182"><label>395.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro-Rodrigues</surname><given-names>TM</given-names></name><name><surname>Laundos</surname><given-names>TL</given-names></name><name><surname>Pereira-Carvalho</surname><given-names>R</given-names></name><name><surname>Batista-Almeida</surname><given-names>D</given-names></name><name><surname>Pereira</surname><given-names>R</given-names></name><name><surname>Coelho-Santos</surname><given-names>V</given-names></name><name><surname>Silva</surname><given-names>AP</given-names></name><name><surname>Fernandes</surname><given-names>R</given-names></name><name><surname>Zuzarte</surname><given-names>M</given-names></name><name><surname>Enguita</surname><given-names>FJ</given-names></name><name><surname>Costa</surname><given-names>MC</given-names></name><name><surname>Pinto-do-Ó</surname><given-names>P</given-names></name><name><surname>Pinto</surname><given-names>MT</given-names></name><name><surname>Gouveia</surname><given-names>P</given-names></name><name><surname>Ferreira</surname><given-names>L</given-names></name><name><surname>Mason</surname><given-names>JC</given-names></name><name><surname>Pereira</surname><given-names>P</given-names></name><name><surname>Kwak</surname><given-names>BR</given-names></name><name><surname>Nascimento</surname><given-names>DS</given-names></name><name><surname>Girão</surname><given-names>H</given-names></name></person-group><article-title xml:lang="en">Exosomes secreted by cardiomyocytes subjected to ischaemia promote cardiac angiogenesis</article-title><source>Cardiovasc Res</source><year>2017</year><volume>113</volume><fpage>1338</fpage><lpage>1350</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvx118</pub-id></mixed-citation></ref><ref id="CR183"><label>396.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maitrias</surname><given-names>P</given-names></name><name><surname>Metzinger-Le Meuth</surname><given-names>V</given-names></name><name><surname>Nader</surname><given-names>J</given-names></name><name><surname>Reix</surname><given-names>T</given-names></name><name><surname>Caus</surname><given-names>T</given-names></name><name><surname>Metzinger</surname><given-names>L</given-names></name></person-group><article-title xml:lang="en">The involvement of miRNA in carotid-related stroke</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2017</year><volume>37</volume><fpage>1608</fpage><lpage>1617</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.117.309233</pub-id></mixed-citation></ref><ref id="CR184"><label>397.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiedt</surname><given-names>S</given-names></name><name><surname>Prestel</surname><given-names>M</given-names></name><name><surname>Malik</surname><given-names>R</given-names></name><name><surname>Schieferdecker</surname><given-names>N</given-names></name><name><surname>Duering</surname><given-names>M</given-names></name><name><surname>Kautzky</surname><given-names>V</given-names></name><name><surname>Stoycheva</surname><given-names>I</given-names></name><name><surname>Böck</surname><given-names>J</given-names></name><name><surname>Northoff</surname><given-names>BH</given-names></name><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>Dorn</surname><given-names>F</given-names></name><name><surname>Krohn</surname><given-names>K</given-names></name><name><surname>Teupser</surname><given-names>D</given-names></name><name><surname>Liesz</surname><given-names>A</given-names></name><name><surname>Plesnila</surname><given-names>N</given-names></name><name><surname>Holdt</surname><given-names>LM</given-names></name><name><surname>Dichgans</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">RNA-Seq identifies circulating miR-125a-5p, miR-125b-5p, and miR-143-3p as potential biomarkers for acute ischemic stroke</article-title><source>Circ Res</source><year>2017</year><volume>121</volume><fpage>970</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.311572</pub-id></mixed-citation></ref><ref id="CR185"><label>398.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>WL</given-names></name><name><surname>Lim</surname><given-names>BT</given-names></name><name><surname>Anene-Nzelu</surname><given-names>CG</given-names></name><name><surname>Ackers-Johnson</surname><given-names>M</given-names></name><name><surname>Dashi</surname><given-names>A</given-names></name><name><surname>See</surname><given-names>K</given-names></name><name><surname>Tiang</surname><given-names>Z</given-names></name><name><surname>Lee</surname><given-names>DP</given-names></name><name><surname>Chua</surname><given-names>WW</given-names></name><name><surname>Luu</surname><given-names>TD</given-names></name><name><surname>Li</surname><given-names>PY</given-names></name><name><surname>Richards</surname><given-names>AM</given-names></name><name><surname>Foo</surname><given-names>RS</given-names></name></person-group><article-title xml:lang="en">A landscape of circular RNA expression in the human heart</article-title><source>Cardiovasc Res</source><year>2017</year><volume>113</volume><fpage>298</fpage><lpage>309</lpage></mixed-citation></ref><ref id="CR186"><label>399.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boeckel</surname><given-names>JN</given-names></name><name><surname>Jaé</surname><given-names>N</given-names></name><name><surname>Heumüller</surname><given-names>AW</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Boon</surname><given-names>RA</given-names></name><name><surname>Stellos</surname><given-names>K</given-names></name><name><surname>Zeiher</surname><given-names>AM</given-names></name><name><surname>John</surname><given-names>D</given-names></name><name><surname>Uchida</surname><given-names>S</given-names></name><name><surname>Dimmeler</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Identification and characterization of hypoxia-regulated endothelial circular RNA</article-title><source>Circ Res</source><year>2015</year><volume>117</volume><fpage>884</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.306319</pub-id></mixed-citation></ref><ref id="CR187"><label>400.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiser-Evans</surname><given-names>MCM</given-names></name></person-group><article-title xml:lang="en">Smooth muscle differentiation control comes full circle. The circular noncoding RNA, circActa2, functions as a miRNA sponge to fine-tune α-SMA expression</article-title><source>Circ Res</source><year>2017</year><volume>121</volume><fpage>591</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.311722</pub-id></mixed-citation></ref><ref id="CR188"><label>401.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ieguchi</surname><given-names>K</given-names></name><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Davari</surname><given-names>P</given-names></name><name><surname>Taniguchi</surname><given-names>Y</given-names></name><name><surname>Sekiguchi</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Takada</surname><given-names>YK</given-names></name><name><surname>Takada</surname><given-names>Y</given-names></name></person-group><article-title xml:lang="en">Direct binding of the EGF-like domain of neuregulin-1 to integrins (α<sub>V</sub>β<sub>3</sub> and α<sub>6</sub>β<sub>4</sub>) is involved in neuregulin-1/ErbB signaling</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>31388</fpage><lpage>31398</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.113878</pub-id></mixed-citation></ref><ref id="CR189"><label>402.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Zhang</surname><given-names>ML</given-names></name><name><surname>Zhao</surname><given-names>XS</given-names></name><name><surname>Zhao</surname><given-names>HY</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Wen</surname><given-names>JK</given-names></name></person-group><article-title xml:lang="en">A novel regulatory mechanism of smooth muscle α-actin expression by NRG-1/circACTA2/miR-548f-5p axis</article-title><source>Circ Res</source><year>2017</year><volume>121</volume><fpage>628</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.311441</pub-id></mixed-citation></ref><ref id="CR190"><label>403.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name></person-group><article-title xml:lang="en">The Ikaros family of zinc-finger proteins</article-title><source>Acta Pharm Sin B</source><year>2016</year><volume>6</volume><fpage>513</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2016.06.002</pub-id></mixed-citation></ref><ref id="CR191"><label>404.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>P</given-names></name><name><surname>Chang</surname><given-names>CP</given-names></name></person-group><article-title xml:lang="en">Myheart hits the core of chromatin</article-title><source>Cell Cycle</source><year>2015</year><volume>14</volume><fpage>787</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1080/15384101.2015.1010963</pub-id></mixed-citation></ref><ref id="CR192"><label>405.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>MC</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>QQ</given-names></name><name><surname>Xie</surname><given-names>HY</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>LM</given-names></name><name><surname>Chen</surname><given-names>LM</given-names></name><name><surname>Zheng</surname><given-names>SS</given-names></name></person-group><article-title xml:lang="en">Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation</article-title><source>Med Oncol</source><year>2012</year><volume>29</volume><fpage>1810</fpage><lpage>1816</lpage><pub-id pub-id-type="doi">10.1007/s12032-011-0004-z</pub-id></mixed-citation></ref><ref id="CR193"><label>406.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gast</surname><given-names>M</given-names></name><name><surname>Schroen</surname><given-names>B</given-names></name><name><surname>Voigt</surname><given-names>A</given-names></name><name><surname>Haas</surname><given-names>J</given-names></name><name><surname>Kuehl</surname><given-names>U</given-names></name><name><surname>Lassner</surname><given-names>D</given-names></name><name><surname>Skurk</surname><given-names>C</given-names></name><name><surname>Escher</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Kratzer</surname><given-names>A</given-names></name><name><surname>Michalik</surname><given-names>K</given-names></name><name><surname>Papageorgiou</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>T</given-names></name><name><surname>Loebel</surname><given-names>M</given-names></name><name><surname>Wilk</surname><given-names>S</given-names></name><name><surname>Althof</surname><given-names>N</given-names></name><name><surname>Prasanth</surname><given-names>KV</given-names></name><name><surname>Katus</surname><given-names>H</given-names></name><name><surname>Meder</surname><given-names>B</given-names></name><name><surname>Nakagawa</surname><given-names>S</given-names></name><name><surname>Scheibenbogen</surname><given-names>C</given-names></name><name><surname>Schultheiss</surname><given-names>HP</given-names></name><name><surname>Landmesser</surname><given-names>U</given-names></name><name><surname>Dimmeler</surname><given-names>S</given-names></name><name><surname>Heymans</surname><given-names>S</given-names></name><name><surname>Poller</surname><given-names>W</given-names></name></person-group><article-title xml:lang="en">Long noncoding RNA MALAT1-derived mascRNA is involved in cardiovascular innate immunity</article-title><source>J Mol Cell Biol</source><year>2016</year><volume>8</volume><fpage>178</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1093/jmcb/mjw003</pub-id></mixed-citation></ref><ref id="CR194"><label>407.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>XJ</given-names></name><name><surname>Ji</surname><given-names>YX</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Deng</surname><given-names>KQ</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Yokota</surname><given-names>T</given-names></name><name><surname>Ang</surname><given-names>YS</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Cass</surname><given-names>A</given-names></name><name><surname>Vondriska</surname><given-names>TM</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Deb</surname><given-names>A</given-names></name><name><surname>Srivastava</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>HT</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title xml:lang="en">The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy</article-title><source>Nat Med</source><year>2016</year><volume>22</volume><fpage>1131</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1038/nm.4179</pub-id></mixed-citation></ref><ref id="CR195"><label>408.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooke</surname><given-names>JP</given-names></name><name><surname>Leeper</surname><given-names>NJ</given-names></name></person-group><article-title xml:lang="en">A missing LNC in vascular diseases</article-title><source>Circ Res</source><year>2017</year><volume>121</volume><fpage>320</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.311493</pub-id></mixed-citation></ref><ref id="CR196"><label>409.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bischoff</surname><given-names>FC</given-names></name><name><surname>Werner</surname><given-names>A</given-names></name><name><surname>John</surname><given-names>D</given-names></name><name><surname>Boeckel</surname><given-names>JN</given-names></name><name><surname>Melissari</surname><given-names>MT</given-names></name><name><surname>Grote</surname><given-names>P</given-names></name><name><surname>Glaser</surname><given-names>SF</given-names></name><name><surname>Demolli</surname><given-names>S</given-names></name><name><surname>Uchida</surname><given-names>S</given-names></name><name><surname>Michalik</surname><given-names>KM</given-names></name><name><surname>Meder</surname><given-names>B</given-names></name><name><surname>Katus</surname><given-names>HA</given-names></name><name><surname>Haas</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Pullamsetti</surname><given-names>SS</given-names></name><name><surname>Seeger</surname><given-names>W</given-names></name><name><surname>Zeiher</surname><given-names>AM</given-names></name><name><surname>Dimmeler</surname><given-names>S</given-names></name><name><surname>Zehendner</surname><given-names>CM</given-names></name></person-group><article-title xml:lang="en">Identification and functional characterization of hypoxia-induced endoplasmic reticulum stress regulating lncRNA (HypERlnc) in pericytes</article-title><source>Circ Res</source><year>2017</year><volume>121</volume><fpage>368</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.310531</pub-id></mixed-citation></ref><ref id="CR197"><label>410.</label><mixed-citation publication-type="other">Liu SJ, Horlbeck MA, Cho SW, Birk HS, Malatesta M, He D, Attenello FJ, Villalta JE, Cho MY, Chen Y, Mandegar MA, Olvera MP, Gilbert LA, Conklin BR, Chang HY, Weissman JS, Lim DA (2017) CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. Science 355:eaah7111</mixed-citation></ref><ref id="CR198"><label>411.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalik</surname><given-names>KM</given-names></name><name><surname>You</surname><given-names>X</given-names></name><name><surname>Manavski</surname><given-names>Y</given-names></name><name><surname>Doddaballapur</surname><given-names>A</given-names></name><name><surname>Zörnig</surname><given-names>M</given-names></name><name><surname>Braun</surname><given-names>T</given-names></name><name><surname>John</surname><given-names>D</given-names></name><name><surname>Ponomareva</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Uchida</surname><given-names>S</given-names></name><name><surname>Boon</surname><given-names>RA</given-names></name><name><surname>Dimmeler</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth</article-title><source>Circ Res</source><year>2014</year><volume>114</volume><fpage>1389</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.303265</pub-id></mixed-citation></ref><ref id="CR199"><label>412.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>WJ</given-names></name><name><surname>Chen</surname><given-names>YW</given-names></name><name><surname>Shen</surname><given-names>F</given-names></name><name><surname>Zeng</surname><given-names>JY</given-names></name><name><surname>Wei</surname><given-names>YF</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>LM</given-names></name></person-group><article-title xml:lang="en">Expression changes of long noncoding RNA in the process of endothelial cell activation</article-title><source>Cell Physiol Biochem</source><year>2017</year><volume>41</volume><fpage>115</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1159/000455980</pub-id></mixed-citation></ref><ref id="CR200"><label>413.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name></person-group><article-title xml:lang="en">Long non-coding RNAs as regulators of angiogenesis: a mini-review</article-title><source>Cell Mol Med Res</source><year>2017</year><volume>1</volume><fpage>7</fpage><lpage>10</lpage></mixed-citation></ref><ref id="CR201"><label>414.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leisegang</surname><given-names>MS</given-names></name><name><surname>Fork</surname><given-names>C</given-names></name><name><surname>Josipovic</surname><given-names>I</given-names></name><name><surname>Richter</surname><given-names>FM</given-names></name><name><surname>Preussner</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>MJ</given-names></name><name><surname>Epah</surname><given-names>J</given-names></name><name><surname>Hofmann</surname><given-names>P</given-names></name><name><surname>Günther</surname><given-names>S</given-names></name><name><surname>Moll</surname><given-names>F</given-names></name><name><surname>Valasarajan</surname><given-names>C</given-names></name><name><surname>Heidler</surname><given-names>J</given-names></name><name><surname>Ponomareva</surname><given-names>Y</given-names></name><name><surname>Freiman</surname><given-names>MT</given-names></name><name><surname>Maegdefessel</surname><given-names>L</given-names></name><name><surname>Plate</surname><given-names>KH</given-names></name><name><surname>Mittelbronn</surname><given-names>M</given-names></name><name><surname>Uchida</surname><given-names>S</given-names></name><name><surname>Künne</surname><given-names>C</given-names></name><name><surname>Stellos</surname><given-names>K</given-names></name><name><surname>Schermuly</surname><given-names>RT</given-names></name><name><surname>Weissmann</surname><given-names>N</given-names></name><name><surname>Devraj</surname><given-names>K</given-names></name><name><surname>Wittig</surname><given-names>I</given-names></name><name><surname>Boon</surname><given-names>RA</given-names></name><name><surname>Dimmeler</surname><given-names>S</given-names></name><name><surname>Pullamsetti</surname><given-names>SS</given-names></name><name><surname>Looso</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>FJ</given-names></name><name><surname>Brandes</surname><given-names>RP</given-names></name></person-group><article-title xml:lang="en">Long noncoding RNA MANTIS facilitates endothelial angiogenic function</article-title><source>Circulation</source><year>2017</year><volume>136</volume><fpage>65</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.026991</pub-id></mixed-citation></ref><ref id="CR202"><label>415.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulberdaa</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>E</given-names></name><name><surname>Ballantyne</surname><given-names>M</given-names></name><name><surname>Garcia</surname><given-names>R</given-names></name><name><surname>Descamps</surname><given-names>B</given-names></name><name><surname>Angelini</surname><given-names>GD</given-names></name><name><surname>Brittan</surname><given-names>M</given-names></name><name><surname>Hunter</surname><given-names>A</given-names></name><name><surname>McBride</surname><given-names>M</given-names></name><name><surname>McClure</surname><given-names>J</given-names></name><name><surname>Miano</surname><given-names>JM</given-names></name><name><surname>Emanueli</surname><given-names>C</given-names></name><name><surname>Mills</surname><given-names>NL</given-names></name><name><surname>Mountford</surname><given-names>JC</given-names></name><name><surname>Baker</surname><given-names>AH</given-names></name></person-group><article-title xml:lang="en">A role for the long noncoding RNA SENCR in commitment and function of endothelial cells</article-title><source>Mol Ther</source><year>2016</year><volume>24</volume><fpage>978</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1038/mt.2016.41</pub-id></mixed-citation></ref><ref id="CR203"><label>416.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Jose</surname><given-names>PA</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">Plasma long non-coding RNA, CoroMarker, a novel biomarker for diagnosis of coronary artery disease</article-title><source>Clin Sci</source><year>2015</year><volume>129</volume><fpage>675</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1042/CS20150121</pub-id></mixed-citation></ref><ref id="CR204"><label>417.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savinainen</surname><given-names>JR</given-names></name><name><surname>Patel</surname><given-names>JZ</given-names></name><name><surname>Parkkari</surname><given-names>T</given-names></name><name><surname>Navia-Paldanius</surname><given-names>D</given-names></name><name><surname>Marjamaa</surname><given-names>JJ</given-names></name><name><surname>Laitinen</surname><given-names>T</given-names></name><name><surname>Nevalainen</surname><given-names>T</given-names></name><name><surname>Laitinen</surname><given-names>JT</given-names></name></person-group><article-title xml:lang="en">Biochemical and pharmacological characterization of the human lymphocyte antigen B-associated transcript 5 (BAT5/ABHD16A)</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0109869</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2014PLoSO...9j9869S</pub-id></mixed-citation></ref><ref id="CR205"><label>418.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spies</surname><given-names>T</given-names></name><name><surname>Bresnahan</surname><given-names>M</given-names></name><name><surname>Strominger</surname><given-names>JL</given-names></name></person-group><article-title xml:lang="en">Human major histocompatibility complex contains a minimum of 19 genes between the complement cluster and HLA-B</article-title><source>Proc Natl Acad Sci USA</source><year>1989</year><volume>86</volume><fpage>8955</fpage><lpage>8958</lpage><pub-id pub-id-type="doi">10.1073/pnas.86.22.8955</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">1989PNAS...86.8955S</pub-id></mixed-citation></ref><ref id="CR206"><label>419.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>YY</given-names></name><name><surname>Lin</surname><given-names>YJ</given-names></name><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>DY</given-names></name><name><surname>Hsu</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>YK</given-names></name><name><surname>Hsu</surname><given-names>KH</given-names></name><name><surname>Tsai</surname><given-names>FJ</given-names></name></person-group><article-title xml:lang="en">Human lymphocyte antigen B-associated transcript 2, 3, and 5 polymorphisms and haplotypes are associated with susceptibility of Kawasaki disease and coronary artery aneurysm</article-title><source>J Clin Lab Anal</source><year>2010</year><volume>24</volume><fpage>262</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1002/jcla.20409</pub-id></mixed-citation></ref><ref id="CR207"><label>420.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Jose</surname><given-names>PA</given-names></name><name><surname>Zeng</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name></person-group><article-title xml:lang="en">Circulating “lncRNA OTTHUMT00000387022” from monocytes as a novel biomarker for coronary artery disease</article-title><source>Cardiovasc Res</source><year>2016</year><volume>112</volume><fpage>714</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvw022</pub-id></mixed-citation></ref><ref id="CR208"><label>421.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klattenhoff</surname><given-names>CA</given-names></name><name><surname>Scheuermann</surname><given-names>JC</given-names></name><name><surname>Surface</surname><given-names>LE</given-names></name><name><surname>Bradley</surname><given-names>RK</given-names></name><name><surname>Fields</surname><given-names>PA</given-names></name><name><surname>Steinhauser</surname><given-names>ML</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><name><surname>Butty</surname><given-names>VL</given-names></name><name><surname>Torrey</surname><given-names>L</given-names></name><name><surname>Haas</surname><given-names>S</given-names></name><name><surname>Abo</surname><given-names>R</given-names></name><name><surname>Tabebordbar</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>RT</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Boyer</surname><given-names>LA</given-names></name></person-group><article-title xml:lang="en">Braveheart, a long noncoding RNA required for cardiovascular lineage commitment</article-title><source>Cell</source><year>2013</year><volume>152</volume><fpage>570</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.01.003</pub-id></mixed-citation></ref><ref id="CR209"><label>422.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grote</surname><given-names>P</given-names></name><name><surname>Herrmann</surname><given-names>BG</given-names></name></person-group><article-title xml:lang="en">The long non-coding RNA Fendrr links epigenetic control mechanisms to gene regulatory networks in mammalian embryogenesis</article-title><source>RNA Biol</source><year>2013</year><volume>10</volume><fpage>1579</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.4161/rna.26165</pub-id></mixed-citation></ref><ref id="CR210"><label>423.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>LY</given-names></name><name><surname>Long</surname><given-names>B</given-names></name><name><surname>Yuan</surname><given-names>SM</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>CY</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>XJ</given-names></name><name><surname>Li</surname><given-names>PF</given-names></name></person-group><article-title xml:lang="en">The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489</article-title><source>Circ Res</source><year>2014</year><volume>114</volume><fpage>1377</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.302476</pub-id></mixed-citation></ref><ref id="CR211"><label>424.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Shang</surname><given-names>C</given-names></name><name><surname>Nurnberg</surname><given-names>ST</given-names></name><name><surname>Jin</surname><given-names>KK</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Lin</surname><given-names>CJ</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Chien</surname><given-names>HC</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Ashley</surname><given-names>E</given-names></name><name><surname>Bernstein</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>PS</given-names></name><name><surname>Chen</surname><given-names>HS</given-names></name><name><surname>Quertermous</surname><given-names>T</given-names></name><name><surname>Chang</surname><given-names>CP</given-names></name></person-group><article-title xml:lang="en">A long noncoding RNA protects the heart from pathological hypertrophy</article-title><source>Nature</source><year>2014</year><volume>514</volume><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1038/nature13596</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2014Natur.514..102H</pub-id></mixed-citation></ref><ref id="CR212"><label>425.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Long</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>LY</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>QY</given-names></name><name><surname>Liu</surname><given-names>CY</given-names></name><name><surname>Fan</surname><given-names>YY</given-names></name><name><surname>Li</surname><given-names>PF</given-names></name></person-group><article-title xml:lang="en">CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume><fpage>3596</fpage><pub-id pub-id-type="doi">10.1038/ncomms4596</pub-id></mixed-citation></ref><ref id="CR213"><label>426.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>T</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title xml:lang="en">Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway</article-title><source>Cancer Res</source><year>2015</year><volume>75</volume><fpage>846</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-1192</pub-id></mixed-citation></ref><ref id="CR214"><label>427.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legnini</surname><given-names>I</given-names></name><name><surname>Morlando</surname><given-names>M</given-names></name><name><surname>Mangiavacchi</surname><given-names>A</given-names></name><name><surname>Fatica</surname><given-names>A</given-names></name><name><surname>Bozzoni</surname><given-names>I</given-names></name></person-group><article-title xml:lang="en">A feedforward regulatory loop between HuR and the long noncoding RNA linc-MD1 controls early phases of myogenesis</article-title><source>Mol Cell</source><year>2014</year><volume>53</volume><fpage>506</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.12.012</pub-id></mixed-citation></ref><ref id="CR215"><label>428.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name><name><surname>Shi</surname><given-names>KH</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>LP</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en">Long noncoding RNA H19 controls DUSP5/ERK1/2 axis in cardiac fibroblast proliferation and fibrosis</article-title><source>Cardiovasc Pathol</source><year>2016</year><volume>25</volume><fpage>381</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/j.carpath.2016.05.005</pub-id></mixed-citation></ref><ref id="CR216"><label>429.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>HH</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Su</surname><given-names>YM</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>M</given-names></name><name><surname>Cai</surname><given-names>XX</given-names></name><name><surname>Ji</surname><given-names>XP</given-names></name></person-group><article-title xml:lang="en">The circular RNA Cdr1as promotes myocardial infarction by mediating the regulation of miR7a on its target genes expression</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0151753</pub-id></mixed-citation></ref><ref id="CR217"><label>430.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viereck</surname><given-names>J</given-names></name><name><surname>Thum</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Long noncoding RNAs in pathological cardiac remodeling</article-title><source>Circ Res</source><year>2017</year><volume>120</volume><fpage>262</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.310174</pub-id></mixed-citation></ref><ref id="CR218"><label>431.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>M</given-names></name><name><surname>Pintacuda</surname><given-names>G</given-names></name><name><surname>Masui</surname><given-names>O</given-names></name><name><surname>Koseki</surname><given-names>Y</given-names></name><name><surname>Gdula</surname><given-names>M</given-names></name><name><surname>Cerase</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>D</given-names></name><name><surname>Mould</surname><given-names>A</given-names></name><name><surname>Innocent</surname><given-names>CV</given-names></name><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Schermelleh</surname><given-names>L</given-names></name><name><surname>Nesterova</surname><given-names>TB</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Brockdorff</surname><given-names>N</given-names></name></person-group><article-title xml:lang="en">PCGF3/5–PRC1 initiates Polycomb recruitment in X chromosome inactivation</article-title><source>Science</source><year>2017</year><volume>356</volume><fpage>1081</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1126/science.aal2512</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2017Sci...356.1081A</pub-id></mixed-citation></ref><ref id="CR219"><label>432.</label><mixed-citation publication-type="other">Viereck J, Kumarswamy R, Foinquinos A, Xiao K, Avramopoulos P, Kunz M, Dittrich M, Maetzig T, Zimmer K, Remke J, Just A, Fendrich J, Scherf K, Bolesani E, Schambach A, Weidemann F, Zweigerdt R, de Windt LJ, Engelhardt S, Dandekar T, Batkai S, Thum T (2016) Long noncoding RNA Chast promotes cardiac remodeling. Sci Transl Med 8:326ra22</mixed-citation></ref><ref id="CR220"><label>433.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumarswamy</surname><given-names>R</given-names></name><name><surname>Bauters</surname><given-names>C</given-names></name><name><surname>Volkmann</surname><given-names>I</given-names></name><name><surname>Maury</surname><given-names>F</given-names></name><name><surname>Fetisch</surname><given-names>J</given-names></name><name><surname>Holzmann</surname><given-names>A</given-names></name><name><surname>Lemesle</surname><given-names>G</given-names></name><name><surname>de Groote</surname><given-names>P</given-names></name><name><surname>Pinet</surname><given-names>F</given-names></name><name><surname>Thum</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure</article-title><source>Circ Res</source><year>2014</year><volume>114</volume><fpage>1569</fpage><lpage>1575</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.303915</pub-id></mixed-citation></ref><ref id="CR221"><label>434.</label><mixed-citation publication-type="other">Micheletti R, Plaisance I, Abraham BJ, Sarre A, Ting CC, Alexanian M, Maric D, Maison D, Nemir M, Young RA, Schroen B, González A, Ounzain S, Pedrazzini T (2017) The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci Transl Med 9:eaai9118</mixed-citation></ref><ref id="CR222"><label>435.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerszten</surname><given-names>RE</given-names></name><name><surname>Wang</surname><given-names>TJ</given-names></name></person-group><article-title xml:lang="en">The search for new cardiovascular biomarkers</article-title><source>Nature</source><year>2008</year><volume>451</volume><fpage>949</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1038/nature06802</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2008Natur.451..949G</pub-id></mixed-citation></ref><ref id="CR223"><label>436.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emmer</surname><given-names>BT</given-names></name><name><surname>Ginsburg</surname><given-names>D</given-names></name><name><surname>Desch</surname><given-names>KC</given-names></name></person-group><article-title xml:lang="en">Von Willebrand factor and ADAMTS13. Too much or too little of a good thing?</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2016</year><volume>36</volume><fpage>2281</fpage><lpage>2282</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.116.308531</pub-id></mixed-citation></ref><ref id="CR224"><label>437.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonneveld</surname><given-names>MA</given-names></name><name><surname>Franco</surname><given-names>OH</given-names></name><name><surname>Ikram</surname><given-names>MA</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Kavousi</surname><given-names>M</given-names></name><name><surname>de Maat</surname><given-names>MP</given-names></name><name><surname>Leebeek</surname><given-names>FW</given-names></name></person-group><article-title xml:lang="en">Von Willebrand Factor, ADAMTS13, and the risk of mortality: The Rotterdam Study</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2016</year><volume>36</volume><fpage>2446</fpage><lpage>2451</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.116.308225</pub-id></mixed-citation></ref><ref id="CR225"><label>438.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rydén</surname><given-names>L</given-names></name><name><surname>Buhlin</surname><given-names>K</given-names></name><name><surname>Ekstrand</surname><given-names>E</given-names></name><name><surname>de Faire</surname><given-names>U</given-names></name><name><surname>Gustafsson</surname><given-names>A</given-names></name><name><surname>Holmer</surname><given-names>J</given-names></name><name><surname>Kjellström</surname><given-names>B</given-names></name><name><surname>Lindahl</surname><given-names>B</given-names></name><name><surname>Norhammar</surname><given-names>A</given-names></name><name><surname>Nygren</surname><given-names>Å</given-names></name><name><surname>Näsman</surname><given-names>P</given-names></name><name><surname>Rathnayake</surname><given-names>N</given-names></name><name><surname>Svenungsson</surname><given-names>E</given-names></name><name><surname>Klinge</surname><given-names>B</given-names></name></person-group><article-title xml:lang="en">Periodontitis increases the risk of a first myocardial infarction: a report from the PAROKRANK study</article-title><source>Circulation</source><year>2016</year><volume>133</volume><fpage>576</fpage><lpage>583</lpage></mixed-citation></ref><ref id="CR226"><label>439.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>KC</given-names></name><name><surname>Gaze</surname><given-names>DC</given-names></name><name><surname>Collinson</surname><given-names>PO</given-names></name><name><surname>Marber</surname><given-names>MS</given-names></name></person-group><article-title xml:lang="en">Cardiac troponins: from myocardial infarction to chronic disease</article-title><source>Cardiovasc Res</source><year>2017</year><volume>113</volume><fpage>1708</fpage><lpage>1718</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvx183</pub-id></mixed-citation></ref><ref id="CR227"><label>440.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaier</surname><given-names>TE</given-names></name><name><surname>Twerenbold</surname><given-names>R</given-names></name><name><surname>Puelacher</surname><given-names>C</given-names></name><name><surname>Marjot</surname><given-names>J</given-names></name><name><surname>Imambaccus</surname><given-names>N</given-names></name><name><surname>Boeddinghaus</surname><given-names>J</given-names></name><name><surname>Nestelberger</surname><given-names>T</given-names></name><name><surname>Badertscher</surname><given-names>P</given-names></name><name><surname>Sabti</surname><given-names>Z</given-names></name><name><surname>Giménez</surname><given-names>MR</given-names></name><name><surname>Wildi</surname><given-names>K</given-names></name><name><surname>Hillinger</surname><given-names>P</given-names></name><name><surname>Grimm</surname><given-names>K</given-names></name><name><surname>Loeffel</surname><given-names>S</given-names></name><name><surname>Shrestha</surname><given-names>S</given-names></name><name><surname>Widmer</surname><given-names>DF</given-names></name><name><surname>Cupa</surname><given-names>J</given-names></name><name><surname>Kozhuharov</surname><given-names>N</given-names></name><name><surname>Miró</surname><given-names>Ò</given-names></name><name><surname>Martín-Sánchez</surname><given-names>FJ</given-names></name><name><surname>Morawiec</surname><given-names>B</given-names></name><name><surname>Rentsch</surname><given-names>K</given-names></name><name><surname>Lohrmann</surname><given-names>J</given-names></name><name><surname>Kloos</surname><given-names>W</given-names></name><name><surname>Osswald</surname><given-names>S</given-names></name><name><surname>Reichlin</surname><given-names>T</given-names></name><name><surname>Weber</surname><given-names>E</given-names></name><name><surname>Marber</surname><given-names>M</given-names></name><name><surname>Mueller</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">Direct comparison of cardiac myosin-binding protein C with cardiac troponins for the early diagnosis of acute myocardial infarction</article-title><source>Circulation</source><year>2017</year><volume>136</volume><fpage>1495</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.028084</pub-id></mixed-citation></ref><ref id="CR228"><label>441.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Olson</surname><given-names>KC</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Prosdocimo</surname><given-names>DA</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Jeyaraj</surname><given-names>D</given-names></name><name><surname>Youn</surname><given-names>JY</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Rau</surname><given-names>CD</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Ilkayeva</surname><given-names>O</given-names></name><name><surname>Gui</surname><given-names>WJ</given-names></name><name><surname>Williams</surname><given-names>NS</given-names></name><name><surname>Wynn</surname><given-names>RM</given-names></name><name><surname>Newgard</surname><given-names>CB</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Chuang</surname><given-names>DT</given-names></name><name><surname>Schulze</surname><given-names>PC</given-names></name><name><surname>Lynch</surname><given-names>C</given-names></name><name><surname>Jain</surname><given-names>MK</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title xml:lang="en">Catabolic defect of branched-chain amino acids promotes heart failure</article-title><source>Circulation</source><year>2016</year><volume>133</volume><fpage>2038</fpage><lpage>2049</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.020226</pub-id></mixed-citation></ref><ref id="CR229"><label>442.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klingenberg</surname><given-names>R</given-names></name><name><surname>Aghlmandi</surname><given-names>S</given-names></name><name><surname>Liebetrau</surname><given-names>C</given-names></name><name><surname>Räber</surname><given-names>L</given-names></name><name><surname>Gencer</surname><given-names>B</given-names></name><name><surname>Nanchen</surname><given-names>D</given-names></name><name><surname>Carballo</surname><given-names>D</given-names></name><name><surname>Akhmedov</surname><given-names>A</given-names></name><name><surname>Montecucco</surname><given-names>F</given-names></name><name><surname>Zoller</surname><given-names>S</given-names></name><name><surname>Brokopp</surname><given-names>C</given-names></name><name><surname>Heg</surname><given-names>D</given-names></name><name><surname>Jüni</surname><given-names>P</given-names></name><name><surname>Marti Soler</surname><given-names>H</given-names></name><name><surname>Marques-Vidal</surname><given-names>PM</given-names></name><name><surname>Vollenweider</surname><given-names>P</given-names></name><name><surname>Dörr</surname><given-names>O</given-names></name><name><surname>Rodondi</surname><given-names>N</given-names></name><name><surname>Mach</surname><given-names>F</given-names></name><name><surname>Windecker</surname><given-names>S</given-names></name><name><surname>Landmesser</surname><given-names>U</given-names></name><name><surname>von Eckardstein</surname><given-names>A</given-names></name><name><surname>Hamm</surname><given-names>CW</given-names></name><name><surname>Matter</surname><given-names>CM</given-names></name><name><surname>Lüscher</surname><given-names>TF</given-names></name></person-group><article-title xml:lang="en">Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><fpage>3493</fpage><lpage>3502</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx640</pub-id></mixed-citation></ref><ref id="CR230"><label>443.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Mo</surname><given-names>FE</given-names></name><name><surname>Lau</surname><given-names>LF</given-names></name></person-group><article-title xml:lang="en">The angiogenic factor Cyr61 activates a genetic program for wound healing in human skin fibroblasts</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>47329</fpage><lpage>47337</lpage><pub-id pub-id-type="doi">10.1074/jbc.M107666200</pub-id></mixed-citation></ref><ref id="CR231"><label>444.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Herrick</surname><given-names>DJ</given-names></name><name><surname>Rosenbloom</surname><given-names>J</given-names></name><name><surname>Chaqour</surname><given-names>B</given-names></name></person-group><article-title xml:lang="en">Cyr61 mediates the expression of VEGF, α<sub>V</sub>-integrin, and α-actin genes through cytoskeletally based mechanotransduction mechanisms in bladder smooth muscle cells</article-title><source>J Appl Physiol</source><year>2005</year><volume>98</volume><fpage>2344</fpage><lpage>2354</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.01093.2004</pub-id></mixed-citation></ref><ref id="CR232"><label>445.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smathers</surname><given-names>RL</given-names></name><name><surname>Petersen</surname><given-names>DR</given-names></name></person-group><article-title xml:lang="en">The human fatty acid-binding protein family: evolutionary divergences and functions</article-title><source>Hum Genomics</source><year>2011</year><volume>5</volume><fpage>170</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1186/1479-7364-5-3-170</pub-id></mixed-citation></ref><ref id="CR233"><label>446.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaninotto</surname><given-names>M</given-names></name><name><surname>Mion</surname><given-names>MM</given-names></name><name><surname>Novello</surname><given-names>E</given-names></name><name><surname>Altinier</surname><given-names>S</given-names></name><name><surname>Rocco</surname><given-names>S</given-names></name><name><surname>Cacciavillani</surname><given-names>L</given-names></name><name><surname>Perazzolo Marra</surname><given-names>M</given-names></name><name><surname>Iliceto</surname><given-names>S</given-names></name><name><surname>Plebani</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">Analytical and clinical evaluation of a new heart-type fatty acid-binding protein automated assay</article-title><source>Clin Chem Lab Med</source><year>2006</year><volume>44</volume><fpage>1383</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1515/CCLM.2006.246</pub-id></mixed-citation></ref><ref id="CR234"><label>447.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCann</surname><given-names>CJ</given-names></name><name><surname>Glover</surname><given-names>BM</given-names></name><name><surname>Menown</surname><given-names>IB</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>McEneny</surname><given-names>J</given-names></name><name><surname>Owens</surname><given-names>CG</given-names></name><name><surname>Smith</surname><given-names>B</given-names></name><name><surname>Sharpe</surname><given-names>PC</given-names></name><name><surname>Young</surname><given-names>IS</given-names></name><name><surname>Adgey</surname><given-names>JA</given-names></name></person-group><article-title xml:lang="en">Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T</article-title><source>Eur Heart J</source><year>2008</year><volume>29</volume><fpage>2843</fpage><lpage>2850</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehn363</pub-id></mixed-citation></ref><ref id="CR235"><label>448.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuseya</surname><given-names>T</given-names></name><name><surname>Furuhashi</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Hoshina</surname><given-names>K</given-names></name><name><surname>Mita</surname><given-names>T</given-names></name><name><surname>Ishimura</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Miura</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Ectopic fatty acid-binding protein 4 expression in the vascular endothelium is involved in neointima formation after vascular injury</article-title><source>J Am Heart Assoc</source><year>2017</year><volume>6</volume><pub-id pub-id-type="doi">10.1161/JAHA.117.006377</pub-id></mixed-citation></ref><ref id="CR236"><label>449.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tillett</surname><given-names>WS</given-names></name><name><surname>Francis</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus</article-title><source>J Exp Med</source><year>1930</year><volume>52</volume><fpage>561</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1084/jem.52.4.561</pub-id></mixed-citation></ref><ref id="CR237"><label>450.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pepys</surname><given-names>MB</given-names></name><name><surname>Hirschfield</surname><given-names>GM</given-names></name></person-group><article-title xml:lang="en">C-reactive protein: a critical update</article-title><source>J Clin Invest</source><year>2003</year><volume>111</volume><fpage>1805</fpage><lpage>1812</lpage><pub-id pub-id-type="doi">10.1172/JCI200318921</pub-id></mixed-citation></ref><ref id="CR238"><label>451.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turu</surname><given-names>MM</given-names></name><name><surname>Slevin</surname><given-names>M</given-names></name><name><surname>Matou</surname><given-names>S</given-names></name><name><surname>West</surname><given-names>D</given-names></name><name><surname>Rodríguez</surname><given-names>C</given-names></name><name><surname>Luque</surname><given-names>A</given-names></name><name><surname>Grau-Olivares</surname><given-names>M</given-names></name><name><surname>Badimon</surname><given-names>L</given-names></name><name><surname>Martinez-Gonzalez</surname><given-names>J</given-names></name><name><surname>Krupinski</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en">C-reactive protein exerts angiogenic effects on vascular endothelial cells and modulates associated signalling pathways and gene expression</article-title><source>BMC Cell Biol</source><year>2008</year><volume>9</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1186/1471-2121-9-47</pub-id></mixed-citation></ref><ref id="CR239"><label>452.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habersberger</surname><given-names>J</given-names></name><name><surname>Strang</surname><given-names>F</given-names></name><name><surname>Scheichl</surname><given-names>A</given-names></name><name><surname>Htun</surname><given-names>N</given-names></name><name><surname>Bassler</surname><given-names>N</given-names></name><name><surname>Merivirta</surname><given-names>RM</given-names></name><name><surname>Diehl</surname><given-names>P</given-names></name><name><surname>Krippner</surname><given-names>G</given-names></name><name><surname>Meikle</surname><given-names>P</given-names></name><name><surname>Eisenhardt</surname><given-names>SU</given-names></name><name><surname>Meredith</surname><given-names>I</given-names></name><name><surname>Peter</surname><given-names>K</given-names></name></person-group><article-title xml:lang="en">Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction</article-title><source>Cardiovasc Res</source><year>2012</year><volume>96</volume><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvs237</pub-id></mixed-citation></ref><ref id="CR240"><label>453.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khreiss</surname><given-names>T</given-names></name><name><surname>József</surname><given-names>L</given-names></name><name><surname>Potempa</surname><given-names>LA</given-names></name><name><surname>Filep</surname><given-names>JG</given-names></name></person-group><article-title xml:lang="en">Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils</article-title><source>Circ Res</source><year>2005</year><volume>97</volume><fpage>690</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000183881.11739.CB</pub-id></mixed-citation></ref><ref id="CR241"><label>454.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Rose</surname><given-names>L</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Cook</surname><given-names>NR</given-names></name></person-group><article-title xml:lang="en">Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><fpage>1557</fpage><lpage>1565</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa021993</pub-id></mixed-citation></ref><ref id="CR242"><label>455.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, Vago L, Pasqualini F, Signorini S, Soldateschi D, Tarli L, Schweiger C, Fresco C, Cecere R, Tognoni G, Mantovani A; Lipid Assessment Trial Italian Network (LATIN) Investigators</collab></person-group><article-title xml:lang="en">Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction</article-title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>2349</fpage><lpage>2354</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000145167.30987.2E</pub-id></mixed-citation></ref><ref id="CR243"><label>456.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Travers</surname><given-names>JG</given-names></name><name><surname>Schafer</surname><given-names>AE</given-names></name><name><surname>Blaxall</surname><given-names>BC</given-names></name></person-group><article-title xml:lang="en">GRK2 in lymphocytes. Expanding the arsenal of heart failure prognostics</article-title><source>Circ Res</source><year>2016</year><volume>118</volume><fpage>1049</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.308542</pub-id></mixed-citation></ref><ref id="CR244"><label>457.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rengo</surname><given-names>G</given-names></name><name><surname>Pagano</surname><given-names>G</given-names></name><name><surname>Perrone-Filardi</surname><given-names>P</given-names></name><name><surname>Femminella</surname><given-names>GD</given-names></name><name><surname>Parisi</surname><given-names>V</given-names></name><name><surname>Cannavo</surname><given-names>A</given-names></name><name><surname>Liccardo</surname><given-names>D</given-names></name><name><surname>Komici</surname><given-names>K</given-names></name><name><surname>Gambino</surname><given-names>G</given-names></name><name><surname>D’Amico</surname><given-names>ML</given-names></name><name><surname>de Lucia</surname><given-names>C</given-names></name><name><surname>Paolillo</surname><given-names>S</given-names></name><name><surname>Trimarco</surname><given-names>B</given-names></name><name><surname>Vitale</surname><given-names>DF</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Koch</surname><given-names>WJ</given-names></name><name><surname>Leosco</surname><given-names>D</given-names></name></person-group><article-title xml:lang="en">Prognostic value of lymphocyte G protein-coupled receptor kinase-2 protein levels in patients with heart failure</article-title><source>Circ Res</source><year>2016</year><volume>118</volume><fpage>1116</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.308207</pub-id></mixed-citation></ref><ref id="CR245"><label>458.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>R</given-names></name><name><surname>Schilling</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Carter</surname><given-names>RL</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Yoo</surname><given-names>SM</given-names></name><name><surname>Traynham</surname><given-names>CJ</given-names></name><name><surname>Koch</surname><given-names>WJ</given-names></name><name><surname>Cheung</surname><given-names>JY</given-names></name><name><surname>Tilley</surname><given-names>DG</given-names></name><name><surname>Benovic</surname><given-names>JL</given-names></name></person-group><article-title xml:lang="en">β-Arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction</article-title><source>Proc Natl Acad Sci USA</source><year>2016</year><volume>113</volume><fpage>E4107</fpage><lpage>E4116</lpage><pub-id pub-id-type="doi">10.1073/pnas.1606267113</pub-id></mixed-citation></ref><ref id="CR246"><label>459.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>SJ</given-names></name><name><surname>Bazzaz</surname><given-names>AA</given-names></name><name><surname>Arif</surname><given-names>AI</given-names></name></person-group><article-title xml:lang="en">Activity of the enzyme γ-glutamyl transferase (GGT) as a prognostic tool for heart failures</article-title><source>Adv Biosci Biotechnol</source><year>2017</year><volume>8</volume><fpage>324</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.4236/abb.2017.89024</pub-id></mixed-citation></ref><ref id="CR247"><label>460.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shobeiri</surname><given-names>N</given-names></name><name><surname>Bendeck</surname><given-names>MP</given-names></name></person-group><article-title xml:lang="en">Interleukin-1β is a key biomarker and mediator of inflammatory vascular calcification</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2017</year><volume>37</volume><fpage>179</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.116.308724</pub-id></mixed-citation></ref><ref id="CR248"><label>461.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceneri</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Young</surname><given-names>BD</given-names></name><name><surname>Healy</surname><given-names>A</given-names></name><name><surname>Coskun</surname><given-names>S</given-names></name><name><surname>Vasavada</surname><given-names>H</given-names></name><name><surname>Yarovinsky</surname><given-names>TO</given-names></name><name><surname>Ike</surname><given-names>K</given-names></name><name><surname>Pardi</surname><given-names>R</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Tellides</surname><given-names>G</given-names></name><name><surname>Hirschi</surname><given-names>K</given-names></name><name><surname>Meadows</surname><given-names>J</given-names></name><name><surname>Soufer</surname><given-names>R</given-names></name><name><surname>Chun</surname><given-names>HJ</given-names></name><name><surname>Sadeghi</surname><given-names>M</given-names></name><name><surname>Bender</surname><given-names>JR</given-names></name><name><surname>Morrison</surname><given-names>AR</given-names></name></person-group><article-title xml:lang="en">Rac2 modulates atherosclerotic calcification by regulating macrophage interleukin-1β production</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2017</year><volume>37</volume><fpage>328</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.116.308507</pub-id></mixed-citation></ref><ref id="CR249"><label>462.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loyer</surname><given-names>X</given-names></name><name><surname>Vion</surname><given-names>AC</given-names></name><name><surname>Tedgui</surname><given-names>A</given-names></name><name><surname>Boulanger</surname><given-names>CM</given-names></name></person-group><article-title xml:lang="en">Microvesicles as cell–cell messengers in cardiovascular diseases</article-title><source>Circ Res</source><year>2014</year><volume>114</volume><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.113.300858</pub-id></mixed-citation></ref><ref id="CR250"><label>463.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolios</surname><given-names>G</given-names></name><name><surname>Valatas</surname><given-names>V</given-names></name><name><surname>Kouroumalis</surname><given-names>E</given-names></name></person-group><article-title xml:lang="en">Role of Kupffer cells in the pathogenesis of liver disease</article-title><source>World J Gastroenterol</source><year>2006</year><volume>12</volume><fpage>7413</fpage><lpage>7420</lpage><pub-id pub-id-type="doi">10.3748/wjg.v12.i46.7413</pub-id></mixed-citation></ref><ref id="CR251"><label>464.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>F</given-names></name><name><surname>Nickenig</surname><given-names>G</given-names></name><name><surname>Werner</surname><given-names>N</given-names></name></person-group><article-title xml:lang="en">Extracellular vesicles in cardiovascular disease. Potential applications in diagnosis, prognosis, and epidemiology</article-title><source>Circ Res</source><year>2017</year><volume>120</volume><fpage>1649</fpage><lpage>1657</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.310752</pub-id></mixed-citation></ref><ref id="CR252"><label>465.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>HK</given-names></name><name><surname>Jang</surname><given-names>JJ</given-names></name><name><surname>Kaji</surname><given-names>S</given-names></name><name><surname>Spektor</surname><given-names>G</given-names></name><name><surname>Fong</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>BS</given-names></name><name><surname>Schatzman</surname><given-names>R</given-names></name><name><surname>Quertermous</surname><given-names>T</given-names></name><name><surname>Cooke</surname><given-names>JP</given-names></name></person-group><article-title xml:lang="en">Developmental endothelial locus-1 (Del-1), a novel angiogenic protein: its role in ischemia</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>1314</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000118465.36018.2D</pub-id></mixed-citation></ref><ref id="CR253"><label>466.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kowal</surname><given-names>J</given-names></name><name><surname>Arras</surname><given-names>G</given-names></name><name><surname>Colombo</surname><given-names>M</given-names></name><name><surname>Jouve</surname><given-names>M</given-names></name><name><surname>Morath</surname><given-names>JP</given-names></name><name><surname>Primdal-Bengtson</surname><given-names>B</given-names></name><name><surname>Dingli</surname><given-names>F</given-names></name><name><surname>Loew</surname><given-names>D</given-names></name><name><surname>Tkach</surname><given-names>M</given-names></name><name><surname>Théry</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes</article-title><source>Proc Natl Acad Sci USA</source><year>2016</year><volume>113</volume><fpage>E968</fpage><lpage>E977</lpage><pub-id pub-id-type="doi">10.1073/pnas.1521230113</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2016PNAS..113E.968K</pub-id></mixed-citation></ref><ref id="CR254"><label>467.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez</surname><given-names>MC</given-names></name></person-group><article-title xml:lang="en">Extracellular vesicles: small but strong</article-title><source>Cardiovasc Res</source><year>2013</year><volume>100</volume><fpage>350</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvt242</pub-id></mixed-citation></ref><ref id="CR255"><label>468.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aliotta</surname><given-names>JM</given-names></name><name><surname>Pereira</surname><given-names>M</given-names></name><name><surname>Amaral</surname><given-names>A</given-names></name><name><surname>Sorokina</surname><given-names>A</given-names></name><name><surname>Igbinoba</surname><given-names>Z</given-names></name><name><surname>Hasslinger</surname><given-names>A</given-names></name><name><surname>El-Bizri</surname><given-names>R</given-names></name><name><surname>Rounds</surname><given-names>SI</given-names></name><name><surname>Quesenberry</surname><given-names>PJ</given-names></name><name><surname>Klinger</surname><given-names>JR</given-names></name></person-group><article-title xml:lang="en">Induction of pulmonary hypertensive changes by extracellular vesicles from monocrotaline-treated mice</article-title><source>Cardiovasc Res</source><year>2013</year><volume>100</volume><fpage>354</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvt184</pub-id></mixed-citation></ref><ref id="CR256"><label>469.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imjeti</surname><given-names>NS</given-names></name><name><surname>Menck</surname><given-names>K</given-names></name><name><surname>Egea-Jimenez</surname><given-names>AL</given-names></name><name><surname>Lecointre</surname><given-names>C</given-names></name><name><surname>Lembo</surname><given-names>F</given-names></name><name><surname>Bouguenina</surname><given-names>H</given-names></name><name><surname>Badache</surname><given-names>A</given-names></name><name><surname>Ghossoub</surname><given-names>R</given-names></name><name><surname>David</surname><given-names>G</given-names></name><name><surname>Roche</surname><given-names>S</given-names></name><name><surname>Zimmermann</surname><given-names>P</given-names></name></person-group><article-title xml:lang="en">Syntenin mediates SRC function in exosomal cell-to-cell communication</article-title><source>Proc Natl Acad Sci USA</source><year>2017</year><volume>114</volume><fpage>12495</fpage><lpage>12500</lpage><pub-id pub-id-type="doi">10.1073/pnas.1713433114</pub-id></mixed-citation></ref><ref id="CR257"><label>470.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aliotta</surname><given-names>JM</given-names></name><name><surname>Pereira</surname><given-names>M</given-names></name><name><surname>Wen</surname><given-names>S</given-names></name><name><surname>Dooner</surname><given-names>MS</given-names></name><name><surname>Del Tatto</surname><given-names>M</given-names></name><name><surname>Papa</surname><given-names>E</given-names></name><name><surname>Goldberg</surname><given-names>LR</given-names></name><name><surname>Baird</surname><given-names>GL</given-names></name><name><surname>Ventetuolo</surname><given-names>CE</given-names></name><name><surname>Quesenberry</surname><given-names>PJ</given-names></name><name><surname>Klinger</surname><given-names>JR</given-names></name></person-group><article-title xml:lang="en">Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice</article-title><source>Cardiovasc Res</source><year>2016</year><volume>110</volume><fpage>319</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvw054</pub-id></mixed-citation></ref><ref id="CR258"><label>471.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>W</given-names></name><name><surname>Riopel</surname><given-names>M</given-names></name><name><surname>Bandyopadhyay</surname><given-names>G</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Birmingham</surname><given-names>A</given-names></name><name><surname>Seo</surname><given-names>JB</given-names></name><name><surname>Ofrecio</surname><given-names>JM</given-names></name><name><surname>Wollam</surname><given-names>J</given-names></name><name><surname>Hernandez-Carretero</surname><given-names>A</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Olefsky</surname><given-names>JM</given-names></name></person-group><article-title xml:lang="en">Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity</article-title><source>Cell</source><year>2017</year><volume>171</volume><fpage>372</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.08.035</pub-id></mixed-citation></ref><ref id="CR259"><label>472.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Oh</surname><given-names>DY</given-names></name><name><surname>Bandyopadhyay</surname><given-names>G</given-names></name><name><surname>Lagakos</surname><given-names>WS</given-names></name><name><surname>Talukdar</surname><given-names>S</given-names></name><name><surname>Osborn</surname><given-names>O</given-names></name><name><surname>Johnson</surname><given-names>A</given-names></name><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Maris</surname><given-names>M</given-names></name><name><surname>Ofrecio</surname><given-names>JM</given-names></name><name><surname>Taguchi</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Olefsky</surname><given-names>JM</given-names></name></person-group><article-title xml:lang="en">LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes</article-title><source>Nat Med</source><year>2015</year><volume>21</volume><fpage>239</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1038/nm.3800</pub-id></mixed-citation></ref><ref id="CR260"><label>473.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bošnjak</surname><given-names>I</given-names></name><name><surname>Bedeković</surname><given-names>D</given-names></name><name><surname>Selthofer-Relatić</surname><given-names>K</given-names></name><name><surname>Bilić-Ćurčić</surname><given-names>I</given-names></name></person-group><article-title xml:lang="en">Galectin-3: a heart failure biomarker as sign of active coronary heart disease</article-title><source>World J Cardiovasc Dis</source><year>2017</year><volume>7</volume><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.4236/wjcd.2017.711035</pub-id></mixed-citation></ref><ref id="CR261"><label>474.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Chu</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title xml:lang="en">A feed-forward loop between lncARSR and YAP activity promotes expansion of renal tumour-initiating cells</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>12692</fpage><pub-id pub-id-type="doi">10.1038/ncomms12692</pub-id><pub-id pub-id-type="other" assigning-authority="NASA Astrophysics Data System">2016NatCo...712692Q</pub-id></mixed-citation></ref><ref id="CR262"><label>475.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>ZJ</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>XF</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>ZY</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>YM</given-names></name><name><surname>Fang</surname><given-names>ZY</given-names></name><name><surname>Xu</surname><given-names>ZP</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>DS</given-names></name><name><surname>Miao</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>HY</given-names></name><name><surname>Sun</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Wang</surname><given-names>LH</given-names></name></person-group><article-title xml:lang="en">Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA</article-title><source>Cancer Cell</source><year>2016</year><volume>29</volume><fpage>653</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.03.004</pub-id></mixed-citation></ref><ref id="CR263"><label>476.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbas</surname><given-names>M</given-names></name><name><surname>Jesel</surname><given-names>L</given-names></name><name><surname>Auger</surname><given-names>C</given-names></name><name><surname>Amoura</surname><given-names>L</given-names></name><name><surname>Messas</surname><given-names>N</given-names></name><name><surname>Manin</surname><given-names>G</given-names></name><name><surname>Rumig</surname><given-names>C</given-names></name><name><surname>León-González</surname><given-names>AJ</given-names></name><name><surname>Ribeiro</surname><given-names>TP</given-names></name><name><surname>Silva</surname><given-names>GC</given-names></name><name><surname>Abou-Merhi</surname><given-names>R</given-names></name><name><surname>Hamade</surname><given-names>E</given-names></name><name><surname>Hecker</surname><given-names>M</given-names></name><name><surname>Georg</surname><given-names>Y</given-names></name><name><surname>Chakfe</surname><given-names>N</given-names></name><name><surname>Ohlmann</surname><given-names>P</given-names></name><name><surname>Schini-Kerth</surname><given-names>VB</given-names></name><name><surname>Toti</surname><given-names>F</given-names></name><name><surname>Morel</surname><given-names>O</given-names></name></person-group><article-title xml:lang="en">Endothelial microparticles from acute coronary syndrome patients induce premature coronary artery endothelial cell aging and thrombogenicity. Role of the Ang II/AT<sub>1</sub> receptor/NADPH oxidase-mediated activation of MAPKs and PI3-kinase pathways</article-title><source>Circulation</source><year>2017</year><volume>135</volume><fpage>280</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.017513</pub-id></mixed-citation></ref><ref id="CR264"><label>477.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maisel</surname><given-names>AS</given-names></name><name><surname>Di Somma</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2)</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><fpage>2325</fpage><lpage>2333</lpage></mixed-citation></ref><ref id="CR265"><label>478.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waeber</surname><given-names>B</given-names></name><name><surname>Feihl</surname><given-names>F</given-names></name></person-group><article-title xml:lang="en">Plasma renin levels: the lower the better in terms of cardiovascular risk?</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><fpage>2634</fpage><lpage>2635</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehs245</pub-id></mixed-citation></ref><ref id="CR266"><label>479.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhardwaj</surname><given-names>A</given-names></name><name><surname>Januzzi</surname><given-names>JL</given-names></name></person-group><article-title xml:lang="en">ST2: a novel biomarker for heart failure</article-title><source>Expert Rev Mol Diagn</source><year>2010</year><volume>10</volume><fpage>459</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1586/erm.10.25</pub-id></mixed-citation></ref><ref id="CR267"><label>480.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dieplinger</surname><given-names>B</given-names></name><name><surname>Mueller</surname><given-names>T</given-names></name></person-group><article-title xml:lang="en">Soluble ST2 in heart failure</article-title><source>Clin Chim Acta</source><year>2015</year><volume>443</volume><fpage>57</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2014.09.021</pub-id></mixed-citation></ref><ref id="CR268"><label>481.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>S</given-names></name><name><surname>Ridley</surname><given-names>AJ</given-names></name><name><surname>Lutz</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">The function of Rho-associated kinases ROCK1 and ROCK2 in the pathogenesis of cardiovascular disease</article-title><source>Front Pharmacol</source><year>2015</year><volume>6</volume><fpage>276</fpage><pub-id pub-id-type="doi">10.3389/fphar.2015.00276</pub-id></mixed-citation></ref><ref id="CR269"><label>482.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surma</surname><given-names>M</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en">Rho kinase as a therapeutic target in cardiovascular disease</article-title><source>Future Cardiol</source><year>2011</year><volume>7</volume><fpage>657</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.2217/fca.11.51</pub-id></mixed-citation></ref><ref id="CR270"><label>483.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimokawa</surname><given-names>H</given-names></name><name><surname>Satoh</surname><given-names>K</given-names></name></person-group><article-title xml:lang="en">Translational research on Rho-kinase in cardiovascular medicine</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2015</year><volume>35</volume><fpage>1756</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.115.305353</pub-id></mixed-citation></ref><ref id="CR271"><label>484.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filep</surname><given-names>JG</given-names></name></person-group><article-title xml:lang="en">Context-dependent signalling in platelets in vascular diseases: ROCK2 around thrombosis</article-title><source>Cardiovasc Res</source><year>2017</year><volume>113</volume><fpage>1267</fpage><lpage>1269</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvx141</pub-id></mixed-citation></ref><ref id="CR272"><label>485.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sladojevic</surname><given-names>N</given-names></name><name><surname>Oh</surname><given-names>GT</given-names></name><name><surname>Kim</surname><given-names>HH</given-names></name><name><surname>Beaulieu</surname><given-names>LM</given-names></name><name><surname>Falet</surname><given-names>H</given-names></name><name><surname>Kamiński</surname><given-names>K</given-names></name><name><surname>Freedman</surname><given-names>JE</given-names></name><name><surname>Liao</surname><given-names>JK</given-names></name></person-group><article-title xml:lang="en">Decreased thromboembolic stroke but not atherosclerosis or vascular remodelling in mice with ROCK2-deficient platelets</article-title><source>Cardiovasc Res</source><year>2017</year><volume>113</volume><fpage>1307</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvx071</pub-id></mixed-citation></ref><ref id="CR273"><label>486.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merkus</surname><given-names>D</given-names></name><name><surname>Tune</surname><given-names>JD</given-names></name></person-group><article-title xml:lang="en">ROCK as a molecular bond connecting coronary microvascular and cardiac remodelling</article-title><source>Cardiovasc Res</source><year>2017</year><volume>113</volume><fpage>1273</fpage><lpage>1275</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvx139</pub-id></mixed-citation></ref><ref id="CR274"><label>487.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>SH</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Hein</surname><given-names>TW</given-names></name><name><surname>Kuo</surname><given-names>L</given-names></name></person-group><article-title xml:lang="en">Enhanced endothelin-1/Rho-kinase signalling and coronary microvascular dysfunction in hypertensive myocardial hypertrophy</article-title><source>Cardiovasc Res</source><year>2017</year><volume>113</volume><fpage>1329</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvx103</pub-id></mixed-citation></ref></ref-list></ref-list><fn-group><fn id="Fn1"><label>1</label><p id="Par4">Prognosis, in general, refers to the expected course of a disease without treatment (natural prognosis) or after treatment (clinical prognosis). Prognosis is determined by certain endpoints (e.g., absence of complication recurrence). Prognosis is ameliorated by the technical improvement of medical and surgical interventions.</p></fn><fn id="Fn2"><label>2</label><p id="Par24">Plasmatic LDL concentration is generally not measured directly; it is instead estimated from its cholesterol concentration (LDL<sup>CS</sup>), a measure of the total amount of cholesterol contained in LDLs [<xref ref-type="bibr" rid="CR13">225</xref>]. In general, LDL<sup>CS</sup> concentration and LDL number are highly correlated. However, in the metabolic syndrome, diabetes, and hypertriglyceridemia, plasmatic concentrations of LDL and LDL<sup>CS</sup> become discordant because of the predominance of small, dense, cholesterol-poor LDLs. Therefore, plasmatic LDL<sup>CS</sup> concentration does not accurately reflect LDL concentration, requiring measurement of LDL number and apolipoprotein B (ApoB) concentration.</p></fn><fn id="Fn3"><label>3</label><p id="Par56">The risk for <index-term id="ITerm15"><term>Stroke</term></index-term>stroke is twice as high in Black American people than in the White American population [<xref ref-type="bibr" rid="CR18">230</xref>]. In North America, Hispanic and Latino Americans are at an increased risk for stroke. American Indians have an increased incidence of stroke compared with non-Hispanic Whites.</p></fn><fn id="Fn4"><label>4</label><p id="Par60">PCSK, proprotein convertase subtilisin/kexin. The secretory proprotein convertase (PC) category comprises nine members (PCSK1–PCSK9). The first member, PCSK1, is also called neuroendocrine convertase NEC1 and prohormone and PC1 and PC3; PCSK3 corresponds to furin (FUR: FeS upstream region) and PCSK8 to membrane-bound transcription factor site-1 peptidase (MBTPS1), or simply site peptidase S1P, and subtilisin–kexin isozyme SKI1, which cleaves membrane-bound transcription factors at nonbasic residues [<xref ref-type="bibr" rid="CR21">233</xref>]. PCSK9 cleaves itself once, and the secreted inactive peptidase transfers low- (LDLR) and very-low-density lipoprotein receptors (VLDLRs) to the endosomal compartment for lysosomal degradation. It reduces inflammation in a LDLR-dependent manner [<xref ref-type="bibr" rid="CR21">233</xref>].</p></fn><fn id="Fn5"><label>5</label><p id="Par70">Although some smokers neither experience an infarct nor develop a cancer, smoking represents a strong risk factor for atherosclerosis and aneurysms.</p></fn><fn id="Fn6"><label>6</label><p id="Par74">Nutrient restriction and changes in dietary composition improve health during aging. In people (age 20–70 years) who consume a fasting mimicking diet (FMD; low in sugars and proteins but high in unsaturated lipids) for 5 days per month for 3 months and maintain their normal diet during the other periods in addition to their lifestyle and in control subjects who have an unrestricted diet for 3 months and who then switch to the fasting mode, FMD can reduce body weight and lipid-based depot, blood pressure, concentrations of insulin-like growth factor (IGF1), fasting glucose, triglycerides (TGs), total cholesterol, LDL<sup>CS</sup>, and CRP, especially in individuals at risk for CVD [<xref ref-type="bibr" rid="CR24">236</xref>].</p></fn><fn id="Fn7"><label>7</label><p id="Par82">The <sub>NT</sub>proBNP fragment is a HF marker used to evaluate its severity.</p></fn><fn id="Fn8"><label>8</label><p id="Par87"><sup>D</sup>Dimer signals the presence of a <index-term id="ITerm23"><term>Thrombus</term></index-term>thrombus. Plasmatic<sup>D</sup>dimer measurement is used when <index-term id="ITerm24"><term>deep vein thrombosis</term></index-term>deep vein thrombosis and <index-term id="ITerm25"><term>Pulmonary embolism</term></index-term>pulmonary embolism are suspected (concentration≥250 ng/ml) [<xref ref-type="bibr" rid="CR25">237</xref>]. <sup>D</sup>Dimer is the degradation product of crosslinked fibrin by coagulation factor-<italic>XIII</italic> and hence reflects activated hemostasis. Venous thrombosis usually results from venous stasis due to immobility or obstruction, a hypercoagulable state linked to triggers of the blood coagulation cascade, and possible wall injury.</p></fn><fn id="Fn9"><label>9</label><p id="Par91">Cardiac troponins cTnnT and cTnnI in addition to <index-term id="ITerm27"><term>CK</term></index-term>creatine kinase (CK) are widely used markers when myocardial infarction is suspected owing to their sensitivity and specificity for cardiomyocyte (CMC) necrosis.</p></fn><fn id="Fn10"><label>10</label><p id="Par100">Intensive statin therapy to lower LDL concentration has severe side effects.</p></fn><fn id="Fn11"><label>11</label><p id="Par105">TMAO is synthesized from trimethylamine (TMA), which is generated by the action of gut microbiota from dietary choline and phosphatidylcholine (lecithin). The gut microbial metabolism of trimethylammonium-containing nutrients (e.g., choline, phosphatidylcholine, and <sup>L</sup>carnitine) forms TMA. In the liver, flavin-containing monooxygenase (FMO) converts TMA into TMAO. TMA is a gas that is oxygenated within living animals to form TMAO by FMO1 and FMO3. It can also be produced from <sup>L</sup>carnitine that is first converted into the intermediate metabolite γ-butyrobetaine and then into TMA, which is subsequently processed into TMAO by host hepatic FMO3 [<xref ref-type="bibr" rid="CR31">243</xref>]. Trimethylamine oxide accumulates in organs as an osmolyte or is eliminated by the kidney. Several bacterial categories produce TMA and TMAO, Anaeroplasmataceae, Deferribacteraceae, Enterobacteriaceae, and Prevotellaceae. In the human intestine, eight species from two different phyla (Firmicutes and Proteobacteria) and six genera (Anaerococcus hydrogenalis, Clostridium asparagiforme, hathewayi, and sporogenes, Escherichia fergusonii, Proteus penneri, Providencia rettgeri, and Edwardsiella tarda) and the choline-degrading sulfate-reducing bacterium Desulfovibrio desulfuricans synthesize TMA from choline. Trimethylamine oxide can be metabolized to small methylated amines, such as tri-, di-, and monomethylamine, which are precursors of marine aerosols and the greenhouse gas nitrous oxide in the marine atmosphere [<xref ref-type="bibr" rid="CR31">243</xref>].</p></fn><fn id="Fn12"><label>12</label><p id="Par106">The term <italic>elasmobranch</italic> refers to cartilaginous fishes, such as sharks, sawfish, rays, and skates, which are endowed with rows of replaceable teeth and the five to seven gill slits on each side of their body. Selachians (group Selachii) consist of the sharks and dogfishes. Fishes of the class <italic>Chondrichthyes</italic> possess a cartilaginous skeleton, whereas bony fishes of the class <italic>Osteichthyes</italic> have a bony skeleton. The subclass Elasmobranchii contains about 1150 species of saltwater- and freshwater-dwelling fishes, which have various sizes and shapes, from the giant whale shark and huge manta ray to the dwarf lanternshark and tiny short-nosed electric ray, and from the hammerhead shark to sawfish.</p></fn><fn id="Fn13"><label>13</label><p id="Par107">In organisms that concentrate urea as an osmolyte and buoyancy factor, TMAO restores protein structure and their enzyme function [<xref ref-type="bibr" rid="CR31">243</xref>].</p></fn><fn id="Fn14"><label>14</label><p id="Par116">Typical background concentrations of PM<sub>10</sub> in North America or Western Europe range from 20 to 50 μg/m<sup>3</sup> [<xref ref-type="bibr" rid="CR34">246</xref>].</p></fn><fn id="Fn15"><label>15</label><p id="Par130">Release by activated endothelium of CD62+ (selectin+ ) microparticles is linked to a high inflammatory state that accompanies acute cardiovascular events.</p></fn><fn id="Fn16"><label>16</label><p id="Par140">Outdoor air pollution is carcinogenic to humans. The PM component of air pollution is associated with increased cancer incidence, especially cancer of the lung [<xref ref-type="bibr" rid="CR43">255</xref>].</p></fn><fn id="Fn17"><label>17</label><p id="Par164">Aerosol particle equivalent diameter describes the size of nonspherical particles defined according to a specific physical property or measurement technique (aerodynamic, mobility, volume, mass, envelop, and projected area equivalent diameter). The aerodynamic equivalent diameter is defined as the diameter of a spherical particle with unit density that has the same terminal settling velocity as the actual particle.</p></fn><fn id="Fn18"><label>18</label><p id="Par185">Nanoparticles have at least 1 dimension smaller than 100 nm. Airborne nanoparticles are referred to as nano-aerosols and ultrafine PMs. They are produced mainly by combustion (transportation, indoor fumes, smoking, heating biomass, burning) and nanotechnology (e.g., use of injectable and inhalable drugs and tracers). Other sources include polymers, laser printers, and photocopiers, along with cleaning, agriculture, and welding. Nanoparticles have a large surface area-to-volume ratio, hence a higher surface reactivity. Their deposition in the pulmonary acinus is high (&gt; 90%), hence facilitating subsequent entry into the bloodstream.</p></fn><fn id="Fn19"><label>19</label><p id="Par207">Angiotensin-2 (<italic>II</italic>) is also abbreviated as Ang<italic>II</italic>.</p></fn><fn id="Fn20"><label>20</label><p id="Par214">A consensus sequence is an amino acid sequence of proteins that is generally used for intra- or intermolecular interactions, which enables the classification of functional sites [<xref ref-type="bibr" rid="CR58">270</xref>]. Phosphorylation sites recognized by kinases represent a first type of consensus sequence. Another consensus sequence type is the <italic>leucine zipper</italic> in DNA-binding proteins, every seventh amino acid residue being a leucine.</p></fn><fn id="Fn21"><label>21</label><p id="Par216">In humans, LysRS generates diadenosine tetraphosphate (AP<sub>4</sub>A) to activate mastocytes. This signaling effector binds to histidine triad nucleotide-binding protein HinT (HinT1), also called adenosine 5<italic>′</italic>-monophosphoramidase and protein kinase-C inhibitor PKCI1 (PKCNH1), thereby lowering its interaction with the transcription factor MiTF (bHLHe32) that then dissociates from LysRS and HinT, which transactivates its responsive genes [<xref ref-type="bibr" rid="CR57">269</xref>]. Once it is released by TNFSF1 (tumor-necrosis factor-α, one member of the TNF superfamily consisting of 19 ligands and 29 receptors), LysRS is secreted and can then also act as a proinflammatory cytokine that binds to macrophages, thereby priming TNFSF1 production and migration (positive feedback loop). TNFSF1 activates NFκB and the MAPK module (ERKs, P38MAPKs, and JNKs).</p></fn><fn id="Fn22"><label>22</label><p id="Par218">Mitochondrial TyrRS and LeuRS possess a splicing factor-like activity; they assist in the excision of group-<italic>I</italic> introns [<xref ref-type="bibr" rid="CR59">271</xref>].</p></fn><fn id="Fn23"><label>23</label><p id="Par220">The UPR comprises a set of signaling cascades that are activated in response to accumulation of unfolded proteins in the endoplasmic reticulum (ER). These pathways slow translation and raise protein degradation but augment production of UPR mediators. When it fails, continued UPR activation triggers apoptosis. Loss-of-function mutations in aaRSs and molecules that bind to aaRSs (e.g., inhibitors of glutamyl–prolyl– and Thr–tRNA synthetase halofuginone and borrelidin, respectively) along with nutrient depletion can provoke ER stress and elicit the UPR [<xref ref-type="bibr" rid="CR60">272</xref>].</p></fn><fn id="Fn24"><label>24</label><p id="Par221">Increased concentrations of unfolded proteins activate eIF2α K3 in the endoplasmic reticulum membrane, which phosphorylates eukaryotic initiation factor eiF2α and activates ATF4, an inducer of the transcription of genes involved in protein degradation, translation, and autophagy.</p></fn><fn id="Fn25"><label>25</label><p id="Par223">Most of the JmjC domain-containing proteins function as demethylases, a subgroup serving as histone demethylases, affecting chromatin accessibility and subsequently gene transcription. Many members of the JmjC category are involved in cellular differentiation and proliferation. JmjD8 synthesis is upregulated during endothelial differentiation of murine embryonic stem cells (ESCs). JmjD8 is exclusively detected in the cytoplasm [<xref ref-type="bibr" rid="CR62">274</xref>].</p></fn><fn id="Fn26"><label>26</label><p id="Par224">Members of the JmjC category regulate angiogenesis, such as JmjC domain-containing histone demethylase JHDM1b (KDM2b), which elicits endothelial network formation in vitro via fibroblast growth factor (FGF2); bifunctional arginine demethylase and lysyl hydroxylase JMJD6, which acts in endothelial sprouting via Vegfr1 splicing control; and Jumonji and ARID domain-containing demethylase JARID1b (KDM5b), which represses transcription of the proangiogenic genes HOXA5 and Ccl14 [<xref ref-type="bibr" rid="CR62">274</xref>]. Hypoxia induces the production of several JmjC domain-containing proteins, such as JHDM2a (KDM3a) and JmjD2b (KDM4b) to JmjD2d (KDM4c).</p></fn><fn id="Fn27"><label>27</label><p id="Par227">LncRNAs are transcribed by RNA polymerase-2 upon stimulation in a cell type-specific manner. They control the spatiotemporal pattern of gene transcription and determine the developmental stage [<xref ref-type="bibr" rid="CR63">275</xref>].</p></fn><fn id="Fn28"><label>28</label><p id="Par228">LncRNAs can act as molecular sponges. In particular, they can function as sinks for RNA-binding proteins, such as transcription factors, chromatin modifiers, or other regulators, in addition to miRs and splicing factors [<xref ref-type="bibr" rid="CR63">275</xref>].</p></fn><fn id="Fn29"><label>29</label><p id="Par229">LncRNAs can serve not only as scaffolds but also as guides for epigenetic and transcription factors. They can bind to proteins and hence determine the localization of ribonucleoproteic complexes. They can guide in cis (on neighboring genes) or trans (on distant genes) [<xref ref-type="bibr" rid="CR63">275</xref>].</p></fn><fn id="Fn30"><label>30</label><p id="Par230">LncRNAs can serve as platforms for relevant molecules, simultaneously tethering multiple effectory partners, which may then act as transcriptional activators or repressors [<xref ref-type="bibr" rid="CR63">275</xref>].</p></fn><fn id="Fn31"><label>31</label><p id="Par232">The letter Y refers to the cytoplasmic location and the term Ro to the patient name in whom it was first identified.</p></fn><fn id="Fn32"><label>32</label><p id="Par234">The term La also refers to the name of the patient in whom it was first identified. The protein La is required for the accurate and efficient termination of transcription by RNA polymerase-3 and binds the 3<italic>′</italic>-polyuridine tail of newly synthesized RNAs in the nucleus [<xref ref-type="bibr" rid="CR64">276</xref>]. In addition to Ro60 and La, several other proteins interact with a subset of <sup>Y</sup>RNAs such as nucleolin.</p></fn><fn id="Fn33"><label>33</label><p id="Par235">The most common type of autoantibody in lupus is an antinuclear antibody.</p></fn><fn id="Fn34"><label>34</label><p id="Par236">Sjögren’s syndrome affects glands such as those that produce tears and saliva. In fact, it alters the entire body, most commonly in older women.</p></fn><fn id="Fn35"><label>35</label><p id="Par238">The SRP connects to the nascent peptide that emerges from the large subunit of the ribosome and then targets the nascent polypeptide–ribosome complex to the SRP receptor in the rough endoplasmic reticulum.</p></fn><fn id="Fn36"><label>36</label><p id="Par240">Also known as vault1.</p></fn><fn id="Fn37"><label>37</label><p id="Par241">Poly<sup>ADP</sup>ribose polymerase PARP4 is also termed vault poly<sup>ADP</sup>ribose polymerase (VPARP) and vault3.</p></fn><fn id="Fn38"><label>38</label><p id="Par242">Telomerase-associated protein TEP1 is also named vault2.</p></fn><fn id="Fn39"><label>39</label><p id="Par243">Vault RNA2-1 is also called cord blood lymphocyte-derived ncRNA CBL3.</p></fn><fn id="Fn40"><label>40</label><p id="Par245">For example, steroid receptor activator (SRA) is an ncRNA that, dependently and independently of ligands, acts as a transcriptional coactivator supporting transactivation mediated by steroid hormone nuclear receptors and encodes steroid receptor RNA activator SRA1 (or SRAP) that antagonizes SRA ncRNA at steroid hormone receptors [<xref ref-type="bibr" rid="CR67">279</xref>–<xref ref-type="bibr" rid="CR68">281</xref>]. The ncRNA SRA, DDX5, and DDX17 are coactivators of myogenic differentiation factor MyoD1 (a.k.a., myogenic factor MyF3 and bHLHc1) [<xref ref-type="bibr" rid="CR10">194</xref>].</p></fn><fn id="Fn41"><label>41</label><p id="Par247">The transcript that encodes MyoD family inhibitor domain-containing protein MDFIC binds to and translationally activates positive transcription elongation factor PTEFb, as it removes <index-term id="ITerm128"><term><sup>7SK</sup>RNA</term></index-term><sup>7SK</sup>RNA from the inhibitory complex formed by hexamethylene bis-acetamide-inducible protein (HEXIMs) and <sup>7SK</sup>RNA [<xref ref-type="bibr" rid="CR70">283</xref>]. The PTEFb factor is also a protein kinase that phosphorylates RNA polymerase-2 in addition to other transcription factors. It is composed of CDK9 and cyclin CcnT1, CcnT2, or CcnK. Two genes encode small cytoplasmic <sup>7S</sup>RNA species K and L, which are transcribed by RNA polymerase-3.</p></fn><fn id="Fn42"><label>42</label><p id="Par248">Also known as tumor protein that is translationally controlled TPT1 (or TCPT), histamine-releasing factor, and p23.</p></fn><fn id="Fn43"><label>43</label><p id="Par254">DGCR: DiGeorge syndrome critical region gene product.</p></fn><fn id="Fn44"><label>44</label><p id="Par255">Argonaute proteins (Ago1–Ago4) form the core of the RISC. They serve as binding modules for small RNAs, including microRNAs. Only one strand of the short double-stranded precursor, the guide strand, is linked to the Ago protein. During a loading step, the small dsRNA dicer product binds to Ago. Then, the passenger strand is displaced and the guide strand is stably linked to Ago. Only Ago2 is catalytically active, whereas Ago1, Ago3, and Ago4 operate on miRs independently of cleavage. Ago2 cleaves the passenger strand and displaces it. The bound small RNA strand guides Ago to complementary target sites on mRNAs. On the mRNA, Agos recruit a member of the TNRC6 family (TNRC6: trinucleotide repeat-containing glycine–tryptophan-enriched proteins [TNRC6a–TNRC6c]). These scaffolds recruit de-adenylation enzymes that remove the polyadenylated tail of the mRNA [<xref ref-type="bibr" rid="CR71">284</xref>]. Afterward, decapping enzymes are recruited and mRNA is degraded.</p><p id="Par256">Argonautes are targets of regulatory post-translational modifications. When miR genesis is impaired, Agos are ubiquitinated and degraded in the proteasome. On the other hand, hydroxylation of Pro700 increases Ago stability [<xref ref-type="bibr" rid="CR71">284</xref>]. Their parylation impedes their repression in stress granules. Ago2 is phosphorylated at Ser387 by the MAPK module, thereby affecting localization of Agos into processing bodies, and by PKB3, shifting Ago2 activity from cleavage to translational repression. A C-terminal Ser–Thr cluster is phosphorylated at five residues. In humans, hyperphosphorylation does not affect microRNA binding, localization, or cleavage activity of Ago2, but mRNA binding [<xref ref-type="bibr" rid="CR71">284</xref>].</p></fn><fn id="Fn45"><label>45</label><p id="Par269">Members of the MIR200 family form two clusters in humans, genes encoding miR200b, miR200a, and miR429 residing in chromosome 1 (1p36 locus) and miR200c and miR141 in chromosome 12 (12p13 locus).</p><p id="Par270">Both ROS and NO induce expression of MIR200 family members. Nitric oxide promotes differentiation of ESCs to the mesendoderm and then cardiovascular lineages directly and via MIR200 family members. In ECs subjected to hydrogen peroxide (200 μmol/l; exposure period range 8–24 h), miR200c and miR141 are the most upregulated miRs, their synthesis rising more than eightfold [<xref ref-type="bibr" rid="CR77">290</xref>]. In addition, miR200c targets the apoptosis inhibitor PTPn13, thereby sensitizing tumoral cells to apoptosis.</p><p id="Par271">In addition, <index-term id="ITerm140"><term>Hypoxia</term></index-term>hypoxia favors formation of miR429 that targets HIF1α.</p><p id="Par272"><index-term id="ITerm141"><term>Cancer</term></index-term>Furthermore, <index-term id="ITerm142"><term>Epithelial–mesenchymal transition</term></index-term>MiR200 family members inhibit epithelial–mesenchymal transition (EMT), as they target <index-term id="ITerm143"><term>ZEB</term></index-term>the transcriptional repressors of the CDH1 gene that encodes E-cadherin, zinc finger-containing E-box-binding homeobox-derived (homeodomain-containing) proteins ZEB1 and ZEB2 [<xref ref-type="bibr" rid="CR78">291</xref>].</p><p id="Par273">Epithelial–mesenchymal (EMT) and mesenchymal–epithelial transitions (METs) occur in tumorigenesis. E-cadherin maintains the epithelial phenotype. On the other hand, EMT is characterized by the loss of E-cadherin, cell polarity, cell–cell and cell–matrix contact, in addition to gain in cell motility. Various transcription factors (FoxC1, Snai1, Twist, ZEB1, and ZEB2) induce EMT transition.</p><p id="Par274">MiRs favor tumor development (miR21, miR155, and members of the miR17-92 cluster) or suppress it (Let7, miR15a, miR16, and miR34a) [<xref ref-type="bibr" rid="CR78">291</xref>]. Several miRs support metastasis (miR10b, miR21, miR373, and miR520c) or impede it (miR126, miR200, and miR335). Conversely, ZEB1 can repress production of miR141 and miR200c. In addition, ZEB1 and ZEB2 prevent the production of crumbs homolog Crb3 and lethal giant larvae homolog LLGL2, which are involved in the establishment of epitheliocyte polarity.</p><p id="Par275">Nanog, an important ESC agent, represses transcription of the MIR200B and MIR200B genes, at least in colorectal cancerous cells [<xref ref-type="bibr" rid="CR79">292</xref>].</p><p id="Par276">MiR200 promotes METs, as it suppresses multiple members of the ZEB2 and Snai1 transcriptional repressor complexes [<xref ref-type="bibr" rid="CR80">293</xref>]. MiR200c targets cartilage-associated protein, FHOD1 (formin homology-2 domain-containing protein), Map3k1, Mapk12, Smad2, Smad5, Snai1, TOB1 (transducer of ERBB2/HER2), Xbp1, YWHAB (14-3-3β), YWHAG (14-3-3γ), and Zfp36, Smad2 and Smad5 binding to ZEB2, and 14-3-3β and 14-3-3γ to Snai1 [<xref ref-type="bibr" rid="CR80">293</xref>]. MiR200 suppresses TGFβ and bone morphogenetic protein (BMP) signaling, promoting epithelial gene expression and suppressing cell invasion. Conversely, TGFβ downregulates expression of MIR200 family members.</p></fn><fn id="Fn46"><label>46</label><p id="Par279"><italic>Mechano-miRs</italic> include miR19a, miR21, miR23b, miR92a, miR101, miR126, miR145, miR148a, miR155, miR221, and miR663 [<xref ref-type="bibr" rid="CR81">294</xref>].</p></fn><fn id="Fn47"><label>47</label><p id="Par280">RARα: retinoid acid receptor-α (NR1b1); RARE: retinoid acid-responsive element; RXRα: retinoid X receptor-α (NR2b1). RARs recruit RXRs to activate gene expression and HDACs to inhibit gene transcription.</p></fn><fn id="Fn48"><label>48</label><p id="Par282">Also known as cellubrevin and synaptobrevin-3.</p></fn><fn id="Fn49"><label>49</label><p id="Par293">Glycosidases hydrolyze carbohydrate chains. <italic>Exoglycosidases</italic> release monosaccharides from nonreducing ends of oligosaccharides and sugar chains of glycoproteins and glycolipids (e.g., α-fucosidase and β-galactosidase). <italic>Endoglycosidases</italic>, which were originally detected in bacteria and plants, and now identified in mammals and hence humans, hydrolyze the inner part of the sugar chains. They process N- and O-linked sugar chains of glycoproteins. Polysaccharide lyases cleave specific glycosidic linkages in acidic polysaccharides and depolymerize GAGs. This category of enzymes includes heparin and HS lyases (heparinases and heparitinases), chondroitin lyases (chondroitinases), and hyaluronate lyases (hyaluronidases). Heparin lyase-1 (heparinase) degrades heparin and very weakly HS, whereas heparin lyase-3 (heparitinase) degrades HS, but not other GAGs.</p><p id="Par294">Macrophages cocultured with vascular smooth myocytes degrade HSPGs of the vSMC surface, decrease the myofilament number within vSMCs, and induce vSMC phenotypic change [<xref ref-type="bibr" rid="CR84">297</xref>].</p></fn><fn id="Fn50"><label>50</label><p id="Par297">Heparan sulfate (HS) chains of HSPGs determine ligand binding and hence function. They contain N-sulfated, acetylated, and unmodified glucosamine and O-sulfate groups at characteristic positions.</p><p id="Par298">Heparan sulfate 6-O-endosulfatases, Sulf1 and Sulf2, selectively remove sulfate from the C6 position of glucosamine in the HS chain, desulfating HSPG and preventing signaling due to decayed interaction between growth factors and their coreceptors on the cell surface and, hence, diminishing the cell proliferation rate but facilitating apoptosis in response to stimuli.</p></fn><fn id="Fn51"><label>51</label><p id="Par307">Two types of actin nucleation factors, the actin-related protein ARP2–ARP3 complex and formins, nucleate branched actin meshwork and linear filamentous actin, respectively, in lamellipodia and filopodia. Activity of the ARP2–ARP3 complex, which is weak, increases upon its interaction with nucleation-promoting factors. Nucleation-promoting factors (NPFs) are classified into two sets. Set-<italic>I</italic> NPFs are further categorized into five subsets [<xref ref-type="bibr" rid="CR87">300</xref>]: (1) Wiskott–Aldrich syndrome protein (WAS or WASP) and WAS-like (WASL or neural WASP [nWASP]); (2) WASP family verprolin homolog (wave); (3) WASP and SCAR homolog (WASH); (4) WASP homolog associated with actin, membranes, and microtubules (WHAMM); and (5) junction-mediating and regulatory protein, which acts both as a nuclear P53 cofactor and as a cytoplasmic regulator of actin dynamics. Set-<italic>II</italic> NPFs contains a major member, cortactin, which interacts with the ARP2–ARP3 complex and enhances its actin nucleation activity. Cortactin also interacts with WAS and WASL, synergistically activating the ARP2–ARP3 complex by WAS, WASL, and cortactin. In addition, actin elongation factors, such as proteins of the Ena/VASP (enabled homolog and vasodilator-stimulated phosphoprotein) family, regulate the extension of lamellipodia and filopodia. Formins also function as actin elongation factors.</p><p id="Par308">The wave proteins (wave1–wave3) promote actin nucleation by the ARP2–ARP3 complex via the wave regulatory complex (WRC), which scaffolds actin monomers and the ARP2–ARP3 complex. ERK phosphorylates wave2 and Abl interactor AbI1, a WRC component, enabling interaction of WRC with the ARP2–ARP3 complex and actin [<xref ref-type="bibr" rid="CR87">300</xref>].</p><p id="Par309">The monomeric GTPases, CDC42, Rac, and Rho, regulate the activity and localization of effectors, activating actin nucleation factors and P21-activated kinase (PAK). The latter phosphorylates (activates) LIMK, which phosphorylates (inhibits) actin-severing cofilin, and (activates) filamin-A, a <sup>F</sup>actin crosslinker [<xref ref-type="bibr" rid="CR87">300</xref>]. Guanine nucleotide-exchange factors (GEFs) activate small GTPases, whereas GTPase-activating proteins (GAPs) inactivate them. Extracellular-signal-regulated kinase (ERK) phosphorylates (inhibits) RhoGAP31, a GAP for Rac and CDC42, Furthermore, among the three Rac isozymes (Rac1–Rac3), ERK phosphorylates (inhibits) Rac1 in the cytosol, but launches Rac1 translocation to the nucleus, promoting cell proliferation rather than motion.</p></fn><fn id="Fn52"><label>52</label><p id="Par311">SH3 domain-containing protein SH3P2 is also called SH3 domain-containing protein SH3D3 and mainly osteoclast-stimulating factor OSF1, an intracellular protein produced by osteoclasts that indirectly promotes osteoclast formation and bone resorption.</p></fn><fn id="Fn53"><label>53</label><p id="Par312">Myosin-1E interacts with both cell membranes and actin filaments. Class-<italic>I</italic> myosins can serve as crosslinkers that connect and generate force between actin filaments and membranes, thereby regulating plasma membrane tension. The Myo1e SH3 domain acts as a recruiter of effectors involved in myosin-based and actin nucleation-based force generation at the plasma membrane, such as dynamin, synaptojanin-1, and the WASL–WIPF1 (nWASP–WIP) complex at the membrane–cytoskeleton interface [<xref ref-type="bibr" rid="CR88">301</xref>].</p></fn><fn id="Fn54"><label>54</label><p id="Par326">Filamentous actin-associated proteins, such as caldesmon, calponin, smoothelin, and tropomyosin, regulate actomyosin interaction and thus smooth muscle contraction. Calponin binds to actin in a Ca<sup>2+</sup>-independent manner in smooth myocytes, thereby lessening <sup>Mg</sup>ATPase activity and hence the actomyosin crossbridge cycling rate up to arresting actin filament movement. Calponin–actin interaction is suppressed, and inhibition by calponin of the actomyosin <sup>Mg</sup>ATPase is relieved upon phosphorylation of calponin by PKC or CamK2. Actin-linked caldesmon also inhibits actomyosin <sup>Mg</sup>ATPase and thus lowers actin sliding velocity; inhibition of actomyosin <sup>Mg</sup>ATPase is also reversed by caldesmon phosphorylation.</p></fn><fn id="Fn55"><label>55</label><p id="Par329">The first glycoprotein of the OLFM (olfactomedin) family was discovered in the olfactory neuroepithelium of the bullfrog, Rana catesbeiana. This member is secreted into the nasal lumen, where it homopolymerizes at the lower mucus layer in contact with chemosensory dendritic cilia and was assumed to serve as a differentiation signal for dendritic knobs of chemosensory neurons, which are replaced throughout adult life from stem cells in the base of the olfactory neuroepithelium [<xref ref-type="bibr" rid="CR90">303</xref>].</p><p id="Par330">The family of olfactomedin domain-containing proteins consists of 13 known members in mammals. Most of these proteins are secreted glycoproteins, other family members being membrane-bound proteins that may serve as receptors [<xref ref-type="bibr" rid="CR91">304</xref>]. They operate in neurogenesis, neural crest formation, dorsal ventral patterning, intercellular adhesion, cell cycle regulation, and tumorigenesis. They modulate Wnt and BMP signaling.</p><p id="Par331">Olfactomedins possess the canonical olfactomedin sequence. They intervene in the early neurogenesis, functional organization of the nervous system, and synaptic stability, in addition to hematopoiesis. They also play a role in cell adhesion and differentiation. They are categorized into eight subsets in the animal kingdom, the subset <italic>II</italic> including the family of latrophilins, which are G-protein-coupled receptors with an extracellular olfactomedin domain near the N-terminus [<xref ref-type="bibr" rid="CR90">303</xref>]. Human olfactomedins and olfactomedin-like proteins (OlfmL) are encoded by different genes (OLFM1–OLFM4, OLFML1, OLFML2A–OLFML2B, and OLFML3, GLDN [gliomedin, or colmedin], LPHN1–LPHN3 [latrophilins], and MYOC [myocilin]) [<xref ref-type="bibr" rid="CR91">304</xref>].</p><p id="Par332">The neuronal olfactomedin, Olfm1 (a.k.a. noelin-1 and pancortin), which abounds in the hippocampus and cortex, is also expressed in the embryonic heart. Olfm2 (or noelin-2) resides in the pancreas and prostate, Olfm3 (or optimedin) in the cerebellum, and Olfm4 (or tiarin) in the small intestine, colon, and prostate [<xref ref-type="bibr" rid="CR90">303</xref>]. The secreted glycoprotein OlfmL1 is highly expressed in the heart, lung, small intestine, liver, and spleen (but not in the brain) [<xref ref-type="bibr" rid="CR91">304</xref>]. OlfmL2a and Olfm2b (photomedin-1 and -2) form homodimers and oligomers, OlfmL2a being predominantly detected in the photoreceptor layer and OlfmL2b in the retina. OlfmL3 is preferentially formed in the placenta. Gliomedin is a type-<italic>II</italic> transmembrane protein, which can be cleaved by BMP1 and tolloid-like metallopeptidases. It is synthesized in the central and peripheral nervous systems. Latrophilins Lphn1 and Lphn3 (or lectomedin-1 to -3) are preferentially produced in the brain and retina and Lphn2 in other organs [<xref ref-type="bibr" rid="CR91">304</xref>].</p><p id="Par333">Myocilin belongs to a family of olfactomedin domain-containing proteins. It abounds in various types of muscles (e.g., the ocular ciliary muscle, papillary sphincter, skeletal muscles, and the heart). This OLFM member is also called trabecular meshwork-induced glucocorticoid response protein (TIGR), glaucoma-1A primary open angle (Glc1a, or GPOA), and juvenile-onset primary open-angle glaucoma (JOAG1), as gain-of-function MYOC gene mutations at the GLC1A locus on chromosomal locus 1q21-q31 engender autosomal dominant juvenile- and adult-onset primary open-angle glaucoma, a gradual blindness due to ocular neuropathies involving retinal ganglion cell death and the optic nerve layer. Myocilin and its two proteolytic fragments, N- and C-terminal fragments, are synthesized in the eye, that is, the retina, iris, optic nerve, in addition to the trabecular meshwork and ocular ciliary body, which regulate aqueous humor secretion in the anterior ocular chamber and hence intraocular pressure (IOP), abnormally high IOP levels being a strong risk factor in primary open angle glaucoma. This secreted glycoprotein regulates activation of different pathways in adjacent cells to control cell–matrix and cell–cell adhesion; cytoskeleton organization, which involves activation of Rac1 and JNK; and cell migration using the FAK1–PI3K axis. Myocilin induces stress fiber formation via the Wnt pathway; its action is repressed by secreted frizzled-related protein sFRP1 and sFRP3 (which are not highly produced in the sites of myocilin synthesis) and Wnt inhibitory factor WIF1 [<xref ref-type="bibr" rid="CR92">305</xref>]. Myocilin is a regulator of muscle hypertrophy through the components of dystrophin-associated protein complex (DAPC). It interacts with α1-syntrophin, a DAPC component, and provokes phosphorylation of several regulators of muscle size [<xref ref-type="bibr" rid="CR93">306</xref>]. It does indeed support the association of α1-syntrophin, NOS1, and α-dystroglycan with DAPC, thereby promoting binding of laminin to α-dystroglycan and PKB activity. It increases phosphorylation of the muscle size regulators PKB and FoxO3 and decreases expression of the muscle atrophy markers, muscle-specific RING finger protein MuRF1 and atrogin-1.</p></fn><fn id="Fn56"><label>56</label><p id="Par344">Its defective activity enables NFκB activation, which launches synthesis of inflammatory cytokines (e.g., TNFSF1 and IL1β), adhesion molecules (e.g., vcam1), and procoagulant factors (e.g., tissue factor).</p></fn><fn id="Fn57"><label>57</label><p id="Par394">The mammalian hippo pathway is composed of core kinases (STK3/4 and LaTS1/2), adaptors (WW45 for STK3/4 and MOBKLs for LaTS1/2), effectors (YAP1/2 and WWTR1 [or Taz]), and transcription factors (TEAD1–TEAD4). The STK3 and STK4 kinases phosphorylate (activate) the LaTS1 and LaTS2 kinases, which then phosphorylate YAP (Ser127), thereby yielding a docking site for 14-3-3 that sequesters YAP in the cytoplasm. Otherwise, YAP translocates into the nucleus, associates with TEADs, and promotes transcription of genes involved in cell proliferation and survival.</p></fn><fn id="Fn58"><label>58</label><p id="Par405">The FAM3B family comprises four members (Fam3a–Fam3d). Fam3b is synthesized in β cells of pancreatic islets and stored in insulin+ granules. Upon glucose stimulation, production of full-length Fam3b and secretion of cleaved Fam3b rise via PKA, PKC, ERK1, ERK2, and CREB, along with PI3K and ROS [<xref ref-type="bibr" rid="CR139">352</xref>]. Fam3b maintains β cell function and induces hepatic gluconeogenic gene expression and glucose output during starvation.</p></fn><fn id="Fn59"><label>59</label><p id="Par409">PAPPa: pregnancy-associated plasma protein-A. It is also called IGF-dependent IGFBP4 peptidase (IGFBP4ase). Thus, it activates IGF, relieving its inhibition by IGFBP4 upon IGFBP4 cleavage. It was originally identified in the placenta and abounds in vSMCs.</p></fn><fn id="Fn60"><label>60</label><p id="Par418">For example, certain microRNAs directly target <index-term id="ITerm299"><term>ABC</term></index-term>the transporter ABCa1, which enables the efflux of cholesterol from cells to ApoA1 and nascent HDL, such as miR10b, miR17, miR19b, miR26, miR27a, miR27b, miR33a, miR33b, miR33a<sup>⋆</sup>, miR33b<sup>⋆</sup>, miR93, miR101, miR106b, miR128, miR144, miR145, miR148a, miR302a, and miR758, whereas miR223 regulates ABCa1 indirectly, hence suppressing HDL synthesis [<xref ref-type="bibr" rid="CR148">361</xref>].</p></fn><fn id="Fn61"><label>61</label><p id="Par419">MiR24 targets insulin-induced gene InsIG1.</p></fn><fn id="Fn62"><label>62</label><p id="Par420">In the liver, miR29 impedes lipoprotein lipase synthesis.</p></fn><fn id="Fn63"><label>63</label><p id="Par421">In the liver, miR30c represses <index-term id="ITerm301"><term>Microsomal triglyceride transfer protein</term></index-term>microsomal triglyceride transfer protein, which is needed for lipoprotein assembly. Hepatic miR30c reduces lipid synthesis and lipoprotein secretion [<xref ref-type="bibr" rid="CR148">361</xref>].</p></fn><fn id="Fn64"><label>64</label><p id="Par422">MiR33 targets ABCa1 and thus suppresses HDL synthesis. MiR33a and miR33b are encoded in introns of the genes coding for the basic helix–loop–helix and leucine zipper (bHLHLZ) transcription factors sterol regulatory element-binding proteins SREBP2 (bHLHd2) and SREBP1 (bHLHd1), respectively. More precisely, the mir33b gene resides in intron 17 of the Srebp1 gene on chromosome 17 and miR33a in intron 16 of the Srebp2 gene on chromosome 22 [<xref ref-type="bibr" rid="CR149">362</xref>]. Both miR33a and miR33b are cotranscribed with their host genes and regulate cholesterol and fatty acid metabolism. MiR33a and miR33b target enzymes of fatty acid oxidation, such as carnitine <sup>O</sup>octaniltransferase and palmitoyltransferase-1A (CPT1a), hydroxyacyl-CoA dehydrogenase HADHb, sirtuin-6, and <index-term id="ITerm302"><term>AMPK</term></index-term>AMPKα. MiR33a and miR33b also target insulin receptor substrate IRS2 of the insulin pathway in the liver. Therefore, miR33a and miR33b reduce fatty acid oxidation in addition to insulin signaling. The Srebp1 transcript engenders two major spliced variants (SREBP1a and SREBP1c). Whereas SREBP2 regulates cholesterol synthesis and metabolism (e.g., via HMGCR and transporters LDLR, ABCa1, ABCg1, and endolysosomal NPC1), SREBP1a mostly transactivates both lipogenic and cholesterogenic genes, and SREBP1c controls fatty acid synthesis (e.g., via fatty acid synthase) in the liver and adipose tissue [<xref ref-type="bibr" rid="CR150">363</xref>]. In addition, miR33 attenuates hepatic secretion of VLDL<sup>TG</sup>, as it targets <sup>N</sup>ethylmaleimide-sensitive factor, a component of exocytosis. Expression of miR33 is upregulated, and those of the products of the mitochondrial regulatory genes PGC1α, SLC25a25, NRF1, and <sup>Mt</sup>TFa are downregulated in atherosclerotic plaques [<xref ref-type="bibr" rid="CR148">361</xref>]. Prevention of miR33 action enhances cellular cholesterol efflux and HDL genesis via ABCa1, thereby attenuating progression and even favoring regression of atherosclerosis in mice [<xref ref-type="bibr" rid="CR151">364</xref>].</p></fn><fn id="Fn65"><label>65</label><p id="Par423">MicroRNAs are generated from primary transcripts processed into precursors and then a duplex of miR strands (5p and 3p strand). Most often, only the guide or mature strand is stable and active, but, in some cases, the passenger or star strand can regulate distinct targets. In addition to the guide strand miR33-5p, the passenger strand miR33<sup>⋆</sup>, or miR33-3p, is involved in the regulation of cholesterol, lipid, and glucose metabolism, as its substrates contribute to cholesterol efflux (e.g., ABCA1), fatty acid metabolism, and insulin signaling [<xref ref-type="bibr" rid="CR148">361</xref>].</p></fn><fn id="Fn66"><label>66</label><p id="Par424">MiR122 is the predominant miR in the liver (&gt; 70% total hepatic miRs) [<xref ref-type="bibr" rid="CR148">361</xref>]. It indirectly regulates transcripts linked to cholesterol and fatty acid metabolism in addition to <index-term id="ITerm303"><term>AMPK</term></index-term>AMPK and glucose 6-phosphatase and direct activators of hepcidin expression.</p></fn><fn id="Fn67"><label>67</label><p id="Par425">MiR144 regulates cholesterol metabolism and transport in the liver and macrophages. In the liver, <index-term id="ITerm304"><term>FXR (NR1h4/5)</term></index-term>the bile acid receptor FXR upregulates miR144, which eliminates the ABCA1 transcript. In macrophages, activated <index-term id="ITerm305"><term>LXR (NR1h2/3)</term></index-term>LXR upregulates miR144 and downregulates ABCa1 [<xref ref-type="bibr" rid="CR148">361</xref>].</p></fn><fn id="Fn68"><label>68</label><p id="Par426">MiR148a-3p is a major regulator of lipoprotein metabolism in hepatocytes and macrophages. Hepatic miR148a-3p hinders LDLR and ABCa1 synthesis, thereby increasing LDL<sup>CS</sup> level and decreasing HDL<sup>CS</sup> level in the blood [<xref ref-type="bibr" rid="CR148">361</xref>].</p></fn><fn id="Fn69"><label>69</label><p id="Par427">In hepatocytes, miR223, the formation of which is controlled by cholesterol concentration (low cholesterol levels suppressing miR223 production), reduces cholesterol synthesis, as it represses cytoplasmic hydroxymethylglutaryl-CoA synthase HMGCS1 and sterol C4-methyloxidase-like protein (SC4MOL or methylsterol mono-oxygenase), and precludes HDL<sup>CS</sup> uptake, as it targets <index-term id="ITerm306"><term>ScaR</term></index-term>ScaB1 [<xref ref-type="bibr" rid="CR148">361</xref>]. On the other hand, miR223 promotes cholesterol efflux, as it degrades <index-term id="ITerm307"><term>SP</term></index-term>SP3 that antagonizes SP1-mediated activation of ABCa1 synthesis [<xref ref-type="bibr" rid="CR152">365</xref>].</p></fn><fn id="Fn70"><label>70</label><p id="Par428">Activated circulating cells, in particular platelets, release miRs (e.g., miR21, miR24, miR126, miR191, and miR223). On the other hand, the liver constantly secretes miR122 [<xref ref-type="bibr" rid="CR148">361</xref>].</p></fn><fn id="Fn71"><label>71</label><p id="Par430">Also known as long-chain fatty acid–CoA ligase LACS4.</p></fn><fn id="Fn72"><label>72</label><p id="Par444">Cerebral neuronal mitochondria remove H<sub>2</sub>O<sub>2</sub> using malate and glutamate, which feed NADH into <sup>ETC</sup>complex-<italic>I</italic> and, to a lesser extent, succinate, which feeds FADH<sub>2</sub> to <sup>ETC</sup>complex-<italic>II</italic>.</p></fn><fn id="Fn73"><label>73</label><p id="Par455">Glutaminase (GSL) converts glutamine to glutamate, which is further catabolized in the TCAC for the production of ATP.</p></fn><fn id="Fn74"><label>74</label><p id="Par456">MyC promotes glutaminolysis and causes a reprogramming of mitochondrial metabolism according to glutamine catabolism and TCAC anaplerosis [<xref ref-type="bibr" rid="CR75">288</xref>]. Although miR23a and miR23b target mitochondrial GSL, Myc upregulates GSL synthesis, as it downregulates the expression of miR23a and miR23b. MiR23 production also decreases under redox stress.</p><p id="Par457">Glutamine is a nitrogen donor for de novo purine and pyrimidine synthesis [<xref ref-type="bibr" rid="CR161">374</xref>]. It is catabolized to aspartate for adenosine nucleotide formation. It is also involved in the production of glucosamine, a communication node between glucose and glutamine metabolism and an agent of glycoprotein synthesis, in addition to proteins for cell growth and proliferation. Glutamine is linked to MyC concentration and transcriptional activity. In some cell types, deregulated expression of MYC, which happens in multiple tumor types, enhances glutamine utilization and renders cell survival dependent on glutamine (glutamine addiction).</p><p id="Par458">The transcription factor MyC binds to gene promoters and enhancers residing within an open chromatin structure. It promotes cell growth and proliferation via its influence on cell metabolism. It raises aerobic glycolysis. It increases uptake of glutamine, as it promotes transcription of genes encoding glutamine transporters, enzymes of glutamine metabolism, and microRNAs that control expression of these genes [<xref ref-type="bibr" rid="CR162">375</xref>].</p><p id="Par459">The MYC transcript is targeted by microRNAs, such as Let7, miR 17-19b, and members of the miR34 family, among others [<xref ref-type="bibr" rid="CR162">375</xref>]. Several stress-responsive pathways also suppress MyC formation.</p><p id="Par460">Cancerous cells that produce high MyC levels due to Wnt pathway mutations are not addicted to glutamine but undergo a reversible cell cycle arrest upon glutamine deprivation [<xref ref-type="bibr" rid="CR162">375</xref>].</p><p id="Par461">Glutamine deprivation rapidly prevents MYC translation, which is associated with diminished transcription, thereby avoiding apoptosis [<xref ref-type="bibr" rid="CR162">375</xref>]. Glutamine contributes to adenosine synthesis; glutamine controls MYC translation via its metabolite adenosine. Adenosine suffices to rescue MyC expression.</p></fn><fn id="Fn75"><label>75</label><p id="Par463">Both miR15 and miR16 impair circulating proangiogenic cell function [<xref ref-type="bibr" rid="CR75">288</xref>].</p></fn><fn id="Fn76"><label>76</label><p id="Par465">PDHK phosphorylates (inactivates) pyruvate dehydrogenase (PDH), which converts pyruvate to acetyl-CoA, which is oxidized in the TCAC.</p></fn><fn id="Fn77"><label>77</label><p id="Par471">NElFa: negative elongation factor-A, which is also termed Wolf–Hirschhorn syndrome candidate protein-2 (WHSC2).</p></fn><fn id="Fn78"><label>78</label><p id="Par476">Membrane rafts, which are plasmalemmal nanodomains enriched in cholesterol and glycosphingolipids, and caveolae, a subcategory of rafts characterized by invaginations of the plasma membrane containing caveolin-1, are platforms for signaling effectors, that is, plasmalemmal surface receptors, such as growth factor and T-cell receptors in addition to members of tumor-necrosis factor receptor superfamily (TNFRSF), and intracellular cortical signaling mediators. Cholesterol depletion decreases membrane raft density and BCL2L1 concentration, inactivates PKB, and activates caspase-3, hence provoking anoikis-like apoptosis [<xref ref-type="bibr" rid="CR166">379</xref>]. The PKB kinase, a major regulator of cell survival and proliferation, especially in cancerous cells, phosphorylates (inactivates) proapoptotic proteins and upregulates transcription of genes encoding antiapoptotic agents, such as BCL2L1 and usurpin (CFLAR). The PI3K–PKB signaling axis can reside in membrane rafts, where it can undergo full activation to promote cell survival. The synthetic antitumoral lipids edelfosine and perifosine displace PKB along with other regulatory kinases such as PI3K, PDK1, and TOR from membrane rafts, at least in mantle cell lymphoma, a B-cell-derived neoplasia characterized by the chromosomal translocation t(11;14)(q13;q32), causing aberrant overexpression of cyclin-D1 and deregulation of several pathways, such as the constitutive activation of the PI3K–PKB axis [<xref ref-type="bibr" rid="CR167">380</xref>]. PI3K phosphorylates PI(4,5)P<sub>2</sub> to generate PIP<sub>3</sub>, which tethers to PKB and PDK1 and recruits them to the membrane. At the plasma membrane, PKB is phosphorylated at Thr308 and Ser473 by PDK1 and PDK2, the latter being TOR, DNAPK, or ILK, or even PKB (autophosphorylation). This membrane raft re-organization leads to PKB dephosphorylation, whereas proapoptotic TNFRSF6a is recruited into membrane rafts.</p></fn><fn id="Fn79"><label>79</label><p id="Par482">That is, 2-oxoglutarate dehydrogenase complex component-E2, a rate-controlling enzyme of the TCAC. This enzymatic complex, which catalyzes the conversion of 2-oxoglutarate to succinyl-CoA and CO<sub>2</sub>, contains multiple copies of 2-oxoglutarate dehydrogenase (E1), dihydrolipoamide succinyltransferase (E2), and lipoamide dehydrogenase (E3). Its overproduction in wild-type mice protects against cardiac hypertrophy [<xref ref-type="bibr" rid="CR172">385</xref>].</p><p id="Par483">Conversion of FFAs and glucose accounts for most of the ATP production in the healthy adult heart. At an advanced stage of heart failure, fatty acid oxidation decreases and glycolysis increases.</p><p id="Par484">Glucose is converted to ATP by glycolysis, the TCAC, and the mitochondrial ETC. In glycolysis, glucose is catabolized into two pyruvate, two ATP molecules and two NADH, which can generate five ATPs, assuming 2.5 mol of ATP per mole of NADH.</p><p id="Par485"><index-term id="ITerm362"><term>Tricarboxylic acid cycle</term></index-term>The TCAC inside the mitochondrial matrix processes acetyl-CoA derived from pyruvate, the product of glycolysis, which first undergoes oxidative decarboxylation by the pyruvate dehydrogenase complex that transfers acetyl groups to coenzyme-A (TCAC step 0). Pyruvate can be formed by amino acid catabolism. In addition, amino acid and fatty acid catabolism also directly provide acetyl-CoA.</p><p id="Par486">The TCAC itself begins and ends with oxaloacetate. AcetylCoA combines with oxaloacetic acid to produce citric acid (hence the other TCAC name, citric acid cycle). A series of oxidations occur from citric acid to oxaloacetic acid. The TCAC consumes and produces metabolites relevant to other processes.</p><p id="Par487">Glycolysis and the TCAC oxidize fuels to CO2 to reduce NAD<sup>+</sup> to NADH and FAD to FADH<sub>2</sub>. <index-term id="ITerm363"><term>ETC</term></index-term>In the ETC, the electron carriers NADH and FADH<sub>2</sub> are re-oxidated to oxidatively phosphorylate ADP to ATP; they use their electrons for proton motion across the inner mitochondrial membrane.</p><p id="Par488">The ensemble constituted by three reaction sets (glycolysis, TCAC, and ETC) creates about 30 ATP molecules, assuming 1.5 mol of ATP per mole of FADH<sub>2</sub>, and GDP and GTP are supposed to be equivalent to ADP and ATP (glycolysis: two ATP and two NADH; TCAC step 0: two NADH; TCAC: six NADH, two FADH<sub>2</sub>, and two GTP; ETC: 30 ATP).</p></fn><fn id="Fn80"><label>80</label><p id="Par498">This medical emergency, commonly known as heart attack, is a set of disorders, ranging from unstable angina (i.e., chest pain due to myocardial ischemia) to actual MI.</p></fn><fn id="Fn81"><label>81</label><p id="Par499">MiR1 limits endothelial permeability and promotes angiogenesis, as it represses mRNA encoding seryl tRNA synthetase, in addition to CMC differentiation [<xref ref-type="bibr" rid="CR176">389</xref>]. It shares with miR133 four mRNAs, which encode HCN4, LASP1, PNP, and transgelin-2. MiR1 together with miR155, miR206, and miR613 target liver X receptors, thereby controlling the transcription of the ABCA1 gene.</p></fn><fn id="Fn82"><label>82</label><p id="Par500">MiR145 shares with miR133 2 mRNAs, FSCN1 and Igf1r. MiR145 and miR208 target CDKN1A mRNA [<xref ref-type="bibr" rid="CR176">389</xref>].</p></fn><fn id="Fn83"><label>83</label><p id="Par501">In patients with stable CoAD, miR126 concentration is lowered in circulating microvesicles. However, in patients with unstable plaques, its plasmatic concentration is higher than that of controls [<xref ref-type="bibr" rid="CR176">389</xref>].</p></fn><fn id="Fn84"><label>84</label><p id="Par503">ETS1 is involved in stem cell development and cell senescence and death in addition to regulation of PDGFRA gene transcription in vSMCs [<xref ref-type="bibr" rid="CR176">389</xref>].</p></fn><fn id="Fn85"><label>85</label><p id="Par504">Fscn1: fascin. The actin-bundling protein organizes filamentous actin into actin filament bundles. It acts in the formation of microspikes, membrane ruffles, and stress fibers and hence in cell adhesion and migration in addition to cellular interactions [<xref ref-type="bibr" rid="CR176">389</xref>].</p></fn><fn id="Fn86"><label>86</label><p id="Par505">HCN4: potassium- and sodium-permeable hyperpolarization-activated cyclic nucleotide-gated potassium channel-4. It contributes to the pacemaker current in the heart. An increase in HCN2 and HCN4 activity in hypertrophied ventriculomyocytes prolonged the repolarization stage [<xref ref-type="bibr" rid="CR176">389</xref>].</p></fn><fn id="Fn87"><label>87</label><p id="Par506">Reduced miR133a expression is associated with a lower IGF1R concentration and suppression of vSMC growth via the PKB–FoxO3a pathway [<xref ref-type="bibr" rid="CR176">389</xref>].</p></fn><fn id="Fn88"><label>88</label><p id="Par507">LASP1: LIM and SH3-domain-containing protein-1. It is a member of the ubiquitous LIM protein subfamily of the nebulin group. LASP2 is a splice variant of the nebulin gene and is thus also termed nebulette. The association between the chemokine receptors and LASP1 regulates the migration of inflammatory leukocytes [<xref ref-type="bibr" rid="CR176">389</xref>].</p></fn><fn id="Fn89"><label>89</label><p id="Par508">PNP: purine nucleoside phosphorylase. It is involved in energy-deprived conditions in the metabolism of adenosine during ATP degradation and hence regulation of activated T cells [<xref ref-type="bibr" rid="CR176">389</xref>].</p></fn><fn id="Fn90"><label>90</label><p id="Par509">Tagln: transgelin. MiR133a connects to the 3<italic>′</italic>-UTR of TAGLN2 mRNA, thereby affecting differentiation of smooth myocytes. It intervenes in hypoxia-induced apoptosis via caspase-8 [<xref ref-type="bibr" rid="CR176">389</xref>].</p></fn><fn id="Fn91"><label>91</label><p id="Par511">Colony-stimulating factors CSF1 and CSF2 control the development, functional and phenotypical differentiation, and proliferation of <index-term id="ITerm368"><term>Monocyte</term></index-term>monocytes and <index-term id="ITerm369"><term>Macrophage</term></index-term>macrophages in cooperation with cytokines such as IL4 and IL34, the second CSF1R ligand [<xref ref-type="bibr" rid="CR177">390</xref>]. The <index-term id="ITerm370"><term>Mononuclear phagocyte system</term></index-term><italic>mononuclear phagocyte system</italic>, which participates in inflammation via the elimination of foreign bodies and the organization of different inflammatory phases, includes lineage-committed bone marrow precursors, circulating monocytes, tissue-resident macrophages, and myeloid dendrocytes [<xref ref-type="bibr" rid="CR177">390</xref>]. Monocytes reside in the bloodstream and the bone marrow and spleen before being released into the blood and any tissue before becoming macrophages. Anticipatory inflammation describes the liberation of Ly6C+ classical monocytes from the bone marrow with a diurnal rhythm under the control of BMAL1. Classical monocytes replenish monocyte-derived macrophages in tissues, differentiate to take an <sup>M1</sup> functional phenotype and into Ly6c− cells in blood and bone marrow, initiate the inflammatory response, and serve as antigen-presenting tissular monocytes following antigen uptake in tissues and recirculation to lymph nodes. Patrolling Ly6C− monocytes constitutes a blood cell subset that scans the endothelial surface in search of damage and pathogens and phagocytose endothelial particles. Macrophages maintain tissue integrity, as they eliminate damaged cells, cellular debris, and degraded matrix components. <sup>M2</sup>macrophage (anti-inflammatory phenotype) can promote tumor growth, whereas <sup>M1</sup>macrophage (pro-inflammatory phenotype) removes pathogens and virally infected and cancerous cells.</p></fn><fn id="Fn92"><label>92</label><p id="Par512">TIMP2 plays a greater protective role than TIMP1 in atherosclerosis and aneurysm formation [<xref ref-type="bibr" rid="CR179">392</xref>]. TIMP2 suppresses MMP14 formation by monocytes and macrophages. CSF2 also raises MMP12 expression in macrophages.</p></fn><fn id="Fn93"><label>93</label><p id="Par513">MiR205 targets Timp3 in ECs [<xref ref-type="bibr" rid="CR179">392</xref>].</p></fn><fn id="Fn94"><label>94</label><p id="Par524">ZNF292: zinc finger-containing protein-292.</p></fn><fn id="Fn95"><label>95</label><p id="Par525">AFF1: AF4–FMR2 family member-1.</p></fn><fn id="Fn96"><label>96</label><p id="Par526">DENND4c: DENN domain-containing protein-4C.</p></fn><fn id="Fn97"><label>97</label><p id="Par527">SRSF4: Ser/Arg-rich splicing factor-4.</p></fn><fn id="Fn98"><label>98</label><p id="Par528">Thsd: thrombospondin.</p></fn><fn id="Fn99"><label>99</label><p id="Par532">Neuregulins (NRg1–NRg4) belong to the EGF family.</p></fn><fn id="Fn100"><label>100</label><p id="Par534">DNA-binding protein ikaros is a transcriptional regulator of hematopoietic cell differentiation, which, in particular, operates in the development of B and T lymphocytes. It targets two chromatin-remodeling complexes, nurd and BAF, in RBCs [<xref ref-type="bibr" rid="CR7">108</xref>]. It is implicated in normal apoptosis in adult erythroid cells.</p><p id="Par535">The Ikaros family of zinc finger-containing transcription factors include several subtypes encoded by five genes (IKZF1–IKZF5), that is, Ikaros, Aiolos, Helios, Eos, and Pegasus (in Greek mythology, Iκαρo<italic>ς</italic> [Latin <italic>Icarus</italic>], is the son of <italic>Δ</italic>αιδαλo<italic>ς</italic> [Latin <italic>Daedalus</italic>], the craftsman, artist, and creator of the Labyrinth, Aιoλo<italic>ς</italic> [Latin <italic>Aeolus</italic>] the god keeper of winds, Hλιo<italic>ς</italic> [Latin <italic>Helius</italic>] one of the Titans and personification of the Sun, his Titan sister Hω<italic>ς</italic> [Latin <italic>Aurora</italic>] the goddess of the Dawn, and <italic>Π</italic>ηγασo<italic>ς</italic> [Latin <italic>Pegasus</italic>], the winged horse). Alternative splicing produces additional isoforms from each of the five homologous transcripts. They also lodge in nonhematopoietic organs [<xref ref-type="bibr" rid="CR190">403</xref>].</p></fn><fn id="Fn101"><label>101</label><p id="Par550">Also known as trithorax homolog Trx1 and histone Lys methyltransferase KMT2a.</p></fn><fn id="Fn102"><label>102</label><p id="Par553">Neat1: nuclear paraspeckle-enriched assembly transcript-1. It is also dubbed virus-inducible noncoding RNA (vinc) and men&#x01d716;. The mouse locus Men1 (multiple endocrine neoplasia-1) in the chromosomal region 19qA produces two ncRNA isoforms, the menβ and smaller men&#x01d716; transcripts.</p></fn><fn id="Fn103"><label>103</label><p id="Par554">Neat2 is also called metastasis-associated lung adenocarcinoma transcript malat1. It was first found in metastasizing nonsmall-cell lung carcinomas. It is upregulated by hypoxia and regulates EC proliferation and hence angiogenesis, among other tasks.</p><p id="Par555"><index-term id="ITerm398"><term>Cancer</term></index-term>In addition, neat2 can serve as both a diagnostic and a prognostic marker in cancers. Inhibition of neat2 can decrease cell motility and increase apoptosis [<xref ref-type="bibr" rid="CR192">405</xref>]. Neat2 may predict tumor recurrence after liver transplantation.</p></fn><fn id="Fn104"><label>104</label><p id="Par556">mascRNA: malat1-associated small cytoplasmic RNA.</p></fn><fn id="Fn105"><label>105</label><p id="Par559">Neutral sphingomyelinase-2 regulates secretion of exosomes and microRNAs [<xref ref-type="bibr" rid="CR163">376</xref>].</p></fn><fn id="Fn106"><label>106</label><p id="Par564">Also known as ENSG00000262454.</p></fn><fn id="Fn107"><label>107</label><p id="Par570">Neat2: nuclear-enriched assembly transcript, or metastasis-associated lung adenocarcinoma transcript malat1. It was first found in metastasizing nonsmall-cell lung carcinomas and is upregulated by hypoxia. It regulates EC proliferation and hence angiogenesis.</p><p id="Par571"><index-term id="ITerm408"><term>Cancer</term></index-term>In addition, neat2 can serve as both a diagnostic and a prognostic marker in cancers. Inhibition of neat2 can decrease cell motility and increase apoptosis [<xref ref-type="bibr" rid="CR192">405</xref>]. Neat2 may predict tumor recurrence after liver transplantation.</p></fn><fn id="Fn108"><label>108</label><p id="Par572">Tug1: taurine upregulated gene transcript-1.</p></fn><fn id="Fn109"><label>109</label><p id="Par573">Meg3: maternally expressed gene transcript-3.</p></fn><fn id="Fn110"><label>110</label><p id="Par574">Polycomb chromobox homolog CBx4, a sumo ligase, is also called polycomb protein-2 (Pc2).</p></fn><fn id="Fn111"><label>111</label><p id="Par576">Also known as PDZ domain-containing protein PDZK3.</p></fn><fn id="Fn112"><label>112</label><p id="Par578">Also known as ENST00000446910, chromosome 21 open reading frame C21orf130, DSCAM1-3, and pred42.</p></fn><fn id="Fn113"><label>113</label><p id="Par579">Mir503hg: miR503 host gene. lincRNA maps onto chromosome X (Xq26). It may serve as a tumor marker.</p></fn><fn id="Fn114"><label>114</label><p id="Par581">Meg3: maternally expressed gene transcript-3.</p></fn><fn id="Fn115"><label>115</label><p id="Par583">Neat2: nuclear-enriched assembly transcript-2. It is also called metastasis-associated lung adenocarcinoma transcript malat1.</p></fn><fn id="Fn116"><label>116</label><p id="Par585">Igf2as: IGF2 antisense RNA.</p></fn><fn id="Fn117"><label>117</label><p id="Par587">Miat: myocardial infarction-associated transcript.</p></fn><fn id="Fn118"><label>118</label><p id="Par589">It corresponds to n342419. Mantises are carnivorous insects.</p></fn><fn id="Fn119"><label>119</label><p id="Par591">Sencr: smooth myocyte- and EC-enriched migration/differentiation-associated lncRNA.</p></fn><fn id="Fn120"><label>120</label><p id="Par593">Human mitochondrial DNA encodes 2 rRNAs, 22 tRNAs, and 13 proteins of the respiratory chain.</p></fn><fn id="Fn121"><label>121</label><p id="Par594">About 99% of the mitochondrial proteome is encoded by the nuclear genome and synthesized in the cytoplasm as precursors imported into mitochondria, especially for proteins involved in replication, transcription, and translation of the mitochondrial genome and for several components of oxidative phosphorylation. Altered mitochondrial protein import causes accumulation of mistargeted, nuclearly encoded mitochondrial protein precursors in the cytosol, priming <italic>mitochondrial precursor protein accumulation stress</italic> response, which comprises a global reduction in protein translation and an increase in the proteasomal degradation of proteins.</p></fn><fn id="Fn122"><label>122</label><p id="Par596">A decrease in ATP production is sensed by <index-term id="ITerm422"><term>AMPK</term></index-term>AMPK, which increases cellular NAD<sup>+</sup> concentration, thereby activating sirtuin-1, which activates PGC1α and subsequently mitochondrial genesis and energy metabolism [<xref ref-type="bibr" rid="CR155">368</xref>].</p></fn><fn id="Fn123"><label>123</label><p id="Par597">Impaired mitochondrial genesis and function stimulate P53, which represses PGC1α- and PGC1β-driven programs [<xref ref-type="bibr" rid="CR155">368</xref>]. Activation of PARP1 and PARP2 in response to DNA breaks lowers cellular NAD<sup>+</sup> concentration, thereby precluding the activity of sirtuin-1 and hence mitochondrial function.</p></fn><fn id="Fn124"><label>124</label><p id="Par600">Acetyl-CoA and <sup>S</sup>adenosylmethionine, which are substrates for acetylation and methylation of histones, respectively, affect the chromatin state and hence gene transcription. Calcium release from mitochondria stimulates transcriptional programs that rely on NFAT and NFκB. The NAD<sup>+</sup>/ NADH ratio favors mitochondrion genesis and fatty acid oxidation via sirtuin-1 and -3 and represses ribosomal RNA transcription in the nucleolus. The AMP/ATP imbalance activates catabolism. The NO gas produced by mitochondria hampers oxidative phosphorylation and rRNA maturation.</p></fn><fn id="Fn125"><label>125</label><p id="Par603">SncmtRNA, is preferentially expressed in highly proliferating normal and cancerous cells. Normal proliferating cells express two antisense transcripts of this lncRNA, both of which are downregulated in tumoral cells. Both sense and antisense transcripts of sncmtRNA can reside in the nucleus and may participate in retrograde signaling [<xref ref-type="bibr" rid="CR155">368</xref>]. Three other cell-specific lncRNAs are transcribed by the mitochondrial genome and processed by the mitochondrial RNase-P protein MRPP1 encoded in the nucleus. <index-term id="ITerm425"><term>Lipcar lincRNA</term></index-term>Another lncRNA encoded by the mitochondrial genome is the chimeric (fusion) transcript lipcar formed between the 5<italic>′</italic>-end of the PGHS2 gene and 3<italic>′</italic>-end of the CYTB gene, which is detected in plasma from HF patients.</p></fn><fn id="Fn126"><label>126</label><p id="Par604">The lincRNA sammson, which predominantly localizes to the cytoplasm of human melanoblasts, is associated with mitochondria. Among sammson interactors, the complement component-1 q-subcomponent-binding protein (C1qBP; or glycoprotein GC1qBP), a trimer that primarily localizes to the mitochondrial matrix and multifunctional chaperone, interacts with hyaluronan (hence its other name hyaluronan-binding protein [HaBP1]) regulates mitoribosome assembly and mitochondrial protein synthesis; sammson hence supports mitochondrial protein synthesis. Another sammson binding partner, 5<italic>′</italic>–3<italic>′</italic>-exoribonuclease XRN2, is required for rRNA maturation in the nucleus.</p></fn><fn id="Fn127"><label>127</label><p id="Par608">CoroMarker is the lncRNA AC100865.1, which is stably detected in plasmatic vesicles probably released from monocytes [<xref ref-type="bibr" rid="CR203">416</xref>]. It is sensitive to coronary artery disease.</p></fn><fn id="Fn128"><label>128</label><p id="Par609">BAT: human lymphocyte antigen HLA<sub>B</sub>-associated transcript (protein-coding mRNA).</p><p id="Par610">Spliceosome ATP-dependent RNA helicase HLA<sub>B</sub>-associated transcript product BAT1, which is a splicing factor required for association with U2 small nuclear ribonucleoprotein (hence its other alias UAP56), is also called DEAD (Asp–Glu–Ala–Asp) box-containing protein DDx39b.</p><p id="Par611">Large proline-rich HLA<sub>B</sub>-associated transcript product BAT2, which is also termed proline-rich coiled coil-containing protein PrRC2a, may contribute to pre-mRNA splicing regulation.</p><p id="Par612">HLA<sub>B</sub>-associated transcript BAT3 is also named large proline-rich protein scythe, an inducer of apoptosis, which is involved in DNA damage-induced apoptosis, and BCL2-associated athanogene (BAG) family molecular chaperone regulator BAG6. It prevents aggregation of misfolded proteins as a component of the BAT3 cytosolic protein quality control complex. It maintains target proteins in a soluble state and participates in their proper delivery to the endoplasmic reticulum; otherwise, it promotes their sorting to the proteasome for degradation after ubiquitination.</p><p id="Par613">The protein BAT5 is also termed αβ-hydrolase domain -containing protein αβ Hd16a, a lipase that preferentially processes long-chain unsaturated monoacylglycerols. It hydrolyzes medium-chain saturated (C14:0) and long-chain unsaturated (C18:1, C18:2, and C20:4) monoacylglycerols and 15-deoxy (12,14)-prostaglandin-J<sub>2</sub> 2-glycerol ester and has slight diacylglycerol and TAG activity [<xref ref-type="bibr" rid="CR204">417</xref>].</p><p id="Par614">The human major histocompatibility complex (MHC), which mediates interactions among leukocytes and between leukocytes and other cell types, is categorized into class-<italic>I</italic> (with three major sets: HLA<sub>A</sub>–HLA<sub>C</sub>) and -<italic>II</italic> (HLA<sub>DP</sub>, HLA<sub>DQ</sub>, and HLA<sub>DR</sub>) immunity genes (i.e., antigen-processing genes), which encode plasmalemmal receptors for antigens that mediate the clonal activation of cytotoxic and helper T lymphocytes, respectively [<xref ref-type="bibr" rid="CR205">418</xref>]. The MHC class-<italic>III</italic> region also contains numerous genes, such as those that encode complement system agents (e.g., factor-B, -C2, and -C4), cytokines (e.g., TNFSF1–TNFSF3), heat shock proteins (HSP70s), and the immunity-related genes encoding BAT1 to BAT9. The BAT1–BAT5 gene cluster localizes to the vicinity of the genes encoding TNFα (TNFSF1) and TNFβ (TNFSF2).</p><p id="Par615">Single nucleotide polymorphisms BAT2 (8671<sup>⋆</sup>G), BAT3 (8854<sup>⋆</sup>C), and BAT5 (22655<sup>⋆</sup>C and 9569<sup>⋆</sup>A) are correlated with the development of Kawasaki disease and coronary artery aneurysm; BAT2, BAT3, and BAT5 haplotypes (ATTGTG and ATCATG) are associated with a higher susceptibility of these maladies [<xref ref-type="bibr" rid="CR206">419</xref>].</p></fn><fn id="Fn129"><label>129</label><p id="Par616">il21ras1: IL21R antisense RNA-1.</p></fn><fn id="Fn130"><label>130</label><p id="Par618">Braveheart (Bvht) is required for the evolution of the nascent mesoderm to a cardiac fate. It enables activation of the core cardiac transcription factors (e.g., GATA4, GATA6, HAND1, HAND2, MesP1, NKx2-5, and TBx5) [<xref ref-type="bibr" rid="CR74">287</xref>]. It functions upstream from mesoderm posterior homolog MesP1 (or bHLHc5), a master regulator of multipotent cardiovascular progenitors, as it targets the core cardiac transcription factors [<xref ref-type="bibr" rid="CR208">421</xref>]. It interacts with the suppressor of zeste SuZ12, a component of the polycomb repressive complex, PRC2, during CMC differentiation, acting as a decoy for PRC2 to exclude PRC2 from the MESP1 promoter in cardiac progenitor cells. MesP1+ progenitors engender all cardiac cell types (CMCs, ECs, and smooth myocytes). In ESCs, Bvht then contributes to the epigenetic regulation of cardiac lineage commitment. Other regulators control mesoderm evolution. <index-term id="ITerm436"><term>FoxF</term></index-term>The transcription factor FoxF1 allows the adequate partition of the lateral mesoderm into splanchnic and somatic mesoderm lineages. <index-term id="ITerm437"><term>fendrr lncRNA</term></index-term>The lncRNA FenDRR (FoxF1 adjacent enhancer-associated noncoding developmental regulatory RNA) is transiently expressed in the lateral mesoderm of mid-gestational mouse embryos and interacts with both repressive PRC2 and activatory MLL complexes, enabling proper differentiation of cells derived from the lateral mesoderm, such as those of the future heart [<xref ref-type="bibr" rid="CR209">422</xref>].</p></fn><fn id="Fn131"><label>131</label><p id="Par619">Expression of the lncRNA myheart is primed during CMC maturation and reduced in hypertension-induced cardiac hypertrophy and HF, an event that correlates with the change in the MYH7/MYH6 ratio during maladaptive cardiac remodeling.</p></fn><fn id="Fn132"><label>132</label><p id="Par621">BRG: brahma (SMARCa2)-related gene product.</p></fn><fn id="Fn133"><label>133</label><p id="Par622">During postnatal cardiac maturation, a switch occurs from β- to α-myosin heavy chain owing to reciprocal up- and downregulation of MYH6 and MYH7 gene expression.</p></fn><fn id="Fn134"><label>134</label><p id="Par629">Hulc: highly upregulated in liver cancer lncRNA. It raises the level of the transcription factor PPARα (nuclear receptor NR1c1), which activates the ACSL1 gene promoter, launching long-chain acylCoA synthase formation [<xref ref-type="bibr" rid="CR213">426</xref>]. It also suppresses miR9 targeting of PPARA mRNA. It thus supports lipogenesis and the accumulation of intracellular TGs and cholesterol.</p></fn><fn id="Fn135"><label>135</label><p id="Par630">lincMD: long intergenic ncRNA muscle differentiation-1. It is a sponge for miR133 and miR135 [<xref ref-type="bibr" rid="CR214">427</xref>]. It regulates specific myogenic factors required for the onset of late muscle gene transcription, such as mastermind-like protein MamL1 and myocyte enhancer factor MEF2c.</p></fn><fn id="Fn136"><label>136</label><p id="Par631">Cdr1as: cerebellar degeneration-related protein-1 (circular) antisense lncRNA. It targets miR7a and miR7b, at least in murine hearts, the expression of which rises in myocardial ischemia–reperfusion injury. These miRs protect myocardium, as they inhibit PARP, an executioner of apoptosis [<xref ref-type="bibr" rid="CR216">429</xref>]. In addition, miR7a synthesis is upregulated by UPR in MI.</p></fn><fn id="Fn137"><label>137</label><p id="Par633">During the cell cycle, cyclin-dependent kinase CDK1 phosphorylates KTM6a (Thr345) and thus enhances the KTM6a–hotair<index-term id="ITerm453"><term>Hotair lncRNA</term></index-term> and –xist<index-term id="ITerm454"><term>Xist lncRNA</term></index-term> binding affinity [<xref ref-type="bibr" rid="CR194">407</xref>].</p><p id="Par634">XX individuals silence one of their X chromosomes using xist, which coats one of the X chromosomes and recruits chromatin-silencing factors such as the polycomb repressor complexes PRC1 and PRC2 via the PCGF3–PCGF5–PRC1 complex (PCGF: polycomb group RING finger protein) [<xref ref-type="bibr" rid="CR218">431</xref>].</p></fn><fn id="Fn138"><label>138</label><p id="Par636">PlekHm1: pleckstrin homology domain-containing protein-M1. The CHAST gene lodges in the opposite PLEKHM1 gene strand.</p></fn><fn id="Fn139"><label>139</label><p id="Par641">wisper; wisp2 superenhancer-associated RNA.</p></fn><fn id="Fn140"><label>140</label><p id="Par642">Also known as lysyl hydroxylase LH2.</p></fn><fn id="Fn141"><label>141</label><p id="Par654">Glycation of hemoglobin, an heterotetrameric ([αβ]<sub>2</sub>) metalloprotein, results from a non-enzymatic reaction between glucose and the β chain. When the blood glucose concentration is elevated, glucose attaches to hemoglobin in RBCs. Glycated hemoglobin (HbA1c) is measured to identify the average plasma glucose concentration over prolonged periods. High HbA1c amounts indicate defective control of the blood glucose concentration and is associated with CVD. Even with a glycohemoglobin concentration below 6.9% (52 mmol/mol), the CVD risk of T1DM patients is on average twice that of the general population [<xref ref-type="bibr" rid="CR2">51</xref>].</p></fn><fn id="Fn142"><label>142</label><p id="Par679">Members of the MYBPC family include three isoforms specific to slow and fast skeletal and cardiac muscles.</p></fn><fn id="Fn143"><label>143</label><p id="Par683">Other markers, such as <sub>NT</sub>proBNP, glycogen phosphorylase-BB, CRP, myeloperoxidase, and MMP-9, do not yield additional information with respect to cardiac troponin-T.</p></fn><fn id="Fn144"><label>144</label><p id="Par686">Cysteine-rich angiogenic inducer CyR61 is also named insulin-like growth factor (IGF)-binding protein IGFBP10 and CTGF, CyR61, NOv family member CCN1. In addition to this heparin-binding matrix protein, the CCN family includes connective tissue growth factor (CTGF or CCN2), nephroblastoma overexpressed protein (NOv1 or CCN3), and Wnt-induced secreted protein WISP1 to WISP3 (or CCN4 to CCN6). It promotes cell proliferation, adhesion, and migration, and hence angiogenesis. It is a ligand for activated platelets binding to integrin-α<sub>2B</sub>β<sub>3</sub> [<xref ref-type="bibr" rid="CR229">442</xref>]. This immediate early gene product is synthesized in response to mechanical stress, hypoxia, and exposure to TNFSF1, TGFβ, and PDGF [<xref ref-type="bibr" rid="CR229">442</xref>]. In cutaneous fibroblasts, it upregulates synthesis of factors involved in angio- and lymphogenesis, inflammation, and matrix remodeling (e.g., VEGFa, VEGFc, MMP1, MMP3, TIMP1, uPA, PAI1, and integrins Itgα<sub>3</sub> and Itgα<sub>5</sub> via ERK1 and ERK2 [<xref ref-type="bibr" rid="CR230">443</xref>]). In smooth myocytes, it can increase the production of VEGF, α<sub>V</sub>Itg, smooth muscle α-actin (Actα), along with myosin heavy chain MyH11 [<xref ref-type="bibr" rid="CR231">444</xref>]. Its gene transcription regulation depends on heparin binding. On the other hand, it downregulates type-<italic>I</italic> collagen α1 and α2 subunits encoded by the COL1A1 and COL1A2 genes.</p></fn><fn id="Fn145"><label>145</label><p id="Par688">iLBP: intracellular lipid-binding protein.</p></fn><fn id="Fn146"><label>146</label><p id="Par695">It was discovered in 1930 by W.S. Tillet and T. Francis as a substance in the serum of patients with acute inflammation linked to lobar pneumonias [<xref ref-type="bibr" rid="CR236">449</xref>]. This substance reacted with the somatic fraction-C derived from pneumococci, a carbohydrate common to the pneumococcus species, which is distinct from both type-specific capsular polysaccharide and nontype-specific somatic nucleoprotein. It is not limited to the serum of individuals with pneumococcal infection but is also observed in sera of patients with streptococcus and staphylococcus infections [<xref ref-type="bibr" rid="CR236">449</xref>].</p></fn><fn id="Fn147"><label>147</label><p id="Par696">The acute-phase response results from tissular damage, inflammation, infection, and cancers. Other acute-phase proteins include peptidase inhibitors in addition to coagulation, complement, and transport proteins, but only CRP and serum amyloid-A have a strong sensitivity and response speed [<xref ref-type="bibr" rid="CR237">450</xref>].</p></fn><fn id="Fn148"><label>148</label><p id="Par697">Extrinsic ligands include many glycans, phospholipids, and other constituents of microorganisms, such as capsular and somatic components of bacteria, fungi, and parasites, along with plant products [<xref ref-type="bibr" rid="CR237">450</xref>]. Once it is connected to its ligands, CRP is recognized by C1q and activates the classical complement pathway, engaging the main adhesion molecule of the complement system C3 and the terminal membrane attack C5–C9 complex. Bound CRP yields secondary binding sites for complement factor-H, thereby regulating alternative pathway amplification.</p></fn><fn id="Fn149"><label>149</label><p id="Par700">Also known as α1-glycoprotein and serum amyloid P-component (SAP). It is encoded by the APCS gene.</p></fn><fn id="Fn150"><label>150</label><p id="Par701">Long pentraxin Ptx3 is also called tumor-necrosis factor-α-induced protein TNFAIP5 and TNF-inducible gene product TSG14.</p></fn><fn id="Fn151"><label>151</label><p id="Par712">γ-Glutamyl transferase, or glutathione hydrolase-1 proenzyme, is a membrane-bound extracellular enzyme that cleaves γ-glutamyl peptide bonds in glutathione and other peptides and transfers the γ-glutamyl moiety to acceptors. In particular, it cleaves the γ-glutamyl bond of extracellular glutathione, releasing free glutamate and the dipeptide cysteinyl–glycine, which is hydrolyzed to cysteine and glycine by dipeptidases, in addition to glutathione conjugates and other γ-glutamyl compounds [<xref ref-type="bibr" rid="CR7">108</xref>]. It can also catalyze transpeptidation, transferring the γ-glutamyl moiety to an acceptor amino acid to form a new γ-glutamyl compound. It has an optimal activity at 37 <sup>∘</sup>C and pH 8.2 [<xref ref-type="bibr" rid="CR246">459</xref>].</p></fn><fn id="Fn152"><label>152</label><p id="Par727">Kupffer cells are also named stellate macrophages and Kupffer–Browicz cells (∼15% of the total liver cell population [<xref ref-type="bibr" rid="CR250">463</xref>]). They line walls within the lumen of hepatic sinusoids formed by sinusoidal ECs (fenestrated discontinuous endothelium), whereas hepatic stellate cells coat sinusoid walls within the perisinusoidal space (or space of Disse) between hepatocytes and sinusoids. Kupffer cells are exposed to bacteria from the gut microbiota in addition to microbial debris and bacterial toxins. These scavenger cells remove material from the portal circulation (dead RBCs, microorganisms, toxins, degenerated cells, immune complexes, and toxics). They are involved in the hepatic response to stressors (e.g., infection, and ischemia). They release chemoattractants for CD8+ cytotoxic and regulatory T lymphocytes. During the progression from non-alcoholic steatosis to steatohepatitis and fibrosis, they produce chitotriosidase, which contributes to hepatic stellate cell activation [<xref ref-type="bibr" rid="CR250">463</xref>]. They also synthesize thromboxane-A2 using PGhS and thus can cause portal hypertension via endothelin-1.</p></fn><fn id="Fn153"><label>153</label><p id="Par730">EDIL3: EGF-like repeat and discoidin-I-like domain-containing protein-3. It is also integrin-binding developmentally regulated EC locus-1 protein DEL1. This angiogenic protein is an extracellular matrix protein expressed by ECs during embryological vascular development. It promotes adhesion of ECs via α<sub>V</sub>β<sub>3</sub>-integrin [<xref ref-type="bibr" rid="CR252">465</xref>]. It also supports EC migration and in vitro angiogenesis, is re-expressed in ischemic adult organs, and stimulates angiogenesis.</p></fn><fn id="Fn154"><label>154</label><p id="Par731">Lactadherin, also called milk fat globule EGF-like motif-containing factor MFGE8 and secreted EGF repeat and discoidin domain-containing protein SED1, promotes VEGF-stimulated neovascularization [<xref ref-type="bibr" rid="CR7">108</xref>, <xref ref-type="bibr" rid="CR10">194</xref>]. It tethers to α<sub>V</sub>β<sub>3</sub>- and α<sub>V</sub>β<sub>5</sub>-integrins. It links apoptotic cells to phagocytes and promotes mucosal healing. It is cleaved into lactadherin short form and medin. Lactadherin on EVs mediates the cellular uptake by binding phosphatidylserine and cell surface integrin subunits α<sub>V</sub> and β<sub>3</sub> on recipient cells [<xref ref-type="bibr" rid="CR251">464</xref>].</p></fn><fn id="Fn155"><label>155</label><p id="Par762">For example, miR34a elicits senescence of endothelial progenitor cells, fibroblasts, and vascular smooth myocytes and precludes angiogenesis. MiR124 attenuates proliferation and migration of hypertensive fibroblasts in addition to their chemokine (CCL2) production.</p></fn><fn id="Fn156"><label>156</label><p id="Par766">The LTb<sub>4</sub>R receptor (BLT<sub>1</sub>) lodges on dendrocytes, granulocytes, macrophages, effector CD8+ T cells, and T<sub>H1</sub>, T<sub>H2</sub>, and T<sub>H17</sub> cells.</p></fn><fn id="Fn157"><label>157</label><p id="Par769">TSG101: tumor susceptibility gene product-101. It is a component of the ESCRT<italic>I</italic> complex, also called vesicular protein sorting VPS23. This subunit contributes to regulating the vesicular transfer of material, the sorting of endocytic ubiquitinated cargos into multivesicular bodies. It is involved in the exosomal release of syndecan, syntenin-1, and tetraspanin-30 (a.k.a. granulophysin and lysosomal-associated membrane protein LAMP3).</p></fn><fn id="Fn158"><label>158</label><p id="Par770">Syntenin-1 (syndecan-binding protein SdcBP1). It is an adaptor implicated in the trafficking of transmembrane proteins, neuro- and immunomodulation, and exosome genesis in cooperation with syndecans Sdc1 and Sdc4 and programmed cell death-6 protein-interacting protein PdCD6IP, and tumorigenesis.</p></fn><fn id="Fn159"><label>159</label><p id="Par772">Sunitinib is used in chemotherapy. This drug is a multitargeting receptor protein Tyr kinase inhibitor, especially of VEGFR and hence an angiogenesis inhibitor. A feedforward loop exists between long nonprotein-coding RNA activated in renal cell carcinoma with sunitinib resistance (lncarsr) and yes-associated protein (YAP) [<xref ref-type="bibr" rid="CR261">474</xref>]. Lncarsr interacts with YAP to hamper its phosphorylation by the large tumor suppressor LaTS1, thereby facilitating YAP nuclear translocation and favoring expansion of renal tumor-initiating cells. Conversely, YAP promotes the transcription of lncarsr.</p></fn><fn id="Fn160"><label>160</label><p id="Par775">Lactadherin is also called sperm-associated antigen (SpAG10), breast epithelial antigen (BA46), secreted EGF repeat and discoidin domain-containing protein (SED1), and milk fat globule-EGF factor (MFGE8). The lactadherin precursor is encoded by the Mfge8 gene [<xref ref-type="bibr" rid="CR6">107</xref>]. It is produced by mammary epitheliocytes; this cell surface protein is secreted as part of the milk fat globule membrane. This 364-amino acid glycoprotein is cleaved into short lactadherin and medin, the latter deriving from the coagulation factor-like domain of lactadherin. Its structure possesses sequences similar to those of EGF-like domain and blood-clotting factors-<italic>V</italic> and -<italic>V</italic> <italic>III</italic> (C1 and C2 domains) [<xref ref-type="bibr" rid="CR10">194</xref>]. In human arteries, it is observed in adventitial microvessels, medial smooth myocytes, and some ECs. It contributes to the phagocytic removal of apoptotic cells and the maintenance of the intestinal epithelial barrier. It supports mucosa healing and angiogenesis [<xref ref-type="bibr" rid="CR7">108</xref>]. It connects to α<sub>V</sub>β<sub>3</sub>- and α<sub>V</sub>β<sub>5</sub>-integrins in addition to phosphatidylserine-enriched cell surfaces, hence promoting cell adhesion.</p></fn><fn id="Fn161"><label>161</label><p id="Par777">Endothelial EVs released from the wetted and basal surface enter the blood circulation and target medial smooth myocytes, respectively.</p></fn><fn id="Fn162"><label>162</label><p id="Par782">πρoγνωσι<italic>ς</italic>: foreknowledge.</p></fn><fn id="Fn163"><label>163</label><p id="Par785">The alias ST2 is an example of ambiguous abbreviation, as ST2 can represent suppression of tumorigenicity-2, syndecan-binding protein-2 (or syntenin-2) encoded by the SDCBP2 gene, and cytosolic dehydroepiandrosterone (DHEA)-preferring sulfotransferase-2A1 (a.k.a. bile salt sulfotransferase, dehydroepiandrosterone sulfotransferase [DHEAST] and hydroxysteroid sulfotransferase [HST]) encoded by the SULT2A1 gene, in addition to interleukin-1 receptor-like 1 (IL1RL1). This member of the IL-1 receptor family is also called IL33R, as its ligand is the cytokine IL-33.</p></fn><fn id="Fn164"><label>164</label><p id="Par787">Also known as calgranulin-B, myeloid-related protein-14, and migration inhibitory factor-related protein-14 (MRP14).</p></fn><fn id="Fn165"><label>165</label><p id="Par803">Also known as myosin phosphatase target subunit MyPT1 and MyPT2 or PP1<sub>r12a∕b</sub>.</p></fn><fn id="Fn166"><label>166</label><p id="Par809">VAMP: vesicle-associated membrane protein.</p></fn></fn-group></back></book-part></book-part-wrapper></records><facets><facet name="subject"><facet-value count="1">Biological and Medical Physics, Biophysics</facet-value><facet-value count="1">Biomedical Engineering and Bioengineering</facet-value><facet-value count="1">Cardiology</facet-value><facet-value count="1">Engineering Fluid Dynamics</facet-value><facet-value count="1">Mathematical and Computational Biology</facet-value><facet-value count="1">Physics</facet-value><facet-value count="1">Systems Biology</facet-value></facet><facet name="keyword"/><facet name="pub"><facet-value count="1">Vasculopathies</facet-value></facet><facet name="year"><facet-value count="1">2018</facet-value></facet><facet name="country"><facet-value count="1">France</facet-value></facet><facet name="type"><facet-value count="1">Book</facet-value></facet></facets></response>
